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Chapter 1 
Introduction
1.1 Overview
Chronic lung disease (CLD) of prematurity is a significant complication of preterm 
birth. The pathogenesis of CLD is linked to a number of risk factors, all of which are 
able to initiate or help to sustain an inflammatory process in the preterm lung and 
which will be further discussed in this chapter. Historically, the neutrophil appears to 
be the key cell of inflammation in this disease and a lack of resolution of neutrophilic 
inflammation, due to delayed or dysregulated neutrophil apoptosis, is thought to be an 
important component of the pathogenesis of CLD. The role of monocytes and 
macrophages in the process and resolution of inflammation is well described but their 
specific role in CLD remains to be elucidated. These concepts and ideas will be 
discussed and further explored in this chapter.
1.2 Prematurity
Preterm delivery is defined by the World Health Organisation as the delivery of an 
infant between 20 and 37 weeks’ gestation (Wen et al., 2004). A normal pregnancy is 
40 weeks in duration. Preterm deliveries account for between 5 and 12% of all births 
(USA 11%; Europe 5-7% (Goldenberg, 2002); Canada 6.5% (Joseph et al., 2001)). In 
industrialised countries, preterm birth is responsible for 70% of neonatal mortality and 
75% of neonatal morbidity (Challis et al., 2001) and contributes to long term 
neurodevelopmental problems, visual impairment (Repka, 2002) and lung 
dysfunction. Early preterm births i.e. those before 32 weeks’ gestation, have the 
highest rates of morbidity and mortality (Lumley, 1993).
Secular trends in preterm births show a steady increase since the early 1980s (Wen et 
al., 2004). This may reflect increasing numbers of multiple births due to assisted 
reproduction techniques as well as the advent of more accurate dating of pregnancies 
by routine ultrasound scanning. In addition, changes in the way births are registered 
may contribute to the increasing trend, as infants which may previously have been
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registered as stillborn or miscarried are now being reflected as preterm births (Wen et 
al., 2004).
Outcomes for infants bom preterm are improving dramatically (Joseph et al., 2002, 
Horbar et al., 2002) however there are also larger numbers of surviving infants who 
have a significant disability (Wood et al., 2000).
1.3 Normal lung development
The normal development of the human lung can be divided into 5 phases (Kotecha, 
2000b, Kotecha, 2000a, Langston et al., 1984, Langston and Thurlbeck, 1982, 
Coalson, 2003) (Figure 1.1):
embryonic/embryonal phase (0 to 7 weeks’ gestation). The lung begins 
development as an outgrowth from the ventral aspect of the primitive foregut 
in the embryo and undergoes repetitive dichotomous branching to form the 
tracheobronchial tree. The developing airways are accompanied by branches 
of the pulmonary artery which is derived from the 6 aortic arch, 
pseudoglandular phase (7 to 16/17 weeks’ gestation). Airway and blood 
vessel branching continues to the level of the terminal bronchiole. Epithelial 
cells and cartilage differentiate. Pre-acinar vascular development is completed, 
canalicular phase (16/17 to 26/28 weeks’ gestation). The respiratory 
bronchiole, alveolar duct and primitive alveoli are formed. Type II epithelial 
cells begin to differentiate. The distal pulmonary circulation begins to develop 
to the level of capillaries at around 20 weeks.
saccular phase (26/28 to 32/36 weeks’ gestation). Airway walls thin and gas- 
exchange area is enlarged. Secondary crests, which are the progenitors of 
alveolar development, subdivide the cylindrical saccules of the alveolar duct, 
alveolar phase (32/36 weeks’ gestation to 2 years postnatally). Alveoli 
increase in number to around 300-600 million (Thurlbeck, 1982) and there is 
an increase in acinar complexity by increased extension and thinning of 
secondary crests.
17
Figure 1.1 Stages o f normal lung development (Kotecha, 2000a)
1.4 Respiratory distress syndrome
Respiratory distress syndrome (RDS) is the most immediately life threatening 
condition to affect most infants bom significantly preterm (i.e. before 32 weeks’ 
gestation). RDS is a major cause of morbidity and mortality in preterm infants. It is 
primarily caused by a deficiency of pulmonary surfactant, which is usually produced 
by pulmonary type II epithelial cells after about 30-32 weeks’ gestation (Fraser et al., 
2004).
Infants with RDS present soon after birth with respiratory distress, tachypnoea, 
intercostal, subcostal and sternal recession, grunting, cyanosis and reduced breath 
sounds. If untreated, the infant will progress to fatigue, apnoea, hypoxia and 
respiratory failure which may require assisted ventilation (Fraser et al., 2004). In RDS 
the lungs are stiff and non-compliant, needing high ventilatory pressures and thus 
increasing the risk of complications e.g. pneumothorax, pneumomediastinum and 
pulmonary interstitial emphysema (Fraser et al., 2004).
Over the past 20-30 years administration of antenatal glucocorticoids to pregnant 
women at risk of preterm delivery has reduced mortality in preterm infants by 40% 
(Roberts and Dalziel, 2006). Surfactant replacement treatment with bovine 
(Survanta®, beractant, Abbott, Berkshire, UK) or porcine (Curosurf ®, poractant alfa, 
Chiesi Pharmaceuticals, Cheadle, UK ) surfactants has also achieved a 30-65%
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reduction in pneumothorax, thus significantly improving clinical outcomes in RDS 
(Fraser et al., 2004).
1.4.1 RDS at tissue level
RDS is characterised by impaired gas exchange, decreased lung compliance, 
pulmonary oedema due to loss of integrity of the alveolar-capillary barrier, 
impairment of normal surfactant function and an increased tendency of alveoli to 
collapse (Gitto et al., 2001).
Histologically, normal newborn lungs have few or no inflammatory cells in either 
term or preterm infants (Robertson, 1964). Bronchoalveolar lavage (BAL) fluid of 
babies bom without risk factors for infection contains <105 cells, some debris and 
very few neutrophils (also called polymorphonuclear leucocytes (PMN)) (Grigg et al.,
1993). RDS is characterised by alveolar neutrophil infiltration, which disappears as 
the condition resolves (Grigg et al., 1991). Neutrophils appear soon after initiation of 
ventilation in animal models and the appearance of neutrophils correlates with lung 
oedema and the appearance of early indicators of lung injury (Carlton et al., 1997). 
There is a parallel decrease in circulating neutrophils (Jobe and Bancalari, 2001) with 
systemic activation of the cells (Brus et al., 1996, Nupponen et al., 2002a).
1.5 Chronic Lung Disease of Prematurity
The most important long term complication of RDS is CLD. The incidence of CLD 
has been rising over the past decade despite antenatal steroid administration and 
surfactant treatment (Fraser et al., 2004).
The current definition of CLD is applied to infants who continue to require oxygen 
supplementation beyond 28 days of age or, more recently and more epidemiologically 
useful, beyond 36 weeks’ corrected gestational age and who have characteristic chest 
x-ray changes (Kotecha, 1999).
Despite improvements in neonatal care, mechanical ventilatory techniques and the use 
of exogenous surfactant, CLD remains the most common complication in babies
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under 1kg birth weight (Jobe, 1999), occurring in 51% of infants with a birth weight 
of 501-750 g (Fanaroff et al., 1995, Costeloe et al., 2000) and 35% of infants 
weighing 751-1000 g (Fanaroff et al., 1995, Stevenson et al., 1998). The reported 
incidence of CLD varies widely, especially due to the different definitions of the 
condition currently in use (Bancalari et al., 2003). However, most sources agree that it 
is uncommon in infants bom at more than 32 weeks’ gestation (Bancalari et al., 2003) 
and infrequent at birth weights of more than 1200 g. Gentler ventilation techniques, 
antenatal steroids and surfactant treatment have reduced severe lung injury especially 
in older gestations but there are still some, particularly low birth weight (LBW), 
infants who initially show minimal evidence of RDS but progress to CLD -  many of 
these infants have had possible exposure to chorioamnionitis (Rojas et al., 1995).
Some infants with CLD have severe lung disease requiring assisted ventilation for 
many months and supplemental oxygen for months or years. In addition, CLD is 
associated with poor developmental outcome in survivors (Welty, 2005) -  it is an 
independent risk factor for cerebral palsy (Teberg et al., 1991). This is probably due 
to a generalised inflammatory state in the perinatal period which leads to both lung 
and central nervous system damage (Welty, 2005).
1.5.1 “New BPD”
Northway et al (Northway et al., 1967, Jobe and Bancalari, 2001) originally described 
bronchopulmonary dysplasia (BPD) as lung injury in preterm infants resulting from 
oxygen and mechanical ventilation. The terms BPD and CLD have become used 
interchangeably. The form of CLD described by Northway et al (Northway et al., 
1967) was characterised by interstitial and alveolar oedema in the early stages and 
progressed to persistent airway inflammation with significant alveolar septal fibrosis 
and small airway disease. Chest radiographs showed severe over inflation with a 
mixture of cystic emphysema and areas of fibrosis with volume loss (Jobe and 
Ikegami, 1998, Bancalari et al., 2003, Husain et al., 1998). This clinical and 
radiographic presentation is now seldom seen, except in a few term infants who 
survive severe meconium aspiration syndrome or congenital diaphragmatic hernia and 
experience prolonged high pressure ventilation (Jobe and Ikegami, 1998).
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The clinical and pathological presentation of CLD described by Northway in 1967 
(Northway et al., 1967) has now become infrequent due to the use of antenatal 
steroids, surfactant and modem ventilation techniques (Husain et al., 1998, Bancalari 
et al., 2003). Now we see a histologically different, clinically milder form of CLD or 
so-called “new BPD”. Infants with “new BPD” have CLD with less fibrosis which is 
more diffuse (Husain et al., 1998), more uniform lung inflation, fewer and larger 
alveoli, increased elastic tissue and decreased pulmonary microvascular development 
(Jobe and Bancalari, 2001). Chest radiographs initially show uniformly hazy and 
dense lung fields which progress over time to a lacy parenchymal pattern with 
moderate hyperinflation but few large cysts (Toce et al., 1984).
Jobe and Ikegami (Jobe and Ikegami, 1998) hypothesise that the “new BPD” is no 
longer the primary injury and repair mechanism of “old” BPD but rather a sequence 
of maldevelopment of the lung which is caused by interference with/interruption of 
the normal developmental signalling for maturation and alveolarisation of the preterm 
lung.
Alveolar and capillary growth are disrupted in the immature lung causing 
developmental arrest and abnormal lung repair (Coalson, 2003, Coalson et al., 1995). 
The common thread in decreased alveolarisation is a persistent increase in airway 
leucocyte count and over expression of cytokines, particularly tumour necrosis factor 
a (TNF-a), transforming growth factor p (TGF P), interleukin (IL)-l 1 and IL-6 in 
airway secretions (Jobe, 1999, Ogden et al., 1984). These pro-inflammatory mediators 
interfere with as yet unknown signalling pathways which are important in lung 
maturation and alveolarisation, with the highest risk being in the most immature 
infants (Jobe and Ikegami, 1998, Jobe, 1999).
The development of the secondary crest (28-36 weeks) is a critical event in the 
process of septation and thus of normal acinar development (Coalson et al., 1999, 
Husain et al., 1998). Coalson et al showed that oxygen alone can arrest septation in 
the saccular stage of lung development in a baboon model of CLD (Coalson et al., 
1999).
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The effects of oxygen and/or pro-inflammatory cytokines result in decreased 
alveolarisation and abnormal capillary morphology along with variable 
fibroproliferation in the interstitium and abnormal elastic fibre deposition giving the 
overall histopathological features of what we see as CLD (Coalson, 2003).
1.5.2 Risk factors for the development of CLD
The traditional view holds that CLD is caused simply by mechanical ventilation and 
oxidant injury (Jobe and Bancalari, 2001). This view underestimates the complex 
pathogenesis of CLD which probably involves the interaction of numerous factors, 
including mainly immature lung (preterm birth), oxygen injury (premature initiation 
of pulmonary gas exchange resulting in relative hyperoxia), volutrauma (mechanical 
ventilation) and an inflammatory response (Coalson, 2003). Additional risk factors 
include babies who are small for gestational age (SGA), the severity of RDS, duration 
of ventilation, duration of oxygen administration, patent ductus arteriosus (PDA), 
chorioamnionitis and postnatal bacterial sepsis (Amon et al., 1993, Fraser et al.,
2004). Fluid overload, most frequently iatrogenic, has also been implicated in the 
causation of CLD (Shah, 2003, Truog et al., 2007). These factors act additively or 
synergistically to result in lung injury (Jobe and Bancalari, 2001).
a) Hyperoxia
Endogenous antioxidant activity is relatively deficient at birth and preterm infants 
have particularly low levels of antioxidants (Rodriguez-Pierce et al., 1994). The intra­
uterine environment is relatively hypoxic thus all infants are exposed to relative 
hyperoxia at birth. In addition to this, most preterm infants are exposed to increased 
inspired oxygen concentrations during their treatment. The generation of reactive 
oxygen species can initiate severe inflammatory changes and lung damage especially 
if antioxidant activity is inadequate (Davis et al., 1991).
Davis et al (Davis et al., 1991) showed that hyperoxia consistently evokes a more 
significant inflammatory response and subsequent acute lung injury than barotrauma 
alone, even in adult lung models. Hyperoxia increases pro-inflammatory cytokine 
production (tumour necrosis factor-a (TNF-a), interleukin-1 (IL-1), interleukin-6 (IL-
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6) and interleukin-8 (IL-8)) from alveolar macrophages, fibroblasts, type II 
pneumocytes and endothelial cells (Metinko et al., 1992). Hyperoxia also aggravates 
the destructive effects of elastase (Bruce et al., 1987, Bruce et al., 1985, Bruce et al., 
1992).
b) Mechanical ventilation
Any mechanical ventilation may be injurious to preterm lungs (Jobe and Bancalari, 
2001). Mechanical ventilation causes barotrauma and volutrauma due to high peak 
inspiratory pressures (>35 cm water) (Taghizadeh and Reynolds, 1976, Tremblay et 
al., 1997). The exact mechanism for the damage caused by ventilation is unclear, 
however it is thought that positive pressure ventilation disrupts the lung epithelium by 
over distension of the airways (Oei et al., 2003) leading to leucocyte (particularly 
neutrophil) (Oei et al., 2003) migration to the lungs, increased alveolar-capillary 
membrane permeability and alveolar and interstitial oedema. Over distension can 
stimulate the inflammatory cascade by release of TNF-a, IL-1, IL-6 and IL-8 
(Vlahakis et al., 1999, Yoder et al., 2000).
Low end expiratory pressures (Taghizadeh and Reynolds, 1976, Tremblay et al.,
1997) may also cause lung injury by causing cytokine release and promoting 
accumulation and activation of peripheral leucocytes in the lungs (Muscedere et al.,
1994).
c) Infection
Antenatal infection is thought to be a major cause of preterm labour. Microbial 
invasion of the amniotic fluid increases leucocyte recruitment and cytokine 
production (Keelan et al., 2003) which promote further neutrophil activation and 
cervical ripening and dilation. This leads to exposure and weakening of fetal 
membranes and prostaglandin release, which stimulates uterine contractions 
(Goldenberg et al., 2000).
Up to 80% of women delivering at <28 weeks’ gestation have evidence of intrauterine 
infection, compared to 10-15% of those delivering at term (Goldenberg et al., 2000).
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Up to 48% of spontaneous preterm deliveries may be due to infection (Gomez et al., 
1997) however it is often subclinical (Klein and Gibbs, 2004). Microbial invasion of 
the amniotic cavity could be identified in 16% of patients in preterm labour with 
intact membranes (Jacobsson et al., 2003) and 21% with preterm prelabour rupture of 
membranes (pPROM) (Satar et al., 2008). This contrasts with the findings of Miralles 
et al (Miralles et al., 2005) who applied polymerase chain reaction (PCR) techniques 
to detect microbial 16S ribosomal RNA (rRNA) genes to identify the presence of 
microbial colonisation in intrauterine samples from women delivering at <33 weeks 
and in gastric fluid or bronchoalveolar lavage fluid from their newborns. They 
reported microbial genes in at least one tissue or fluid sample (gastric aspirate, 
amniotic fluid, BAL, fetal membranes or placenta) in 70% of deliveries after pPROM 
and 80% after preterm labour with intact membranes.
The organisms frequently responsible for antenatal intra-uterine infection are from the 
cervicovaginal flora -  Mycoplasma spp., Gardnerella vaginalis, Ureaplasma spp. 
(present in the lower genital tract of 40-80% of pregnant women (van Waarde et al., 
1997) and the most common organism grown in the amniotic fluid in 
chorioamnionitis), Chlamydia trachomatis and other anaerobes (Wasiela et al., 2001). 
Additionally, Group B streptococci are an important cause of intra-uterine infection as 
well as a leading cause of early and late neonatal infection (Gibbs et al., 2004).
Animal models in which Ureaplasma urealyticum is injected into the amniotic fluid 
of pregnant baboons have demonstrated the ability of the organism to provoke an 
inflammatory response in the lungs of the preterm animal once delivered (Yoder et 
al., 2003) and they may go on to develop CLD.
There is a group of very low birth weight (VLBW) (<1500 g) infants who develop 
CLD without developing RDS at birth. Some of these infants may be ventilated (with 
low peak inspiratory pressures and low inspired oxygen concentrations) for apnoea or 
poor respiratory effort and others may have very mild RDS which responds well to 
surfactant treatment (Rojas et al., 1995). This group of infants develop a requirement 
for supplemental oxygen and ventilatory support over the first 2 weeks of life. A 
number of these babies will have been exposed to chorioamnionitis (Speer, 2001). 
Colonisation or infection with U. urealyticum appears to protect preterm infants from 
the developing RDS but predisposes them to CLD, independent of gestation
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(Hannaford et al., 1999).
Chorioamnionitis was present antenatally in 92% of infants who developed CLD 
compared to 62% of infants who did not (Yoon et al., 1997). Histological 
chorioamnionitis was noted in 33% of infants weighing <2000 g with RDS compared 
to 82% without RDS (Watterberg et al., 1996). In contrast, 63% of babies with CLD 
had exposure to chorioamnionitis compared to 21% of babies without CLD 
(Watterberg et al., 1996). Together these data suggest a subgroup of preterm babies 
who are exposed to chorioamnionitis are destined to develop CLD and that antenatal 
infection appears to have a specific role in triggering the inflammatory response in 
fetal lung (Watterberg et al., 1996). Antenatal infection may prime fetal lungs such 
that minimally injurious postnatal events, like gentle mechanical ventilation, provoke 
an excessive inflammatory response in neonatal airways and lung tissue (Speer,
2004).
Increased IL-lp has been noted on day 1 of life in tracheal lavage fluid of babies who 
developed CLD, suggesting pulmonary inflammation prior to delivery (Watterberg et 
al., 1996). Antenatal exposure to pro-inflammatory cytokines (IL-6, TNF-a and IL-8) 
has been identified as a risk factor for developing CLD (Yoon et al., 1997). An 
increase in neutrophils in tracheal aspirates at birth, implies the pathogenesis of CLD 
commences antenatally (Kim et al., 2004). The presence of pPROM for more than 24 
hours is independently associated with raised BAL cell counts (Giles et al., 2000).
The importance of pro-inflammatory cytokines and pro-fibrotic growth factors, such 
as transforming growth factor-P (TGF-P), which are increased in infants who develop 
CLD, lies in the fact that these factors are also important in promoting normal lung 
growth (Thibeault et al., 2000).
Antenatal infection and inflammation have also been strongly implicated in the 
pathogenesis of other important neonatal complications, particularly cerebral palsy 
(Girard et al., 2009).
The major association, other than birth weight and gestational age, with CLD is 
postnatal sepsis (Rojas et al., 1995) which is an independent risk factor for the 
development of CLD. Bacterial infections (Liljedahl et al., 2004, Cordero et al., 1997)
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as well as viruses like cytomegalovirus (CMV) and adenovirus (Sawyer et al., 1987, 
Couroucli et al., 2000) have all been suggested to increase CLD.
d) Ureaplasma
The role of Ureaplasma in neonatal morbidity and mortality has long been 
controversial. Ureaplasmas are eubacteria which belong to the class Mollicutes. They 
do not have cell walls and are thought to be the smallest free-living, self-replicating 
cells. They are limited by the lack of cell wall to a parasitic existence in eukaryotic 
cells. Ureaplasmas were previously designated “T-my coplasma” but later the genus 
Ureaplasma was designated in view of their use of urea as a metabolic substrate. 
Ureaplasma urealyticum was the only species known to infect humans and this 
species was recently subdivided into 2 separate species, U. urealyticum and U. 
parvum, on the basis of their 16S rRNA gene sequences.
Ureaplasma spp. has been shown to be implicated in preterm labour, spontaneous 
abortion and stillbirth (Embree and Embil, 1980, Schelonka and Waites, 2007, 
Kataoka et al., 2006). Up to 80% of women have been reported to be colonised with 
genital mycoplasmas (Quinn et al., 1983) and as many as 22% of women with 
pPROM or preterm labour have evidence of U. urealyticum in their amniotic fluid 
(Kirchner et al., 2007).
Transmission of Ureaplasma from a colonised or infected mother depends on a 
number of variables, particularly 
gestation
Preterm infants appear to be more likely to become colonised than their term 
counterparts (Alfa et al., 1995) with the rate of vertical transmission ranging 
between 18% and 55% for term infants and 29% and 55% for preterm infants 
(Sanchez, 1993). 
birthweight
A higher risk of vertical transmission of Ureaplasma in babies of lower birth 
weight has been reported. For example in babies weighing <1000 g at birth 
transmission may be up to 89% (Sanchez and Regan, 1990) but a transmission 
rate of only 15% has been reported among infants of >1500 g birthweight
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(Kafetzis et al., 2004). Alfa et al (Alfa et al., 1995) showed that VLBW 
(<1500 g) infants were at significantly higher risk of acquiring Ureaplasma 
spp. in their respiratory tract than larger preterm infants. It is difficult to 
control for the effects of preterm labour and delivery among these infants as 
Ureaplasma may be a causative factor in the preterm birth which resulted in 
the infant being classified as low birthwieght.
- route of delivery
Aaltonen et al (Aaltonen et al., 2006) reported a series of 49 infants bom at 
<30 weeks’ gestation, in which 45% of 33 spontaneous deliveries were 
colonised with Ureaplasma but none of the electively delivered infants 
appeared to be colonised. Goldenberg et al (Goldenberg et al., 2008) also 
reported a higher prevalence of U. urealyticum or Mycoplasma hominis in 
umbilical cord blood among 351 mother/baby pairs at 23-32 weeks where 
infants had delivered spontaneously rather than electively.
- pPROM
Infants with Ureaplasma are more likely to have been bom following pPROM 
than those not colonised (Pandey et al., 2007).
Ureaplasma is thought to infect or colonise up to 37% of newborns (Abele-Hom et 
al., 1998) and has been implicated in neonatal morbidity and mortality including 
congenital pneumonia, low birthweight, intrauterine growth restriction (Embree et al., 
1980), central nervous system infections (Waites et al., 1990, Neal et al., 1994, 
Hentschel et al., 1993, Chung et al., 2007, Rao et al., 2002) and a systemic 
inflammatory response (Ohlsson et al., 1993, Ollikainen et al., 1998).
Cultrera et al (Cultrera et al., 2006) studied the relationship between RDS and 
Ureaplasma in 50 babies of <37 weeks’ gestation. Fifteen out of 24 babies with RDS 
had U. urealyticum or U. parvum detected and only 4 of 26 babies without RDS were 
colonised with either organism, thus suggesting that Ureaplasma plays a role in the 
development of RDS. In contrast, Hannaford et al (Hannaford et al., 1999) showed 
significantly decreased incidence of RDS in infants of <28 weeks’ gestation who were 
colonised with Ureaplasma but many of the colonised infants progressed to develop 
CLD which is in keeping with data showing an association between chorioamnionitis 
and development of CLD from Watterberg and colleagues (Watterberg et al., 1996).
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The association between the presence of Ureaplasma and the development of CLD 
remains controversial. Pulmonary Ureaplasma colonisation is strongly linked to 
preterm delivery and the question remains if this pulmonary colonisation is an 
independent risk factor for CLD. The consistent observation in many publications is 
the difficulty in interpreting evidence from available studies due to small sample 
sizes, vastly different inclusion criteria, different methods of sampling and testing, 
and different diagnostic criteria for various outcomes including CLD. A 1995 meta­
analysis included 1479 babies from 17 studies (Wang et al., 1995) and reported a 
significant association between CLD diagnosed at 28 days of life and Ureaplasma 
colonisation with an overall relative risk of 1.72 (95% confidence intervals 1.5-1.96). 
Data on CLD at 36 weeks corrected gestation were not available.
Since that review, several further studies have been completed, including one by 
Kotecha et al (Kotecha et al., 2004) who sought Ureaplasma in BAL fluid from 17 
preterm neonates without clinical or laboratory evidence of infection in either the 
mother or infant and reported that of 6 infants who were positive for U. urealyticum, 5 
developed CLD whereas only 4 of the 11 babies without Ureaplasma developed 
CLD. In a cohort of 126 preterm deliveries, Kafetzis et al (Kafetzis et al., 2004) found 
a significant increase in CLD as well as mortality among Ureaplasma colonised 
infants and vanWaarde et al (van Waarde et al., 1997) found that Ureaplasma was 
significantly associated with both CLD and lower gestational age but logistic 
regression analysis failed to show a correlation between Ureaplasma colonisation and 
CLD. In 2005, a further meta-analysis (Schelonka et al., 2005) including 23 studies 
and 2216 babies showed an odds ratio of 2.83 (95% confidence intervals 2.29-3.51) 
for the relationship between the presence of Ureaplasma and CLD diagnosed at 28 
days of life. There were 751 babies for whom data were available regarding CLD at 
36 weeks’ gestation, again this showed a significant association.
More recent studies continue to fuel the controversy: Pandey et al (Pandey et al.,
2007) reported no role for Ureaplasma in the development of CLD in a group of 100 
babies of <34 weeks’ gestation. Goldenberg et al (Goldenberg et al., 2008) studied 
351 mother/baby pairs at 23-32 weeks, where the umbilical cord blood showed 
evidence of Ureaplasma or M. hominis and showed a probable association of U.
28
urealyticum with the development of CLD. In other studies, U. urealyticum colonised 
infants have shown a non-significant trend towards higher neonatal morbidity (longer 
ventilation, longer hospital stay, younger gestational age, higher incidence of CLD 
and more late onset sepsis) (Kirchner et al., 2007). The role of Ureaplasma in CLD is 
further complicated by the identification of different patterns of Ureaplasma 
colonisation in the preterm neonate (persistently positive, early transient and late 
acquisition) which may also impact on the likelihood of a colonised neonate 
developing CLD, with only the “persistently positive” group showing a higher rate of 
CLD (Castro-Alcaraz et al., 2002).
If Ureaplasma has a causative role in the pathogenesis of CLD, it would be 
reasonable to expect the incidence of CLD to decrease by eradicating its colonisation 
with antibiotic treatment. Once again the literature contains a number of small sample 
size studies which vary in the time of commencement of treatment, type and duration 
of antibiotic therapy and many lack documentation of eradication of the organism at 
the end of the course of treatment. However, only two randomised controlled trials 
have been included in the Cochrane review by Mabanta et al (Mabanta et al., 2003) 
examining studies investigating the treatment of Ureaplasma to decrease the rate of 
CLD. In the first study, Lyon et al (Lyon et al., 1998) treated infants prior to knowing 
their colonisation status and showed no change in the number of infants who 
developed CLD. In the second study, Jonsson et al (Jonsson et al., 1998) treated only 
those infants with positive cultures from endotracheal or nasopharyngeal samples and 
were able to show a reduction in colonisation but not CLD. Together these two 
studies included only 37 colonised patients and there was no significant reduction in 
CLD with treatment in either study — disparate study designs prevented the results 
from being combined in the meta-analysis.
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1.6 Inflammation
There is now a wealth of evidence that lung inflammation, caused initially by the 
innate immune response, is a central key participant in the pathophysiology of CLD 
(Welty, 2005), with all the known risk factors for CLD being able to give rise to 
inflammation. CLD appears to begin as an acute lung injury which then initiates a 
series of inflammatory responses. This in turn evolves into the typical clinical and 
pathological features of CLD (Davis et al., 1991) but how the risk factors impact at 
the cellular and molecular level is not well described.
1.6.1 The process of inflammation
Inflammation is important to (Janeway et al., 2004):
- deliver effector molecules and cells to the site of infection or wounding and 
augment the killing of micro-organisms,
provide a physical barrier to the spread of infection by causing microvascular 
coagulation,
- promote the repair of injured tissue.
Inflammation is characterised by:
an inductive or initiation phase (Han and Ulevitch, 2005) characterised by 
neutrophil infiltration followed by 
a sustained response and then
- resolution (Han and Ulevitch, 2005) or failure of resolution, leading to 
chronicity of inflammation.
1.6.1.1 Initiation
Any harmful tissue event (infection, trauma, anoxia) is perceived mainly by tissue 
resident macrophages and monocytes which secrete cytokines (IL-1 and TNF) which 
act to stimulate other cells to produce a second wave of cytokines (IL-1, IL-2, IL-6 
and IL- 8) which serve to amplify the inflammatory response as well as to recruit 
inflammatory cells (neutrophils, monocytes, macrophages) and systems (complement, 
coagulation cascade).
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a) The neutrophil
Figure 3.42 Graphs showing ratio o f neutrophils to macrophages for individual babies 
with 3 or more BAL samples.
Neutrophils are the most numerous of the granulocytes and are the key effector cell of 
the innate immune system (Sabroe et al., 2005). They are produced in the bone 
marrow from myeloid stem cells and have a relatively short lifespan in the circulation 
of 8-20 hours (Akgul and Edwards, 2003). Neutrophils are abundant in the blood but 
are not present in normal healthy tissue (Janeway et al., 2004). Healthy adult BAL 
fluid has <10% neutrophils (Committee, 1990). They are the first cells to arrive at a 
site of inflammation (Savill et al., 1989b, Haslett, 1999) and their survival time 
increases significantly in tissues where they are exposed to pro-inflammatory signals 
(Akgul and Edwards, 2003).
Merritt et al (Merritt et al., 1983) first described the cellular changes in tracheal 
aspirate fluid (TAF) in the development of CLD. They examined the TAF of 26 
ventilated infants and identified neutrophils as the predominant cell type in RDS.
They found significantly higher cell counts in TAF from preterm infants with RDS, 
and particularly in the infants who went on to develop CLD, than in term infants 
ventilated for non-respiratory reasons. By day three of life infants who would develop 
CLD had neutrophil counts a hundred times that of the term controls and ten times
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that of preterm infants whose RDS resolved. It was also found that the cell count 
started to fall after three days in infants whose RDS resolved but elevated neutrophil 
counts persisted for weeks in those getting CLD (Amon et al., 1993, Kotecha et al.,
1995).
A study by Amon et al (Amon et al., 1993) showed that infants who progressed to 
CLD had significantly more neutrophils in BAL on day 5 and 7 than infants whose 
RDS resolved. They identified that the persistence of high neutrophil counts at day 7 
was a risk factor for the development of CLD. More recently Kotecha et al confirmed 
that airway neutrophilia is associated with the development of CLD by studying BAL 
fluid from 32 babies for up to 21 days (134 BAL samples) and 9 term controls 
(Kotecha et al., 1995). They found higher mean cell counts in CLD babies at day 10, 
mainly due to an increase in neutrophil count.
b) Initiation of inflammation by neutrophils
Neutrophils gain access to the interstitium of the lung by migrating from the blood. 
This migration is facilitated by interaction between adhesion molecules on the 
leucocyte surface and endothelial cells. L-selectin on leucocytes and P- and E- 
selectins on endothelial cells mediate neutrophil rolling along the endothelium. Firm 
adhesion and transmigration are mediated by p 2 integrins and intercellular adhesion 
molecules (ICAM).
ICAM-1 is a glycoprotein that facilitates cell-to-cell contact. It is expressed in 
response to IL-1 stimulation. It binds to CD1 lb/CD 18 on neutrophils and helps to 
regulate neutrophil diapedesis. Increased soluble ICAM-1 has been found in TAF of 
infants with early CLD (Kojima et al., 1993) and a role for ICAM-1 has been 
suggested in oxygen-induced lung injury.
CD1 lb/CD 18 and ICAM are increased in neutrophils from BAL fluid of babies who 
develop CLD (Kotecha et al., 1998, Kotecha et al., 1995). Soluble L-selectin increases 
and remains persistently high in CLD babies -  this may reflect leucocyte traffic in the 
lung i.e. continued neutrophil migration in babies developing CLD (Kotecha et al.,
1998).
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Tissue transmigration may serve to activate neutrophils and also impart anti-apoptotic 
signals, although cells retain their susceptibility to Fas (Sexton and Walsh, 2005).
Once activated the neutrophils are able to initiate a cascade of defence mechanisms.
c) Toll-like Receptors
Toll-like receptors (TLR) are a family of pattern recognition receptors (Dabbagh and 
Lewis, 2003) of which at least 10 have been described (Sabroe et al., 2005, Stevens,
2005). TLR initiate host defence in response to unique molecular patterns presented 
by invading organisms (Strieter et al., 2003, Dabbagh and Lewis, 2003) and are also 
able to respond to certain host molecules (hyaluronan, heat shock proteins, 
fibronectin, fibrinogen, surfactant protein-A (SP-A), necrotic cell products and 
reactive oxygen species (ROS)) (Dabbagh and Lewis, 2003, Chaudhuri et al., 2005, 
Qureshi et al., 2006). TLR are activated via TIRAP (also called TIR) (Toll-IL-1- 
receptor domain containing adapter protein) and MyD88 which in turn lead to NF-kB 
activation and the expression of cytokines (TNF-a, IL-1 (3, IL-6, IL-8) which amplify 
the inflammatory response (Stevens, 2005, Forster-Waldl et al., 2005, Dabbagh and 
Lewis, 2003, Aliprantis et al., 1999). TLR are also important in the formation of the 
adaptive immune response via dendritic cells (Dabbagh and Lewis, 2003).
Neutrophils express all the TLR except TLR 3 (Sabroe et al., 2005). TLR 2 and 4 
regulate important neutrophil functions including (Sabroe et al., 2005):
- recruitment (CD1 lb/CD 18 upregulation, L-selectin shedding, adhesion) 
migration and chemotaxis
activation (increased reactive oxygen species (ROS) production, increased 
degranulation, increased phagocytosis, cytokine generation, NF-kB activation) 
survival (inhibition of apoptosis via NF-kB and other molecules).
Neutrophils have TLR 2 and 4 at lower levels than monocytes (Sabroe et al., 2005). 
TLR 2 but not TLR 4 expression is increased on the neutrophil surface in the presence 
of pro-inflammatory cytokines (Kurt-Jones et al., 2002). Bacterial lipoproteins can 
mediate apoptosis via TLR 2 in monocytes and epithelial cells (Aliprantis et al., 1999)
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but there is conflicting evidence in neutrophils (Power et al., 2004, Sabroe et al.,
2003, Lotz et al., 2004, Aleman et al., 2004).
TLR 4 is the principal lipopolysaccharide (LPS) receptor and is known to reduce 
apoptosis (programmed cell death) in lung epithelial cells in response to hyperoxia 
(Qureshi et al., 2006). CD 14, MD-2 and LBP (LPS binding protein) are involved in 
the presentation of LPS to TLR 4 (Chaudhuri et al., 2005). There is less TLR 4 on 
preterm monocytes than term or adult monocytes thus there may be decreased 
cytokine production from monocytes after LPS exposure in preterm infants (Forster- 
Waldl et al., 2005). Genetically impaired TLR 4 function has been described in 
association with chronic inflammatory conditions, like inflammatory bowel disease in 
adults (Sabroe et al., 2005).
The TLR are an important part of the innate immune response, however TLR function 
and expression in neonatal neutrophils is not well described. The role of TLR in the 
pathogenesis of CLD is unknown.
1.6.1.2 Sustained Response
Once in the tissues, neutrophils recognise and engulf micro-organisms by 
phagocytosis. Once inside the neutrophil, organisms are killed and degraded by the 
production and release of ROS and granule proteins which are delivered to 
phagosomes and the extra-cellular environment.
The “respiratory burst” in neutrophils is usually triggered by phagocytosis and 
generates ROS. Superoxide is generated via NADPH oxidase and converted by 
superoxide dismutase (SOD) to H2O2 . H2O2 is in turn converted to hydroxyl radicals 
and hypochlorous acid (Janeway et al., 2004). These reactive oxygen species are 
directly cytotoxic and are effective in neutralising invading micro-organisms but are 
injurious to tissues if released outside of the neutrophil.
Neutrophils store anti-microbial, cytotoxic and proteolytic digestive proteins in their 
cytoplasmic granules (Cheah et al., 2005a). They contain four different granule types, 
namely azurophil, specific, gelatinase and secretory granules (Moraes et al., 2006),
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with each granule containing a number of different proteins. The granule contents are 
released upon phagocytosis or when neutrophils disintegrate. Similarly to ROS, 
uncontrolled release of granule contents may also cause injury to surrounding tissues.
a) Chemokines and cytokines
Cytokines are a category of small molecules that are used extensively in cellular 
communication. The term cytokine encompasses a large and diverse family of 
polypeptide regulators that are produced by many different cell types and usually 
circulate in picomolar concentrations that can increase up to 1,000-fold during trauma 
or infection.
Pro-inflammatory cytokines may be elevated in newborns due to fetal exposure to 
maternal inflammatory mediators, postnatal infection or due to mediator release by 
ventilator-induced injury (Gitto et al., 2001). Activated neutrophils are among the 
many different cell types that are able to synthesise various inflammatory mediators 
including chemokines and cytokines to recruit and regulate responses of other effector 
cells including macrophages, T-cells and other neutrophils (Theilgaard-Monch et al., 
2004).
The cytokine response in neonatal lungs may be immature or simply different to that 
seen in adults (Gitto et al., 2001). A number of studies have examined which 
cytokines are responsible for the cellular influx seen in RDS and it has been shown 
that airway secretions of infants developing CLD, in particular, have numerous 
chemotactic factors for neutrophil and macrophage recruitment (including C5a 
(complement component 5a), LTB4 (leukotriene B4), TNF-a, IL-8, PAF (platelet 
activating factor), ICAM-1, fibronectin and elastin degradation products (Lecart et al., 
2000, Kotecha et al., 1995, Kotecha, 1996)).
Various cytokines and chemokines have been studied in CLD in both human infants 
and in animal models of the disease. While animal models are useful in that 
experimental conditions can be very tightly controlled and regulated, results cannot 
always be directly extrapolated to human neonatal populations. In previous years, the 
analysis of inflammatory mediators in BAL fluid has been limited by the types of
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assay available, however newer multiplexed assays are becoming more common and 
are likely to be used extensively in the analysis of multiple mediators in small volume 
samples such as BAL fluid in the future.
Groneck et al showed that although multiple pro-inflammatory and chemotactic 
factors are present in the airspaces of ventilated preterm infants, they are present in 
higher concentration in those who develop CLD (Groneck and Speer, 1995). They had 
already established (Groneck et al., 1994) by examining the TAF from 59 ventilated 
infants that the supernatants from BAL samples of infants who developed CLD were 
significantly more chemotactic to adult peripheral blood neutrophils than those of 
infants who did not develop CLD. As with the cell count, the chemotactic activity in 
the supernatants increased in both groups from day one until day five before falling 
again in infants whose RDS resolved while staying high in infants who developed 
CLD.
i) Chemokines
IL-8 is probably one of the most important chemoattractants for neutrophils and the 
most extensively investigated in preterm infants (Groneck et al., 2001, Truog et al., 
2007, Munshi et al., 1997, D'Angio et al., 2002, Baier et al., 2002). It is produced by 
alveolar macrophages, neutrophils, fibroblasts, type II epithelial cells and endothelial 
cells and particularly by stimulated monocytes under the influence of TNF-a or LPS 
(Groneck et al., 1994). The IL-8 receptor (CD 128) is expressed in many different cell 
types. IL-8 is uniquely able to specifically activate neutrophils where it causes the 
release of enzymes from granules, enhances the metabolism of reactive oxygen 
species and increases chemotaxis and the expression of adhesion molecules.
IL-8 concentrations were shown to be up to 200 times higher in TAF than plasma and 
further increased in infants who develop CLD when compared to infants whose RDS 
resolves (Groneck et al., 1994, Kotecha et al., 1995, Jonsson et al., 1997).
Observations of the timing of the peak concentration of IL-8 are not consistent. IL-8 
was significantly elevated on first day of life (immediately preceding the marked peak 
in neutrophil count) in babies who progressed to CLD in one study (Munshi et al.,
1997) but in another study (Kotecha et al., 1995) IL-8 was elevated around day 10
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coinciding with the neutrophil peak. These differences were attributed to differences 
in sampling techniques between the two studies and possible clinical differences 
between the patient groups such as the presence of infection.
MCP-1 (monocyte chemotactic protein-1) belongs to the family of chemotactic 
cytokines known as chemokines. MCP-1 is expressed by monocytes, vascular 
endothelial cells, smooth muscle cells, and human type II pneumocytes under the 
influence of LPS and IL-1. MCP-1 is chemotactic for monocytes. It regulates the 
expression of certain cell surface antigens (like CD1 lb) and the expression of other 
cytokines (IL-1 and IL-6)
MCP-1 was measured in serial TAF samples from 56 preterm newborns by Baier et al 
(Baier et al., 2002, Baier et al., 2001) who noted that MCP-1 rose over the first week 
of life and the highest levels were found in infants who developed CLD. MCP-1 has 
been found to be elevated in airway secretions where Ureaplasma urealyticum has 
been detected (Baier et al., 2001).
The two MIP (macrophage inflammatory protein) proteins are the major factors 
produced by macrophages following their stimulation with bacterial endotoxins. Both 
proteins are involved in activation of granulocytes. Both forms of MIP-1 stimulate the 
production of reactive oxygen species in neutrophils and the release of lysosomal 
enzymes. They also induce the synthesis of other pro-inflammatory cytokines such as 
IL-1, IL-6 and TNF. M IP-la stimulates TNF secretion by macrophages, whereas 
MIP-lp antagonizes this effect.
The two forms of MIP-1 enhance the activities of GM-CSF and promote the growth 
of mature haematopoietic progenitor cells. M IP-la (but not MIP-ip) also acts as an 
inhibitor of the proliferation of immature haematopoietic stem cells and has therefore 
been called “stem cell inhibitor”. M IP-la and MIP-ip have been found to be elevated 
in preterm infants, particularly those developing CLD (Baier et al., 2004) and those 
exposed to hyperoxic conditions (D’Angio et al., 1998).
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ii) Cytokines
As well as chemotactic cytokines, pro-inflammatory cytokines such as IL-ip, IL-6 
and TNF-a are elevated in the lung lavage fluid of infants developing CLD and have 
been well studied (Jonsson et al., 1997, Kotecha, 1996, Patterson et al., 1998).
ILl-p is the predominant form of IL-1 in humans. It is produced by activated 
macrophages and by peripheral blood neutrophils, however monocytes are the main 
source of secreted IL-1, particularly in response to other cytokines (TNF-a and 
interferons) and invading pathogens. Many other cell types, including endothelial 
cells, fibroblasts, smooth muscle cells and lymphocytes also produce IL-1. It has a 
wide range of biological activities, both locally and systemically. IL-1 helps to initiate 
and modify the inflammatory cascade by promoting the chemotaxis, adhesion and 
activation of neutrophils and increasing secretion of inflammatory proteins such as 
proteases. IL-1 synergises with GM-CSF in promoting macrophage colony growth.
Increased concentrations of IL-1 p in tracheal aspirates are associated with the need for 
mechanical ventilation and supplemental oxygen as seen in CLD (Kotecha, 1996, 
Cayabyab et al., 2003). IL-1 p has the ability to prolong survival of neutrophils by 
reducing apoptosis and this may be its key role in the development of CLD (Colotta et 
al., 1992). IL-1 p has also been implicated in the disruption of postnatal lung 
morphology and growth in mice (Bry et al., 2007) and this may be relevant to the 
altered lung structure seen in infants with “new” CLD.
IL-6 is a pleiotropic cytokine and is one of the major physiological mediators of acute 
phase reactions. It has a role in upregulation of the inflammatory response but may 
also have anti-inflammatory effects via inhibition of TNF-a production in 
macrophages (Aderka et al., 1989). It is produced by many different cell types. The 
main sources in vivo are stimulated monocytes and endothelial cells but macrophages 
(including alveolar macrophages), lymphocytes, smooth muscle cells and eosinophils 
can also produce IL-6 after stimulation by IL-1, LPS and TNF among others. IL-6 can 
also stimulate or inhibit its own synthesis, depending upon the cell type. Intratracheal 
IL-6 has been shown to block LPS induced lung injury in rabbits (Ulich et al., 1991).
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IL-6 was significantly elevated on day 3 and 5 in babies who developed CLD (Munshi 
et al., 1997). Bagchi et al (Bagchi et al., 1994) studied 30 infants of <33 weeks’ 
gestation who were ventilated for RDS along with 10 controls ventilated for non- 
respiratory reasons (cardiac or gastrointestinal surgery) and found IL-6 activity was 
15 fold higher on day 1 in infants who would go on to develop CLD than in controls 
and 6.6 fold higher in babies with RDS compared to controls at the same time point. 
IL-6 activity remained elevated for the first 2 weeks of life in babies who developed 
CLD before returning to similar levels to controls by day 28. Jonsson et al suggested 
that elevated IL-6 levels may be predictive for the development of CLD (Jonsson et 
al., 1997).
TNF is a member of the TNF ligand superfamily. There are two molecular species of 
TNF, known as TNF-a (cachectin) and TNF-P (lymphotoxin), which generally 
display similar biological activities in vitro, although TNF-P is often less potent or has 
partial agonist activity.
TNF-a is derived mainly from macrophages and monocytes following stimulation by 
LPS, interferons, IL-2, GM-CSF, immune complexes or platelet activating factor. It is 
a potent chemoattractant for neutrophils and also enhances their adherence, 
phagocytic and cytotoxic abilities (Strieter et al., 2003). It activates NF-kB and can 
prolong the survival of neutrophils by reducing apoptosis (Colotta et al., 1992). It 
stimulates phagocytosis in macrophages and modulates the expression of other 
cytokines, including IL-1 and IL-6 (Bagchi et al., 1994). TNF-a can be found on 
monocytes and T-cells after cell activation where it mediates cell destruction by direct 
cell-to-cell contacts. It is also a potent promoter of angiogenesis.
TNF-a was undetectable in controls and low in infants with RDS but peaked at day 14 
in babies who progressed to CLD (Bagchi et al., 1994). TNF-a was elevated in BAL 
samples taken early in the ventilatory course of preterm infants with the worst 
pulmonary outcomes in one study (Mahieu et al., 2005).
IL-10 is predominantly an anti-inflammatory cytokine which inhibits production of 
pro-inflammatory cytokines like TNF-a, IL-lp, IL-6, IL-8, GM-CSF and G-CSF from 
monocytes and macrophages (Liles et al., 1996, de Waal Malefyt et al., 1991,
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Fiorentino et al., 1991) and is known to promote neutrophil apoptosis (Cox, 1996). It 
also inhibits antigen presentation and macrophage killing. It is produced by stimulated 
lymphocytes and by monocytes following cell activation by LPS.
IL-10 may be developmentally regulated, as shown by IL-10 being undetectable in 17 
preterm ventilated babies but expressed in term infants ventilated for persistent 
pulmonary hypertension or meconium aspiration syndrome (Whicher and Evans,
1990, Spits and de Waal Malefyt, 1992, Jones et al., 1996). IL-10 was lacking from 
the lung secretions of preterm infants in one study which may help to explain the 
continuing inflammatory process in these infants (Jones et al., 1996). In two other 
studies, IL-10 was detected in the lungs of preterm infants but was lower in infants 
who developed CLD or showed an early increase and then a fall to lower levels than 
in infants with RDS (McColm et al., 2000, Beresford and Shaw, 2002).
G-CSF is secreted by monocytes, macrophages and neutrophils after cell activation. 
The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, IL-1 and GM- 
CSF. It stimulates the proliferation and differentiation of granulocytes and is able to 
activate neutrophils. G-CSF synergises with other cytokines, including GM-CSF. The 
G-CSF receptor (CD114) is expressed on all granulocytes as well as on endothelial 
cells.
GM-CSF is vital for the proliferation and differentiation of progenitors of 
granulocytes and macrophages. It enhances microbicidal activity, oxidative 
metabolism and phagocytotic activity of neutrophils and macrophages. GM-CSF 
receptors are expressed on the cell surface of myeloid cells and also on non- 
haematopoietic cells such as endothelial cells.
Neither G-CSF nor GM-CSF has been extensively studied in the preterm infant 
population but both have been detected in BAL fluid, with increasing levels recorded 
in infants developing CLD (Papoff et al., 2001).
Vascular Endothelial Growth Factor (VEGF) is a growth factor which has a role in 
the control of angiogenesis and thus plays a crucial role in alveolar development 
because of the very close relationship between vascular development and the 
development of the lung. It is produced by a plethora of cell types, including
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macrophages and lung epithelial cells. Its receptor is expressed on vascular 
endothelial cells. VEGF stimulates the proliferation of vascular endothelial cells and 
significantly influences vascular permeability. VEGF plays an important role in 
neovascularisation under physiological conditions and its synthesis is induced by 
hypoxia. It is also a potent chemoattractant for monocytes and is able to induce the 
synthesis of metalloproteinases which degrade interstitial collagen.
A number of investigators have found reduced VEGF levels in animal models of CLD 
(Bland et al., 2007, Tambunting et al., 2005). Lassus et al found a reduction in VEGF 
in human infants who developed CLD infants (Lassus et al., 1999) whereas Currie et 
al (Currie et al., 2001) found no difference between term and preterm infants with or 
without CLD. It has also been proposed that either elevated or decreased VEGF levels 
can mediate lung injury and emphysematous changes (Voelkel et al., 2006).
TGF-p is a protein which controls proliferation and cellular differentiation in many 
cell types and also acts as an inducer of apoptosis. TGF-p exists in three isoforms, 
namely TGF-pi, TGF-p2 and TGF-p3. Immunocytochemistry studies have localised 
TGF-p to alveolar macrophages obtained by BAL (Kotecha et al., 1996a).
In the past, TGF-p measurement in neonatal lung has produced variable results, 
possibly because of difficulty in finding an appropriate assay. Elevated levels of TGF- 
P have been shown in the presence of chorioamnionitis and in developing CLD 
(Kotecha et al., 1996a, Ichiba et al., 2009, Jonsson et al., 2000). TGF-P levels were 
also found to correlate with the duration of oxygen administration (Ichiba et al.,
2009). However, using two other methods, TGF-P levels were shown to be decreased 
in a similar population of preterm infants developing CLD (Choi et al., 2008) 
compared to controls.
b) Proteases
Human neutrophil elastase is the most abundant of the proteases in the lung and the 
vast majority is produced by neutrophils (Lee and Downey, 2001). Elastase is a serine 
protease and is stored in the intra-cytoplasmic azurophilic granules of neutrophils, 
from where it can be released at the time of neutrophil activation. In addition to its
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bactericidal role, elastase may also have an important role as a chemotactic agent, 
being capable of induction of IL-8 (Nakamura et al., 1992) and leukotriene B4 
(Hubbard et al., 1991) production.
Elastase is capable of digesting elastin, an important structural component of lung 
tissue. Elastin is relatively conserved throughout life and once damaged or destroyed 
is difficult to replace (Bigatel et al., 1999), and repair to elastin networks often results 
in malformed and dysfunctional elastin filaments (Finlay et al., 1996).
Neutrophil elastase is also capable of digesting almost all components of the 
extracellular matrix including collagens types I-IV, fibronectin, laminin and 
proteoglycans. The tissue damage that an excess of uninhibited protease activity can 
cause has been demonstrated in animal models (Lucey et al., 1985).
In the pre-surfactant era high elastase activity was detected in the majority of lung 
lavage samples from infants who developed CLD (Merritt et al., 1983, Ogden et al., 
1984, Watterberg et al., 1994). More recently, a number of studies have found elastase 
in only a minority of samples from the lungs of preterm infants and questioned the 
relationship of elastase to the development of CLD (Speer et al., 1993, Groneck et al., 
1994, Sveger et al., 2002, Sluis et al., 1994).
Matrix metalloproteinases (MMP) are proteases which are important in normal lung 
development (Greenlee et al., 2007) when appropriately controlled by specific 
protease inhibitors but their unregulated activity, particularly MMP-8 and 9, may be 
associated with the development of CLD (Sweet et al., 2004, Ekekezie et al., 2004, 
Cederqvist et al., 2001).
1.6.1.3 Resolution/Chronicity
Chronic inflammation is a continuous interaction between pro-inflammatory 
mechanisms which act to cause tissue injury and those mechanisms which act to 
promote resolution of inflammation. It is possible that either uncontrolled pro- 
inflammatory events, resulting in ongoing initiation of inflammation and/or continued
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infiltration and recruitment of neutrophils, or inefficient resolution processes result in 
chronic inflammation (Haslett, 1999).
Neutrophil contents, like elastase, described above, are not only histotoxic but are also 
able to amplify the inflammatory response by cleaving matrix proteins (Haslett, 1999, 
Savill et al., 1989b). The indiscriminate release of these contents as a consequence of 
neutrophil lysis can damage host tissue and lead to persistence of the inflammatory 
response (Haslett et al., 1994). Thus the fate of neutrophils is central to the resolution 
of inflammation (Savill et al., 1989a). Neutrophil persistence characterises the early 
stages of chronic inflammation (Koenig et al., 2005). Failure to achieve removal of 
neutrophils and their toxic products from a site of inflammation is associated with 
chronic/persistent inflammation (Whyte et al., 1993). Apoptosis, or programmed cell 
death, is critical to the resolution of inflammation as it promotes the removal of effete 
neutrophils by the reticuloendothelial system.
The persistence of neutrophil infiltration in babies with RDS is strongly associated 
with the development of CLD (Ogden et al., 1984). Grigg et al showed that 
neutrophils are cleared by apoptosis in RDS (Grigg et al., 1991), leading to the 
hypothesis that preterm babies are more at risk of lung injury because of reduced, 
delayed or impaired neutrophil apoptosis (Kotecha et al., 2003, Oei et al., 2003). 
Inhibition of apoptosis could result in more viable neutrophils persisting in the tissues 
or more necrotic neutrophils releasing their toxic contents into tissues and thus 
causing more lung injury (Matute-Bello et al., 1997).
a) Resolution
The usual outcome of inflammation is resolution and repair of damaged tissue rather 
than persistent or chronic inflammation and continued tissue damage (Serhan and 
Savill, 2005). It is unknown why some stimuli produce inflammation which 
completely resolves and others provoke a persistent reaction with tissue destruction 
and scarring or fibrosis (Haslett, 1999).
The resolution of inflammation requires: (Haslett, 1999)
- removal of the inflammatory stimulus
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removal and/or destruction of pro-inflammatory mediators 
cessation of granulocyte migration
restoration of normal vascular permeability and removal of extravasated fluid
stop granulocytes secreting pro-inflammatory and histotoxic substances
arrival of monocytes and their differentiation to macrophages
removal of debris and cells (apoptosis)
final removal of monocytes and macrophages
repair of injured tissue
In this process there are multiple points at which dysregulation may occur (Han and 
Ulevitch, 2005).
During the initial phase of resolution of the inflammatory response, prostaglandins are 
generated which are essential for control of blood flow and blood vessel dilatation for 
leucocytes to adhere and undergo diapedesis. The generation of arachidonic acid 
metabolites (e.g. lipoxins) retard entry of new neutrophils to the site of inflammation, 
reduce vascular permeability, promote non-phlogistic (not causing 
fever/inflammation) infiltration of monocytes and stimulate macrophages to ingest 
and clear apoptotic neutrophils (Serhan and Savill, 2005).
In order to resolve inflammation, neutrophil activity must be curtailed and senescent 
neutrophils disposed of so healing can occur (Oei et al., 2003). In healthy systems 
neutrophils undergo apoptosis (programmed cell death) and rapid clearance which has 
the effect of limiting tissue injury and promoting resolution of inflammation (Haslett,
1999). Cells which are not cleared by phagocytes undergo necrosis and disintegrate, 
releasing their toxic contents, which serve as a further pro-inflammatory stimulus 
(Savill et al., 2002).
Activated neutrophils initiate an apoptotic programme which facilitates resolution of 
inflammation and prevents tissue damage which would be caused by necrotic cell 
lysis (Kobayashi et al., 2003a, Kobayashi et al., 2003b). Following the initial pro- 
inflammatory response, a further transcriptional response occurs which promotes 
apoptosis. As part of this, upregulation of genes for pro-apoptotic proteins (TNF-a,
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TRAIL and their receptors, caspase 1, Bax and TLR 2 signalling pathway 
components) and downregulation of receptors for inflammatory mediators occurs.
1.7 Apoptosis
The term apoptosis was coined in 1972 by Kerr et al (Kerr et al., 1972) and is derived 
from ancient Greek, meaning “falling, as of leaves from a tree”. It was originally 
defined to mean a physiological or programmed form of cell death, affecting cells 
scattered throughout a tissue, which does not induce inflammation and allows for 
clearance of cells with minimal local injury.
Apoptosis is different to necrosis, which is defined as accidental cell death due to the 
effect of, for example, toxins, hypoxia or extremes of temperature. Primary necrosis is 
a passive process and tends to affect large numbers of neighbouring cells. It is 
characterised by swelling and bursting of the cell with release of cellular contents and 
is a pro-inflammatory stimulus in most tissues. Secondary necrosis is the 
disintegration of cells which have originally undergone apoptosis but have not been 
ingested or cleared by phagocytes possibly because the load of apoptotic cells exceeds 
the capacity for clearance by phagocytes (Savill et al., 2002).
Apoptosis pathways are broadly similar in phylogenetically diverse organisms which 
suggests that apoptosis and the phagocytosis of apoptotic cells are important 
regulatory mechanisms which have been conserved through evolution (Giles et al., 
2000). Apoptosis is important in a variety of biological systems for normal cell 
turnover and maintenance of cellular homeostasis, immune system regulation and the 
resolution of inflammation, embryonic development and tissue atrophy and 
remodelling, among others. Apoptosis is normally involved in the structural 
maturation of the lung, particularly in reducing the number of fibroblasts and type II 
epithelial cells in thinning of the alveolar septae in animal studies (Schittny et al.,
1998).
Apoptosis is a complex process, influenced by the cell’s internal genetic code and by 
its external environment and requires the co-ordinated action of multiple sub- 
programmes to be effectively carried out (Hengartner, 2000). Inappropriate or
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dysregulated apoptosis is implicated in pathologies such as Alzheimer’s disease, 
Huntingdon’s disease, ischaemia-reperfusion injury, autoimmune disorders and some 
cancers (Cohen, 1997).
1.7.1 Neutrophil apoptosis
Neutrophil apoptosis has a major regulatory role in many biological processes, 
including the inflammatory response (Matute-Bello et al., 1997). Apoptosis is 
important in the resolution of inflammation as it leads to functional downregulation 
and clearance of neutrophils. Neutrophils have a constitutive apoptosis programme 
which is hastened during activation of the cell to ensure clearance from sites of 
inflammation before they become necrotic and release their toxic contents (Cheah et 
al., 2005a).
Neutrophil apoptosis is characterised by stereotypical cell morphological changes 
(Savill et al., 1989b, Cohen, 1997) which are not seen in circulating neutrophils 
(Wyllie et al., 1980):
condensation and fragmentation of nuclear chromatin and nucleolar 
prominence,
compaction of cytoplasmic organelles, swelling of the endoplasmic reticulum 
and cytoplasmic vacuolation, 
a decrease in cell volume 
- and eventually alterations to the plasma membrane resulting in recognition by 
phagocytes and phagocytosis.
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Figure 1.3 Apoptotic neutrophils showing condensation o f the nucleus, cytoplasmic 
vacuolation and decrease in cell volume (Pitrak, 1997).
During apoptosis the cell membrane and organelles remain intact and there is no 
leakage of cell contents. The neutrophil loses the ability to degranulate and the ability 
to phagocytose (Haslett, 1999, Savill et al., 1989b). Neutrophil nuclear chromatin 
becomes fragmented in a characteristic intemucleosomal pattern, where each 
fragment is a multiple of 180bp. This is thought to represent endogenous 
endonuclease activation. (Savill et al., 1989b)
Neutrophils which have been aged in culture show the characteristic changes of 
apoptosis but still exclude trypan blue and show little spontaneous release of 
myeloperoxidase (MPO) for up to 24 hours in culture. Thereafter more cells fail to 
exclude trypan blue, balloon and disintegrate -  undergoing necrosis and releasing 
their toxic contents (Savill et al., 1989b).
1.7.2 Mechanism/process of apoptosis
Two main apoptosis pathways are thought to occur in neutrophils (Akgul and 
Edwards, 2003):
- “extrinsic” or “death receptor” pathways (via Fas, TRAIL and TNF receptors) 
which directly activate the caspase cascade via caspase 8 
“intrinsic apoptosis pathway” which involves mitochondria and the Bcl2 
family of genes and activates the caspase cascade via caspase 9.
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1.7.2.1 Extrinsic or death receptor pathways
a) Fas
The Fas/FasL pathway is important for apoptosis in various cell types (Liles et al., 
1996), including neutrophils.
Fas (CD95/Apo-l) is a cell surface molecule (type 1 membrane protein) belonging to 
the TNF/nerve growth factor receptor family (Hanna et al., 2005, Nagata and 
Golstein, 1995). There is variable but wide expression of Fas in different tissues 
(Nagata and Golstein, 1995) including neutrophils (Hanna et al., 2005, Liles et al.,
1996) which express more Fas than other leucocytes (Liles et al., 1996).
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Fas ligand (FasL/CD95L) is a type 2 membrane protein with a homotrimeric structure 
(Nagata and Golstein, 1995). Constitutive expression of FasL is relatively limited 
(Akgul and Edwards, 2003, Hanna et al., 2005). Monocytes/ and macrophages are 
known to produce and express high levels of FasL (Kiener et al., 1997) and can 
induce Fas mediated neutrophil death (Brown and Savill, 1999). There are conflicting 
reports of FasL expression on human neutrophils (Serrao et al., 2001, Renshaw et al.,
2000, Brown and Savill, 1999, Hanna et al., 2005, Liles et al., 1996) probably as a 
result of differing neutrophil processing techniques, culture conditions, cultures being 
“contaminated” with monocytes and antibody detection differences.
Soluble FasL (sFasL) is derived from cleavage of membrane bound FasL by matrix 
metalloproteinases. Neutrophils undergoing apoptosis may liberate sFasL and thus 
weakly induce apoptosis of neighbouring cells in a paracrine manner (Serrao et al.,
2001, Liles et al., 1996). Soluble FasL is able to induce a profound chemotactic 
response in neutrophils (Ottonello et al., 1999, Seino et al., 1998).
FasL binds to the Fas “death receptor” and causes the target cell to undergo apoptosis. 
In order to trigger apoptosis, Fas needs to be cross-linked (Nagata and Golstein,
1995). Cross-linking of Fas by trimeric FasL results in clustering of intracellular death 
domains and the recruitment of adaptor proteins (Akgul and Edwards, 2003). The 
main adaptor protein in this pathway is FADD (Fas-associated death domain- 
containing protein). Interaction of Fas with FasL (or anti-Fas antibody) activates the 
FADD/MORT1 complex which contains a death effector domain which allows it to 
interact with caspase 8 (Akgul and Edwards, 2003). Pro-caspase 8 is cleaved to 
become an active enzyme and thus initiates activation of other caspases including 
caspase 3 (Luo et al., 2003). The binding of FasL to Fas also activates p38 MAP 
kinase and PI3-K (Hanna et al., 2005) and recruits RIP-1 (receptor interacting 
protein), the activation of which may be sufficient to induce apoptosis (Walczak and 
Krammer, 2000).
The Fas pathway is independent of extracellular calcium ions and is inhibited by Bcl2 
proteins (Nagata and Golstein, 1995). Fas-mediated apoptosis may heavily depend on 
the involvement of ROS (especially H2 O2) (Kasahara et al., 1997) but the role of ROS 
in triggering apoptosis via the Fas pathway is controversial. High levels of ROS can
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prevent caspase function and ROS may be involved in the Fas-mediated signalling 
system (Kasahara et al., 1997). Anti-Fas IgM mimics FasL activity in vitro. This 
antibody activates Fas and increases apoptosis in adult neutrophils (Liles et al., 1996, 
Hanna et al., 2005).
The Fas/FasL pathway is not the only mechanism for induction of apoptosis in 
neutrophils. Apoptosis still occurs if the Fas/FasL pathway is blocked (Liles et al.,
1996). However, Fas-mediated neutrophil apoptosis can be reduced by G-CSF, GM- 
CSF, EFNy (Interferon gamma), TNF-a and dexamethasone (Liles et al., 1996) but Fas 
ligation, even in the presence of these pro-inflammatory survival signals, causes 
apoptosis, in other words, inflammatory neutrophils retain their ability to respond to 
Fas death signals (Renshaw et al., 2000).
Fas and FasL have been studied in neonatal and paediatric blood samples (Ennaciri et 
al., 2006, Hanna et al., 2005, Sarandakou et al., 2003), but not in lung lavage samples 
in this age group.
b) TNF-a
TNF-a is a potent pro-inflammatory cytokine produced by macrophages, monocytes 
and other cell types (lymphocytes, fibroblasts) in response to injury, inflammation or 
infection (Baud and Karin, 2001).
There are two receptors for TNF-a, namely TNFR1 and TNFR2, which are both type 
1 trans-membrane proteins. TNFR1 binding recruits TRADD (TNFR1 associated 
death domain protein) which in turn recruits FADD and then caspase 8 resulting in 
apoptosis. TNFR1 binding also recruits RIP-1 (receptor interacting protein) and 
TRAF2 (TNF receptor associated factor 2) which result in NF-kB and AP-1 (via 
MAPK, JNK, p38) activation and pro-inflammation (Baud and Karin, 2001). Fas is a 
better activator of apoptosis than TNF-a because it is a poor activator of NF-kB, 
which acts to counteract the pro-apoptotic signal (Baud and Karin, 2001). TNFR2 
binding directly recruits TRAF2 which recruits TRAF 1 and increases inflammation 
(Baud and Karin, 2001).
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TNF-a is able to accelerate neutrophil apoptosis at early time points via TNFR1 but 
later inhibits apoptosis (after 12 hours in vitro) probably due to NF-kB activation 
(Baud and Karin, 2001, Murray et al., 1997).
c) Tumour necrosis factor-Related Apoptosis Inducing Ligand
TNF-related apoptosis inducing ligand (TRAIL) is a pro-apoptotic member of the 
TNF superfamily (Renshaw et al., 2003). It is a 281-amino acid type II 
transmembrane protein, closely related to FasL and, like FasL has a homotrimeric 
subunit structure (Pitti et al., 1996, Wiley et al., 1995). TRAIL is expressed on 
macrophages, monocytes and also T cells and NK cells and induces apoptosis when 
over-expressed (Walczak and Krammer, 2000).
TRAIL interacts with TRAIL-R1 and TRAIL-R2 which are “death receptors” and 
with TRAIL-R3 and TRAIL-R4 which may be decoy receptors, although resistance to 
TRAIL may be mediated at an intracellular level as well (Walczak and Krammer,
2000). Neutrophils have been found to contain mRNA for TRAIL, TRAIL-R2 and 
TRAIL-R3. TRAIL-R2 and TRAIL-R3 are expressed on the surface of neutrophils 
but TRAIL, TRAIL-R1 and TRAIL-R4 are not (Renshaw et al., 2003).
Signalling via TRAIL R1 and TRAIL R2 has 2 distinct pathways -  one resulting in 
apoptosis (major outcome) and the other in cell survival. The apoptosis pathway 
begins with recruitment of FADD. The DED (death effector domain) then recruits 
pro-caspase 8, which self-cleaves and then activates caspase 3 amongst others.
TRAIL receptors can also cause cell survival via NF-kB but NF-kB alone is 
insufficient to prevent apoptosis - a caspase inhibitor is also required (Kimberley and 
Screaton, 2004).
It is likely that TRAIL is rapidly cleaved from the cell surface by proteases, in a 
similar way to FasL cleavage. TRAIL has no effect on neutrophil chemotaxis, unlike 
FasL (Renshaw et al., 2003). Similar to FasL, TRAIL requires cross-linking of 
receptors for its activity (Renshaw et al., 2003) and TRAIL uses a caspase-dependent 
pathway to kill its target cell. Bcl2 and Bcl-xL do not protect cells from TRAIL- 
induced apoptosis (Walczak and Krammer, 2000).
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d) Caspases
A number of proteases play an important role in apoptosis including serine proteases, 
calpains, proteasomes and IL-1 p converting enzyme (ICE)-like proteases (cysteine 
proteases) called caspases (Cohen, 1997). Most of the morphological changes of 
apoptosis are the result of caspase activity (Hengartner, 2000).
Caspases are a family of cysteine proteases which are activated specifically in 
apoptotic cells. Over a dozen caspases have been identified which act on close to 100 
caspase substrates characterised to date. All caspases recognise specific polypeptide 
sequences and cleave their substrates after aspartic acid residues (Hengartner, 2000). 
Caspases can be inhibited by inhibitors of apoptosis (LAP) proteins (Hengartner, 
2000).
Caspases selectively cleave a set of target proteins usually inactivating them (Wyllie, 
1980). Additionally, caspases cleave nuclear lamins causing characteristic nuclear 
shrinkage and budding (Rao et al., 1996) and cleave cytoskeletal proteins (like fodrin 
and gelsolin) causing loss of cell shape (Kothakota et al., 1997). Not all caspases are 
required in a single cell for cell death to occur - some may be tissue specific (Cohen,
1997). Most caspases are activated by cleavage and are able to activate each other, 
especially caspases 3, 6 and 7 which are the more abundant, workhorses of apoptosis 
(Hengartner, 2000).
Caspase 3 is a key executioner of apoptosis, responsible for the cleavage of many key 
proteins (Cohen, 1997). It is widely distributed especially in cells of the immune 
system. Caspase 3 cleaves substrate at Asp-Xaa-Xaa-Asp (DXXD) motif (also seen in 
caspase 2, 6, 9) (Cohen, 1997). Caspase 3 activation is an early apoptotic event which 
precedes phosphatidylserine (PS) exposure. Proteolytic activation of caspase 3 occurs 
when initiator caspases cleave pro-caspase 3 (32kDa) into 2 subunits (p20/pl7 and 
p i2) (Cheah et al., 2005a). Cytoskeletal components function as substrates for caspase 
3. Caspase 3 may mediate the cleavage of the cytoskeletal element, fodrin, which is 
linked to PS expression on the outer plasma membrane (Luo et al., 2003). Decreased 
apoptosis has been observed in caspase 3 deficient mice (Cohen, 1997).
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Caspase 6 has a high homology with caspase 3 and may be activated by it. Caspase 6 
is the only caspase to cleave lamins, structural proteins of the nuclear envelope 
(Cohen, 1997).
Caspase 7 is also similar to caspase 3 and may be an important effector of apoptosis 
(Cohen, 1997) via the Fas pathway but caspase 7 is only minimally expressed in 
neutrophils (Luo et al., 2003).
Caspase 8 is involved in regulation of Fas or TNF-mediated apoptosis. It is a key 
initiator of apoptosis and is able to activate all the other caspases (Cohen, 1997). It 
can also be activated by protein-protein interactions i.e. several caspase 8 molecules 
can aggregate together at a death effector domain and activate themselves, without the 
need for cleavage by another molecule (Hengartner, 2000). Caspase 8-dependent 
cleavage of Bid and subsequent release of cytochrome c integrates the extrinsic and 
intrinsic pathways of apoptosis (Beere, 2005).
Caspase 9 is similar in structure to caspase 3 and is also activated by caspase 3 
(Cohen, 1997). Caspase 9 has a complex activation process and requires both 
cytochrome c and Apaf-1 for its activation (Luo et al., 2003, Hengartner, 2000).
1.7.2.2 Intrinsic apoptosis pathway
Within the cell, mitochondria sequester pro-apoptotic proteins e.g. cytochrome c -  
which, in addition to its involvement in oxidative phosphorylation, is important as a 
co-factor with caspase 9 (Hengartner, 2000). Pro-apoptotic proteins like cytochrome 
c, apoptosis inducing factor (AIF), endonuclease G and Smac/DIABLO are released 
from mitochondria under the influence of the opposing pro- and antiapoptotic 
members of the Bcl2 family of genes (Beere, 2005, Hengartner, 2000).
The Bcl2 family are a group of apoptotic regulators (Hengartner, 2000) which are 
divided into 3 sub-groups:
Group 1 (Bcl2, Bcl-xl) which are anti-apoptotic 
Group 2 (Bax, Bak, Bad) which are pro-apoptotic
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Group 3 (Bid, Bim, Bmf) which are pro-apoptotic.
Other Bcl-2 proteins include Bcl-w, Bcl-xs, and Mcl-1.
Bcl-2 family proteins acting on the mitochondria are probably among the key 
regulators of the apoptotic response (Cook et al., 1999). In one study, peripheral blood 
neutrophils in adult subjects expressed Bak, Bad, Bcl-w and Bfl-1, but hardly 
expressed Bcl-2, Bcl-xL, Bik, and Bax (Santos-Beneit and Mollinedo, 2000). In 
contrast, another study (Ohta et al., 1995) showed expression of Bax, but not other 
members of the Bcl-2 family in neutrophils, which may reflect the fact that they have 
the shortest life-span among blood leucocytes.
The expression of Bcl-2 family proteins in the human neonate in comparison to adults 
has been studied to a very limited extent (Hanna et al., 2005). Some differences have 
been shown in expression of the proteins in the cerebral cortex of term and preterm 
guinea pig fetuses (Abedin et al., 2005) and in the cardiac myocytes (Cook et al.,
1999) and neuronal tissue of rats (Vekrellis et al., 1997).
a) Bcl-xl
Bcl-xl stands for ’’Basal cell lymphoma-extra large’’. It is an anti-apoptotic, 
transmembrane protein, found particularly in the mitochondrial membranes of cells 
that are long-lived and postmitotic, such as adult brain cells. Bcl-xl appears to be the 
dominant regulator of apoptosis. It is known as the survival protein because of its cell 
death repressor activity.
Two different models of Bcl-xl function have been proposed. In one, Bcl-xl binds to 
an activator, thereby preventing Bax activation. In the other, Bcl-xl binds directly to 
activated Bax (Deming and Rathmell, 2006, Harada and Grant, 2003).
b) Bax
Bax is another homologue of the Bcl-2 gene, which acts as a facilitator of apoptotic 
cell death (Ohta et al., 1995). Although Bcl-xl and Bax are structurally similar, 
activated Bax forms large oligomers that permeabilise the outer mitochondrial
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membrane, releasing cytochrome c and thereby committing cells to apoptosis, 
whereas Bcl-xl and Bcl-2 inhibit this process (Vekrellis et al., 1997).
c) Mcl-1
Mcl-1 (Myeloid cell leukaemia sequence 1) is an anti-apoptotic member of the Bcl-2 
family (Michels et al., 2005) and plays a critical role in promoting the survival of 
lymphocytes and haematopoietic stem cells (Dzhagalov et al., 2007). Mcl-1 promotes 
cell survival by interfering in the cascade of events leading to release of cytochrome c 
from mitochondria. It has a short half life and is a highly regulated protein, induced 
by a wide range of survival signals, including the cytokine TNF-a (Cross et al., 2008) 
and also rapidly downregulated during apoptosis. Regulation of Mcl-1 expression 
occurs at multiple levels, allowing for either the rapid induction or elimination of the 
protein in response to different cellular events. This suggests that Mcl-1 can play an 
early role in response to signals directing either cell survival or cell death (Michels et 
al., 2005).
Accumulating evidence suggests that Mcl-1 plays a critical pro-survival role in the 
development and maintenance of both normal and malignant tissues as well as being 
required for embryonic development and the function of the immune system. 
Targeting of Mcl-1 may be useful as a therapeutic strategy in malignancy, 
inflammatory conditions and infectious disease where Mcl-1 may play a major role in 
suppressing apoptosis (Michels et al., 2005).
Studies have implicated Mcl-1 in regulating the survival of both neutrophils and 
macrophages (Dzhagalov et al., 2007). Mcl-1 conditional knockout mice had a severe 
defect in neutrophil survival, whereas macrophage survival was normal. The 
granulocytes in the blood, spleen and bone marrow of Mcl-1 conditional knockout 
mice exhibited a 2- to 3-fold higher apoptotic rate than in control animals. In contrast, 
macrophages from Mcl-1-deficient mice showed normal survival. Interestingly, Mcl-1 
can also be cleaved by caspases during apoptosis to produce a cell death promoting 
molecule (Michels et al., 2005).
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Overall it is the fine balance of expression of Bcl-2 family proteins which may 
regulate the life and death of haematolymphoid cells at different stages of cell 
differentiation and activation. Interactions between Bax, Bcl-xl, Bcl-2 and Mcl-1 play 
an important role in the control of cell death or survival (Ohta et al., 1995).
1.7.3 Control/modulation of apoptosis
The cellular environment influences apoptosis (Allgaier et al., 1998). The interplay 
between extrinsic (inflammatory milieu) and intrinsic (endogenous programme of 
constitutive apoptosis) factors will determine neutrophil longevity (Renshaw et al.,
2000). Cell immaturity may also influence the rate of apoptosis, although the 
mechanism of this is uncertain (Allgaier et al., 1998).
Various inflammatory mediators can modulate neutrophil apoptosis. The presence of 
pro-inflammatory factors (GM-CSF, G-CSF, TNF-a, IFN gamma, IL-2, IL-6, C5a) 
and glucocorticoids inhibit neutrophil apoptosis (Haslett, 1999, Leavey et al., 1998, 
Liles et al., 1996, Allgaier et al., 1998, Colotta et al., 1992, Lee et al., 1993, Matute- 
Bello et al., 1997). Neutrophil apoptosis may also be delayed by the presence of 
elevated extra-cellular calcium, LPS (Lee et al., 1993, Liles et al., 1996), hypoxia and 
corticosteroids (Allgaier et al., 1998, Haslett, 1999). NF-kB is a transcription factor 
which regulates the expression of many pro-inflammatory proteins including 
cytokines and adhesion molecules and generates anti-apoptotic signals (Cheah et al., 
2005a).
Inhibition of apoptosis serves to preserve and prolong the functional lifespan of the 
neutrophils (Lee et al., 1993). Neutrophil survival may benefit the host by more 
neutrophils remaining active at the site of inflammation to neutralise pathogens (Liles 
et al., 1996) (Leavey et al., 1998) but neutrophils are also capable of producing more 
tissue damage at the inflammatory site if they do not undergo apoptosis at an 
appropriate rate (Kasahara et al., 1997, Leavey et al., 1998).
Apoptosis may be enhanced by cycloheximide, TNF-a and nitric oxide donors 
(Haslett, 1999). Of clinical importance is that a number of drugs in common use may 
alter neutrophil apoptosis. It is increased by erythromycin (Healy et al., 2002) and
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theophyllines (Yasui et al., 2000) and decreased by glucocorticoids (McColl et al., 
2007) -  all 3 of which are commonly used in clinical neonatal practice.
NF-kB is an ubiquitously expressed transcription factor. It plays a role in expression 
of genes that regulate apoptosis, as well as controlling cell proliferation, 
differentiation, immune and inflammatory responses (Shishodia and Aggarwal, 2002). 
Usually, in non-stimulated cells, NF-kB is found in the cytoplasm, in complex with 
inhibitory proteins of the I-kB family (Beg and Baldwin, 1993, Finco et al., 1994) 
which inhibit its ability to bind to DNA. In response to a wide range of stimuli, I-kB 
is rapidly phosphorylated and degraded, allowing NF-kB translocation to the nucleus, 
DNA binding and transcription of target genes (Chu et al., 1997, Karin, 1999).
There are numerous reports showing the anti-apoptotic effect of N F - k B  (Shishodia 
and Aggarwal, 2002, Whyte et al., 1997, Ward et al., 1999). N F - k B  regulates 
apoptosis by regulating expression of genes that play a role in blocking apoptosis (e.g. 
LAP) and it may also have role in the activity of Bel 2.
1.7.4 Results of apoptosis
The onset of apoptosis is closely associated with functional impairment of neutrophils 
and their “isolation” from stimulation by inflammatory mediators (Whyte et al.,
1993). Whyte et al (Whyte et al., 1993) showed significant reductions in a number of 
neutrophil functions with the onset of apoptosis, including 
reduction in spreading ability,
reduced neutrophil polarisation (both spontaneous and in response to 
stimulation in vitro),
- reduced phagocytosis of opsonised particles,
reduced chemotaxis in both stimulated and unstimulated cells, 
reduced MPO enzyme release in response to stimulation and 
reduced superoxide anion release.
Dransfield et al (Dransfield et al., 1995) also showed that the ability of neutrophils to 
secrete granular contents was reduced with the onset of apoptosis and that their 
adhesive ability is also reduced as part of the damage limitation strategy of apoptosis.
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Some functional loss may precede the onset of morphologically recognisable 
apoptosis (Whyte et al., 1993).
The process of apoptosis induces changes to the expression of various cell surface 
markers and receptors related to cell function e.g. CD 16 (Haslett, 1999). Some of 
these alterations are important for neutrophil function (Dransfield et al., 1995).
CD1 lb and CD1 lc are increased on apoptotic neutrophils (but may be functionally 
inert), but CD 15, CD43, CD62L, CD35, CD1 la are decreased. CD66 expression is 
maintained (Dransfield et al., 1995). Other surface changes may be important for 
recognition of apoptotic neutrophils by macrophages, so that phagocytosis can occur 
and the apoptotic neutrophils can be “mopped up” before the onset of secondary 
necrosis.
a) CD16
CD 16 (Fey receptor III) mediates the binding of immunoglobulin opsonised particles 
to phagocytes (Dransfield et al., 1994). Neutrophil apoptosis is accompanied by 
proteolytic cleavage of CD 16 from the cell surface (Dransfield et al., 1995). Not all 
CD 16 is removed and the CD 16 remaining on CD 16 low apoptotic cells is the portion 
that is relatively resistant to protease cleavage (Dransfield et al., 1994). Levels of 
CD 16 expression can therefore be used to define apoptotic and non-apoptotic cells 
(Dransfield et al., 1994) as the number of CD 16 low cells strongly correlates with the 
number of apoptotic cells in culture.
b) Phosphatidylserine
Phosphatidylserine (PS) is a lipid normally confined to the inner leaflet of the plasma 
membrane. Its extemalisation is early and widespread in apoptosis, regardless of the 
apoptosis initiating stimulus (Martin et al., 1995). The extemalisation of PS has been 
proposed to occur during apoptosis as a result of an increase in intracellular calcium 
which activates the scramblases. Also, aminophospholipid translocase activity is 
thought to be suppressed by the increased calcium concentration, with the overall 
result that PS equilibrates between the inner and outer leaflets of the plasma 
membrane (Vance and Steenbergen, 2005). Changes in PS localisation can be
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detected before the morphological changes of apoptosis can be seen by microscopy. 
The extemalisation of PS appears to be one of the signals by which apoptotic cells are 
recognised and subsequently removed by phagocytes (Vance and Steenbergen, 2005).
Apoptotic neutrophils would normally be rapidly ingested by macrophages before 
losing membrane integrity. In the absence of macrophages or in conditions where 
macrophages do not adequately recognise apoptotic cells (cations, low pH, 
autoantibodies) or where macrophage clearance pathways are overwhelmed by large 
numbers of apoptotic cells, secondary necrosis will occur leading to liberation of the 
neutrophil contents and local tissue damage (Haslett, 1999).
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1.8. Mononuclear phagocytes
1.8.1 Monocytes
Monocytes appear in the circulation as early as 20 weeks’ gestation (Forster-Waldl et 
al., 2005). They can be rapidly recruited to the lung when required, usually following 
neutrophil influx. Monocytes are able to phagocytose cell debris and inflammatory 
products (Rosseau et al., 2000b, Gordon and Read, 2002). They can produce pro- 
inflammatory cytokines, ROS and proteolytic enzymes and may contribute to acute 
and chronic lung inflammation (Maus et al., 2002a). Monocytes have an important 
role in T-cell and macrophage activation via cytokine signalling (Gordon and Read,
2002) and may be important in the alveoli even in the absence of inflammation to 
expand the alveolar macrophage (AM) pool (Maus et al., 2002a).
The process and interactions of monocyte trafficking across the pulmonary 
endothelial/alveolar epithelial barrier in vivo are poorly characterised, when compared 
to what is known about neutrophil migration (Maus et al., 2002a). What is known is 
that the monocyte response is dependent largely on CD1 lb/CD 18 on monocytes and 
ICAM-1 on pulmonary epithelial and endothelial cells (Maus et al., 2002b).
Peripheral blood monocytes which are precursors of alveolar macrophages have an 
immature monocyte-like immunophenotype and may have augmented release of pro- 
inflammatory mediators (Rosseau et al., 2000a). In addition, recruited monocytes 
have increased CD 14 expression when compared to peripheral blood monocytes and 
have greater TNF-a response to LPS (Maus et al., 2002b).
Monocytes from newborn infants have reduced capacity to phagocytose apoptotic 
cells (Kramer et al., 2003) which may be important in the persistence of neutrophils in 
CLD. There may be some significant differences between adult and infant monocytes 
which may play a role in the pathogenesis of CLD, for example H2 O2 production in 
response to LPS in preterm and term sheep monocytes is reduced and delayed and 
monocytes from preterm infants have decreased HLA-DR expression (Hallwirth et al., 
2004). CD 14 expression on monocytes has been shown to be the same as adults 
(Forster-Waldl et al., 2005) but, paradoxically, also been shown to be gestation- 
dependent (Gengenbacher et al., 1998).
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1.8.2 Alveolar macrophages
%
Fig 1.5 An alveolar macrophage by light microscopy. Image from Ohio State University 
Department o f Pathology (www.pathology.med.ohio-state.edu)
Alveolar macrophages (AM) originate in the bone marrow as monocytes from 
haemopoetic precursor cells (Gordon and Read, 2002) and are the major resident 
population of immunocompetent cells in the lower respiratory tract. AM are resident 
lung phagocytes but are relatively poor antigen presenting cells. However they are 
able to release an array of inflammatory mediators (oxygen radicals, proteases, 
arachidonic acid metabolites and cytokines) and are thus implicated in the 
pathogenesis of lung injury (Maus et al., 1998). Resident macrophages in the 
peritoneum live for about 2 weeks in an uninflamed state (Bellingan et al., 1996).
Monocytes from the circulation enter the fetal lung in the third trimester in response 
to MCP-1, specific for the recruitment of mononuclear leucocytes, and mature to 
tissue macrophages under the influence of local factors (type II alveolar cells, 
bronchial epithelium, cytokines, surfactant) (Gordon and Read, 2002, Rosseau et al., 
2000a). Most only differentiate into macrophages after term birth (Alenghat and 
Esterly, 1984, Bellanti et al., 1979, Kramer et al., 2003). The presence of AM in the 
infant lung correlates mainly with the length of postnatal survival and the presence of 
pulmonary lesions. Gestational age shows some correlation in post-mortem studies 
but is not thought to be a major influence on the presence of AM as they can be seen
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as early as 20 weeks’ gestation if an infection such as congenital pneumonia is present 
(Alenghat and Esterly, 1984).
Alveolar macrophages account for 95% of the cell burden in healthy lung BAL fluid, 
with the remaining cells being lymphocytes (Gordon and Read, 2002). Macrophages 
which are present in the lung in acute inflammation have been found to be monocytic 
in origin, rather than as a result of proliferation of resident tissue macrophages which 
are terminally differentiated and not able to proliferate (Rosseau et al., 2000a, Van 
Furth et al., 1973).
Amon et al (Amon et al., 1993) showed that infants who progressed to CLD had 
fewer macrophages in BAL fluid on day 5 and 7 than infants whose RDS resolved. 
Macrophages peaked at around day 4 in other studies and persisted in the lung in CLD 
infants (Ogden et al., 1984, Clement et al., 1988).
1.8.3 Macrophage recognition of apoptotic cells
The final step in the process of apoptosis is the phagocytosis of cell “corpses”. The 
uptake of senescent neutrophils by macrophages was recognised by Metchnikoff in 
1891 but the process of apoptotic cell removal by professional phagocytes is complex 
and remains incompletely described at the molecular level. It has 2 central elements, 
namely
recognition (“eat me”)
- engulfment/phagocytosis (Lauber et al., 2004).
Neutrophil uptake by macrophages occurs via a number of specific recognition 
mechanisms, with different signals mediating recognition and engulfment (Lauber et 
al., 2004).
The process of apoptosis leads to recognition of apoptotic cells by macrophages 
(Savill et al., 1989b). This recognition process is complex (Lauber et al., 2004, Savill 
et al., 2002) and there are many possible receptors on the phagocyte for many 
different markers on apoptotic cells (Giles et al., 2000). Macrophage recognition of 
apoptotic neutrophils is different to recognition for red blood cells or apoptotic
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thymocytes (Savill et al., 1989a). Macrophage receptors for opsonins (Fc, C3b, iC3b) 
or for advanced glycosylated end products of proteins or N-acetylglucosamine- 
specific lectin may not be used in apoptotic neutrophil recognition (Savill et al., 
1989b). Apoptotic cells may be at different stages of apoptosis, so different mediators 
of phagocytosis in early and late apoptosis may be required (Giles et al., 2000). 
Recruited monocytes may also have to undergo a maturation process before they are 
able to recognise and remove apoptotic neutrophils as macrophages (Newman et al., 
1982).
PS is a well known “eat me” signal but the underlying mechanism of this signal to the 
macrophage is incompletely understood. PS is recognised by several different 
receptors, possibly including a specific PS receptor (Fadok et al., 2000) but may bind 
to it via a bridging molecule. It has been shown that the extemalisation of PS alone is 
insufficient for phagocytosis by macrophages in vitro (Devitt et al., 2003). The 
mechanism of recognition of apoptotic cells via PS may vary with different 
macrophage populations (Fadok et al., 1992).
Phagocytosis via the PS receptor pathway produces an increase in TGFp-1. TGFp-1 is 
multi-functional and modulates diverse cellular activities e.g. inhibits growth and 
differentiation of many cell types and regulates inflammatory response (Huynh et al., 
2002).
There are a number of other possible signals which mediate apoptotic neutrophil 
recognition by macrophages (Savill et al., 1990, Lauber et al., 2004), including 
(Figure 1.6):
The thrombospondin (TSP) receptor (CD36, a class B scavenger receptor) is 
an 88kD macrophage surface molecule. It acts as a receptor for a wide range 
of cells and molecules, including thrombospondin 1, and is synthesised and 
secreted by neutrophils and macrophages in culture (Savill et al., 1992). 
Macrophage synthesised thrombospondin mediates neutrophil/macrophage 
interaction by forming a molecular bridge between the cells. TSP binds to 
CD36 and to the vitronectin (avP3) receptor (Savill et al., 1992). This 
recognition process appears to be dependent on Ca++ and Mg++ for the 
interaction to occur. CD36 may also be able to work independently of the
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vitronectin receptor because transfecting CD36 into non-professional phagocytes 
induces the ability to phagocytose apoptotic neutrophils (Ren et al., 1995) 
some resembling oxidised LDL,
- sites to bind C lq and C3b/bi,
- collectin binding sites e.g. for MBL, SP-A, SP-D,
- CD91,
- ABC-1 (ATP binding cassette 1 transporter),
- class A scavenger receptor and
- CD 14 is a 55kDa glycoprotein cell surface receptor and differentiation marker
(Ziegler-Heitbrock and Ulevitch, 1993). It functions as a receptor for LPS and is 
found on mononuclear phagocytes and activated neutrophils (Hasday et al., 1997). 
CD 14 is capable of interactions with phospholipids and could function as alternative 
PS receptor but does not appear to do so (Devitt et al., 2003).
Apoptotic Cell
CD31
I n t e g r h
Figure 1.6 Diagram showing the numerous possible signals which mediate interactions 
between apoptotic cells and phagocytes (Vandivier et al., 2006).
Phagocytosis clears dead neutrophils but could also initiate a signal to macrophages to begin 
the process of egress from the inflamed site to draining lymphatics and lymph nodes 
(Bellingan et al., 1996, Serhan and Savill, 2005).
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1.8.4 Rate/regulation
Recognition and ingestion of neutrophils occurs very rapidly. In vitro, neutrophils can 
be phagocytosed by macrophages and digested to the point of being unable to be 
assessed morphologically within 30 minutes (Savill et al., 1989a).
The rate of macrophage ingestion of apoptotic cells can be altered. Macrophage 
clearance of apoptotic cells can be enhanced by various early inflammatory cytokines 
and by corticosteroids and CD44 ligation (Haslett, 1999). Surfactant protein A (SP-A) 
and, to a lesser extent, surfactant protein D (SP-D) accelerate alveolar macrophage 
phagocytosis of apoptotic neutrophils (Schagat et al., 2001).
Macrophage recognition of apoptotic cells is inhibited by cationic monosaccharides, 
amino sugars, heparin and basic amino acids and low pH. Changes in interstitial pH 
and release of charged molecules are well documented in inflammation -  this could 
delay macrophage uptake of apoptotic neutrophils and potentially lead to neutrophil 
disintegration during secondary necrosis and thus persistence of inflammation and 
exacerbation of tissue injury (Haslett, 1999, Savill et al., 1989b).
1.8.5 Outcome
Phagocytosis usually provokes a marked pro-inflammatory response from 
macrophages, however, macrophages do not have their usual inflammatory response 
to ingested apoptotic neutrophils (Haslett, 1999).
Phagocytosis of apoptotic neutrophils results in:
Suppression of release of pro-inflammatory agents like IL-ip, GM-CSF, IL-8, 
LT C4 and TNF-a (Fadok et al., 1998). ThromboxaneB2 release is suppressed 
to lower than normal background level (Meagher et al., 1992).
An increase in release of anti-inflammatory factors like IL-10, TGFp, 
prostaglandinE2 and PAF (Fadok et al., 1998).
Release of FasL from monocytes and macrophages and thus further Fas- 
mediated apoptosis of neutrophils (Brown and Savill, 1999).
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Macrophages retain their ability to liberate pro-inflammatory cytokines after apoptotic 
neutrophils are phagocytosed and digested, thus the “anti-inflammatory” effect of 
ingesting apoptotic neutrophils is dependent on the macrophage recognising that the 
neutrophil it is about to ingest is apoptotic, not as a result of the apoptotic particle 
itself. Ingestion of opsonised apoptotic neutrophils is able to cause a pro- 
inflammatory reaction (Meagher et al., 1992).
1.9 Neutrophil apoptosis in adult respiratory disease
Adult/Acute Respiratory Distress Syndrome (ARDS) is considered to be similar to 
neonatal RDS in some respects, particularly as neutrophil apoptosis is thought to play 
a significant role in its pathogenesis and patient outcome.
Matute-Bello et al (Matute-Bello et al., 1997) investigated neutrophil apoptosis in 34 
ARDS patients as well as 13 patients at risk for ARDS and a group of healthy adult 
controls. Neutrophil apoptosis was suppressed in ARDS and this effect was maximal 
in early disease but there was no significant difference in patients who survived 
compared to those who died from the disease. They also showed that BAL fluid was 
anti-apoptotic to human neutrophils and that apoptosis suppression is mostly mediated 
by anti-apoptotic cytokines, of which G-CSF and GM-CSF were most important in 
prolonging neutrophil survival.
Rosseau et al (Rosseau et al., 2000a) studied 49 ARDS patients by repeated BAL 
sampling. The first BAL sample on each patient showed an increase in total cell count 
with massive neutrophil influx and an overall expansion of the alveolar macrophage 
population due to peripheral blood monocytes being recruited to the alveolar 
compartment. Sequential samples showed increasing macrophage counts and 
neutrophil counts decreased only slightly. They found two sub-groups of patients - 
one in which there was a transition to a mature macrophage phenotype and another 
which had prolonged predominance of immature monocyte-like macrophages. There 
was a clinical correlation with improved oxygenation index, lung function and 
survival in the mature macrophages group.
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Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of 
adult lungs. Exacerbations of COPD are associated with viral or bacterial infection 
and airway inflammation, accumulation of neutrophils in the bronchial tree, tissue 
damage and bronchial obstruction. Increased neutrophil accumulation in COPD has 
been related to prolonged neutrophil survival/decreased apoptosis, similar to events in 
ARDS or bacterial pneumonia (Droemann et al., 2000, Matute-Bello et al., 1997).
Pletz et al (Pletz et al., 2004) studied 36 COPD patients and 10 healthy non-smoking 
volunteers and showed reduced spontaneous apoptosis in peripheral blood neutrophils 
during exacerbations of COPD and an increased rate during recovery.
1.10 Neonatal vs. adult neutrophils
There is a well recognised developmental immaturity of the neonatal immune system 
as evidenced by several studies on umbilical cord blood samples (Bortolussi et al., 
1993, Koenig et al., 1996).
Neutrophils from term newborn infants have shown defects in:
adherence (of which CD 1 lb/CD 18 is an important mediator), 
transendothelial migration (Anderson et al., 1990), 
chemotaxis (marked),
phagocytosis and oxidative metabolism and
non-oxygen dependent bactericidal activity (Levy et al., 1999)
All of which may contribute to the increased susceptibility of newborns to infection.
CD1 lb is part of the integrin family and mediates cell adhesion to the endothelium 
(Koenig et al., 2005). It is highly expressed on neutrophils and less is found on 
monocytes/macrophages. CD1 lb in combination with CD 18 forms CR3, a receptor 
for C3bi. Both quantitative and qualitative defects in CD1 lb have been described in 
neonatal neutrophils. CD1 lb has been found in equivalent amounts on adult 
neutrophils and those of vaginally delivered neonates but is lower in babies bom by 
Caesarean section (Nupponen et al., 2002a, Molloy et al., 2004, Abughali et al.,
1994). However, there are also contradictory reports that non-apoptotic neutrophils 
from cord blood express more CD1 lb than adult neutrophils but that the total cell
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content of CD1 lb/CD 18 is lower in neonates (Koenig et al., 2005) (Abughali et al.,
1994). Both term and preterm infants have significantly less upregulation of CD1 lb in 
response to stimulation (Anderson et al., 1987, Bruce et al., 1987, Nupponen et al., 
2002a). Upregulated CD1 lb may be protective against Fas-mediated apoptosis 
(Watson et al., 1997, Coxon et al., 1996).
Neonatal neutrophils have deficiencies in specific granule number and also possibly 
abnormal morphology of specific granules (Ambruso et al., 1984). Neonatal 
neutrophils have diminished lactoferrin (from specific granules) but release of 
lactoferrin on stimulation is comparable to adults (Ambruso et al., 1984, Anderson et 
al., 1987). Azurophilic granules in neonates contain less BPI
(bactericidal/permeability increasing protein), which has a high affinity for LPS, than 
adults and preterm neonates and have a lower capacity to release BPI than term 
infants or adults (Levy et al., 1999, Nupponen et al., 2002b) - this may be a reason for 
the increased susceptibility of newborns to Gram negative infections. However, large 
variations between amounts of BPI present in neonatal neutrophils have been noted 
(Levy et al., 1999). Neonatal neutrophils release very similar amounts of MPO 
(Nupponen et al., 2002a, Levy et al., 1999) from azurophilic granules when compared 
to adults. MPO and BPI both occur in the azurophil granules, so low BPI is probably 
not due to a problem with its release from the granule.
The oxygen-dependent killing ability of neonatal neutrophils shows some conflicting 
data and ROS killing capacity may be increased or decreased in neonates. Nupponen 
et al showed that preterm infants and infants with proven sepsis have reduced ROS 
(Nupponen et al., 2001) but there is enhanced release of ROS in non-apoptotic cells of 
cord blood compared to adult after 24 hours in culture (Koenig et al., 2005). This may 
be an important factor in tissue injury.
Cord blood neutrophils may have less capacity to undergo apoptosis than adult 
neutrophils (Allgaier et al., 1998, Luo et al., 2003). Several recent studies have shown 
reduced or delayed apoptosis, both spontaneous and induced, in neonatal compared to 
adult neutrophils (Oei et al., 2003, Molloy et al., 2004, Hanna et al., 2005, Allgaier et 
al., 1998). The reasons for this delay in apoptosis are unclear but there are a number 
of possible causes:
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- Lower levels of pro-apoptotic proteins in neonates (Bak, Bax, Bad) (Hanna et 
al., 2005).
Reduced pro-caspase 3 and caspase 3 amount and activity in neonates (Hanna 
et al., 2005, Luo et al., 2003), but similar levels of caspases 1 and 8.
- Caspase 9 may also be reduced in neonates (Molloy et al., 2005).
- FasL appears to be reduced in neonates (Hanna et al., 2005) although there are 
similar amounts of Fas on the surface of neonatal and adult neutrophils 
(Allgaier et al., 1998). Anti-Fas antibody did not induce apoptosis 
significantly in neutrophils of infants bom by Caesarean section whereas adult 
neutrophils and neutrophils from vaginally delivered neonates had a 
significant increase in apoptosis with Anti-Fas antibody (Hanna et al., 2005, 
Molloy et al., 2004, Allgaier et al., 1998).
Molloy et al (Molloy et al., 2004) showed that spontaneous neonatal 
neutrophil apoptosis is delayed in infants bom by Caesarean section and 
further delayed if an infant is vaginally delivered. Labour may thus cause 
“priming” of neutrophils and prolong their survival (Weinberger et al., 2007). 
Neonatal neutrophils may have altered responses to extracellular stimuli. For 
example, G-CSF (and not GM-CSF) further delays apoptosis in neonatal 
neutrophils. Both substances delay it in adults. In neonates at high risk for 
infection, neither substance delays apoptosis (Molloy et al., 2005). GM-CSF 
increases CD1 lb expression and ROS production but G-CSF has no effect 
(Molloy et al., 2005) possibly because there are reduced G-CSF receptors on 
neonatal neutrophils (Gessler et al., 1999).
However not all studies have shown a delay in neonatal neutrophil apoptosis. Uguz et 
al (Uguz et al., 2002) found increased Fas expression on neonatal neutrophils 
(following Caesarean delivery) compared to adult neutrophils and more rapid 
apoptosis in neonatal neutrophils.
Apoptotic neutrophils have diminished functional capacity. The function of surviving 
neutrophils is more important in disease processes. Koenig et al (Koenig et al., 2005) 
showed that neonatal neutrophils with prolonged survival exhibited enhanced 
inflammatory and cytotoxic responsiveness with more CD1 lb expressed and 
enhanced release of ROS compared to surviving adult neutrophils.
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1.11 Neutrophil apoptosis in chronic lung disease of prematurity
Grigg et al (Grigg et al., 1991) produced the first report of neutrophil apoptosis and 
removal by macrophages in neonatal lungs. They studied 8 babies - five <34 weeks’ 
gestation who were ventilated for RDS and three >34 weeks’ gestation without RDS. 
Intact neutrophils were identified within macrophages in BAL fluid by detecting 
MPO on cytospins and by electron microscopy. The neutrophils showed features of 
apoptosis by light microscopy. They questioned the pathophysiological relevance of 
this process in neonatal lung inflammation as their findings did not correlate with 
clinical outcome.
In a study of 52 babies, 23 of which were preterm and ventilated for RDS (Oei et al.,
2003), twice weekly tracheal aspirates were performed. Cell counts from the aspirates 
were lowest in preterm infants who did not progress to CLD and highest in term 
infants. All the samples were neutrophil predominant but the lowest proportion of 
neutrophils was in preterm infants who did not progress to CLD. Term babies had the 
highest proportion of apoptotic neutrophils in the first week, significantly more than 
all the preterm infants or the CLD group alone. There were significantly fewer 
apoptotic neutrophils in the first 4 days in the CLD group than in the RDS-only group 
or in term infants. They concluded that neutrophil apoptosis increases with gestational 
maturity and thus preterm babies may be more at risk of lung injury because of 
reduced neutrophil apoptosis. They also studied IL-10 in all the aspirate samples but 
found no correlation between IL-10 and apoptosis in any group.
Kotecha et al (Kotecha et al., 2003) studied 134 BAL samples from 32 infants who 
were ventilated for RDS. They found that the development of CLD is associated with 
persistent neutrophilia in BAL samples with the difference between RDS and CLD 
apparent at day 10. Macrophage counts were significantly higher in the RDS group on 
day 4. The percentage of apoptotic neutrophils in the BAL samples increased from 
1% on day 1 to 17% on day 7 in RDS but fell from 4.1% on day 1 to 0.7% at 7 days in 
the CLD group. The differences were statistically significant on day 7. In other words, 
increased survival may be the mechanism of neutrophil persistence in CLD. They also 
studied BAL fluid apoptotic activity against adult neutrophils and found RDS BAL 
fluid was significantly pro-apoptotic on days 1 and 2, which was not seen in BAL of
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babies who progressed to CLD. They also looked at GM-CSF, TNF-a and IL-10 but 
found no correlation between the levels and the amount of neutrophil apoptosis on 
day 1.
In apoptosis, cytochrome c released from mitochondria triggers cleavage of pro- 
caspase 9 which leads to activation of caspase 3 (Hanna et al., 2005). Caspase 3 levels 
in tracheal aspirate fluid (TAF) were studied in 27 ventilated preterm infants with 
RDS, 14 of whom developed CLD (Cheah et al., 2005a). No statistically significant 
relationship was found between caspase 3 activation and the development of CLD. 
The role of caspase 3 in the differences between neonatal and adult neutrophil 
apoptosis is still unclear.
1.12 Summary
The progression of RDS to CLD, rather than its resolution, is a cause of significant 
morbidity and mortality among infants bom at preterm gestations. CLD is thought to 
be a process of lung maldevelopment, predisposed to by ventilation, hyperoxia and 
pulmonary and systemic infection in the preterm infant. These risk factors all play a 
role in the generation of an innate inflammatory response in the lung, in which 
neutrophils are the predominant cell type. This neutrophilic inflammation needs to 
resolve by a process of neutrophil apoptosis and ingestion of the effete neutrophils by 
macrophages in order for RDS to resolve. It has been postulated that a failure of this 
resolution process is an important factor in the development of CLD.
It has previously been shown that apoptosis in neonatal neutrophils may be 
significantly delayed when compared to adults but the reason and mechanism for this 
remain unclear.
1.13 Aims and hypotheses
This project aims to describe the cellular component of BAL fluid from preterm 
infants who have RDS which resolves and compare this with preterm infants who 
develop CLD and with term infants who have no pulmonary pathology, using flow 
cytometry, a novel technique for this type of sample in this population of patients.
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1. I aim to characterise the BAL cells in terms of their cell type (neutrophil or 
macrophage) and then further characterise the different cell types according to 
their cell surface markers. The differences in BAL cells between infants in 
whom microbial infection or colonisation is detected will be described. I hope 
to be able to identify a factor or characteristic of the BAL cells which may 
predict the later development of CLD.
2. I will study macrophage surface markers as I hypothesise that a difference in 
these markers may highlight an altered ability to interact with and ultimately 
phagocytose apoptotic neutrophils, contributing to the pathogenesis of CLD.
3. I will determine the proportion of apoptotic cells in each BAL sample as well 
as an indication of the apoptotic activity of the BAL supernatant and compare 
this between groups, seeking a relationship between, in particular, neutrophil 
apoptosis and the pathogenesis of CLD,
4. I will attempt to understand the relationship between the different BAL 
cellular components and some of the inflammatory substances present in the 
BAL supernatant and the development of CLD as well as some of the 
relationships between the BAL supernatant, neutrophil apoptosis and the 
presence of microbial infection or colonisation.
5. In light of the association between infection and the development of CLD and 
the controversy in neonatal circles regarding the role of Ureaplasma in this 
disease, I will attempt to relate BAL cell and supernatant findings to the 
presence of micro-organisms in BAL samples.
6. It is probable that neutrophil apoptosis is delayed in newborn infants and I aim 
to confirm this and compare it between infants and adults, using umbilical 
cord blood, before going on to investigate possible mechanisms for any 
dysregulation of apoptosis in the newborn. This dysregulation of apoptosis 
may occur as a result of:
neutrophil factors, which will be investigated in BAL samples and in cord 
blood,
dysfunctional macrophage recognition or phagocytosis of apoptotic 
neutrophils, and macrophage surface markers will be investigated in BAL, 
the inflammatory environment in which the neutrophils find themselves, 
leading to analysis of some of the constituents of BAL supernatants, 
particularly in relation to apoptosis.
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Chapter 2 
Materials and Methods
Chapter 2
Materials and Methods
2.1 Chronic Lung Disease of Prematurity study
2.1.1 Patient Group
Patients were recruited in the regional neonatal intensive care unit at the University 
Hospital of Wales, Cardiff between February 2006 and June 2008.
Two groups of infants were recruited:
• Preterm infants (<32 weeks’ gestation) who required mechanical ventilation 
were recruited within the first 12 hours of life. This group was later subdivided 
into those infants who went on to develop CLD (oxygen dependence at 36 
weeks’ corrected gestation) and those infants whose RDS resolved.
• Term control infants (>37 weeks’ gestation) who required mechanical 
ventilation for non-respiratory reasons (for example infants ventilated peri- 
operatively for gastroschisis).
I excluded (did not recruit) any infant ventilated for hypoxic ischaemic 
encephalopathy, those with known chromosomal abnormalities and infants who were 
so unwell that they were extremely likely to die or be unlikely to tolerate the lavage 
procedure.
Parents whose infants met the study criteria were approached either prior to, or shortly 
after, delivery and invited to participate in the study. The study was explained to them 
and they were given an information leaflet about the study (appendix 1) before fully 
informed, written consent was obtained.
The study was approved by the Cardiff and Vale NHS Trust Research and 
Development committee and the South East Wales Research and Ethics Committee 
(Reference number 05/WSE04/85, 7th September 2005).
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2.1.2 Bronchoalveolar lavages
Infants requiring mechanical ventilation regularly have endotracheal suction 
performed as part of their routine care. Bronchoalveolar lavage (BAL) is a well 
established clinical and research technique that is safe and well tolerated (Grigg et al., 
1992, Shields and Riedler, 2000) in mechanically ventilated neonates (Vyas et al., 
2002), provides reproducible results and no long term adverse effects (Kotecha, 1999, 
Vyas et al., 2002).
For the purpose of this study, BAL was performed daily for the first week of life and 
then twice weekly until the infant was 28 days old or until the infant was extubated, 
whichever occurred first. Preterm infants in the neonatal unit in Cardiff routinely 
receive exogenous surfactant therapy at birth and again at 12 hours of age. In order to 
minimise any wash out of surfactant, the first BAL was performed at 12 hours of age, 
immediately prior to the administration of the second surfactant dose. Timing of 
subsequent lavages was co-ordinated daily with the nursing staff on the neonatal unit 
in order to replace the routine endotracheal suction and avoid extra suctioning 
procedures being performed on the infant. If an infant was judged too unwell by the 
attending clinician to tolerate a BAL, the procedure was withheld.
Bronchoalveolar lavages were performed using the guidelines set out by the European 
Respiratory Society task force on BAL in children (de Blic et al., 2000). The 
procedure was performed with the infant lying supine and the head turned to the left, 
thus increasing the likelihood of the suction catheter being introduced into the right 
lower lobe. If the infant was conventionally ventilated, the ventilator was briefly 
disconnected and a size 6 French Gauge (FG) catheter was gently introduced down 
the endotracheal tube until resistance was felt. If the infant was receiving high 
frequency oscillatory ventilation (HFOV) the procedure was carried out using the in­
line suction port to avoid the need to disconnect the ventilator. Once resistance to 
further advancement of the catheter was felt, 1 ml/kg of 0.9% saline (up to a 
maximum of 2 ml) was instilled via the catheter. The catheter was then connected to 
8-12 kPa of suction pressure and the lavage fluid was suctioned back and collected in 
a suction trap as the catheter was withdrawn. The ventilator was then reconnected and 
the infant’s heart rate and saturations, which may have dipped during suction, were
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allowed to return to normal before the procedure was repeated a second time. The 
BAL fluid was pooled from the two lavages, placed on ice and immediately 
transported to the laboratory for analysis.
2.1.3 Processing of bronchoalveolar lavage samples
The sample was transported on ice from the patient’s bedside to the laboratory within 
10 minutes of collection. An aliquot of 25 pi was taken from the BAL sample at this 
stage for culture for Ureaplasma (see 2.1.6 below). The sample was placed in a pre­
cooled centrifuge (Jencons, Leighton Buzzard, UK) and centrifuged at 4°C at 1 000 
xg for 10 minutes, resulting in the sample being separated into a cell pellet and 
supernatant. The supernatant was carefully removed and stored as 25 pi aliquots at - 
80°C for later analysis.
The cell pellet was re-suspended in 1 ml of phosphate buffered saline (PBS) with 5 
mM EDTA. In order to break up the thick mucus present in most of the lavage 
samples, 100 pi of 50 pg/ml dithiothreitol (DTT), a reducing agent, was added to the 
resuspended cell pellet and incubated for 15 minutes at room temperature. A cell 
count was performed on the re-suspended cells using a haemocytometer. A portion of 
the sample was mixed with an equal volume of trypan blue (Invitrogen, Paisley, UK) 
prior to counting, in order to facilitate counting and gain information about cell 
viability.
2.1.3.1 Use of DTT as a mucolytic
a) Effect of DTT of neutrophil surface antigens at different concentrations
A sample of 15 ml of peripheral venous blood was drawn from an adult volunteer and 
placed in a tube containing 1.5 ml of 3.8% sodium citrate (Martindale 
Pharmaceuticals, Romford, UK). The blood was then mixed with 3 ml of 6% dextran 
70 (Baxter Healthcare Ltd, Thetford, UK) and left to stand at room temperature for 40 
minutes. This allowed the red blood cells to sediment to the bottom of the tube, 
leaving a clear interface between an upper layer of serum containing leucocytes and a 
lower layer containing red blood cells. The leucocyte portion was carefully aspirated
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from the red blood cell layer and placed in a sterile universal container. The 
leucocytes were then centrifuged at 400 xg for 5 minutes, washed twice in 20 ml of 
flow cytometry (FACS) buffer and then resuspended in FACS buffer to a given 
volume. The resulting suspension was divided into two equal aliquots. To one aliquot, 
DTT was added at a concentration of 50 pg/ml and to the other, an equal volume of 
PBS (diluent for DTT) was added. Both tubes were left to stand at room temperature 
for 15 minutes.
Each sample was then centrifuged at 400 xg for 5 minutes and washed twice in 20 ml 
of FACS buffer to remove any trace of DTT. Thereafter each sample was counted on 
a haemocytometer and resuspended to a density of 106cells/ml using FACS buffer.
Cells were then placed into a round-bottomed 96 well plate (Nunc brand, Fisher 
Scientific, Loughborough, UK) (105cells/well) and prepared for flow cytometry as 
described in 2.1.4.1 (below). Wells were allocated for each isotype control antibody 
and for each surface marker that I intended to use. Each antibody was tested in 
duplicate and the experiment was performed on 3 occasions.
A further, similar set of experiments were performed, using concentrations of DTT of 
0, 5, 25, 50, 100 and 200 pg/ml.
2.1.3.2 Cytospins
At least 2 cytospins per BAL sample were made from the re-suspended cells, using a 
Cytospin 3 (Shandon, Runcorn, UK). A volume of 50 pi of cells resuspended in 
FACS buffer at a density of 0.5 x 106 cells/ml was added to the cytospins chamber 
and spun at 300 rpm for 4 minutes. The cytospins were air dried for at least 24 hours 
and then fixed in methanol and frozen at -20°C. The cytospins were defrosted and 
stained with Diff-Quik (Medion Diagnostics, Limerick, Ireland) before a differential 
cell count was obtained by counting at least 300 cells per sample under direct vision 
with a high powered light microscope. Counting for the neonatal arm of the study was 
performed by Miss Sharon Gill, laboratory technician in the Department of
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Respiratory Medicine at the University of Sheffield, who was blinded to the clinical 
condition of the children.
2.1.4 Analysis of bronchoalveolar lavage cell pellet
2.1.4.1 Preparation of samples for cell phenotype analysis by flow cytometry
Following the haemocytometer count, the remaining cells were washed in 20 ml flow 
cytometry buffer (PBS containing 0.1% sodium azide, 1% bovine serum albumin, 5% 
fetal calf serum and 5 mM EDTA) to remove the DTT and then resuspended to a 
density of ~106 cells/ml in flow cytometry buffer
Using a round bottomed 96 well plate, 100 pi of the cell suspension was added to 
each well, including wells for all antibody staining as well as controls. The number of 
cells obtained from the lavages varied greatly and the combinations of antibodies 
which could therefore be used was limited by the number of cells in some samples. 
Three separate templates (appendix 2) were designed to be used, depending on the 
number of cells obtained from the BAL sample in order to maximise the information 
obtained but still obtain a standard minimum data set for each lavage.
All antibodies were monoclonal mouse anti-human antibodies, produced 
commercially for use in flow cytometry and used in appropriate titres (Table 2.1).
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Anti&en Antibody clone IsotvDe Conjugate Cells identified
(suDDlier)
CD llb ICRF44
(eBioscience, San 
Diego, CA)
IgGl Biotin Monocytes, 
macrophages, 
granulocytes, activated 
lymphocytes
HLA-DR G46-6
(BD Pharmingen, 
Oxford, UK)
IgG2a Allophycocyanin
(APC)
Macrophages, 
monocytes, B cells
CD16 3G8
(BioLegend, San 
Diego, CA)
IgGl Phycoerythrin
(PE)
Neutrophils, activated 
monocytes (also Natural 
Killer (NK) cells and 
dendritic cells)
CD36 TR9
(BioLegend)
IgGl PE Monocytes, 
Macrophages (also 
platelets and 
erythrocytes)
CD15 HI98
(BioLegend)
IgM APC Neutrophils
CD14 61D3
(Southern Biotech, 
Birmingham, AL)
IgGl Biotin Monocytes,
macrophages, dendritic 
cells
TLR 2 TL2.1
(eBioscience)
IgG2a Biotin Any cell expressing TLR 
2
TLR4 HTA125
(eBioscience)
IgG2a Biotin Any cell expressing TLR 
4
IgGl
isotype
control
(eBioscience) IgGl Biotin
IgGl
isotype
control
MOPC-21
(BioLegend)
IgGl PE
IgG2a
isotype
control
(eBioscience) IgG2a Biotin
IgG2a
isotype
control
(eBioscience) IgG2a APC
IgM
isotype
control
MM-30
(BioLegend)
IgM APC
Table 2.1 Table showing the antibodies which were used, their isotype, the flurophor 
to which they were conjugated and an indication o f the cell type which each antibody 
could be used to identify, together with the selected isotype controls.
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The cells in the plate were then incubated for 30 minutes at 4°C in a blocking buffer 
containing PBS, 0.1% sodium azide, 1% BSA, 1% heat inactivated normal mouse 
serum and 5 mM EDTA, to block non-specific antibody binding sites on the cell 
surface. The cells were then centrifuged at 500 xg for 4 minutes and the supernatant 
removed. Biotinylated antibodies were diluted in flow cytometry buffer at pre­
determined optimal concentrations and 80 pi of the appropriate antibody solution was 
added to each well of the plate. Wells not requiring antibody at this stage received the 
same volume of flow cytometry buffer alone. The plate was incubated at 4°C for 30 
minutes. Following the incubation, cells were centrifuged at 500 xg for 4 minutes and 
then washed 3 times using 200 pi of flow cytometry buffer. Secondary fluorescent 
conjugated reagents or directly conjugated antibodies, again diluted to pre-determined 
optimal concentrations in 80 pi of flow cytometry buffer, were added to the cells and 
a further incubation at 4°C for 30 minutes followed. Thereafter, cells were again 
washed 3 times and resuspended in 200 pi flow cytometry buffer. Samples were then 
transferred to test tubes ready for immediate FACS analysis.
2.1.4.2 Preparation of samples for apoptosis analysis by flow cytometry
Cells obtained by BAL for apoptosis analysis were stained using phycoerythrin- 
conjugated Annexin-V (MBL International, Woburn, MA) which binds to exposed 
phosphatidyl serine on the cell membrane of apoptotic and necrotic cells and To-Pro-3 
(Invitrogen, Paisley, UK) which binds to DNA exposed in cells undergoing necrosis.
Cells were prepared in a similar way to those for phenotypic analysis. After the initial 
blocking step, cells were incubated in flow cytometry buffer for 30 minutes at 4°C 
and then washed three times in Annexin-V binding buffer (AVBB) (BD Pharmingen, 
Oxford, UK) to remove any EDTA containing flow cytometry buffer. Annexin-V 
binding to phosphatidylserine is a calcium dependent process which would be 
prevented by the presence of EDTA. An appropriate, pre-determined, volume of 
Annexin-V-PE was diluted in AVBB (5 jul of Annexin-V-PE per 100 pi AVBB) and 
80 pi of this solution was added to each appropriate well. As a negative control, 
Annexin-V-PE was added to AVBB containing 20 mM EDTA which would prevent 
Annexin-V binding and 80 pi of this solution was added to the appropriate well of the 
plate. The plate was then incubated at 4°C for 30 minutes before washing three times
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in AVBB. The cells were resuspended in either in 100 pi To-Pro-3 solution (diluted 
1:30 000 with AVBB) or AVBB, as appropriate, and transfered to FACS tubes, each 
containing 100 pi Annexin-V binding buffer, for analysis.
2.1.4.3 FACS analysis
All processed BAL samples were analysed on the same Becton Dickinson 
FACScalibur flow cytometer (Becton Dickinson, Oxford, UK) immediately following 
staining, regardless of the time of day or night.
All samples had appropriate negative and positive control antibodies included in the 
staining panel and compensation was adjusted appropriately for each individual 
sample. A polyhedral gate was drawn in order to exclude cell debris (very low 
forward and side scatter) and 10 000 gated events were collected for each control and 
each antibody combination.
In order to ensure consistency between FACS measurements over the duration of the 
project, Spherotech Ultra Rainbow beads (Spherotech, Lake Forest, IL) were run on 
the FACS machine from time to time and results compared and any minor variations 
noted so they could be adjusted for.
FACS data was analysed using Cellquest software (Becton Dickinson, Oxford, UK).
2.1.4 Polymerase chain reaction (PCR) for 16S rRNA
Ribosomes are the cellular organelles that translate messenger RNA into proteins. 
Eukaryotic ribosomes have a sedimentation of rate of 80 Svedburg (S) units, while 
prokaryotic ribosomes are highly homologous and have a sedimentation rate of 70S. 
The 70S ribosome consists of 2 subunits:- a smaller 30S subunit and a larger 50S 
subunit. The 30S subunit contains a 16S ribosomal RNA (rRNA) transcript 
associated with 21 bacterial proteins. The 16S rRNA is distinct from the analogous 
18S eukaryotic equivalent, but conserved enough amongst prokaryotes that primers 
can be designed that detect the presence of most bacteria without cross-reacting with 
eukaryotic host sequences. The presence of 16S rRNA gene is thus indicative of the
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presence of bacteria in a sample. Polymerase chain reaction (PCR) may be used to 
amplify the DNA that codes for 16S rRNA, without concern for RNA degradation, 
and is used to demonstrate the presence of bacterial DNA within a sample (Lane, 
1991).
In order to examine the relationship between bacterial presence in the airways and the 
development of CLD, 16S rRNA gene PCR was performed on the DNA extracted 
from any remaining BAL cell pellet after sufficient material had been obtained for 
flow cytometry analysis. The DNA extraction, PCR and sequencing was performed 
by Mr Michael Beeton, a PhD student in the department of Child Health in Cardiff.
2.1.5.1 DNA extraction
The DNA extraction was performed using a kit from Qiagen (Crawley, UK) in 
accordance with the manufacturer’s instructions.
The cell pellet was resuspended and the cells dissolved using 0.5 ml of lysis buffer. 
Equilibration buffer was then added and the cellular debris removed by centrifugation 
at 15 000 xg for 20 minutes at 4°C. The supernatant, containing the nucleic acids, was 
removed and ice cold isopropanol added, causing the nucleic acids in the sample to 
precipitate. The mixture was centrifuged at 15 000 xg for 30 minutes and this time the 
nucleic acids formed a pellet. The supernatant was discarded and the nucleic acids 
were resolublised in 150 pi of lysis buffer and heated for 6 minutes at 60°C. Then 
1.35 ml of equilibration buffer was added and any debris removed by centrifugation 
for 5 minutes at 5 000 xg. The supernatant, containing the nucleic acids, was removed 
and added to the top of an equilibrated Qiagen® tip, which is a small column 
containing resin beads. In the first run through the column, RNA binds to the column, 
whilst the DNA passes through and is collected. A wash buffer is added to the column 
and an elution buffer is used to remove the RNA from the column; this is collected for 
separate analysis. The collected DNA is added back to the column and, due to a 
change in the buffer, this now binds to the column. DNA elution buffer is then added 
to the column and a purer DNA sample is collected. The DNA is then precipitated 
with isopropanol and centrifuged to give a pellet of DNA. This pellet is washed twice 
in 70% ethanol before being resuspended in 100 pi of RNase-free water and heated to
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60°C for 6 minutes. The extracted DNA was then stored in this state at -20°C until the 
PCR was performed.
2.1.5.2 16S rRNA gene PCR
The PCR was performed by making a “master mixture” of Taq polymerase (Go Taq, 
Promega, Southampton, UK), forward and reverse primers consisting of 20 base pairs 
complementary to 16S rRNA (Forward 5’-3’ AGAGTTTGATCCTGGCTCAG, 
Reverse 5’-3* ACGGCTACCTTGTTACGACTT) (Weisburg et al., 1991) ordered 
from MWG Biotech, Ebersberr, Germany), deoxynucleoside triphosphates, 
magnesium (to aid nucleotide binding), buffer and water to a final volume of 20 pi.
In a PCR tube (Starlab, Milton Keynes), 19.5 pi of the master mixture and 0.5 pi of 
extracted DNA were mixed. Further tubes containing a positive control with known 
bacterial DNA and a negative control with no DNA were also made up. The PCR 
tubes were then placed in a thermocycler (Quanta QD96, Quanta Biotech, Byfleet, 
UK). This heats the mixture to 94°C for one minute to denature the DNA, then cools 
the sample to 67°C for 40 seconds to allow annealing of the primers to the open 
strands of DNA and then the sample is heated to 72°C for one minute which is the 
optimal temperature for the Taq polymerase to extend the primer to a full 
complementary strand of DNA. Detection of bacterial 16S rRNA genes was optimised 
by performing 20 such cycles but with each cycle the temperature of the annealing 
step was reduced by 1°C. A second set of 20 cycles was then performed using 94°C 
for one minute, 47°C for a further minute and 72°C for 90 seconds. The mixture was 
kept at 72°C for eight minutes before finally being cooled to 4°C then stored at -20°C 
until needed.
2.1.5.3 DNA Gel Electrophoresis of PCR products
To visualise amplified DNA and determine the size of DNA product, gel 
electrophoresis was performed. The gel was made up by adding lg agarose 
(Invitrogen, Paisley, UK) to 100 ml of 0.5X Tris borate EDTA (TBE) (Sigma- 
Aldrich, Irvine, UK) and 1 pi of the intercalating agent, ethidium bromide. The lanes 
were loaded with samples, positive control, negative control as well as a DNA ladder 
(Hyperladder 1, Bioline, London, UK) consisting of several strands of DNA of known
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length. The gel electrophoresis was run at 130V until the bromophenol blue in the 
sample loading buffer had moved sufficiently to indicate good separation had 
occurred (about 30 minutes). The gel was placed under a transilluminator and 
ethidium bromide which has intercalated into the amplified DNA fluoresces and was 
captured by a digital camera. Those samples that contain 16S rRNA as well as the 
positive control have a visible band at 1.2 kbp. Successful extraction of DNA from 
samples was judged by a second amplification to detect the human mitochondrial 
cyclo-oxygenase (HMCO) gene using specific primers and cycling conditions. 
Samples that failed to show either 16S rRNA or HMCO genes were considered 
indeterminate, while samples that were positive for HMCO but negative for 16S 
rRNA were deemed to be free of bacterial infection.
2.1.5.4 Sequencing of 16s rRNA genes to identify organisms
Samples that were positive for 16s rRNA genes went on to have the 16s rRNA gene 
sequenced in order to identify the organism that was present in the lavage (Lane, 
1991). If an infant had several samples in which the 16s rRNA gene was detected then 
the first positive sample and/or the sample closest to the peak BAL cell count was 
sequenced.
Selected samples had the 16s rRNA gene PCR repeated, as in section 2.1.5.2, and 
scaled up five fold to yield a sufficient quantity of DNA for sequencing. These were 
pooled and purified using a Novagen spin-prep PCR clean-up kit ™ (Merck 
Chemicals, Nottingham, UK), according to the manufacturer’s instructions, to remove 
the nucleotides, primers and enzymes and leave only the amplified 16s rRNA genes. 
The genes are then fluorescently labelled using the BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, Warrington, UK), according to the 
manufacturer’s instructions and analysed by an ABI Prism 3130x1 Genetic Analyzer, 
(Applied Biosystems). This enabled different organisms to be identified as each has a 
specific variation in their 16s rRNA gene. Gene sequences were analysed using 
BLAST (Basic Local Alignment Search Tool) via the National Center for 
Biotechnology Information, U.S. National Library of Medicine 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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2.1.6 Detection of Ureaplasma in bronchoalveolar lavage samples
In order to further study the controversial association between Ureaplasma and CLD, 
as soon as each BAL sample had been obtained, 25 jul of BAL was placed into 2ml of 
Ureaplasma-spQcific culture medium (Mycoplasma Experience, Surrey, UK). This 
culture was incubated at 37°C for 5 days.
Ureaplasma contains the enzyme urease which breaks down urea. This causes a 
change in the pH of the culture medium, resulting in the orange culture medium 
turning a clear cherry red indicating a positive culture, usually within 24 hours. 
Cultures which remained orange were negative. Some cultures became cloudy due to 
the presence of other microbes which prevented accurate interpretation of any colour 
change and these samples were subjected to PCR for 16S r RNA and for Ureaplasma 
(see 2.1.5.2 above) in order to obtain an accurate assessment of the microbial 
colonisation in the sample.
2.1.7 Analysis of bronchoalveolar lavage supernatant
2.1.7.1 Elastase Activity Assay
One of the secondary objectives of this study was to measure enzymatically active 
elastase that was present in our lavage samples as a marker of “tissue damage 
potential “. I therefore performed a kinetic activity assay on all the lavage samples. 
Measurement of the rate of chromogenic conversion of the colourless Suc-Ala-Ala- 
Pro-Val-pNA substrate to a yellow product is a well established technique for 
measuring elastase activity and has been used previously in bronchoalveolar lavage 
samples from both neonatal and cystic fibrosis patients (Birrer et al., 1994, Speer et 
al., 1993, Sluis et al., 1994).
Stocks of standard human neutrophil elastase (Athens Research and Technology, 
Athens, GA) were prepared by reconstituting 100 pg of lyophilized elastase powder in 
a 200 pi solution of 50mM sodium acetate (pH 5.5) and 150 mM sodium chloride.
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The 16.9 pM enzyme solution was then divided into 20 pi aliquots and stored at - 
20°C.
To make up a standard curve, a 20 pi aliquot of elastase was thawed and diluted using 
activity buffer (0.1 M Tris (Fisher Scientific, Loughborough, UK), 0.5 M Sodium 
Chloride, pH 7.4, 0.05% Triton X-100) to make up concentrations of 20 nM, 10 nM, 5 
nM, 2.5 nM, 1.25 nM, 0.625 nM and 0.3125 nM of neutrophil elastase. These 
standard dilutions were then added in duplicate to a 96 well plate at a volume of 100 
pi per well.
BAL supernatants were thawed and 10 pi from each sample was added to the 96 well 
plate, again in duplicate, and made up to 100 pi with the activity buffer.
A stock solution of neutrophil elastase-specific chromogenic substrate, Suc-Ala-Ala- 
Pro-Val-pNA (Bachem, St Helens, UK), was prepared by reconstituting 50 mg of 
lyophilized powder in 10 ml dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Irvine,
UK). The 8.67 mM substrate solution was divided into lmL aliquots and stored at - 
20°C.
Prior to use, the substrate was thawed and diluted to a 2 mM concentration using 
“activity buffer”. Each well of the 96 well plate containing sample or standard 
concentrations of neutrophil elastase received 100 pi of the substrate solution. The 
kinetic assay was read at 405 nm in a heated (37°C) plate reader (Dynex Magellan 
Industries, Chantilly, VA) which shakes the plate and takes readings at 1 minute 
intervals for an hour. Integral Dynex Revelation software calculates concentration of 
elastase by comparing the rate of substrate conversion in the samples against the 
standard curve of purified elastase.
Any samples with elastase activity in excess of the standard curve were diluted further 
and reanalysed. The standard curve profile was examined for its consistency and 
concordance between duplicate values was also assessed.
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2.1.7.2 Cytometric Bead Array (CBA)
The environment in which the BAL cells are found may also have a profound effect 
on the behaviour of the cells, as well as reflecting products produced by them.
CBA is a technique which uses the ability of flow cytometry to discriminate between 
particles on the basis of size and color. CBA uses a series of beads with distinct 
fluorescence intensities which have been coated with specific capture antibodies to 
simultaneously detect multiple soluble analytes. Each bead in the CBA kit acts as a 
capture surface for a specific protein, in this case cytokines. A single set of diluted 
standards is used to generate a standard curve for each analyte so that concentrations 
of the cytokine can be determined in each sample. I used this technique to measure 
concentrations of 12 potentially relevant cytokines in BAL samples.
The CBA work was performed in the Central Biotechnology Services at University of 
Sheffield on my behalf. BAL samples were defrosted and 25 pi of BAL was diluted 
1:10 for MCP-1, EL-8, IL-6, MIP-1 a, MIP-1 p and G-CSF or used undiluted for IL-1, 
TNF-a, FasL, IL-10, GM-CSF and VEGF, based on a series of optimisation 
experiments. The samples were then incubated with the antibody-coated beads and the 
subjected to flow cytometry analysis on a FACSArray machine.
2.1.73 Bioassay
In order to assess the pro- or anti-apoptotic activity of BAL supernatants, their ability 
to induce apoptosis in fresh adult neutrophils was studied, similar to Kotecha et al 
(Kotecha et al., 2003). These experiments were performed by Sharon Gill, laboratory 
technician at the Department of Respiratory Medicine, Royal Hallamshire Hospital, 
Sheffield.
Peripheral blood neutrophils from healthy adult volunteers were isolated as described 
in 2.2.2 below and then resuspended in HBSS at a density of 5 x 106/ml. A 50 pi 
aliquot of the cell suspension was mixed with 25 pi of RPMI containing 10% FCS in 
each well of a 96 well plate. BAL supernatants were thawed and 25 pi of BAL was
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added to the neutrophil /RPMI mixture. Each BAL sample was assayed in duplicate at 
2 time points and the rate of spontneous apoptosis in the adult neutrophils was assessed 
by adding 25 pi of 0.9% saline (as this is the fluid in which BAL was originally 
collected from the infants), instead of BAL supernatant, as a control. The plate was 
incubated at 37°C in 5% CO2 for either 5 or 20 hours.
The percentage of apoptotic neutrophils at the outset and at 5 and 20 hours of 
incubation was assessed by cytospins, made as described in 2.1.3 above and stained 
with Diff-Quik.
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2.2 P eriphera l C ord  Blood N eutrophil study
2.2.1 Patient Groups
As well as examining neutrophil apoptosis in cells obtained by bronchoalveolar 
lavage from infants’ lungs, I also aimed to gain information on the differences in rates 
of neutrophil apoptosis between adults and newborn infants.
Blood sampling from healthy term neonates poses a number of ethical concerns and 
there are also clinical constraints on the volume of blood obtainable. For this reason 
umbilical cord blood was used as it is normally discarded following delivery of the 
infant and volumes of up to 40 ml can be obtained relatively easily. Similarly blood 
sampling from preterm neonates poses even more complex ethical issues. Preterm 
infants are infrequently bom by elective Caesarean section due to the more complex 
and higher risk nature of this procedure for the mother at preterm gestations. A 
majority of preterm infants are bom following spontaneous onset of preterm labour 
which may be due to sub-clinical infection in a significant proportion of cases 
(Gomez et al., 1997, Klein and Gibbs, 2004). The combination of possible infection 
along with the activating effect of labour on neutrophils (Molloy et al., 2004, 
Weinberger et al., 2007) made a majority of preterm infants ineligible for our study. 
For this reason, only term infants bom by elective Caesarean section were included in 
the study.
Healthy pregnant women who were undergoing elective Caesarean section (most 
frequently because of previous Caesarean delivery) at 37 weeks’ gestation or more 
were asked in advance of delivery whether cord blood could be taken once their 
infants were bom. An information sheet (appendix 1) was given to the women and 
written, informed consent was obtained.
At the Caesarean section, following delivery of the infant, the placenta is delivered 
and inspected for completeness by the attending midwife, before it is discarded. 
Within 5 minutes of the delivery of the placenta, blood was carefully obtained from 
the umbilical cord vessels using a 21G (green) needle and syringe and immediately 
placed into a 50 ml conical tube and mixed 1:6 with 3.8% sodium citrate (Martindale
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Pharmaceuticals, Romford, UK) to prevent coagulation. The volume of blood 
obtained varied with the size and length of the portion of the umbilical cord available 
for sampling and ranged from less than 5 ml to over 60 ml from different cords.
For comparison, a similar volume of blood from healthy adult volunteers was 
obtained by venepuncture and prepared identically to cord blood samples.
The study was approved by both the Cardiff and Vale NHS Trust’s Research and 
Development committee and the South East Wales Research and Ethics Committee 
(Reference number: 05/WSE04/85, 7th September 2005).
Eight pairs of cord and adult samples were used for apoptosis experiments and four 
further pairs for the RT-PCR (section 2.2.5.3) and RPA (section 2.2.5.2) work.
2.2.2 Isolation of peripheral blood neutrophils
Both adult and cord blood samples were mixed by gentle inversion following 
collection and then centrifuged at 450 xg for 20 minutes at room temperature. The 
plasma (upper layer) was then carefully removed from the cellular component in each 
sample and placed into a clean conical tube. This plasma was centrifuged at 1300 xg 
for 20 minutes at room temperature to remove any remaining red blood cells and 
platelets. This platelet poor plasma (PPP) was saved in a clean 15 ml conical tube and 
used to make up the plasma percoll gradient later.
Percoll (Sigma-Aldrich, Dorset, UK) consists of polyvinylpyrrolidone (PVP)-coated 
colloidal silica particles which are 15-30 nm in diameter (23% w/w in water). The 
PVP coating renders the Percoll non-toxic to cells. Percoll is well suited for density 
gradient experiments due to its low viscosity and low osmolarity.
In a 15 ml conical tube, 1.02 ml of 90% Percoll and 0.98 ml of PPP were mixed (51% 
gradient layer). In a separate container a 42% gradient layer was made consisting of 
0.84 ml of 90% Percoll and 1.16 ml of PPP. This mixture was very carefully layered 
over the 51% layer in the 15 ml tube to avoid mixing of the layers. One or two such
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gradients were made for cord blood and another set for adult blood, depending on the 
original volume of blood obtained.
Following the initial centrifugation step and removal of the plasma layer, the lower 
layer of each sample was gently mixed 1:5 with warmed 6% dextran 70 (Baxter 
Healthcare Ltd, Thetford, UK) and then made up to the original volume of the blood 
sample with warmed 0.9% saline. These mixtures were left to settle at 37°C in a 
waterbath for 30 minutes with the lids loosely on until a clear line of demarcation 
could be observed between the lower layer containing red blood cells and the upper 
layer containing the white blood cells. The upper white blood cell-rich layers were 
carefully removed from the tube and centrifuged at 200 xg for 6 minutes at room 
temperature. The supernatants were discarded and the cell pellets gently resuspended 
in 2 ml of PPP each. These mixtures were then very carefully layered on top of the 
appropriate adult or cord plasma percoll gradient, once again to avoid mixing of the 
layers.
The gradients were centrifuged at 350 xg for 13 minutes at room temperature without 
braking. This allows the formation of 3 layers of cells in each tube. The upper layer 
consists of mononuclear cells, the middle layer contains polymorphonuclear 
leucocytes (mainly neutrophils) and the cell pellet in the bottom of the tube contains 
any remaining red blood cells. The layers were carefully aspirated from the gradient 
and placed into clean tubes.
The neutrophils were then washed once in 20 ml of warmed Hanks buffered saline 
solution (HBSS) without calcium and magnesium and twice more in HBSS with 
calcium and magnesium before being counted on a haemocytometer and resuspended 
at a density of ~106cells/ml in flow cytometry buffer for FACS staining and analysis 
or DMEM containing 5% FCS for culture.
Cytospins of the separated neutrophils were made as described in 2.1.3.1 (above) and 
at least 300 cells per slide were counted to obtain a differential cell count and thus 
confirm the purity (percentage neutrophils) of the separated cells.
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2.2.3 Culture
Working in a sterile hood, 100 pi (105 cells) aliquots of the isolated neutrophils were 
placed into each well of a 96-well flat bottomed plate, allowing at least 1 well per test 
for each subsequent planned timepoint as well as additional wells so that cytospins 
could also be made at each time point.
Half the neutrophils were cultured in DMEM medium alone and a further 100 pi of 
media was added to these wells. The other half of the cells were cultured in medium 
containing 50 ng/ml of bacterial lipopolysaccharide (LPS) from E.coli 0157:B8 
(Sigma-Aldrich, Irvine, UK). For this, a solution of medium containing 100 ng/ml of 
LPS was made up and 100 pi of this solution was added to each appropriate well, 
already containing 100 pi of cells in medium.
The plates were covered with plastic lids and placed in an incubator (Hera cell 240, 
Heraeus) at 37°C containing 5% CO2 for the required period (6 or 20 hours).
To remove cells from the plate at the end of the incubation period, cells were gently 
pipetted up and down twice before placing them in a round bottomed plate (or FACS 
tubes for caspase 3) staining. The plate was centrifuged at 500 xg for 4 minutes to 
pellet the cells and the supernatants were carefully removed and frozen at -80°C for 
later analysis.
Cytospins of apoptotic neutrophils at each time point were made as described in
2.1.3.1 above.
2.2.4.1 Preparation of cord and adult neutrophils for flow cytometry analysis
Using a round bottomed 96 well plate, 100 pi of the cell suspension was added to 
each well, including wells for all antibody staining as well as controls for both adult 
and cord neutrophils, according to a standard template (appendix 2) which I designed 
to assess the purity of neutrophil preparations and any relative difference in the 
expression of cell surface markers at the start of the culture period, using the 
antibodies listed in Table 2.1 (above).
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The cells in the plate were incubated for 30 minutes at 4°C in a blocking buffer 
containing PBS, 0.1% sodium azide, 1% BSA, 1% heat inactivated normal mouse 
serum and 5 mM EDTA, to block non-specific antibody binding sites on the cell 
surface. The cells were then centrifuged at 500 xg for 4 minutes and the supernatant 
removed. Biotinylated antibodies were diluted in flow cytometry buffer at pre­
determined optimal concentrations and 80 pi of the appropriate antibody solution was 
added to each well of the plate. Wells not requiring antibody at this stage received the 
same volume of flow cytometry buffer alone. The plate was incubated at 4°C for 30 
minutes. Following the incubation, cells were centrifuged at 500 xg for 4 minutes and 
then washed 3 times using 200 pi of flow cytometry buffer. Secondary fluorescent 
conjugated reagents or directly conjugated antibodies, again diluted to pre-determined 
optimal concentrations in 80 pi of flow cytometry bufer, were added to the cells and a 
further incubation at 4°C for 30 minutes followed. Thereafter, cells were again 
washed 3 times and resuspended in 200 pi flow cytometry buffer. Samples were then 
transferred to test tubes ready for immediate FACS analysis.
FACS analysis was performed as described for BAL samples in 2.1.4.3 (above).
2.2.4.2 Apoptosis
Isolated neutrophils from both cord and adult blood samples were assessed for the 
proportion of apoptotic cells at the start of the culture period (time 0), again at 6 hours 
from commencement of culture (time 6) and again at the end of the culture period 
(time 20) using annexin-V-PE and To-Pro 3 using an identical staining and FACS 
analysis protocol to that used for BAL samples (see 2.1.4.2 above).
2.2.4.3.1 Caspase 3
The amount of activated caspase 3 in cord and adult neutrophils was assessed at each 
of the three time points using Apo Logix ™ - SR Sulforhodamine Caspase Detection 
Kit (Peninsula Laboratories Inc, California, USA) according to the manufacturer’s 
instructions.
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Caspases specifically recognise a 4 amino acid sequence on their substrate, which in 
the case of Caspase 3 is the DEVD sequence. Sulforhodamine (SR)-labelled - DEVD 
-  fluoromethyl ketone (FMK) (SR-DEVD-FMK) is a potent inhibitor of caspase 
activity which enters the cell and binds irreversibly to activated caspase 3, rendering 
these cells visible by flow cytometry. It has lower binding affinity for caspases 8, 7, 
10 and 6.
A stock solution of SR-DEVD-FMK was made up by reconstituting the supplied vial 
of the peptide with 50 pi of DMSO to give a 150x stock solution which was stored in 
aliquots at -20°C. Immediately prior to use the 150x solution was thawed and diluted 
1 part SR-DEVD-FMK to 4 parts PBS to give the 30x working dilution.
Neutrophils were prepared as described in 2.2.4.1 above and then resuspended at a 
density of 106 cells/ml in tissue culture medium and divided into 300 pi aliquots in 
FACS tubes, allowing a control and a test sample for each condition. Each tube 
received 10 pi of a 30x working dilution of SR-DEVD-FMK and were gently mixed 
by flicking the tube. The control sample also received 2 pi of Sue-Ala-Ala (Bachem, 
St Helens, UK), an inhibitor of caspase 3 (molar equivalent of 10 pi of SR-DEVD- 
FMK). The tubes were incubated in the dark at 37°C and 5% CO2 for 1 hour.
Following incubation, 2 ml of IX working dilution of the supplied wash buffer was 
added to each tube before centrifuging at 500 xg for 4 minutes. The supernatant was 
discarded and the cells washed twice more, each time with 2 ml of wash buffer per 
tube, before resuspending the cells in 200 pi of flow cytometry buffer for analysis.
2.2.4.3.2 FACS analysis for caspase 3
The pink SR-DEVD-FMK reagent fluoresces in the red spectrum and 10 000 ungated 
events were collected for both control and test samples. Mean fluorescence intensity 
(MFI) was measured as well as the percentage of cells which were positive for 
activated caspase 3 and compared between control and test samples for both adult 
and cord neutrophils.
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2.2.4.4 Bax
1 chose to investigate the pro-apoptotic protein Bax in cord and adult neutrophils. Bax 
is an intracellular protein and thus neutrophils needed to be fixed and then rendered 
permeable to the Bax antibody (monoclonal phycoerythrin-conjugated mouse anti­
human Bax (Clone 2D2), Santa Cruz Biotechnology). The Fix &Perm kit (An Der 
Grub Bio Research GmbH, Austria) was used for this.
Using a 96-well round bottomed plate, 100 pi of neutrophil suspension (either fresh or 
from culture) was added to each required well. The cells were pelleted by centrifuging 
at 500 xg for 4 minutes. Each cell pellet was gently resuspended in 100 pi of Reagent 
A (a fixative containing formaldehyde) and the plate was incubated at room 
temperature, in the dark, for 20 minutes. The cells were then washed twice with 200 
pi of flow cytometry buffer before adding 100 pi of the supplied Reagent B (the 
permeabilising solution) containing an optimal concentration of Bax antibody or 
appropriate isotype control antibody (IgGl-PE (clone MOPC-21, Biolegend). The 
plate was again incubated for 20 minutes at room temperature in the dark before a 
further 2 washes. The cells were resuspended in 200 pi of flow cytometry buffer and 
analysed immediately.
FACS analysis was performed on the same BD FACScalibur machine as the BAL 
analysis, using appropriate settings which were saved and used for every cord/adult 
blood experiment. FACS data was again analysed using CellQuest software.
2.2.S Analysis of neutrophil mRNA Expression
2.2.S.1 Extraction of neutrophil RNA
Neutrophils were isolated by the plasma-Percoll gradient method (section 2.2.2) 
described above and a cell count was performed using a haemocytometer. Neutrophils
2+  2 1
were spun at 450 xg for 6 minutes at room temperature in HBSS with Ca and Mg 
and the cells were resuspended at 107/ml in HBSS with Ca2+ and Mg2+ then 
transferred as 1 ml aliquots to 1.5 ml RNase-free eppendorfs and microcentrifuged at
2 000 rpm for 2 minutes. Each pellet was resuspended in 250 pi cold PBS and
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following resuspension, 750 pi Tri-Reagent was added. The tubes were inverted to 
mix the contents and then incubated at room temperature for 5 minutes for cell lysis to 
occur. Each tube then had 200 pi chloroform added. Again the tubes were inverted 
and incubated at room temperature for a further 15 minutes. Cells were then spun in a 
microcentrifuge at 11,500 rpm for 15 minutes at 4°C. Following this, three layers are 
visible in each tube: at the bottom is a red layer of protein, in the middle a white band 
of DNA and on top a colourless, aqueous layer containing RNA. The top layer was 
carefully aspirated from each tube, without contamination of the sample with the 
DNA layer and transferred to new 1.5 ml RNase-free eppendorfs. The RNA solution 
was further suspended in 500 pi isopropanol per tube and incubated at room 
temperature for 10 minutes, followed by centrifugation at 11,500 rpm for 8 minutes at 
4°C. All the supernatant was carefully removed and discarded and 1ml 75% ethanol 
added (not resuspended) to the pellet to wash the cells. The tubes were centrifuged at 
9200 rpm for 5 minutes at 4°C and, once the supernatants had been removed, the 
pellets were left to air dry. One dry, the pellets were resuspended in 10 pi RNase-free 
water and stored at -80°C until analysis.
2.2.5.2 Ribonuclease (RNase) Protection Assay (RPA)
The RPA is a highly sensitive and specific method for the detection and quantitation 
of mRNA species. The assay uses DNA-dependent RNA polymerases for the 
synthesis of high-specific-activity RNA probes from DNA templates each of distinct 
length and each representing a sequence in a distinct mRNA species. The probe set is 
hybridized in excess to target RNA in solution, after which free probe and other 
single-stranded RNA are digested with RNases. The remaining “RNase-protected” 
probes are purified, resolved on denaturing polyacrylamide gels, and quantified by 
autoradiography. The quantity of each mRNA species in the original RNA sample can 
then be determined based on the intensity of the appropriately-sized, protected probe 
fragment.
The BD RiboQuant Multi-probe RNase Protection Assay System (BD Biosystems) 
was used according to the manufacturer’s instructions to analyse the RNA obtained 
from cord and adult blood nutrophils. The RPAs were performed by Vanessa
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Singleton in the Department of Respiratory Medicine at the Royal Hallamshire 
Hospital, Sheffield, where she has acquired appropriate expertise in this process.
RNA is very sensitive to RNase contamination and degrades very easily, so for this 
reason, all supplies and reagents used were RNase-free.
a) Synthesis of probe
The [a-32P]UTP, GACU nucleotide pool, DTT, 5x transcription buffer and RPA 
template set were brought to room temperature. The following reagents were added, 
in order, to a 1.5 ml Eppendorf tube: 1 pi RNasin, 1 pi GACU nucleotide pool, 2 pi 
DTT, 4 pi 5x transcription buffer, 1 pi RPA template set, 10 pi [a-32P] UTP, 1 pi T7 
RNA polymerase. The T7 RNA polymerase was kept at -20°C until use and returned 
to -20°C immediately after use. These were mixed and then incubated at 37°C for 1 
hour. The reaction was ended by adding 2 pi of DNase, mixed again and incubated at 
37°C for 30 minutes. Each Eppendorf tube then received (in order) 26 pi 20 mM 
EDTA, 25 pi Tris-saturated phenol, 25 pi chloroform:isoamylalcohol (50:1) and 2 pi 
yeast RNA. These were mixed and then micro-centrifuged for 5 minutes at room 
temperature. The upper, aqueous layer was transferred to a new 1.5 ml Eppendorf 
tube and 50 pi of chloroform: isoamylalcohol (50:1) was added. This was mixed and 
then micro-centrifuged for 2 minutes at room temperature. Again the upper, aqueous 
phase was transferred to a new 1.5 ml Eppendorf tube and 50 pi 4M ammonium 
acetate and 250 pi ice-cold 100% ethanol were added. The tubes were mixed by 
inverting them and incubated at -70°C for 30 minutes, after which they were micro- 
centrifuged for 5 minutes at 4°C. The liquid layer was carefully removed and 100 pi 
ice cold 90% ethanol was added before micro-centrifuging for 5 minutes at 4°C. The 
liquid was removed and the contents of the tube allowed to air dry for 5-10 minutes. 
Finally 100 pi of hybridisation buffer was added and the pellet solubilised by gently 
vortexing for 30 seconds. The probe was then stored at -20°C until needed.
b) Hybridisation
The RNA prepared in 2.2.5.1 was removed from -70°C storage and the quantity of 
RNA was measured using a NanoDrop Spectrophotometer ND-100 (Labtech
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International, Lewes, UK). Each RNA sample was diluted to the same concentration 
and had 8 pi of hybridisation buffer added to the sample. The RNA was solublised by 
gently vortexing and then quickly spinning in the microcentrifuge. The chosen probe 
was diluted with hybridisation buffer and 2 pi of diluted probe was added to each 
RNA sample and mixed by pipetting. A drop of mineral oil was then placed on top of 
the mixture. The tubes were then placed in a pre-heated heat block at 90°C and 
immediately turned down to 56°C. They were then left to incubate for 12-16 hours. 
Samples were removed from the heat block 15 minutes prior to the RNase treatments 
and placed at room temperature to allow the temperature to equilibrate slowly.
c) RNase treatment
An RNase cocktail was prepared consisting of 2.5 ml RNase buffer and 6 pi RNase A 
+ T1 mix for twenty samples. To the RNA samples that had been removed from the 
heat block, 100 pi of cocktail was pipetted underneath the mineral oil into the aqueous 
layer and then incubated at 30°C for 45 minutes. During this time, the Proteinase K 
cocktail was prepared, consisting of 390 pi Proteinase K buffer (prewarmed to 37°C 
to solubilize the SDS), 30 pi Proteinase K and 30 pi Yeast tRNA for 20 samples. This 
was mixed and 18 pi added to new, labelled Eppendorf tubes. The aqueous layer was 
then removed from underneath the oil and placed in the vials containing the 
Proteinase K cocktail. This mixture was incubated for 15 minutes at 37°C before 
adding 65 pi of Tris-saturated phenol and 65 pi of chloroform: isoamylalcohol and 
centrifuged for 5 minutes at room temperature. The upper aqueous layer was aspirated 
and transferred to a new tube and 120 pi 4M ammonium acetate and 650 pi ice-cold 
100% alcohol were added. This was mixed by inverting and incubated at -70°C for 30 
minutes, then centrifuged for 15 minutes at 4°C. The liquid supernatant was removed, 
100 pi of ice-cold 90% ethanol added before centrifugation for a further 5 minutes at 
4°C. The ethanol was removed and the pellet allowed to air dry before adding 5 pi of 
loading buffer.
d) Gel Resolution of Protected Probes
The protected probes were then run on a 4.75% acrylamide sequencing gel composed 
of 35.82 g of urea, 22.35 ml dH20 , 7.45 ml of lOx TBE, 8.85 ml of 40% acrylamide,
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9.31 ml of 2% bis acrylamide, 450 pi ammonium persulfate (10%) and 60 pi TEMED. 
Using the recommended acrylamide concentration and acrylamide:bis acrylamide 
ratio is critical for the correct resolution of unprotected and protected probe bands. 
After polymerisation the gel was run in a vertical gel rig with 0.5x TBE running 
buffer in the upper and lower reservoirs.
The samples were heated for 2-3 minutes at 90°C before loading and running the gel. 
Once complete, the gel was removed, dried and exposed to X-ray film. Initial 
exposures were done overnight but finally required exposure for a week for optimal 
results.
In interpreting the film, it is important to note that the probe lengths are greater than 
the “protected” fragment lengths, due to the presence of flanking sequences in the 
probes which do not hybridise with target mRNA.
2.2.5.3 Reverse transcription -  Polymerase Chain Reaction (RT-PCR)
RNA that has been extracted from neutrophils was used for reverse transcription (RT) 
followed by PCR to analyse mRNA expression in a semi-quantitative manner. All 
RNA work was performed using RNase free pipette tips, eppendorfs and solutions.
The RT and PCR were performed by Kate Vaughan in the Department of Respiratory 
Medicine at the Royal Hallamshire Hospital, Sheffield, where she has acquired 
expertise in this process. The RNA was thawed and DNase-treated to remove any 
contaminating DNA by using a DNA -free™ kit (Ambion, Warrington, UK). Using 
this kit 2 pg of RNA was treated with 1 pi of the supplied DNase-I buffer and 1 pi of 
DNase-I for 25 minutes at 37°C, then 2 pi of stop-reagent beads was added and 
incubated for 2 minutes at room temperature before centrifuging the mixture at 10 000 
xg for 90 seconds. The RNA was then transferred to a fresh tube. The quantity of 
RNA was then measured using a NanoDrop Spectrophotometer ND-100 (Labtech 
International, Lewes, UK).
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Following this, the RNA was converted into cDNA as follows:
In thick walled 0.5 ml eppendorfs, each 1 pg of RNA was made up to a volume of
12.4 pi with RNase-free water, then 8 pi of AMV (Avian Myeloblastosis Virus) 
buffer, 16 pi of 10 mM dNTPs and 1.2 pi each of RNasin, Random primers and 
AMV-RT (all reagents from Promega, Southampton, UK). These tubes were then 
placed in an MJ Research Peltier Thermal Cycler-200 which keeps the reaction 
mixture at 23°C for 5 minutes which allows the oligo d(T) primers to anneal to the 
poly-A tails of the RNA. The temperature is raised to 42°C for 2 hours during which 
cDNA is synthesised, catalysed by reverse transcriptase. The mixtures are then heated 
to 99°C for 2 minutes which denatures the reverse transcriptase enzymes to stop the 
reaction. The products are then cooled to 4°C and held at this temperature until the 
resultant cDNA can be used in the quantitative PCR process.
2.2.5.4 Quantitative PCR
Quantitative PCR (Q-PCR) is a technique which is used to amplify and 
simultaneously quantify a specific sequence of DNA. Simply, cDNA samples are 
produced by the RT process (2.2.5.3 above). Specifically designed forward and 
reverse primers are added and annealed to specific cDNA sequences. A specifically 
designed fluorescent reporter probe is also allowed to anneal to the sequence between 
the forward and reverse primers. The probe has a 5’ high energy reporter dye (6- 
FAM) and a 3’ low energy non-fluorescent quencher (TAMRA) attached. Due to the 
close proximity of the reporter to the quencher its fluorescence is prevented. When the 
DNA polymerase (Taqman Gold), which has 5’-exo-nuclease activity, begins to copy 
the cDNA, it reaches the area where the probe has annealed. Using its 5’-exo-nuclease 
activity it cleaves the reporter dye from the quencher, enabling fluorescence of the 
reporter to be detected. This increase in fluorescence corresponds directly to the 
exponential increase in the number of amplicons generated and this is used to 
determine the threshold cycle (CT) in each reaction. The cycle at which fluorescence 
from a sample crosses the threshold is called the cycle threshold (Ct) (the threshold is 
above background) and since we know that the quantity of DNA doubles every cycle 
during the exponential phase, we can accurately quantify relative amounts of DNA in 
the samples by comparing the results to a standard curve produced by real-time PCR 
of serial dilutions of a known amount of DNA and thus make comparisons between
100
samples. The measured amount of product from the gene of interest is divided by the 
amount of product from a housekeeping gene measured in the same sample to 
normalize for possible variation in the amount and quality of DNA/RNA between 
different samples.
The procedure was carried out as follows: Primers/probes, samples and the mastermix 
were kept on ice. A mastermix was made up for each set of primers. For primer/probe 
sets from Applied Biosystems (HIF-la: Hs00153153_ml; p-actin: Hs99999903_ml; 
GAPDH: Hs99999905_m 1; Bcl-xl: Hs99999146_ml; Mcl-1: Hs00172036_ml; Al: 
Hs00187845_ml)(Applied Biosystems, Gloucester, UK) the mastermix consisted of 
lOpl of buffer which contains the DNA polymerase (RT-QP2X-03, Eurogentec, 
Southampton, UK), 1 pi primer/probe set and 8 pi of sterile water. For the HIF-2a 
primer/probe set (HIF-2a: sense = CTCCCACggCCTgTACggACAC; anti-sense 
=AgTgCTCCCgCTgAATgACTCCACT; probe =
CTCggATTgTCACACCTATggCATATC)(Sigma-Genosys, Dorset, UK) the 
mastermix contained 10 pi of buffer, 0.1 pi forward primer, 0.1 pi reverse primer, 
0.02 pi probe and 8.78 pi water.
Standard curves of known amounts of cDNA were made up in water as follows: For 
Bcl-xl and Mcl-1 normoxic neutrophil cDNA was used in 1:4 serial dilutions to 
produce the standard curve. A l, GAPDH and P-actin used 1:10 serial dilutions of 
normoxic cDNA. HIF-la and HIF-2a used hypoxic cDNA in the standard curve at 
serial dilutions of 1:10 for HIF-la and 1:2 for HIF-2a.
Then, 19 pi of each master mix was accurately pipetted into appropriate wells of a 
polypropylene 384-well plate (Greiner, Gloucester, UK) allowing wells for each 
sample to be analysed and the standard curve in duplicate. Thereafter 1 pi of the 
appropriate standard curve concentration or cDNA sample was added to the 
appropriate wells. The plate was covered and sealed (Biorad, Hemel Hempstead, UK) 
then centrifuged at 800 xg for 2 minutes to remove any trapped air bubbles from the 
bottom of the wells.
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The plate was was then placed in the 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Warrington, UK) and allowed to run. Data was analysed using SDS 2.2.1 
software (Applied Biosystems).
2.3 Statistical Analysis
Statistical analysis for this thesis was performed using Microsoft Excel, SPSS, 
Graphpad Prism and Instat as applicable. In general, lavage data were non-parametric 
in nature and comparisons between data sets were made using Mann-Whitney U tests, 
one way ANOVA (Kruskal-Wallis) and Chi Squared analysis, whilst correlations 
between groups were performed using Spearman correlation co-efficients. Data for 
lavages are expressed as median values with interquartile ranges given, to reduce the 
impact of any results which were marked outliers.
For cord and adult blood data results were normally distributed and as such data were 
also expressed as median and interquartile range (IQR) due to small numbers of 
repeat experiments. Significance was taken as a p value <0.05.
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Chapter 3
Bronchoalveolar lavage cell types and influx
3.1 Introduction
The primary focus of this thesis is the nature and progress of the inflammatory 
response in the lungs of preterm infants and how this may influence the development 
ofCLD.
Recent years have seen many significant changes in the treatment of infants bom 
prematurely as well as in the survival and long-term complications in those infants 
who are now surviving extreme preterm birth (Horbar et al., 2002, Wood et al., 2000). 
CLD continues to be the major respiratory complication in preterm infants, both in 
hospital and after discharge (Jobe, 1999). The aberrant lung development which 
“new” CLD is thought to represent is somewhat different to the simple “injury and 
repair” mechanism seen in historically reported “classical” CLD (Jobe, 1999). 
Although the pathogenesis of “new” CLD is multifactorial, the role of neutrophils 
appears to be pivotal. Their role in maintaining the inflammatory process is key to the 
disturbance of lung development seen in “new” CLD.
In this thesis I have sought to clarify the role of neutrophils and other cellular 
components of bronchoalveolar lavage fluid in infants at risk of developing CLD. In 
this chapter I have chosen to specifically examine whether there is a relationship 
between the number or proportion of neutrophils or macrophages in the BAL fluid 
and gestation or the development of CLD. Additionally I have looked in more detail 
at the surface markers on both neutrophils and macrophages in order to assess 
whether there are differences in the phenotypes of the cells present in different groups 
of infants.
It has been suggested that antenatal infection and the intra-uterine environment have 
an important role to play in the development of CLD and I will test this hypothesis by 
looking in more detail at cell counts and cell surface markers in BAL on the first day 
of life; looking particularly at whether any parameter in BAL on day 1 may be
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predictive of the development of CLD. The role of postnatal infection in the 
development of CLD will also be studied further by looking at the effect of the 
presence of microbial DNA on BAL cell counts and cell phenotypes.
In order to obtain the information required to test the above hypotheses, it was 
necessary to first develop a method for working with and obtaining the largest amount 
of relevant data by flow cytometry from the very small amounts of BAL fluid 
obtained from the smallest preterm infants. The development of this method will be 
described in this chapter. Previous studies of BAL cells (Grigg et al., 1991, Oei et al., 
2003, Kotecha et al., 2003) have relied mainly on data from microscopy and 
immunocytochemistry performed on cytospins and I will compare data gained by 
flow cytometry with cytospin findings.
For the purpose of this thesis the definition of CLD as oxygen dependence at 36 
weeks’ corrected gestation will be used as this implies a more severe form of lung 
disease than oxygen dependence at 28 days. It would be reasonable to assume that an 
infant bom at 23 weeks might continue to require supplemental oxygen at 28 days of 
life as this is only a corrected gestation of 27 weeks. The “36-weeks” definition of 
CLD allows infants to be compared at what should be similar stages of lung 
development rather than comparing very different babies who have simply been ex- 
utero for the same length of time.
3.3 Results
3.2.1 Patient Characteristics
Thirty two infants were recruited into the BAL arm of the study between February 
2006 and June 2008. Of these, 27 were bom at less than 32 weeks’ gestation and 5 
were term controls ie. babies who were ventilated for non-respiratory reasons. In the 
preterm group, 6 babies had resolved their RDS by 28 days of life, 20 remained in 
oxygen at this stage (CLD) and 1 infant died before a diagnosis could be assigned. By 
36 weeks’ corrected gestation, 11 of the surviving preterm babies were classified as 
having resolved RDS and the remaining 15 had CLD (Table 3.1).
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The infant who died was the second of non-identical twins, bom at 26+5 weeks’ 
gestation. The first twin died within hours of birth due to respiratory complications of 
prematurity combined with a large congenital diaphragmatic hernia and was not 
recmited into the study. The second (recmited) twin died on day 5 of life as a result of 
pericardial effusion and cardiac tamponade, a rare complication caused by migration 
of an intravenous long line (Pettit, 2003). This infant was excluded from analysis as 
her diagnosis at both 28 days and 36 weeks was unknown.
All 5 of the term control infants were bom with gastroschisis and were operated on 
during the first few hours of life. In most cases, children bom with gastroschisis who 
undergo primary closure of the abdominal defect are ventilated for only a brief period 
following surgery, however some require longer periods of ventilation, particularly if 
the gastroschisis closure is performed as a staged procedure due to a relatively small 
abdominal cavity. Ventilation of term infants for other non-respiratory reasons is 
unusual, the exception being in infants with hypoxic ischemic encephalopathy (HIE) 
and resultant poor respiratory drive. The pathogenesis of HIE implies a period of 
intra-uterine hypoxia which may have pro-inflammatory effects on the lung leaving 
them far from “normal” and for this reason these infants were excluded from the 
study. As a result of the entry criteria, the number of term control infants recmited 
was limited.
A statistically significant difference was found between the gestational age of infants 
who went on to develop CLD (mean 26+2 weeks; median 26+0 weeks, range 23+4 
weeks to 29+3 weeks) and that of infants whose RDS resolved (mean 28 weeks; 
median 27+1 weeks, range 25+4 weeks to 31+6 weeks) (p=0.024). The term infants 
had a median gestation of 38+1 weeks (range 37+2 to 38+3 weeks). The gestational 
age profile of the infants recmited is shown in Figure 3.1.
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Figure 3.1 demonstrates the gestational ages o f the infants recruited, grouped 
according to diagnosis. Each marker represents one infant and the horizontal lines 
represent the median value for each group.
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Figure 3.2 demonstrates the gestational age profile o f the recruited infants. Each bar 
represents infants born during the stated week o f life. Infants between 32 and 37 
weeks ’ gestation were excluded from this study. The colours indicate the diagnostic 
categories to which the infants were assigned.
Patients who developed CLD did not have a significantly lower birth weight (mean 
875g ; median 85Og; range 560-1230g) than infants whose RDS resolved (mean 
1120g; median lOOOg; range 700-1900g, p=0.102, Mann-Whitney U-test), figure 3.3.
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Figure 3.3. Scatterplot comparing birthweight o f infants. Horizontal lines represent 
median values.
There was no difference in the male: female ratio between groups, although all the 
term controls were male which is consistent with the increased incidence of 
gastroschisis in males (Forrester and Merz, 1999, Calzolari et al., 1993, Alvarez and 
Burd, 2007) (Table 3.1). A similar proportion of infants in each group were bom by 
Caesarean section (Table 3.1).
The majority of preterm infants received antenatal steroids (Table 3.1). Not all babies 
in each group had received a full 2-dose course of antenatal steroids (6/11 in the RDS 
group and 9/15 in the CLD group) but this was not a statistically significant difference 
(p=0.46, Chi square test). All 11 babies in the RDS group had received at least one 
dose of steroids which was significantly more than the CLD group where only 10/15 
babies had been at least partially treated (p=0.033). One of the term infants had 
received a course of antenatal steroids for threatened preterm labour several weeks 
prior to delivery.
In line with the neonatal unit policy to administer exogenous surfactant to all 
intubated preterm infants as soon as possible after intubation, 100% of preterm babies 
received exogenous surfactant therapy (Curosurf™, Trinity-Chiesi Pharmaceuticals 
Ltd, UK) (Table 3.1).
There was no statistically significant difference between the number of infants with 
either RDS or CLD who were bom following prolonged rupture of the membranes
(RDS 4/11 and CLD 2/15) (p= 0.18, Fisher’s exact test) or between the groups when 
comparing for suspected maternal infection (based on maternal pyrexia, offensive 
vaginal discharge, elevated maternal CRP or WBC count) (p=0.69, Chi square test) 
(Table 3.1).
All the infants who developed CLD had a patent ductus arteriosus diagnosed during 
their admission compared to only 5/11 babies with RDS (p=0.002, Fisher’s exact 
test). In the CLD group 9/15 required medical (indomethacin) or surgical (ligation) 
intervention compared to only 1 of the 5 in the RDS group (p=0.152, Fisher’s exact 
test) (Table 3.1).
It is not surprising that those infants with apparently worse lung disease, who 
frequently went on to develop CLD, were ventilated for significantly longer than 
those infants whose RDS resolved. CLD infants were ventilated for a median of 36 
days (range 12-92 days) compared to infants whose RDS resolved who were 
ventilated for a median of 4 days (range 2-12 days), p=0.001. As a consequence, 
fewer samples were inevitably obtained from the resolved RDS group than the infants 
who developed CLD (Table 3.1).
Of the 15 infants who developed CLD, 7 were defined as having severe disease using 
the NICHD/NHLBI criteria (Jobe and Bancalari, 2001), as they were on IPPV or 
CPAP and/or requiring >30% oxygen at 36 weeks’ corrected gestation.
In total 207 BALs were performed. Of these 152 were from infants who developed 
CLD, 32 were from infants whose RDS resolved, 4 were from the infant who died and 
19 were from term controls. The median fluid volume recovered from the BALs 
performed was 61% of the volume of fluid introduced (mean 61.2%, range 23.5% - 
145.5%).
An element of bias is inherent in the nature of any study which requires infants to be 
intubated in order for lower airway secretions to be collected. Very few RDS infants 
remained ventilated beyond days 4 and 5 of life, thus it is only possible to make direct 
comparison between groups for the first few days of life and it is not possible to 
comment on what changes may be occurring in infants’ lungs following extubation,
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although we assume that if these infants remain extubated, that any changes within the 
lung are unlikely to be causing any significant respiratory compromise, compared to 
the intubated infants. Clearly for CLD infants, more samples will give the opportunity 
for greater amounts of data to be accumulated and for more peaks or troughs in 
various parameters to occur. Whilst these issues need to be considered when 
comparing groups, the longitudinal nature of our samples in individual infants does 
allow us to assess the nature of the inflammatory response and its resolution in these 
infants and to compare the relationships between numerous parameters for individual 
infants as well as groups of babies. Details of patient demographics are shown in table 
3.1.
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CLD group RDS group Term controls
Number of Patients 15 11 5
Number of Samples 152 32 19
Median Gestational Age 26+0 27+1 38+1
(range) (23+4_29+3 w ks) (25+4-31+6 wks) (37+2-38+s wks)
Median Birth Weight 850g lOOOg 2766g
(range) (550-1230g) (700-1900g) (2570-3000g)
Male: Female 7:8 8:3 5:0
Vaginal: Caesarean 
delivery
10:5 5:6 2:3
At least 1 dose antenatal 10/15 (67%) 11/11 (100%) 1/5 (20%)
steroids
Full course steroids 6/15 (40%) 6/11 (55%) 1/5 (20%)
Patent Ductus Arteriosus 15/15(100%) 5/11 (45%) 0/6 (0)%
PDA treated medically 
or surgically
9/15 1/5 0/0
Surfactant therapy (%) 15/15(100%) 11/11 (100%) 0/5 (0%)
Rupture of membranes 2/15(13%) 4/11 (36%) 0/6 (0%)
>24 hours
Infection suspected 
peripartum
7/15 (47%) 6/11 (55%) 0/6 (0%)
Median days of 36 4 3
ventilation (range) (12 - 92 d) (2 - 12 d) (2-9 d)
Table 3.1. Patient characteristics. Values are shown as medians or total numbers with 
percentages in brackets.
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3.2.2 Development of BAL cell processing method
3.2.2.1 DTT
In order to analyse cells from BAL samples, it is necessary to “extract” the cells from 
the thick mucus in which they are enveloped in the airways and thus in the BAL 
sample. Various methods of obtaining cells for analysis from sputum samples have 
been tried, including addition of DTT, deoxyribonuclease (DNAse), N-acetyl-L- 
cysteine, sodium EDTA or trypsin as well as mechanical methods such as mechanical 
blending or filtration of sputum through gauze or glass wool (Tockman et al., 1995, 
Pang et al., 1995). Given the very small volume (frequently less then 1 ml) of 
neonatal BAL samples, I felt that mechanical methods were unlikely to yield 
sufficient remaining sample for analysis and could potentially damage or activate any 
cells present. The use of DTT is the most frequently cited method in the literature in a 
range of concentrations, the most frequently used being around 50 pg/ml (Lensmar et 
al., 1998, Saraiva-Romanholo et al., 2003).
DTT is a reducing agent which breaks down disulphide bonds in sputum, rendering it 
less viscous and allowing cells within a sputum sample to be liberated for analysis. I 
was concerned that the reducing effect of DTT may alter the conformation of cell 
surface markers, thus changing the binding properties of the antibodies I was using for 
flow cytometry.
Although DTT has been used frequently in studies on adult sputum, there have been 
limited descriptions of its effect on cell surface markers detected by flow cytometry 
(Dominguez-Ortega et al., 2002, Loppow et al., 2000, Qiu and Tan, 1999) and these 
did not include a number of the antibodies which I was planning to use.
I studied the effect of DTT on the detection of the cell surface markers I had chosen to 
study in our neonatal BAL samples by exposing adult peripheral blood leucocytes to 
DTT and comparing cell surface marker expression against cells from the same blood 
sample not exposed to DTT.
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Two sets of experiments were performed - firstly to assess the effect of DTT on cell 
surface marker detection by flow cytometry and secondly to determine the optimal 
concentration of DTT.
There was no difference in the mean fluorescence intensity between DTT treated and 
untreated cells using DTT at a concentration of 50 jag/ml (Figure 3.4).
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Figure 3.4 Graphs showing mean (and standard deviation) fluorescence intensity for 
19 different antibodies by flow cytometry in DTT treated and untreated peripheral 
blood neutrophils. n=6 DTT treated and 6 untreated.
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Adding DTT to clinical BAL samples according to the method described above 
produced a visible alteration in the viscosity of the mucus component of the BAL 
sample, making the cell pellet easier to resuspend with much less vigorous pipetting, 
which could otherwise potentially have activated the neutrophils.
Flow cytometry analysis showed no significant difference in the mean fluorescence 
intensity between DTT treated and untreated cells for all of the antibodies and isotype 
controls used, which suggested that DTT did not cause a change in any of the epitopes 
to which our antibodies would bind. Thus, DTT at 50 pg/ml for 15 minutes at room 
temperature was selected as the method of dealing with the mucus component of BAL 
samples in order to obtain an appropriate cell suspension for analysis, particularly for 
flow cytometry purposes. All BAL samples were treated in this way before analysis.
3.2.2.2 Working with very small numbers of cells
One of the biggest challenges of designing flow cytometry experiments on neonatal 
lung lavage samples is to be able to use the very small amount of sample available to 
obtain the largest possible amount of information. From previous studies (Mildner et 
al., 2005, Curley et al., 2004) and previous experience gained in our laboratory, I was 
able to estimate that the average return from a BAL procedure was of the order of 50- 
60% of the fluid instilled, however reported cell counts in the returned BAL varied 
widely.
Using mixed peripheral blood leucocyte populations, separated using dextran 
sedimentation, as described in section 2.2.2,1 was able to optimise antibody 
concentrations for each antibody used, working with 105 cells in 100 pi of buffer in 
each well of the 96 well plate in which the cells were being stained. The number of 
cells was then reduced to as few as 3xl04 cells with a corresponding reduction in 
antibody added and I was still able to obtain 10 000 gated events on the flow 
cytometer with similar mean cell fluorescence values when cells were analysed. It 
was then possible, once sufficient cells for cytospin preparation had been removed 
from the BAL sample, to calculate the number of aliquots of at least 30 000 cells into 
which the remaining sample could be divided for flow cytometry staining. With cell
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counts as low as 3x10 /ml or as high as 2x10 /ml, 3 templates were designed so that a 
basic level of information could be obtained from all BAL samples and additional 
data could be obtained from samples in which there was a relative abundance of cells 
(appendix 2). Even so, there were 3 BAL samples, of the 207 obtained, in which there 
were so few cells that only Annexin-V/To-Pro-3 staining for apoptosis was possible.
3.2.3 Flow cytometry of neonatal BAL samples
I was unable to find published flow cytometry plots of neonatal lung lavage, although 
some data for adult lung lavage has been published in this format (Rosseau et al., 
2000a, Guth et al., 2009). By running antibody-stained and unstained BAL cells from 
8 infants of different gestations and postnatal ages, appropriate flow cytometer 
settings were developed which could be used across the range of samples. These 8 
BAL samples were obtained from infants enrolled in another study of BAL samples in 
our department and were surplus to the requirements of the study. I am very grateful 
to Dr Phil Davies for his generosity in sharing these samples with me.
3.3 Bronchoalveolar lavage cell counts
Cell counts were performed using a haemocytometer and differentials performed by 
flow cytometry and by microscopy. The microscopy was undertaken by Sharon Gill 
using cytospins, as described in section 2.1.3.1.
3.3.1 Non-viable cells
Cells counted on the haemocytometer were stained with trypan blue (section 2.1.3 of 
Materials and Methods) to assess the viability of the BAL cells. The mean percentage 
of non-viable cells was 14.8% (range 0-60%). There was no significant difference 
between term and preterm infants (Mann-Whitney U-test, p=0.90), nor between 
babies who developed CLD and those whose RDS resolved (Mann-Whitney U-test, 
p=0.75) (Figure 3.5).
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Figure 3.5 Graph showing the median percentage o f non-viable (trypan blue positive 
staining) cells in all the BAL samples on different days o f collection. The error bars 
represent interquartile ranges.
3.3.2 Debris in BALs
From the outset it was noticeable that there was a large amount of low forward 
scatter/low side scatter material present in BAL samples which did not stain with any 
of the antibodies which I used to detect neutrophils or monocytes/macrophages by 
flow cytometry. The material was seen in the lower left-hand comer of the FSC/SSC 
plots, indicating material of small size and low granularity (Figure 3.6). It was most 
abundant in the first few days of life and reduced as the babies got older. From 
cytospins, much of this material was thought to be damaged fragments of cells and 
cell membranes, platelets and red blood cells and which I termed “debris”.
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Figure 3.6 Forward scatter (FSC) (horizontal axis) vs side scatter (SSC) (vertical 
axis) flow cytometry plots showing low forward scatter/low side scatter material 
identified as debris in BAL samples. Figure 3.6A represents a sample taken on day 1, 
figure B is a sample from the same baby on day 7 and figure C is from the same baby 
on day 20. R1 corresponds to the cells marked in red and the percentage o f the 
sample represented by the red area.
In order to further elucidate the nature of this debris, I used a phycoerythrin- 
conjugated antibody to CD59 (Mouse anti-human CD59-PE, Caltag Laboratories, 
Buckingham, UK), a complement regulatory protein (protectin) which is found on all 
human cells. Most of the material I had labelled debris was positive for CD59, 
indicating that it originated from human cells (Figure 3.7). The proportion of the 
sample that was CD59 positive however, was variable and was higher in the earliest 
BAL samples from each baby. Of the 207 samples taken, 5 were noted to be blood 
stained and these samples had very large amounts of so-called debris, an example of 
which can be seen in Figure 3.7. Additionally antibodies to CD3 and CD4 were used 
to identify lymphocytes There were no lymphocytes detected in any of the 10 BAL 
samples from different gestations and postnatal ages which were analysed for these 
markers.
The range of non-cellular (ie. CD59 negative) material varied between 0 and 90% of 
the total number of events counted by the flow cytometer for each sample. In the 
majority of samples it made up around 40% of the total event count. Debris which 
was CD59 negative stained positively for To-Pro-3, indicating the presence of DNA 
among the debris, confirming the possibility that much of the debris consisted of cell 
fragments.
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Figure 3.7 Forward scatter (horizontal axis) vs side scatter (vertical axis) plot (A) 
and histogram (B). “Debris ” in a BAL sample taken on day 16 from a preterm infant 
who developed CLD (Baby Y) is marked in red. The histogram shows only the 
material marked in red in plot shown in (A). The black line represents CD59-PE 
staining o f the “debris ” material and the blue histogram is an appropriate IgGl-PE 
isotype control.
When the amount of debris was averaged over the whole period of ventilation, 
preterm infants had significantly less debris present (p<0.0001) but it can be seen in 
figures 3.8 and 3.9 that the amount of debris in the BAL samples falls steeply over the 
first few days of life and relatively little debris remains in BALs of babies who remain 
ventilated and develop CLD. In the first 5 days of life when term and preterm infants 
can be adequately compared as the term and RDS groups are still ventilated, there was 
no significant difference between the diagnostic groups or between term and preterm 
infants.
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Figure 3.8 Graph showing median (and interquartile range (IQR)) percentage ofBAL 
sample composed o f debris. It can be clearly seen that the amount o f debris present 
was highest in the first few  days o f sampling before decreasing to a consistently lower 
level after the first week o f life.
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Figure 3.9 Graphs showing the median percentage o f BAL samples composed o f  
debris according to (A) diagnosis and (B) gestation. Error bars represent 
interquartile ranges.
For the purpose of analysis of results of FACS plots for the remainder of this thesis, 
the debris material was gated out.
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3.3.3 Total cell counts
Total cell counts obtained by haemocytometer counting were noted to be significantly 
greater in BAL fluid of preterm ventilated infants compared to term controls (Preterm 
median 1.48 xlO6cells/ml, mean 2.24 xlO6 cells/ml, range 0-15 xlO6 cells/ml; Term 
median 0.69 xlO6 cells/ml, mean 0.71 xlO6 cells/ml, range 0.07 -  1.7 xlO6 cells/ml; 
p=0.0002, Mann-Whitney U-test, Figure 3.10B). There was no significant difference 
in total cell counts between infants who went on to develop CLD (mean 2.19 x 106 
cells/ml; range xlO6 cells/ml, median 1.45 xl06cells/ml) compared to infants whose 
RDS resolved (mean 2.44 xlO6 cells/ml; x l06cells/ml, median 1.84, p=0.15, Mann- 
Whitney U-test, Figure 3.10A). However, both RDS and CLD groups were 
significantly different to term babies (Kruskal-Wallis test, p=0.0004, CLD vs term 
p<0.01, RDS vs term p<0.001).
RDS Term Preterm Term
Figure 3.10 Scatterplots showing total cell count in all BAL samples by (A) diagnosis 
and (B) gestation. Horizontal lines represent medians.
The highest recorded (peak) total cell counts in each infant were also noted to be 
significantly greater in BAL fluid of preterm ventilated infants compared to term 
controls (Preterm median 3.86 xlO6 cells/ml, mean 4.70 xlO6 cells/ml, range 0.7-10.9 
xlO6 cells/ml; Term median 1.04 xlO6 cells/ml, mean 1.033 xlO6 cells/ml, range 0.427 
-1 .7  xlO6 cells/ml; p=0.0027, Mann-Whitney U-test) (Figure 3.1 IB). There was 
again no significant difference in peak total cell counts between infants who went on 
to develop CLD (mean 5.21 x 106 cells/ml; range 1.05-10.9 xlO6 cells/ml, median 
5.09 xlO cells/ml) compared to infants whose RDS resolved (mean 3.93 xlO 
cells/ml; range 0.7-7.72 xl06cells/ml, median 3.13 xlO6 cells/ml; p=0.332, Mann- 
Whitney U test) (Figure 3.11 A).
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Figure 3.11 Peak cell count for all infants according to (A) diagnosis and (B) 
gestational group. Horizontal lines display median cell counts.
The day on which the peak cell counts occur was earliest in term babies (median day 
of peak count = day 1, mean 1.25 days), followed by RDS babies (median day 2, 
mean 2.44 days) and finally in babies who get CLD (median day 7, mean 9.5 days) 
(Figure 3.12). This may represent a delay in the ability to mount an inflammatory 
response in the group who get CLD or imply that the processes by which cells are 
removed from the lung are more efficient in term infants. When the cell counts for 
only the first 5 days of life are compared (ie. while babies from all 3 groups remain 
ventilated), the peak cell count in babies who get CLD occurs on a median of day 2.5 
(mean 2.88), implying that, while babies who develop CLD have a peak in total cell 
count during the first 5 days of life, a higher peak cell count occurs after the first 5 
days of life too.
Preterm infants who get CLD have a larger number of samples due to their continuing 
intubation and ventilation. When looking at pooled data for the whole CLD group of 
babies, an apparent second rise in the total cell count, peaking around day 21 can be 
seen in the CLD group after the RDS and term groups have been extubated. In 
practice, when cell counts are measured longitudinally, episodic spikes in cell counts 
were observed, frequently increasing from a low baseline and then returning to 
baseline following such a spike. Individual patients rarely had cell counts that 
resemble the overall median value trends, and this can be seen in the individual 
patient data in figure 3.13. Factors likely to be associated with these episodic spikes 
will be examined in more detail later in this chapter.
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When all three diagnostic groups are compared longitudinally (Figure 3.12), a 
significant difference between the cell counts in the three diagnostic groups can be 
detected on day 5 (p=0.047, Kruskal-Wallis test) although small numbers make 
comparison between the groups difficult. The trend observed is that term infants 
generally have lower total cell counts which fall gradually until extubation, whereas 
preterm infants show a marked rise in total cell count from about day 3 until the end 
of the first week of life.
Preterm infants have consistently higher total cell counts than their term counterparts. 
Possible reasons at this stage could include immaturity of regulation of cell 
recruitment or disposal as well as possibly a different distribution of cell types within 
the total which may predispose to ongoing inflammation.
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Figure 3.12 Graphs showing longitudinal variation in median total cell count for (A) 
babies divided into groups based on diagnosis and (B) babies divided by gestational 
age. Error bars show interquartile ranges. (*p=0.047)
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Figure 3.13 Graphs o f total cell count for individual babies (only babies with 3 or more 
samples are represented). Late spikes in cell counts can be seen in infants ventilated over 
longer periods. Vertical arrow heads indicate that the BAL sample had 16S rRNA genes 
detected, implying the presence o f microbes in the sample.
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3.3.4 D ifferential counts
3.3.4.1 Comparison of BAL FACS data against BAL cytospin data
Differential counts of cells in BAL were obtained both by flow cytometry and by 
counting of cytospin preparations.
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Figure 3.14 Bland-Altman plots showing relationship between the differential count 
obtained by FACS and by microscopy o f counted cytospin preparations for (A) 
neutrophils and (B) macrophages. Horizontal dotted lines represent 95% limits o 
agreement.
Overall, the cytospin preparations gave significantly higher results for the percentage 
of neutrophils in BAL samples (Mean cytospins 73.86; mean FACS 56.14%, 
p<0.0001, Paired t-test) but there was a reasonable level of agreement between the 
two measurements (Figure 3.14A). Cytospins gave significantly lower results for the 
percentage of macrophages in BAL samples than FACS (Mean cytospins 22.0%; 
mean FACS 43.31%, p<0.0001, paired t-test) but again there was agreement between 
the two observations (Figure 3.14B). Possible reasons for this are reviewed in the 
discussion at the end of this chapter.
As identification of cell types by flow cytometry is potentially more accurate and 
enables further differentiation of sub-types of cells, data acquired by flow cytometry 
will be presented for all following cell type data.
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3.3.4.2 N eutrophil counts
Neutrophils were the predominant cell type in the majority of BAL samples, as 
identified by the expression of CD 15 on the cell surface.
Preterm infants had significantly higher neutrophil counts than their term counterparts 
(Preterm mean 0.84 xlO6 cells/ml, median 0.26 xlO6 cells/ml, range 0.01-11.12 xlO6 
cells/ml; Term mean 0.08 xlO6 cells/ml, median 0.04 xlO6 cells/ml, range 0.01-0.32 
xlO6 cells/ml; Mann-Whitney U-test, p=0.001)(Figure 3.15B). The difference in the 
absolute number of neutrophils was highly significant between CLD and term infants 
and between RDS and term infants (CLD mean 0.84 xlO6 cells/ml, median 0.25 xlO6 
cells/ml, range 0.01-11.12 xlO6 cells/ml; RDS mean 0.85 xlO6 cells/ml, median 0.62 
xlO6 cells/ml, range 0.1-3.60 xlO6 cells/ml; Term mean 0.08 xlO6 cells/ml, median 
0.04 xlO6 cells/ml, range 0.01-0.32 xlO6 cells/ml; Kruskal-Wallis test, p=0.001, CLD 
vs term <0.01, RDS vs term <0.001) although there was no significant difference 
between babies whose RDS resolved and those who developed CLD (Figure 3.15A).
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Figure 3.15 Scatterplots showing absolute neutrophil counts in BAL samples for 
babies according to (A) diagnosis and (B) gestation. Horizontal lines represent 
medians in each group.
When looking at peak values for neutrophil count, there were no significant 
differences between the peak neutrophil counts measured in the three diagnostic 
groups (Kruskal-Wallis test, p=0.089) (Figure 3.16A) or between term and preterm 
infants (p=0.095, Mann-Whitney U-test) (Figure 3.16B), however there was a 
significant difference (p<0.05) between CLD and term infants (Figure 3.16A) (CLD 
mean 3.64 xlO6 cells/ml, median 2.82 xlO6 cells/ml; RDS mean 1.50 xlO6 cells/ml, 
median 1.19 xlO6 cells/ml; term mean 0.57 xlO6 cells/ml, median 0.25 xlO6 cells/ml;
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preterm mean 2.80 xlO6 cells/ml, median 1.91 xlO6 cells/ml). This suggests that 
overall levels of neutrophils were higher in the preterm infants but that the peak levels 
attained did not differ statistically.
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Figure 3.16 Scatterplots representing peak neutrophil counts for each infant 
according to (A) diagnosis and (B) gestation. Horizontal lines indicate medians.
The days on which these peaks occurred may indicate a difference in the ability of the 
infants to recruit inflammatory cells to the lung. Neutrophil counts achieved their 
peak values earliest in term infants and babies with RDS (Term mean 2.5 days median 
2 days; RDS mean 2.5 days median 2 days) and much later in CLD (mean 10.1 days 
median 7 days) (Figure 3.17A) -  in other words the peak neutrophil counts in the 
CLD group tend to occur after almost all of their RDS and term counterparts had been 
extubated.
If data for only the first 5 days of life are compared, babies who go on to get CLD 
show a peak at a mean of 3.3 days (median 3.5 days) while RDS and term values 
remain unchanged. In other words the peak of neutrophil influx is still somewhat 
delayed in CLD infants compared to RDS and term babies. This may be a true delay 
in postnatal neutrophil influx the CLD group or may be as a result of earlier (perhaps 
antenatal) neutrophil influx in the other two groups or simply because it takes longer 
for such a large number of cells to leave the circulation and migrate into the airways.
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Figure 3.17 Graphs showing median (and interquartile range) neutrophil count over 
time according to (A) diagnostic group and (B) gestational age.
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In figure 3.17(A), it can be seen that in babies whose RDS resolved, the median 
absolute neutrophil count was higher than either of the other groups on each day 
studied. This may be partly as a result of the small number of infants in the group who 
remained ventilated for longer periods, particularly on days 5 and 6, where the result 
shown on the graph represents a “median” of only two or three babies’ results. For 
this reason, patterns of BAL fluid neutrophil counts for individual babies over the 
duration of their time on ventilation may be more informative than aggregated data. 
Data showing the BAL neutrophil counts for individual infants with 3 or more BAL 
samples is shown in Figure 3.18.
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Figure 3.18 Absolute neutrophil count (as identified by flow cytometry) for all infants 
with 3 or more BAL samples taken. Arrows represent days on which microbial DNA was 
isolated from the BAL.
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3.3.4.3 N eutrophil cell surface m arkers
Neutrophils are the first line of defence in the innate immune system. They express a 
number of molecules on the cell surface to enable them to respond to foreign material, 
which include CD 14, TLR2 and TLR4. There were fewer samples assessed for these 
markers as there were frequently insufficient cells available from the BAL sample to 
allow for the additional flow cytometry analysis which these markers required. Of the 
207 samples collected, 80 had neutrophil CD 14 assessed and 87 had TLR 2 and 4 
assessed. I attempted to assess the differences in these cell surface markers in relation 
to gestation and diagnosis as well as any changes in the markers over the duration of 
ventilation.
3.3.4.3.1 CD 14 expression on neutrophils
Quiescent adult neutrophils express low levels of CD 14 on the cell surface (Barth et 
al., 2001, Alexis et al., 2001). Eighty of the 207 BAL samples had sufficient cells 
present in order to look more closely at CD 14 expression on neutrophils. In the BAL 
samples analysed, I saw that some of the most preterm infants had a large proportion 
of the neutrophil population expressing high levels of CD 14, particularly on the first 2 
days of life (Figure 3.20 babies BB, CC and G) compared to term infants (Figure 3.20 
babies H and X). There was no significant difference in the mean CD 14 expression on 
neutrophils between term and preterm infants (p=0.63, term mean 41.43%, median 
29.24%, range 3.5-95.1%; preterm mean 36.52%, median 24.08%, range 0.2-97.2%). 
There was no significant difference between the groups on individual days or between 
term and preterm infants. There were insufficient data to separate infants with RDS 
from those who developed CLD.
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Figure 3.19 Graph showing median percentage o f neutrophils with high CD14 
expression in term and preterm infants. Error bars show interquartile ranges.
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Figure 3.20 Graphs showing the percentage o f neutrophils with high CD 14 
expression in infants with 3 or more BAL samples.
3.3.4.3.2 T L R  2 and  4 expression on neu troph ils
TLR 2 and 4 are both expressed in small amounts on quiescent adult neutrophils 
(Koller et al., 2008, Harter et al., 2004) and in lower amounts in studies on neutrophils 
isolated from umbilical cord blood samples (Viemann et al., 2005, Sadeghi et al., 
2007) and are important for pathogen recognition by the neutrophil. No published 
data on TLR expression in neonatal BAL samples were found.
There was sufficient BAL sample available to study TLR expression on neutrophils in 
87 of the 207 BAL samples. The percentage of BAL neutrophils expressing TLR 2 
and TLR 4 was small, with TLR 2 expression slightly higher than TLR4 and both 
TLR 2 and TLR 4 appeared to change in their expression in parallel with one another 
from sample to sample.
Overall the percentage of neutrophils showing detectable TLR 2 expression in term 
infants was significantly more than in preterm infants even in this small sample 
(p=0.048, term mean 47.66%, median 59.05%, range 2.8-87.7%; preterm mean 
15.0%, median 8.1%, range 0.25-98.89%) (Figure 3.21 A). There was no significant 
difference between infants with RDS and those who developed CLD (p=0.159), nor 
was there any difference in TLR 2 expression between the groups on individual days.
The percentage of neutrophils expressing TLR 4 was also significantly higher in term 
infants than their preterm counterparts (p=0.041, term mean 43.89%, median 51.1%, 
range 1.77-87.7%; preterm mean 11.89%, median 5.63%, range 0-81.2%) (Figure 
3.2IB), but again there was no significance between infants with RDS and those who 
developed CLD nor between the groups on individual days.
Together these data may indicate that preterm neutrophils may have a reduced ability 
to recognise pathogens in the lung, which may allow the pathogen to persist, rather 
than be cleared and potentiate the inflammatory response within the lung.
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Figure 3.21 Graph showing median percentage o f neutrophils with high (A) TLR 2 
and (B) TLR 4 expression in term and preterm infants. Error bars show interquartile 
ranges.
142
tx
pr
ttt
ln
g 
TLR
 
1 
of 
m
ut
ro
pN
U 
tx
pr
xi
ttn
g 
TLR
 
% 
at 
nt
U
ro
pN
It 
up
ro
ot
in
gT
LR
 
* 
* 
of 
na
ut
ro
ph
lls
 
up
ro
ot
in
g 
TL
R
Baby EE -  24 wks, CLD
100- |
8 0 -
8 0 -
o s 10 18 20 25
Day
Baby G -  25 wks, CLD
100-1
8 0 -
so-
4 0 -
0 9 10 15 20 25
0*1
Baby L -  26 wks, CLD
100-1
so
40
20
15 20 25100
Day
Baby N -  25 wks, CLD
100-1
8 0 -
6 0 -
20-
0*1
Baby 0 - 2 6  wks, CLD
100-1
*W*
IX
m
4 0 -
8 20- **
0 5 10 15 20 25
Day
Baby Q -  25 wks, CLD
100-1
2
?*
tX
8 0 -
8 0 -
? 20-
at
0 6 10 15 20 25
Day
Baby R -  29 wks, CLD
100
2
?
*(x
60
15 20 250 5 10
Day
Baby U -  28 wks, CLD
100
so
6 0 -
8*a*
Day
143
ITU 
O
ui*««jdx* 
(widiM
inw 
to 
% 
¥11 But«t*jd»« 
tim
dowM
J ID 
% 
. WU 
&
*•»»*»»• 
*iw
dofln«o 
to 
%
Baby V - 28 wks, CLD
20-
0 ■ 10 20 25
Day
Baby J -  27 wks, RDS
10 20 280
Day
Baby M -  28 wks, RDS
20
Baby S -  26 wks, RDS
100-1
2?*<0I«
4 0 -
**
0 10 18 20 28
Day
Baby T -  26 wks, RDS100
5
!
I so-
4 0
20-
*
8 10 18 20 280
Day
Baby H -  Term
5
f
i
20
*
20
Day
Figure 3.22 Graphs showing the percentage o f neutrophils expressing TLR 2 (black 
line) and TLR 4 (grey line) in individual infants with 3 or more BAL samples.
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3.3.4.4 Macrophages
Cells of the monocyte/macrophage lineage (MNC) were identified using 
combinations of antibodies to CD1 lb, CD 14, CD36 and HLA-DR. Macrophages were 
all CD1 lb positive as well as being either CD36 or HLA-DR positive or both.
The number of macrophages in BAL samples from preterm infants was very 
significantly higher than in term babies (Mann-Whitney U-test, p<0.0001) (Preterm 
median 0.29 xlO6 cells/ml, mean 0.48 xlO6 cells/ml; Term median 0.05 xlO6 cells/ml, 
mean 0.07 xlO6 cells/ml) (Figure 3.23B). There was however no significant difference 
between the CLD and RDS groups (Kruskal-Wallis test, p<0.0001, CLD vs term 
<0.001, RDS vs term <0.01) (CLD median 0.29 xlO6 cells/ml, mean 0.49 xlO6 
cells/ml; RDS median 0.31 xlO6 cells/ml, mean 0.43 xlO6 cells/ml; Term median 0.05 
xlO6 cells/ml, mean 0.07 xlO6 cells/ml) (Figure 3.23A).
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Figure 3.23 Scatterplots showing absolute macrophage count in BAL samples 
according to (A) diagnosis and (B) gestation. Horizontal lines represent medians.
When peaks in the macrophage count are assessed, there is a significant difference 
between the peak number present in term and preterm infants (Mann-Whitney U-test, 
p=0.021) (Term mean 0.13 xlO6 cells/ml, median 0.13 xlO6 cells/ml; preterm mean 
1.34 xlO6 cells/ml, median 1.07 xlO6 cells/ml) (Figure 3.24B). Also, when comparing 
the different diagnostic groups, there is a statistically significant difference between 
the peak macrophage count in term infants and those who get CLD (p<0.05) but not 
between RDS and CLD or between RDS and term babies (Term mean 0.13 xlO6 
cells/ml, median 0.13 xlO6 cells/ml; RDS mean 0.93 xlO6 cells/ml, median 0.49 xlO6 
cells/ml; CLD mean 1.58 xlO6 cells/ml, median 1.60 xlO6 cells/ml; Kruskal-Wallis 
test, p=0.023) (Figure 3.24A).
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Figure 3.24 Scatterplots showing peak macrophage counts fo r  each infant based on 
(A) diagnosis and (B) gestation. Horizontal lines represent medians.
The days on which peak macrophage counts occurred differed in the three groups; 
with term babies experiencing their highest macrophage counts on day 1 (median 1 
day, mean 1.25 days), babies with RDS a little later (median 2 days, mean 2.4 days) 
and CLD even further delayed (median 7 days, mean 9.1 days). These days do not 
agree exactly with the data shown in Figure 3.25 as the peak days were calculated by 
taking the median (or mean) of the days on which the highest count occurred in each 
baby, taking no account of the absolute number of macrophages on that day.
If only the first 5 days of life were reviewed, in order to compare groups of babies 
who were all still ventilated and exclude any later macrophage count increases in the 
group of babies who remained intubated for longer periods, the peak count in the 
CLD group was experienced after an average of 4.1 days (median 4 days), which is 
still later than the other two groups. This may imply a delayed monocyte influx in the 
CLD group relative to the other two groups or simply a longer time being required to 
reach the higher count, similar to that seen in neutrophil influx.
When viewed longitudinally, there is a significant difference among the 3 groups on 
day 5 (Kruskal-Wallis test, p=0.049) (Figure 3.25B) but numbers in each group are 
too small to make further comparisons between the groups. When term and preterm 
infants are compared, preterm infants have significantly higher macrophage counts on 
day 4 and day 5 than their term counterparts (Mann-Whitney U-test, p=0.019 for day 
4; Preterm mean 0.37 xlO6 cells/ml, median 0.27 xlO6 cells/ml; Term mean 0.03 xlO6 
cells/ml, median 0.03 xlO6 cells/ml and p=0.010 for day 5; Preterm mean 0.56 xlO6
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cells/ml, median 0.35 xlO6 cells/ml; Term mean 0.05 xlO6 cells/ml, median 0.04 xlO6 
cells/ml) (Figure 3.25A).
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Figure 3.25 Graphs representing median (and IQR) macrophage count over the 
duration o f the period o f ventilation in all infants, according to (A) diagnosis (* 
p=0.049) and (B) gestation (*p=0.019, **p=0.010).
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Once again, similar to neutrophil counts, aggregated data for groups of babies tend to 
obscure the “spikes” in macrophage count which occur in individual infants, when 
cell counts rise rapidly over a few days from a relatively low baseline and then return 
to baseline levels. Data for individual infants are shown in Figure 3.26.
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3.3.4.5 Sub-types of macrophages
I attempted to differentiate various sub-types of macrophages within the population. 
Macrophages with a monocyte-like phenotype which are immature, newly recruited 
macrophages have higher CD 14 expression than mature alveolar macrophages (Maus 
et al., 2002a). It may be that these immature macrophages have an enhanced ability to 
produce cytokines and other pro-inflammatory mediators (Maus et al., 2002b,
Rosseau et al., 2000a) or reduced ability to phagocytose apoptotic or necrotic cells 
(especially neutrophils). This may account for some of the differences in cell counts 
seen between the different groups of babies.
The median number of CD 14 high expressing macrophages (immature, monocyte-like 
phenotype) is significantly greater in the preterm group of infants (Mann-Whitney U- 
test, p=0.0002) (Figure 3.27) and also when data were compared over time, the 
preterm group showed slightly higher numbers of CD 14 high macrophages than term 
infants (Figure 3.28).
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Figure 3.27 Scatterplot showing the number o f CD 14 high macrophages in term and 
preterm infants. Horizontal lines represent medians.
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Figure 3.29 Scatterplot showing the ratio o f CD 14 high macrophages to the total 
macrophage count. Horizontal lines represent medians.
The immature macrophage phenotype was seen in a larger proportion of the total 
macrophage population in babies of preterm gestations (Mann-Whitney U-test, 
p=0.006) (Preterm median 0.55, mean 0.56; Term median 0.20, mean 0.28) (Figure
153
3.29). It was not possible to compare diagnostic groups as there were insufficient data 
on this parameter for babies in the RDS group.
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Figure 3.30 Graph showing ratio o f immature: total macrophages in BAL from term 
and preterm infants. (Median and IQR shown)
Looking at median values (Figure 3.30) once again obscures the individual variation 
in immature macrophage counts which is more easily seen in data from individual 
babies (Figure 3.31). When individual infant data are reviewed, it can be seen that in a 
number of the most premature infants, immature macrophages frequently make up 
almost 100% of the macrophage population.
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Figure 3.31 Graphs showing immature (CD 14 high): total macrophage count ratios in 
individual infants who had 3 or more samples in which CD 14 on macrophages was 
measured. Vertical arrows again represent samples in which 16S rRNA genes were 
detected.
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Other subtypes of macrophage were also identified. CD36 may confer the ability to 
phagocytose apoptotic neutrophils and may thus be a limiting factor in the clearance 
of apoptotic neutrophils. In keeping with the higher total macrophage counts in 
preterm infants, the number of CD36 + cells was significantly higher in these babies 
too (Preterm mean 0.314 xlO6 cells/ml, median 0.163 xlO6 cells/ml; Term mean 0.039 
xlO6 cells/ml, median 0.039 x 106 cells/ml; Mann-Whitney U-test, p<0.0001) (Figure 
5.32).
******
TermPreterm
Figure 3.32 Scatterplot showing the number o f  CD36 positive cells in term and 
preterm infants. Horizontal lines represent medians.
When looking at the data longitudinally, there was a statistically significantly higher 
number of CD36 positive macrophages in preterm infants on day 5 (Mann-Whitney 
U-test, p=0.0333) (Term mean 0.023 xlO6 cells/ml, median 0.02 xlO6 cells/ml; 
preterm mean 0.35 xlO6 cells/ml, median 0.21 xlO6 cells/ml) (Figure 5.33B).
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Figure 3.33 Graphs showing fluctuations in median CD36 positive macrophage count 
over time in babies by (A) diagnosis and (B) by gestation. (* p=0.033)
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However, when the number of CD36 + cells was analysed as a proportion of the total 
number of macrophages, there was no significant difference in the proportion of 
macrophages that were CD36 + in term and preterm infants (Figure 5.34). There were 
also no differences in the ratio of CD36 + macrophages to total macrophage count 
when compared over time (Figure 3.35)
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Figure 3.34 Scatterplot showing the ratio o f CD36 positive macrophages to the total 
macrophage count in term and preterm infants. Horizontal lines represent medians.
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HLA-DR is expressed at low levels by monocytes and at higher levels by alveolar 
macrophages (Hallwirth et al., 2004). Higher numbers of cells with higher HLA-DR 
expression may indicate the presence of mature alveolar macrophages in the airways. 
Again, as a result of higher overall macrophage numbers, there were statistically more 
HLA-DR strongly positive macrophages present in preterm infants (p=0.0005)
(Figure 3.36).
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Figure 3.36 Scatterplot showing the number o f HLA-DR positive cells in term and 
preterm infants. Horizontal lines represent medians, (p=0.0005)
When viewed longitudinally, there was a significant difference in cell numbers 
between term and preterm infants on day 5 (Mann-Whitney U-test, p=0.015) (Term 
mean 0.037 xlO6 cells/ml, median 0.037 xlO6 cells/ml; preterm mean 0.382 xlO6 
cells/ml, median 0.23 xlO6 cells/ml) (Figure 3.37).
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Figure 3.37 Graphs showing median HLA-DR positive macrophage count according 
to (A) diagnosis and (B) gestation. (* p=0.015)
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When considered as a proportion of the total macrophage count, there was a higher 
proportion of HLA-DR positive macrophages in the term group of babies (Mann- 
Whitney U-test, p=0.013) (Preterm median 0.83, mean 0.74; Term median 1.00, mean 
0.91) (Figure 3.38).
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Figure 3.38 Scatterplot showing ratio o f mature (HLA-DR positive macrophages): 
total macrophage count. Horizontal lines represent medians.
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Figure 3.39 Graphs showing fluctuations in ratio o f mature (HLA-DR positive): total 
macrophages in BAL according to (A) diagnosis and (B) gestation. (* p=0.017)
164
On day 1 there is a significant difference in ratio of HLA-DR positive macrophages to 
total macrophages between term and preterm infants (Mann-Whitney U-test, p=0.017) 
(Term mean 0.94, median 1; preterm mean 0.60, median 0.67) (Figure 3.39) but the 
difference was not significant thereafter (day 2 Mann-Whitney U-test, p=0.0947).
The pattern appears to be of a high proportion of macrophages present in the form of 
alveolar macrophages and lower proportions of monocyte-like macrophages in term 
infants initially but fewer mature macrophages and more immature cells in preterm 
infants. This can be seen in data from individual infants shown in figure 3.40. The 
proportion of both immature and mature macrophages fluctuates in the preterm group 
over the first few weeks of life and this may be related to the presence of infection 
which will be discussed in more detail later.
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Figure 3.40 Graphs showing macrophage markers (CD 14 -  broken line and grey triangles, 
CD36-solid black line and boxes, HLA-DR -  dotted line and open boxes) for individual 
infants with 3 or more BAL samples over the course o f their ventilation period.
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3.3.5 R elationship of neutrophils to m acrophages
As described in section 3.3.4.2 and 3.3.4.3, neutrophil and macrophage counts both 
reach their peak values on later days in CLD babies than in either of the other groups. 
Neutrophil and macrophage numbers also reach their highest levels on the same day 
of life in each group.
CLD RDS Term
Median neutrophil peak day 7 (3.5) 2 2
Median macrophage peak day 7(4) 2 1
Table 3.2 Median days on which peak neutrophil and macrophage counts occurred. 
Figures in brackets indicate on which o f the first 5 days (median) the peak cell counts 
occurred in CLD babies, in order to obtain a fairer comparison with RDS and term 
babies who were only ventilatedfor around 5 days.
When data for individual babies are viewed, it can be seen that neutrophil counts and 
macrophage counts tend to increase simultaneously, rather than consecutively. These 
increases in cell counts may be associated with infection and this will be examined in 
more detail later.
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Figure 3.41 Graphs showing relationship between neutrophil count (solid line) and 
macrophage count (dotted line) for individual babies with 3 or more BAL samples.
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Figure 3.42 Graphs showing ratio o f neutrophils to macrophages for individual babies 
with 3 or more BAL samples.
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When median data are viewed longitudinally, patterns for the ratio between 
neutrophils and macrophages are very similar (Figure 3.43) -  all groups showing an 
early neutrophil spike. There is a second spike which occurs very quickly in RDS and 
term babies but this second rise in the ratio appears to be delayed in CLD babies. The 
later samples (beyond day 7) in CLD babies continue to have a ratio of neutrophils: 
macrophages of >1, indicating an excess of neutrophils until the final sample which 
may be indicative of ongoing neutrophil recruitment or failure of neutrophil clearance 
from the lung, both of which indicate an ongoing inflammatory process in infants 
developing CLD. Term babies seldom seem to have neutrophil numbers in excess of 
the number of macrophages present (ie ratio < 1).
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Figure 3.43 Graphs showing longitudinal relationship between neutrophils and 
macrophages (in the form o f neutrophil: macrophage ratio) in BAL fluid according to 
(A) diagnosis and (B) gestation.
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3.3.6 D ifferences between the  groups on day 1
There is much debate about the antenatal determinants of CLD. It is ethically and 
technically almost impossible to measure the inflammatory process within the lung 
prior to birth. The first available observation of the process was made by us at 12 
hours of age in the majority of infants. The first BAL was performed at 12 hours of 
age in order to have negligible impact on the clinical care of the infant -  preterm 
infants are usually intubated and given a dose of exogenous surfactant via the 
endotracheal tube within seconds to minutes after delivery (unit policy dictates that 
surfactant should ideally be given prior to the first breath in extremely preterm 
infants) -  a BAL procedure at this point would prejudice this process, so BAL was 
performed at 12 hours of age, just prior to the second dose of surfactant being given, 
when the infant would routinely have endotracheal tube suctioning performed.
I compared results of values obtained for all the aforementioned parameters on the 
first day of life in order to ascertain whether any differences existed between the 
groups of infants at this early stage. This may shed light on the in-utero environment 
of the lungs before birth as well as possibly providing some form of prognostic 
indicator of the likely progression of lung disease at a very early stage in the clinical 
course. Such prognostic ability may facilitate specific clinical care interventions to 
prevent or reduce the severity of CLD.
There were 12 babies in the CLD group, 9 with RDS and all 5 term babies who had 
information available about cell counts on day 1 of life. When term babies were 
compared with preterm infants who recovered from RDS and with infants who 
developed CLD, I found no significant differences between the groups for total cell 
count on the first day of life (Kruskal-Wallis test, p=0.24; Term mean 1.027 xlO6 
cells/ml, median 1.04 xlO6 cells/ml; RDS mean 3.345 xlO6 cells/ml, median 1.95 xlO6 
cells/ml; CLD mean 1.702 xlO6 cells/ml, median 1.336 xlO6 cells/ml). As a group, 
preterm infants had slightly higher cell counts on day 1, but this was not a statistically 
significant difference (Mann-Whitney U-test, p=0.17; Term mean 1.027 xlO6 cells/ml, 
median 1.040 xlO6 cells/ml; Preterm mean 2.406 xlO6 cells/ml, median 1.76 xlO6 
cells/ml).
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Figure 3.44 Scatterplots showing total cell counts on day 1 fo r  (A) each diagnostic 
category and (B) the two gestational groups.
Adequate differential cell count data on day 1 were available for 11 babies who 
developed CLD, 7 of the RDS group and 4 of the term infants. The absolute number 
of macrophages was similar in all 3 groups (Kruskal-Wallis test, p=0.297; Term mean 
0.076 xlO6 cells/ml, median 0.077 xlO6 cells/ml; RDS mean 0.874 xlO6 cells/ml, 
median 0.025 xlO6 cells/ml; CLD mean 0.139 xlO6 cells/ml, median 0.023 xlO6 
cells/ml) (Figure 3.45B and D). The median number of neutrophils present on the first 
day of life in the lungs of babies whose RDS resolved was skewed mainly by 2 infants 
who had the highest day 1 neutrophil counts of all the 32 infants recruited. However, 
there was still no significant difference between the groups (Kruskal-Wallis test, 
p=0.279; Term mean 0.07 xlO6 cells/ml, median 0.067 xlO6 cells/ml; RDS mean 1.26 
xlO6 cells/ml, median 0.77 xlO6 cells/ml; CLD mean 0.19 xlO6 cells/ml, median 0.04 
xlO6 cells/ml) (Figure 3.45A and C) when the analysis was performed after excluding 
these 2 infants.
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Figure 3.45 Scatterplots showing neutrophil and macrophage counts on the first day 
of life according to (A and B) diagnostic group and (C and D) gestation.
When macrophage subtypes were assessed, there was no significant difference in the 
proportion or absolute number of macrophages which expressed CD36 and the 
proportion which were HLA-DR positive was also not quite significant (p=0.0502) 
between any of the diagnostic groups. Again the RDS group had two infants with 
results that were markedly different to the remainder of the group. There were 
insufficient data on CD 14 expression on day 1 to make an appropriate comparison.
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Figure 3.46 Scatterplots showing the number o f (A) CD36 positive and (B) HLA-DR 
positive macrophages in BAL fluid on Day 1 and the proportion o f cells which 
expressed (C) CD36 and (D) HLA-DR.
When term and preterm infants were compared, absolute numbers of HLA-DR+ and 
CD36+ cells were similar but, when expressed as a proportion of the total 
macrophage population, term infants had significantly more of their macrophages 
present in mature form on day 1 (p=0.015, median term 1, median preterm 0.62). This 
higher proportion of mature (HLA-DR expressing) macrophage from the outset in 
term infants may represent a significant difference between term and preterm infants, 
particularly with respect to phagocytosis of invading microbes and apoptotic cells.
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Figure 3.47 Scatterplots showing the absolute numbers (A and B) and relative 
proportions (C and D) o f macrophage subtypes in term and preterm infants on day 1.
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3.3.7 The role of infection
3.3.7.1 R elationship of BAL cell counts to the  presence of infection
The importance of infection in the development of CLD and the association with 
neutrophil influx into the lung was examined by detecting the presence of bacterial 
16S ribosomal RNA genes in the BAL cell pellet by PCR as described in section 2.1.5 
of chapter 2. The PCR was carried out by Mr Michael Beeton.
Human mitochondrial cytochrome oxidase (HMCO) is a marker of the presence of 
human mitochondrial DNA. Sufficient cell pellet, as judged by the presence of 
HMCO within the samples, was present in 177/207 samples from 31 of the 32 infants. 
In the remaining 30 samples there was insufficient cell pellet remaining for PCR after 
material had been processed for flow cytometry. Genes for 16S rRNA were detected 
in 35/177 (19.8%) of the tested lavage samples and at some stage in 14/31 infants 
(45.2%).
Significantly more infants who went on to develop CLD had 16S rRNA genes 
detected in their BAL fluid at some point (11/15 or 73.3%) compared to infants whose 
RDS resolved (2/10 or 20%), Chi square test, p=0.0089. The number of preterm 
babies who had 16S rRNA detected (11 CLD + 2 RDS = 13/25 or 52%, 95% Cl 
33.50% - 69.97%) was not statistically greater than that of term control infants (1/5 or 
20%, 95% Cl 2.03% - 64.04%) p=0.1904, probably partly as a result of the small 
number of term infants involved (Table 3.3).
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Babies with 
16s rRNA 
detected
(%)
Babies with 
16s rRNA 
not
detected
(%)
TOTALS
CLD 11 (73.3) 4 (26.7) 15
RDS 2(20) 8(80) 10
Term 1(20) 4(80) 5
Died 0(0) 1(100) 1
TOTALS 14 (45.2) 17 (54.8) 31
Table 3.3 Table showing number (and percentage) o f infants in each diagnostic 
category with and without 16S rRNA detected at any point during their period o f  
ventilation.
Both antenatal and postnatal infection have been implicated in the pathogenesis of 
CLD. In order to further define the possible roles for each of these infections, infants 
with 16S rRNA genes detectable in the first 3 days of life were assumed to have 
acquired these in the antenatal period. Beyond the first 3 days of life, it is more likely 
that micro-organisms in the lung may have been acquired postnatally, while the infant 
was ventilated on the neonatal unit.
There was no significant difference between CLD and RDS babies when compared 
for the presence of 16S rRNA genes in the first 3 days of life (3/15 or 20% in CLD vs 
0/10 or 0% in RDS) (Chi square test, p=0.471) (Table 3.4), nor was there a difference 
between term (1/5 or 20%) and preterm infants (3 CLD + 0 RDS = 3/25 or 12%) 
(p=0.823) in the first 3 days. This may indicate that the hospital-acquired infections 
associated with prolonged ventilation are important in the pathogenesis of CLD, 
rather than antenatal bacterial infection as is commonly thought. However, numbers 
in each group were small.
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Babies with 
16s rRNA 
detected by 
day 3 (%)
Babies with 
16s rRNA 
not
detected by 
day 3 (%)
TOTALS
CLD 3 (20) 12 (80) 15
RDS 0(0) 10(100) 10
Term 1(20) 4(80) 5
Died 0(0) 1(100) 1
TOTALS 14 (45.2) 17 (54.8) 31
Table 3.4 Table showing number (and percentage) o f infants in each diagnostic 
category with and without 16S rRNA detected in BAL samples during the first 3 days 
o f life.
Of the 129 samples from infants developing CLD which were judged to be adequate 
by the presence of HMCO, 28 (21.7%) had 16S rRNA genes detected, which was not 
significantly more than the 6/30 (20%) samples from infants whose RDS resolved, 
p=0.8374. There was also no significant difference in the number of 16S rRNA 
positive samples from preterm infants (34/159, 21.4%) and the 1/14 (7.1%) from term 
control infants (p=0.2035) (Table 3.5). The very small number of term controls makes 
interpretation of this result difficult.
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Samples 
with 16s 
rRNA 
detected
(%)
Samples 
with 16s 
rRNA not 
detected
(%)
TOTALS
CLD 28 (21.7) 101 (78.3) 129
RDS 6(20) 24 (80) 30
Term 1 (7.1) 13 (92.9) 14
Died 0(0) 4(100) 4
TOTALS 35 (19.8) 142 (80.2) 177
Table 3.5 Table showing number (and percentage) o f BAL samples from infants in 
each diagnostic category with and without 16S rRNA detected.
While more infants who developed CLD had 16S rRNA detectable in their BAL 
samples, a similar proportion of individual BAL samples from CLD and RDS babies 
had 16S rRNA genes present. Overall there were 11 babies with a total of 28 positive 
samples who developed CLD and 2 babies whose RDS resolved who supplied a total 
of 6 positive samples.
This information is difficult to interpret but may indicate that babies who develop 
CLD have more than one episode of infection with each being of short duration and 
babies whose RDS resolves tend to have only a single episode prior to being 
extubated. This pattern can be seen from the episodes of 16S rRNA positive BAL 
samples marked on individual babies’ data (arrows on Figures 3.13, 3.18, 3.26, 3.31 -  
particularly babies CC, G and O), but may be more evident from a larger sample. 
Other possible explanations for the differences observed between the frequency of 
detection of 16S rRNA genes between CLD and RDS babies could be that RDS 
infants are only colonised with microbes and CLD babies develop a true infection or 
that the immune response to the presence of a microbe differs between the two groups 
-  neither of these conclusions can be drawn from the data I collected.
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Data were, however, collected on the type of organism from which the 16S rRNA 
genes originated by sequencing of the 16S rRNA PCR product. It can be seen in 
Figure 3.49 that the two infants whose RDS resolved had S. epidermidis identified on 
sequencing of the 16S rRNA genes detected in their BAL samples, an organism not 
generally thought to be a pathogen in the neonatal lung; whereas babies who 
developed CLD had a variety of other organisms identified (but including S. 
epidermidis), which are generally considered to be pathogenic, particularly in the 
neonatal lung.
3.3.7.2 Total cell counts in infection
Samples in which 16S rRNA was detected had significantly higher total cell counts 
than samples which were negative for 16S rRNA (Mann-Whitney U-test, p=0.0001) 
(16S negative median 1.18 xlO6 cells/ml, mean 1.74 xlO6 cells/ml; 16S positive 
median 2.20 xlO6 cells/ml, mean 2.90 xlO6 cells/ml). There was no significant 
difference in the peak cell counts (16S positive median 4.21 xlO6 cells/ml, mean 5.11 
xlO6 cells/ml; 16S negative median 1.95 xlO6 cells/ml, mean 3.33 xlO6 cells/ml) 
(Mann-Whitney U-test, p=0.118)
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Figure 3.48 Scatterplot showing total cell count in BAL according to presence or 
abscence o f 16S rRNA genes in the same sample. Horizontal lines represent medians.
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When the 16S rRNA genes were sequenced, the highest cell counts were associated 
with organisms considered to be pathogens in neonatal practise and lower cell counts 
associated with the presence of S. epidermidis (Figure 3.49).
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Figure 3.49 Scatterplot ofpeak cell count for each diagnostic group. The filled boxes 
were 16S rRNA gene positive and the empty boxes were negative. Sequencing data for  
16S rRNA gene positive organisms is also shown.
3.3.7.3 Neutrophil counts in infection
Neutrophil counts were significantly higher in samples where 16S rRNA genes were 
detected (Mann-Whitney U-test, p=0.0003) (16S negative median 0.12 xlO6cells/ml, 
mean 0.53 x 106cells/ml; 16S positive median 0.67 xlO6cells/ml, mean 1.22 xlO6 
cells/ml) (Figure 3.50) but there was no significant difference in the peak neutrophil 
counts related to the presence of infection (Positive mean 3.65 xlO6 cells/ml, median
2.04 x 106 cells/ml; negative mean 1.37 x 106 cells/ml, median 0.91 xlO6 cells/ml) 
(Mann-Whitney U-test, p=0.105).
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Figure 3.50 Scatterplot showing neutrophil counts in samples with and without the 
presence o f 16S rRNA genes. Horizontal lines represent medians.
Similar to the total cell count, the highest peak neutrophil counts in each baby were 
frequently associated with the presence of an organism considered to be pathogenic in 
the neonatal lung (Figure 3.51). Looking at the data longitudinally for individual 
infants shows that spikes in cell counts are often temporally associated with the 
detection of 16S rRNA genes in the cell pellet. (See individual baby data in Figure 
3.13 previously.)
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Figure 3.51 Scatterplot ofpeak neutrophil count for each diagnostic group. The filled  
boxes were 16S rRNA gene positive and the empty boxes were negative. Sequencing 
data for 16S rRNA gene positive organisms is also shown. One sample (from baby 
BB) was identified as 16S rRNA gene positive but no organism could be sequenced. 
There was no differential cell count for baby A (term) or B (CLD- H. influenza 
detected).
3.3.7.4 Macrophage counts in infection
The macrophage count is also significantly higher in infected babies (Mann-Whitney 
U-test, p=0.0003; 16S negative median 0.17 xlO6 cells/ml, mean 0.40 xlO6 cells/ml; 
Positive median 0.44 xlO6 cells/ml, mean 0.72 xlO6 cells/ml). This suggests that the 
overall total cell count increase is contributed to by both neutrophils and 
macrophages. Once again, there is no significant difference in the peak macrophage 
counts (positive mean 1.07 xlO6 cells/ml, median 0.74 xlO6 cells/ml; negative mean 
1.23 xlO6 cells/ml, median 0.51 xlO6 cells/ml) (Mann-Whitney U-test, p=0.786). The 
individual baby data shown in Figure 3.26 previously also confirm a temporal 
association between the detection of 16S rRNA and an increase in the macrophage 
count.
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Figure 3.52 Scatterplot showing macrophage count in samples with and without 16S 
rRNA detected.
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Figure 3.53 Scatterplot o f peak macrophage count for each diagnostic group. The 
filled boxes were 16S rRNA gene positive and the empty boxes were negative. 
Sequencing data for 16S rRNA gene positive organisms is also shown. One sample 
(from baby BB) was identified as 16S rRNA gene positive but no organism was able to 
be sequenced. There was no differential cell count for baby A (term) or B (CLD- H. 
influenza detected).
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3.3.7.5 Ureaplasma infection/colonisation
In addition to the detection of 16S rRNA for bacterial infection, BAL samples also 
underwent culture in Ureaplasma specific medium (as described in 2.1.6 above) in 
order to detect the presence of Ureaplasma spp. which have been implicated in the 
pathogenesis of CLD but whose exact role remains highly controversial.
In this studied group of patients, infants who went on to develop CLD had 
significantly higher rates of Ureaplasma detected in their BAL fluid at some point 
(8/15 or 53.3%) compared to infants whose RDS resolved (1/10 or 10%) (Chi square 
test, p=0.027). The number of preterm babies who had Ureaplasma detected (9/25 or 
36%) was not statistically greater than that of term control infants (1/5 or 20%) 
(p=0.488).
Babies with 
Ureaplasma 
detected
(%)
Babies with 
Ureaplasma 
not
detected
(%)
TOTALS
CLD 8 (53.3) 7 (46.7) 15
RDS 1(10) 9(90) 10
Term 1(20) 4(80) 5
Died 1(100) 0(0) 1
TOTALS 11 (35.5) 20 (64.5) 31
Table 3.6 Table showing the prevalence o f  Ureaplasma spp. in BAL samples.
In line with current practice and protocols on the neonatal unit, the majority (7/11) of 
infants in whom Ureaplasma was detected did not receive any specific treatment for 
this. Four babies were treated with macrolide antibiotics which resulted in the 
organism being cleared from 2 infants, a highly resistant organism persisting in one 
baby and the organism briefly being cleared before returning after antibiotic treatment 
was discontinued in the fourth infant. All 4 of these babies went on to develop CLD.
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33.1.6 Differential cell counts in babies with Ureaplasma
3.3.7.6.1 Neutrophils
There was no significant difference in either percentage (Mann-Whitney U-test, 
p=0.5839) or absolute neutrophil count (Mann-Whitney U-test, p=0.5388) in babies in 
whom Ureaplasma was detected.
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Figure 3.54 Scatterplot o f neutrophil counts in babies with or without Ureaplasma 
detected. Horizontal lines represent medians.
3.3.7.6.2 Macrophages
Both the percentage macrophages and absolute macrophage counts (Figure 3.55) were 
significantly higher in babies in whom Ureaplasma was detected (Percentages: Mann- 
Whitney U-test, p=0.0045; Negative median 14.2%, mean 18.8%; Positive median 
21.2%, mean 24.5%) (Counts: Mann-Whitney U-test, p=0.038; Negative median 0.21 
xlO6 cells/ml, mean 0.43 xlO6 cells/ml; Positive median 0.31 xlO6 cells/ml, mean 0.53 
xlO6 cells/ml). Peak macrophage counts were also significantly higher in babies with 
positive cultures for Ureaplasma (Mann-Whitney U-test, p=0.006; Negative median
0.40 xlO6 cells/ml, mean 0.77 xlO6 cells/ml; Positive median 1.76 xlO6 cells/ml, mean 
1.74 xlO6 cells/ml).
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Figure 3.55 Scatterplot o f macrophage counts in babies with or without Ureaplasma 
detected. Horizontal lines represent medians.
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Figure 3.56 Scatterplot o f peak macrophage counts o f babies with and without 
Ureaplasma. Horizontal lines represent medians.
33.1.1 Antenatal infection
Once again, I sought to understand if any differences between antenatally infected and 
uninfected infants could be found, by using data from the first day’s BAL sample as 
there is evidence to suggest that the majority of cases of spontaneous preterm labour 
occur as the result of an infective process (Gomez et al., 1997), even if a specific 
organism cannot be isolated or identitifed (Klein and Gibbs, 2004, Sanchez, 1993). I
compared preterm infants bom following spontaneous preterm labour against preterm 
infants bom by elective Caesarean section, when the mother was not in labour.
Preterm labour Elective Caesarean 
section (no labour)
Number of babies 20 6
Median birthweight 
(range)
0.905 kg 
(0.56-1.92 kg)
0.965 kg 
(0.7-1.18 kg)
Median gestation 
(range)
26+z
(23+4- 3 1 +2)
28+1
(27+° -  29+3)
Number with Ureaplasma 
diagnosed
9 0
Number with PROM 5 1
Number with clinical 
suspicion of infection*
11 3
Table 3.7 Table showing characteristics o f preterm infants born following 
spontaneous preterm labour or by elective Caesarean section.
*Clinical suspicion o f infection based on one or more o f the following being recorded 
in the maternal notes prior to delivery: pyrexia, offensive smelling vaginal discharge, 
elevated white blood cell count or C-reactive protein, result o f high vaginal swab 
shows organism/s not considered to be normal flora, uterine tenderness or irritability 
suggestive o f chorioamnionitis.
Infants bom following spontaneous preterm labour were not significantly different in 
weight (p=0.784) from their electively delivered counterparts. The preterm labour 
group had a median gestation which was statistically significantly lower than the 
elective Caesarean group (p=0.0224), possibly related to intrauterine infection 
precipitating the earlier onset of labour in these pregnancies.
It is immediately apparent that all the babies in whom Ureaplasma was detected were 
in the preterm labour group (Chi square test, p=0.042). Ureaplasma is well recognised 
as a cause of preterm labour (Embree and Embil, 1980, Kataoka et al., 2006) and the 
transmission from mother to infant has been shown to be highest in the most preterm 
infants (Alfa et al., 1995). The number of infants in each category with PROM was
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not significantly different (Chi square test, p=0.67), nor was the number with 
suspected infection (Chi square test, p=0.82).
In the preterm labour group, 11/20 infants developed CLD compared to 4/6 of the 
electively delivered infants (Chi square test, p=0.612). Larger numbers of patients 
would be required to make an adequate statistical comparison between the two 
groups.
3.3.7.7.1 Cell counts on day 1 in relation to mode of delivery
The total cell count just failed to reach significance in infants bom following 
spontaneous preterm labour compared to those bom by elective Caesarean section 
(p=0.051), however a larger sample may have produced a significant result.
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Figure 3.57 Scatterplot showing total cell count on the first day o f life for infants born 
following spontaneous onset o f  labour against infants born by elective Caesarean 
section without labour. Horizontal lines represent medians.
There were no significant differences between the two groups with respect to 
differential counts or macrophage subtypes.
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Figure 3.58 Scatterplots comparing infants following spontaneous labour compared 
with those born by elective Caesarean section before the onset o f labour. There were 
no significant differences in (A) proportion o f the sample made up o f neutrophils, (B) 
proportion o f the sample made up o f macrophages, (C) neutrophil count, (D) 
macrophage count, (E & G) proportion or absolute numbers o f macrophages 
expressing CD36 or HLA-DR (F & H).
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3.4 Sum m ary  of key results
1. BAL samples contain large amounts of “debris” and as much as 20% of cells 
may be non-viable.
2. Total cell counts as well as neutrophil and mononuclear cell counts were 
significantly higher in preterm infants but there were no obvious differences in 
cell counts between babies whose RDS resolved and those who progressed to 
CLD.
3. Neutrophils from term BAL samples express more TLR 2 and TLR 4 on the 
cell surface than BAL neutrophils from preterm infants, but the amounts of 
surface CD 14 expression were not significantly different.
4. Mononuclear cells have a more immature phenotype in preterm infants, with 
term infants having a higher proportion of mature alveolar macrophages even 
on the first day of life.
5. Cell counts peak earliest in term babies and those with RDS and later in babies 
who get CLD.
6. Almost no difference can be seen between the groups on the first day of life, 
apart from the higher proportion of mature macrophages present in term 
lavages.
7. There is a significant association between the presence of 16S rRNA genes in 
BAL samples and the development of CLD. This appears to be related to 
infection beyond the first 3 days of life in babies who get CLD. Babies who 
have samples positive for 16S rRNA have higher total, neutrophil and 
mononuclear cell counts.
8. There is a significant relationship between the presence of Ureaplasma spp. 
and the development of CLD and babies with Ureaplasma have significantly 
higher macrophage counts in BAL samples.
9. There were no appreciable differences between infants delivered by elective 
Caesarean section and those bom following spontaneous preterm labour, apart 
from the prevalence of Ureaplasma being significantly higher in the preterm 
labour group.
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3.5 Discussion
3.5.1 Overview
This portion of the study provides a detailed analysis of the inflammatory cell 
infiltrate in the lungs of a group of ventilated term and preterm infants using flow 
cytometry. The study includes 32 infants, of which 27 were less than 32 weeks’ 
gestational age. It is the only study, to my knowledge, that examines in such detail, by 
flow cytometry the cellular constituents of BAL samples in newborn term and preterm 
babies.
The median gestational age for the infants who developed CLD was 26 +0 weeks and 
for those whose RDS resolved it was 27+1 weeks. This was statistically significant 
and it is to be expected that those infants who did not develop CLD were more 
mature. Despite this difference in gestational age, there was no statistically significant 
difference in birthweight between the groups, although babies whose RDS resolved 
had a median birthweight 150 g more than the median for the CLD group. This is 
probably in keeping with a widely held view among neonatologists that infants who 
are “stressed” in-utero (reflected by reduced growth) experience less severe postnatal 
lung disease.
In the majority of the preterm cases, at least one dose of antenatal steroids had been 
administered to the baby’s mother prior to delivery. Less than half of the mothers 
received a second dose of antenatal steroids because, as a result of preterm labour, 
delivery of the infant occurred prior to the second dose being due. This may be a 
source of bias in this study because of the small sample size. Statistics for the neonatal 
unit reveal this cohort of infants to be slightly unusual, in that unit statistics reveal that 
88.5% of infants bom at less than 32 weeks’ gestation in 2007 received a full course 
of antenatal steroids (Cherian et al., 2007). All the preterm infants were intubated at 
birth and received exogenous surfactant therapy. All infants bom with respiratory 
distress received postnatal antibiotics for at least 48 hours, until blood cultures taken 
at birth could be confirmed as negative. Antibiotics were continued for 5 or 7 days if 
infection was proven or clinically suspected.
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The presence of a PDA which required medical or surgical intervention was a 
significant feature of the CLD group. PDA has not been shown to be an independent 
risk factor for CLD (Amon et al., 1993, Fraser et al., 2004). It may be that in this 
relatively small sample, the presence of a PDA in association with lung disease which 
showed signs of clinical progression towards CLD, prompted the attending clinician 
to choose medical or surgical PDA treatment. PDA closure may not have been 
undertaken in the RDS group as these babies may have been felt to be improving 
without the need for PDA closure. Additionally, the signs or symptoms of PDA may 
result in a longer duration of ventilation and the use of higher pressures and inspired 
oxygen levels, each increasing the likelihood of an “at-risk” infant developing CLD.
Our study benefits from the presence of a group of term control infants, who were 
ventilated for non-respiratory reasons. Although there were only five infants recruited 
to this arm of the study, I was able to observe the responses of largely “normal” term 
infant lungs to low pressure, low volume ventilation in air or <28% oxygen and 
compare these with the findings in preterm infants. Recruitment of patients into the 
term control group was not easy due to the stringent entry criteria used in order to try 
to ensure the “normality” of the lungs of the term group. Clearly, healthy term infants 
are not usually ventilated. The main criteria for ventilation of term infants tend to be 
respiratory distress (e.g. secondary to infection or transient tachypnoea of the 
newborn), which would frequently require oxygen concentrations >28%, a key 
exclusion criterion of our study, as hyperoxia has documented pro-inflammatory 
effects on lung (Davis et al., 1991). Alternatively, term infants may be ventilated for 
neurological problems, such as hypoxic ischaemic encephalopathy (HIE). Such 
infants were also excluded from the term control group as the period of hypoxia 
responsible for producing HIE, would also be very likely to trigger inflammatory 
changes within the lung. All of our control group were infants who underwent surgery 
for gastroschisis on the first day of life and required ventilation post-operatively. 
Gastroschisis usually occurs as an isolated anomaly with no associated lung 
pathology, so that at birth the lungs should be healthy. I recognise that gastroschisis 
may be a cause of systemic illness and that even healthy lungs may not remain 
“normal” after a period of ventilation, however, it remains the best control group 
available and a reasonable comparison between ventilated term and preterm lungs. 
Gastroschisis is not a common condition (4.6/10 000 births (Drewett et al., 2006) and
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not every child bom with gastroschisis requires post-operative ventilation for more
than a few hours, which explains why only five term control infants were recruited.
Many studies which have examined lung lavage samples from newborn infants have 
used tracheal aspirate fluid (TAF), however, these samples largely reflect upper 
airway secretions. By using BAL fluid this study analyses inflammatory infiltrates 
from the lower airways, which may be particularly important in CLD where alveolar 
changes (larger, simplified alveoli), rather than more proximal airway abnormalities, 
are seen.
3.5.2 Development of flow cytometry analysis of BAL samples
Flow cytometry has not previously been published as a method for analysis of the 
celllar constituents of neonatal BAL samples. It has, however been used fairly 
extensively in studies of adult lung disease, including COPD and ARDS (Matute- 
Bello et al., 1997, Rosseau et al., 2000a, Pletz et al., 2004). Using the published 
information in the adult literature as a guide, I developed a method for the processing 
and analysis of neonatal BAL samples by flow cytometry, showing that the use of 
DTT as a mucolytic had no effect on any of the antigens which I studied.
Flow cytometry is a potentially more accurate method for identification of cell types 
and surface antigens than previously published techniques for analysis of neonatal 
BAL samples, which include immunocytochemistry and light microscopy and which 
rely on human observation for counting and recording cell types (Grigg et al., 1991, 
Kotecha et al., 2003, Oei et al., 2003). I found significant differences between total 
cell counts and differential counts based on the method used to analyse the cells, 
namely microscopy or flow cytometry.
There are a number of possible reasons for this:-
cytospins varied in quality, dependent on the amount of mucus and/or cellular 
debris present which made counting more difficult and complex.
201
not every child bom with gastroschisis requires post-operative ventilation for more
than a few hours, which explains why only five term control infants were recruited.
Many studies which have examined lung lavage samples from newborn infants have 
used tracheal aspirate fluid (TAF), however, these samples largely reflect upper 
airway secretions. By using BAL fluid this study analyses inflammatory infiltrates 
from the lower airways, which may be particularly important in CLD where alveolar 
changes (larger, simplified alveoli), rather than more proximal airway abnormalities, 
are seen.
3.5.2 Development of flow cytometry analysis of BAL samples
Flow cytometry has not previously been published as a method for analysis of the 
celllar constituents of neonatal BAL samples. It has, however been used fairly 
extensively in studies of adult lung disease, including COPD and ARDS (Matute- 
Bello et al., 1997, Rosseau et al., 2000a, Pletz et al., 2004). Using the published 
information in the adult literature as a guide, I developed a method for the processing 
and analysis of neonatal BAL samples by flow cytometry, showing that the use of 
DTT as a mucolytic had no effect on any of the antigens which I studied.
Flow cytometry is a potentially more accurate method for identification of cell types 
and surface antigens than previously published techniques for analysis of neonatal 
BAL samples, which include immunocytochemistry and light microscopy and which 
rely on human observation for counting and recording cell types (Grigg et al., 1991, 
Kotecha et al., 2003, Oei et al., 2003). I found significant differences between total 
cell counts and differential counts based on the method used to analyse the cells, 
namely microscopy or flow cytometry.
There are a number of possible reasons for this:-
cytospins varied in quality, dependent on the amount of mucus and/or cellular 
debris present which made counting more difficult and complex.
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when very little BAL material was available, there were very few cells on the 
cytospin slide and counted cytospin may not have been representative of the 
whole sample.
when cells on cytospin slides were counted, at least 300 cells were counted for 
each sample in duplicate cytospins. Flow cytometry parameters were set up to 
count at least 10 000 events (with debris gated out). Thus flow cytometry 
differentials are more likely to be accurately representative of the sample. (The 
more events counted on a cytospins, the closer the result was to FACS results.) 
the flow cytometer requires a single cell suspension in order to accurately 
count and identify cells. At times there was clumping of BAL cells due to cell 
activation and/or the presence of mucus. These cell clumps would not be 
accurately counted by the flow cytometer but could be observed and counted 
more accurately on a cytospin slide.
clusters of apoptotic neutrophils on a cytospin slide may have been within a 
macrophage but the macrophage may not have been clearly identified and thus 
its contents would have been individually counted and the macrophage not 
counted. The flow cytometer would simply count the macrophage with its 
ingested contents as 1 large macrophage, not several neutrophils, 
there was some inter-observer difference noted when I re-counted (blinded) a 
proportion of the cytospins
inflammatory or immature macrophages (more monocyte-like phenotype) may 
not have been accurately counted as macrophages because of their small size 
and altered staining on cytospins when compared to more mature 
macrophages.
diff-quik staining of cytospins produced results which were very variable in 
quality and therefore ease of counting. This may have contributed to difficulty 
in correct identification of some cells.
The use of flow cytometry, although potentially more accurate than counted 
cytospins, for the detailed analysis of neonatal BAL samples is a very time consuming 
process. For optimal results in this study, BAL cells were stained with antibodies and 
analysed on the flow cytometer immediately following the lavage procedure to avoid 
any deterioration in the sample quality or any ongoing necrosis or apoptosis of cells. 
The process of obtaining the BAL, separating and staining the cells and FACS
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analysis took at least 4 hours per sample. By virtue of the study design, in which the 
first lavage was done when the infant was 12 hours old to minimise the impact of the 
procedure on clinical care, then repeated daily for 7 days, a large number of the BAL 
samples were taken at night and out of normal working hours, making the acquisition 
of data for the study relatively arduous. Fixation of stained BAL samples using 
paraformaldehyde to allow flow cytometry analysis to be delayed until “office hours” 
was considered but rejected for routine use as fixation changes the forward and side 
scatter patterns of cells on flow cytometry and would only have saved around 30 
minutes per sample. Cytospins, on the other hand, can be made relatively quickly after 
the BAL has been performed and then either fixed or stained for analysis at a more 
convenient time and may thus be more suited for routine clinical applications.
3.5.3 Debris and non-viable cells
A proportion of each BAL sample contained viable cells which could be identified as 
neutrophils or macrophages by either flow cytometry or cytospin slides but there was 
a large amount of non-viable debris in many of the BAL samples. The amount of 
viable material increased with increasing duration of extra-uterine life.
In this study, I think it is likely that the debris is composed mainly of cell fragments as 
shown by CD59 and To-Pro 3 staining, revealing the debris to originate from human 
cells and/or contain DNA. Some of the debris may be artefact, created by the 
processing of the BAL sample. Although every care was taken to be gentle in any 
manipulation of the samples, it is probable that some damage to the cells may be 
caused by the pipetting and centrifugation required to study them. Debris may also 
originate from dead or damaged cells sloughed in-utero during lung growth and 
development -  this may account for the larger amount of debris in initial samples. The 
initiation of an inflammatory process in the lungs may generate more debris in the 
early stages which then reduces as the process becomes established, but this is merely 
speculative as the debris component of BAL samples was not studied in detail.
No other study has reported the amount of non-viable material in infant BAL samples. 
Although there is no significant difference in the amount of debris between groups, 
the composition of the debris may in fact be variable and have an impact on the
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outcome for the infant. The disposal of debris and the pro- or anti-inflammatory 
effects of this may also be of significance in the resolution of RDS or the 
development of CLD.
3.5.4 Cell counts
As with previous studies, this study demonstrates increasing cell counts, particularly 
neutrophils over the first few days of life in preterm infants. In published cohorts, cell 
counts were significantly greater in lavage fluid from infants who went on to develop 
CLD compared to infants whose RDS resolved (Merritt et al., 1983, Ogden et al., 
1984, Watterberg et al., 1994), however this was not found in our group of babies, 
probably as a result of the relatively small number of infants studied. These papers 
also describe a pattern of elevated cell counts which remain high in infants who 
develop CLD compared to counts that rise over the first few days of life but then fall 
in infants whose RDS resolves. It important to note that most such studies have 
grouped data, which will have the effect of smoothing out an individual infant’s 
fluctuations in cell counts. By analysing individual infants as well as grouped data, 
our study demonstrates that whilst overall (median) cell counts increase and remain 
elevated in CLD, individual babies tend to have cell counts which increase in an 
episodic manner and then return to lower levels. Most babies show a cell count rise in 
the first few days of life and then babies who remain intubated have further sporadic 
rises in cell count. Nevertheless, increases in cell counts, and particularly that of 
neutrophils, in BAL fluid demonstrate that inflammatory changes occur.
a) Neutrophil cell surface markers
CD 14 expression on blood neutrophils has been reported to be lower in preterm 
infants than in adults or term babies (Henneke et al., 2003), however I found the 
expression of CD 14 appeared similar between neutrophils from BAL samples in term 
and preterm infants. Individual infants in the preterm group had a large proportion of 
the neutrophil population expressing high levels of CD 14, particularly on the first 2 
days of life. This may reflect antenatal exposure to infection as CD 14 is important in 
the recognition of pathogens by the cells and may be upregulated in the presence of 
LPS (Coimbra et al., 2004).
204
Overall the percentage of neutrophils showing detectable TLR 2 and TLR 4 
expression in term infants was significantly more than in preterm infants even in this 
small sample. TLR 2 expression on leucocytes has been found to be slightly reduced 
in term infants compared to adults in one study of cord and adult blood (Viemann et 
al., 2005) but very similar in another (Sadeghi et al., 2007), however in the second 
study, response to TLR 2 signalling via MyD88 was reduced in newborns. Our 
finding of a significant reduction in the proportion of lung neutrophils expressing 
TLR 2 may indicate a further impairment in the ability of the preterm newborn to 
respond to pulmonary infection.
TLR 4 expression has been reported to increase with gestational age (Sadeghi et al., 
2007) on blood cells and this may hold true for cells which have migrated into the 
airways. My finding of a reduced percentage of lung neutrophils expressing TLR 4 in 
preterm infants is supportive of this. It has been noted that while TLR 2 is upregulated 
markedly in neonatal sepsis, no such alterations are seen in TLR 4 (Viemann et al.,
2005).
b) Macrophages
Macrophages show similar patterns of increase to the total cell count and neutrophil 
count, also showing sporadic peaks in association with the detection of infection in 
the BAL sample. Flow cytometry enables a detailed look at the different sub-types of 
macrophage present in BAL samples and this has not previously been undertaken in 
neonatal BAL fluid. Alveolar monocyte and macrophage phenotypes have been 
studied by flow cytometry in adults with both healthy and diseased lungs (Taylor et 
al., 2000, Umino et al., 1999, Ward et al., 2001). All agree that the study of alveolar 
macrophages by this method is useful but complicated by the high levels of 
autofluorescence of the macrophages and all the studies use different markers to 
classify and differentiate the cells. The only study of alveolar macrophage markers in 
the paediatric population (Grigg et al., 1999) studied BAL fluid from children from 7 
days to 17 years of age using immunocytochemistry and found that relative 
immaturity of alveolar macrophages may be a contributor to increased severity of 
pulmonary infection in young children. BAL samples from preterm infants in our
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study had higher numbers of monocyte-like (CD 14 high) macrophages than term 
babies. Preterm infants also had a higher proportion of the total macrophage count in 
the form of monocyte-like (CD 14 high) macrophages than term babies. Term infants 
had almost all their macrophages displaying high levels of HLA-DR, a marker of a 
mature alveolar macrophage, whereas in preterm infants, this proportion was lower. If 
day 1 alone is reviewed, term babies have a median of around 90% of their 
macrophages expressing high levels of HLA-DR, compared to just over 60% in the 
preterm group.
Together, this implies that the macrophage population in preterm infants is altogether 
less mature at delivery than in term infants. This immature macrophage population 
may be present as a result of rapid and ongoing recruitment of monocytes to the lung 
in the face of continuing inflammation. Immaturity may render the macrophage less 
able to cope with phagocytosis of pathogens, possibly leading to infection becoming 
established rather than being cleared. Immature (monocyte-like) macrophages have 
been shown to have augemented release of pro-inflammatory mediators in adults 
(Rosseau et al., 2000a, Maus et al., 2002c, Maus et al., 2001) and, although this has 
not yet been proven in infants, it is likely that the higher proportion of immature 
macrophages in preterm babies could also alter the ability of the macrophage 
population to modulate cytokine production and lead to further, excess neutrophil 
recruitment, which may overwhelm the macrophage capacity to clear the effete 
neutrophils. In addition, immature macrophages may be less able to phagocytose 
apoptotic neutrophils and this will be discussed in chapter 4. As a result, a large 
number of neutrophils is able to accumulate in the ventilated preterm infant lung.
c) Patterns of influx
The timing of neutrophil versus macrophage influx is of particular note. Previous 
studies (Kotecha et al., 2003) showed a total cell count which rose from birth and 
peaked on about day 4 of life in infants with RDS and on day 10 in infants who 
developed CLD. Our cohort showed peak total cell counts on day 2 in RDS and day 7 
in CLD compared to day 1 in term infants. The Kotecha et al paper only compared 
samples from preterm infants taken twice weekly and not daily as in our project, thus 
possibly missing important peaks in cell counts. Additionally, cell counting by
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cytospins and haemocytometer preparations may have contributed to the differences 
between our project and previously published work as these are to some extent 
operator dependent.
The macrophage count in this study reached its peak on day 10/11. Our data from the 
current cohort show that neutrophil and macrophage counts appear to increase almost 
simultaneously. This perceived difference may be related to the method of cell 
identification (cytospins in Kotecha et al compared to FACS in this study) and also to 
the small sample sizes available in studies of this nature. The Kotecha et al paper also 
did not perform daily samples during the first week of life which may imply that the 
peak cell counts which I observed early in the course of ventilation (days 3 - 4 )  were 
simply missed due to the sampling schedule used.
Not only is the timing of influx of different cell types of interest, but the timing of cell 
influx in the different diagnostic categories is also interesting. Term babies experience 
their peak total cell counts within the first 24 hours, followed by RDS babies and then 
CLD babies have highest cell counts at almost 3 days of age (when looking at first 5 
days alone) or day 7 (for entire ventilated period, but this is influenced by cell count 
fluctuations related to possible infective episodes later in the period of intubation). In 
order to try to elucidate factors which may differentiate between the groups very early 
in their ventilatory course and to shed some light on possible antenatal 
predeterminants of the course of pulmonary inflammation, various parameters were 
analysed on day 1 of life alone. No significant differences in total or differential cell 
counts were observed on the first day of life and for this reason it is unlikely that a 
cell count or differential count from a first day BAL sample would be clinically useful 
in the early identification of infants at highest risk of CLD.
d) Infection
A striking feature of all the longitudinal data for cell counts in individual babies is the 
sudden episodic increases that were observed. The most likely explanation for these 
sudden increases is the innate immune response to pulmonary infection. Ventilated 
preterm infants are at high risk of developing infections and much of neonatal care is 
devoted to preventing or treating these. All infants bom with respiratory distress on
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our unit are started on benzylpenillicin and gentamicin to treat potential infection and 
stringent precautions are in place to minimise nosocomial infection. Despite this, 
episodes of proven or suspected sepsis are common.
Identification of infection in neonates is difficult. Clinically, a variety of signs 
including temperature instability, poor perfusion, increased ventilatory requirements, 
changes in the infant’s usual behaviour or activity levels or poor feed tolerance may 
be noticed. Neonates are frequently treated for “presumed” or “suspected” sepsis 
based on clinical suspicion as all of these signs are non-specific and may not be 
present in the early stages of infection. Laboratory findings such as raised (or 
reduced) white cell counts, reduced platelet counts or elevated C-reactive protein may 
guide clinical judgement and cultures of blood, urine, airway secretions or 
cerebrospinal fluid may or may not identify pathogenic organisms. Special 
investigations such as X-rays may further assist in diagnosis of infection but X-ray 
findings, particularly chest X-ray features associated with infection, may lag behind 
clinical findings both in onset and resolution of changes.
Culture of BAL fluid is the best clinical method to identify a chest infection and 
identify an organism, however growth of a specific organism is frequently difficult to 
obtain given the small volumes of BAL fluid obtained and the widespread and early 
use of antibiotics when infection is suspected. The use of PCR to detect genes coding 
for 16S rRNA has been shown to increase sensitivity of bacterial detection in a 
number of clinical settings compared to standard cultures, such as in amniotic fluid 
(Markenson et al., 1997, Oyarzun et al., 1998) and in cystic fibrosis (Rogers et al.,
2006) and it is now widely used in a research setting. One study has used this 
technique in neonatal BAL fluid (Miralles et al., 2005), however, this only sought the 
presence of 16S rRNA genes on the first day of life and focused mainly on the role of 
antenatal infection on preterm labour. One previous study has used 16S rRNA genes 
to specifically examine the link between infection and pulmonary inflammation in the 
development of CLD (Miralles et al., 2005).
Although infection has been implicated in the development of CLD, there are 
surprisingly relatively few studies to support this. Antenatal infection, particularly 
with Ureaplasma urealyticum has been implicated in the onset of preterm labour
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(Goldenberg et al., 2000) and may be an independent risk factor for the development 
of CLD (Schelonka et al., 2005). Postnatal infection is less well examined. Several 
studies (Rojas et al., 1995, Van Marter et al., 2002, Liljedahl et al., 2004) found an 
association with systemic infection and the development of CLD. Cordero et al 
(Cordero et al., 1997) found that colonisation of the airways with Gram negative 
bacteria was associated with the development of CLD and Groneck et al (Groneck et 
al., 2001) demonstrated increased perinatal infections in tracheal aspirate fluid of 
infants who develop CLD.
Using PCR techniques to identify 16S rRNA genes, I demonstrated the presence of 
bacterial DNA in one fifth (35/177) of BAL samples. This may reflect true lower 
airway bacterial infection, although it is also possible that contamination could occur 
from the endotracheal tube through which the suction catheter must pass to perform 
the BAL. Among babies who developed CLD 11/15 had microbial DNA detected in 
their BAL sample at some stage, compared to 2/10 of the RDS group. The use of 
these PCR techniques would support the hypothesis that development of CLD is 
associated with the presence of bacteria. When the data are reviewed for only the first 
3 days of life, in an attempt to discriminate between antenatally and postnatally 
acquired organisms, the relationship between the presence of 16S rRNA genes and the 
development of CLD is not significant. Although the numbers are small, as this study 
was attempting to develop a methodology for neonatal BAL analysis by flow 
cytometry and not powered to detect differences in the development of CLD related to 
infection, this may suggest that it is infection in those babies who remain intubated 
which may be the cause of the lung injury that leads to the development of CLD, 
rather than antenatally acquired organisms.
The predominant organism detected in this cohort of infants was S. epidermidis. It 
was the only organism identified in the group of babies whose RDS resolved, while 
infants in the CLD group had a variety of organisms identified, including S. 
epidermidis but also a larger number of organisms which are widely recognised as 
pathogenic. The role of S. epidermidis in the neonatal lung is unclear. It is an 
organism which is frequently associated with indwelling venous or arterial catheters 
and S. epidermidis bacteraemia is always promptly treated with antibiotics and 
removal of the catheter, however S. epidermidis may equally colonise the
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endotracheal tube and be found in lung lavage samples. Many neonatal clinicians 
regard this as a contaminant, introduced during endotracheal suction, and will not 
routinely treat an infant for isolation of S. epidermidis from endotracheal secretions. 
Recently, more attention has been paid to the role of S. epidermidis, in particular its 
interaction with the neonatal immune system (Hartel et al., 2008). S. epidermidis 
colonisation of the endotracheal tube may be truly innocuous, however infection of 
the lung itself might be more harmful and the difference between endotracheal tube 
colonisation and true lung infection may help to explain the presence of S. 
epidermidis in both RDS and CLD groups. However, with respect to S. epidermidis, it 
has been previously shown that S. epidermidis is a weaker inducer of the neutrophil 
inflammatory response than an organism like S. aureus (Nilsdotter-Augustinsson et 
al., 2004), which may also in part account for our findings that S. epidermidis 
detection may be less frequently associated with the development of CLD than 
detection of other organisms. Further knowledge of the role of this organism may be a 
useful addition to neonatal care but this would require differentiation of colonisation 
of the endotracheal tube from infection in the lung itself and may thus entail the use of 
an animal model.
Ureaplasma was considered separately from other types of infection as its role in the 
development of CLD is far more controversial among neonatologists, possibly 
because its role in precipitating preterm labour and delivery is difficult to separate 
from the role of prematurity in the development of CLD (Embree and Embil, 1980, 
Schelonka and Waites, 2007, Kataoka et al., 2006). Also, treatment of Ureaplasma 
infection or colonisation has not been shown to reduce the development of CLD, 
although there is very little evidence for this conclusion (Mabanta et al., 2003).
This study supports a significant relationship between the development of CLD and 
the presence of Ureaplasma spp. in the preterm lung.
Overall, our data suggest that the presence of bacteria in the lung is associated with 
increased inflammation within the airways, as evidenced by elevated cell counts. As 
neutrophils enter the lungs they may release their proteases such as elastase and 
MMP-9 as well as reactive oxygen species in response to pathogens. These proteases 
and reactive oxygen species may be responsible for the tissue injury and abberant
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lung growth that is central to the development of CLD. Levels of human neutrophil 
elastase were measured in our samples and its role will be explored further in chapter
5.
3.5.5 Conclusion
In this chapter I have presented flow cytometry data on the cellular component of 
BAL fluid from a group of 32 ventilated term and preterm infants. Detailed flow 
cytometry analysis of BAL cells in this population of patients had not been previously 
published.
I have tried to describe the nature and progress of the inflammatory response in these 
infants and attempted to relate the number, type and sub-type of cells present to the 
development of CLD. Infants who develop CLD have higher cell counts and a larger 
proportion of the pulmonary mononuclear cell population are present in a more 
immature form, which may signify that immaturity of the innate immune system 
predisposes these preterm infants to a more uncontrolled or dysregulated 
inflammatory response and the development of CLD. Longitudinal data for individual 
infants over their entire ventilation course may be more informative regarding the 
development of CLD than looking at groups of babies due to the rapid and variable 
fluctuations in cell counts in individual babies, particularly in response to infection. 
Neither total nor differential cell counts on the first day of life were able to detect 
which infants might go on to develop CLD.
I also related the flow cytometry findings to the presence of bacterial 16S rRNA genes 
and Ureaplasma spp. in the lavage samples to show that infants in whom either 
organism is detected are a greater risk of developing CLD.
211
Chapter 4 
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Chapter 4 
Apoptosis
4.1 Introduction
In chapter 3 I described the cellular component of the inflammatory response in the 
newborn lung, however once inflammatory cells have arrived in the airways, it is 
necessary for them to be removed again in order for the inflammatory process to be 
resolved. A lack of adequate or appropriate resolution of the inflammatory response 
has been linked with the development of CLD (Kotecha et al., 2003).
Cells, particularly neutrophils, are removed from the lung in a number of ways. In 
particular, neutrophils may undergo apoptosis and ingestion by macrophages, which 
helps to resolve inflammation, or they may undergo necrosis, resulting in a 
magnification of the inflammatory cascade. I hypothesised that the development of 
CLD may be linked to a reduction in neutrophil apoptosis, leading to a greater number 
of viable neutrophils remaining in the lung causing tissue injury and ongoing 
inflammation. Additionally, the immature macrophage phenotype demonstrated in 
chapter 3 may have an impact on phagocytosis of neutrophils that have become 
apoptotic, resulting in apoptotic neutrophils undergoing secondary necrosis, further 
increasing inflammation and tissue injury.
In this chapter I shall examine neutrophil apoptosis in BAL samples and endeavour to 
understand the relationships between neutrophil apoptosis and the development of 
CLD. Firstly, I shall attempt to further describe the BAL neutrophil population in 
terms of cell viability, apoptosis or necrosis, hypothesising that babies who go on to 
develop CLD will have fewer apoptotic and more viable and necrotic neutrophils 
present in the lung, contributing to tissue injury. I will also look at the impact of 
infection on neutrophil apoptosis, necrosis and viability in BAL samples. I will review 
data for the first few days of life in an attempt to determine if there is a parameter that 
may be predictive for the development of CLD. Additionally, I shall attempt to 
understand the relationship between the presence of macrophages in BAL samples 
and the apoptotic neutrophil population.
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4.2 Detection of apoptotic cells by cytospins vs FACS
The extemalisation of phosphatidylserine (PS) on the cell membrane is one of the 
early signs of apoptosis. Annexin-V is a protein of the annexin family which 
preferentially binds to negatively charged phospholipids like PS in the presence of 
Ca2+. Changes in PS asymmetry can be detected before morphological changes 
associated with apoptosis have occurred and before the integrity of the cell membrane 
has been lost. The use of a DNA stain (To-Pro 3) aids the differentiation of necrotic 
(Annexin V +, To-Pro 3 +) from apoptotic (Annexin V +, To-Pro 3 -) cells.
Neutrophils were gated on forward/side scatter plots, based on their typical size and 
granularity. This gating was confirmed to be around neutrophils by assessing CD 15 
positivity. The Annexin V and To-Pro 3 characteristics of these cells were then 
assessed.
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Figure 4.1 Flow cytometry plots showing (A) gating on neutrophils (R2) and (B) 
Annexin- V (FL2) and To-Pro 3 (FL4) staining for the gated population.
Using flow cytometry it is possible to detect apoptosis before the morphological 
changes that can be seen on cytospins become apparent, therefore I expected a higher 
percentage of apoptotic cells to be detected by FACS and this was seen in our results, 
where the median percentage of the neutrophil population identified as apoptotic was 
12.38% by FACS and only 1.52% on counted cytospins (Mann-Whitney U-test, 
p<0.0001; Cytospin mean 3.51%, median 1.52%; FACS mean 13.05%, median
2 1 4
12.38%) (Figure 4.2). Data that follow in this chapter are those obtained by flow 
cytometry, rather than on counted cytospins.
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Figure 4.2 (A) Scatterplot showing the percentage o f apoptotic cells in each BAL 
according to two different methods, namely counted on cytospin preparations and 
detected by FACS analysis. Horizontal lines represent medians.
(B) Bland-Altman plot showing comparison between cytospins andflow cytometry for  
detection o f apoptotic cells in BAL samples. Horizontal dotted lines represent 95% 
levels o f agreement.
4.3 Apoptotic neutrophils in BAL samples
The total number of apoptotic cells was not significantly different between either term 
and preterm infants (Preterm median 0.026 xlO6 cells/ml, mean 0.105 xlO6 cells/ml; 
Term median 0.011 xlO6 cells/ml, mean 0.018 xlO6 cells/ml; Mann-Whitney U-test, 
p=0.122), or between any of the diagnostic groups (CLD median 0.024 xlO6 cells/ml, 
mean 0.103 xlO6 cells/ml; RDS median 0.029 xlO6 cells/ml, mean 0.115 xlO6 
cells/ml; Term median 0.011 xlO6 cells/ml, mean 0.018 xlO6 cells/ml; Kruskal-Wallis 
test, p=0.111), although it can be seen that preterm infants, regardless of diagnosis, 
had a tendency to have higher numbers of apoptotic neutrophils present in BAL 
samples (Figure 4.3). This is not surprising in view of the higher absolute number of 
neutrophils present in preterm BAL samples.
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Figure 4.3 Scatterplots (using log scale) showing the absolute number o f apoptotic 
neutrophils in BAL samples according to (A) diagnosis and (B) gestation. Horizontal 
lines represent medians.
However, when the percentage of the neutrophil population which was apoptotic was 
analysed, a significantly higher percentage of the neutrophil population was apoptotic 
in term infants when compared to preterm infants (Preterm median 12.38%, mean 
13.83%; Term median 21.62%, mean 25.68%; Mann-Whitney U-test, p=0.0009) 
(Figure 4.4B). Babies with RDS and those with CLD had very similar proportions of 
the neutrophil population in apoptosis (CLD median 12.52%, mean 13.71%; RDS 
median 10.46%, mean 14.48%; Term median 21.62%, mean 25.68%; Kruskal-Wallis 
test, p=0.0032; CLD vs term <0.01, RDS vs term <0.01) (Figure 4.4A). In other 
words, although preterm infants had higher numbers of neutrophils in BAL samples 
than their term counterparts, the proportion of the neutrophils which were apoptotic 
was significantly smaller in the preterm group.
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Figure 4.4 Scatterplots showing the percentage o f the neutrophil population which 
was apoptotic in BAL samples, according to (A) diagnosis and (B) gestation. 
Horizontal lines represent medians.
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When the data are viewed longitudinally over the entire duration of the ventilated 
period (Figure 4.5), term babies appear to have a sudden surge in the proportion of the 
neutrophil population which is apoptotic over the first 3 days of life and have 
consistently higher percentages of apoptotic neutrophils on all but the first day (Figure 
4.6). There is a statistically significant difference between term and preterm infants on 
day 3 (Figure 4.6). The median percentage of the neutrophil population which is 
apoptotic is very similar between all the groups of babies on day 1 and there is no 
statistically significant difference between the groups on day 2 either (Term mean 
26.61%, median 25.79%; preterm mean 16.04%, median 14.94%; Mann-Whitney U- 
test, p=0.342). However, there is a significant difference between term and preterm 
infants on day 3 (Term mean 42.96%, median 42.96%; preterm mean 13.23%, median 
10.06%; Mann-Whitney U-test, p=0.019). After this point, there are too few data in 
the term group to allow for meaningful comparisons to be made as all but 2 of the 
babies had no usable data for days 4 and 5 due to most having been extubated and 
others having very low total cell counts which did not allow sufficient cells to be 
analysed by flow cytometry for apoptosis. No significant difference in the percentage 
of neutrophils which were apoptotic was found between preterm babies who 
developed CLD and those whose RDS resolved on days 1-7.
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Figure 4.5 Graphs showing changes in percentage o f apoptotic neutrophils over the 
course o f the ventilation period according to (A) diagnosis and (B) gestation. It can 
be seen that there is little difference between the RDS and CLD sub-groups o f preterm 
infants. (*p=0.019)
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Figure 4.6 Scatterplots showing the percentage o f the neutrophil population which is 
apoptotic, comparing term and preterm infants on (A) day 1, (B) day 2 and (C) day 3.
According to figure 4.5 (B), the peak percentage of apoptotic neutrophils is achieved 
in term infants on day 3 and the proportion of apoptotic cells in term infants is 
consistently higher than in preterm infants. The highest proportion of apoptotic cells 
is present in preterm infants on day 5 (if only the first 5 days of life are considered) 
but median proportions of apoptotic neutrophils rise gradually in the preterm group to 
reach their highest level in the final (day 27) BAL sample.
When looking longitudinally at either numbers or proportions of apoptotic cells, 
grouped data for preterm infants show some initial day-to-day variations in apoptotic 
cells followed by a very slowly increasing proportion of apoptotic cells as the CLD 
babies approach the 27th day of life. However, when data from individual babies are 
reviewed, the slow increase in median apoptotic cells can be seen to be contributed to 
by short duration, episodic increases and decreases in the proportion of apoptotic
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Figure 4.7 Graphs showing percentage o f neutrophil population which is apoptotic 
for all babies with 3 or more BAL samples. Vertical arrows represent samples in 
which 16S rRNA was detected.
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There is also a significant difference in the peak percentage of apoptotic neutrophils 
among the 3 groups (CLD mean 20.24%, median 15.52%; RDS mean 10.64%, 
median 7.12%; Term mean 29.53%, median 32.02%; Kruskal-Wallis test, p=0.0395) 
(Figure 4.8). Despite the apparent trend, seen in Figure 4.7, among individual infants 
developing CLD to have higher percentages of apoptotic neutrophils in later B AL 
samples, very little difference can be seen in the median percentage of peak apoptotic 
neutrophils between the first 5 days of life (12.5%) and the whole ventilated period 
(15.5%).
Term Term
Figure 4.8 Scatterplots showing the highest percentage o f apoptotic cells reached in 
each individual infant in (A) the entire ventilated period and (B) the first 5 days o f  
life. Horizontal lines represent medians in each group.
It might be expected that the proportion of apoptotic neutrophils would fluctuate in 
parallel with the total neutrophil count or with the proportion of the total cell count 
made up of neutrophils. In figure 4.9 it can be seen that, in many babies, while 
neutrophil counts are relatively low, the percentage of apoptotic neutrophils are 
relatively high but there are also periods when the neutrophil count and percentage 
apoptotic cells appear to rise simultaneously. Figure 4.10 shows a significant linear 
relationship between the number of neutrophils present and the number of apoptotic 
neutrophils. This may indicate that, in addition to a reduction in the percentage of 
apoptotic neutrophils in preterm infants, lung injury also occurs as a result of an 
inability to clear away any apoptotic neutrophils, which go on to become necrotic.
223
224
Neutrophil count 
(million/ml)
co
co
-* -* N) N) W U  ^o  cn o  cn o  cn o
% apoptotic neutrophils
Neutrophil count 
(million/ml)
CO
CO
co
JO
CO
o cn o
% apoptotic neutrophils
Neutrophil count 
(million/ml)
o  ro cn oo o  to
co
co
JOcn
ro-o
o o ro
% apoptotic neutrophils
Neutrophil count 
(million/ml)
o - * r o c o - * c n o > - > i o o
co
cn
cn
co
roco
tocn
' Q
—* —» to to co coo  cn o  cn o  cn
% apoptotic neutrophils
Neutrophil count 
(million/ml)
o  ^  p  ^  o  ^  o  
o ! 5 ^ c n r o c n c o £ n
CO
•o
CO
CO
cn
co
00,3<SSK88i£8:8
% apoptotic neutrophils
Neutrophil count 
(million/ml)
Q - * I O C O ^ U l O ) N
S
cn
CO
to
10co
fO W W Acn o  cn oo
% apoptotic neutrophils
Neutrophil count 
(million/ml)
Q a | O W ^ U l O ) S
CO
ro
roco
to■o
O  I O A  O)  00 o  to cn
% apoptotic neutrophils
Neutrophil count 
(million/ml)
p o o p  - k - k -*• ON^b)»-*io^b)
:□
co
cn
CO
CO
COoo cn o cn
% apoptotic neutrophils
225
Neutrophil count 
(million/ml)
to
01
fO
o o
% apoptotic neutrophils
Neutrophil count 
(million/ml)
tn  -k  cn ro cn co 01
<0
cn
CO
ro
ro
co
ro ro  to  co
o  01 o  cn o  01
% apoptotic neutrophils
Neutrophil count 
(million/ml)
o  ro
cn
CO
co
ro
co
ro
cno o
% apoptotic neutrophils
Neutrophil count 
(million/ml)
co
CO
o  ro S  S  00 oo  ro A  0 ) 00
% apoptotic neutrophils
Neutrophil count 
(million/ml)
ro  co -c* cn cn -o  00
% apoptotic neutrophils
Neutrophil count 
(million/ml)
o  cn -k  cn ro  cn co
cn
CO
ro
ro
co
o  cn
% apoptotic neutrophils
Baby D - 25 w ks, RDS
1.4
1.2
0.8
0.6
0.4
0.2
Day
Baby J -2 7  w ks, RDS
1.2
■S « 06
a =
|  E 0.4
0.2
Day
Baby M - 28 w k s, RDS
□ ^  
8 I
U
p
3 .5 *
0.5 .
0 I . , .
35
30 5
» f
20 1 c
15 £  
o10 |  
a
5 se0
3 5 7 9 11 13 15 17 19 21 23 25 27
Day
Baby S -  26 w k s, RDS
3.5 25
31 -20
JO
IE
1^2.5.
J i  2. L . 15
1
I
I f 15 c . 10 o
I  1-Z 0.5 ■ 
0 •
I . 5 
. 0
o.oa«S*
1 3 5 7 9 11 13 15 17 19 21 23 25 27 
Day
Baby T - 26 w ks, RDS
2 5 - 40
<5 □ .3 5  £
c
C. ■
- 3 0  a
3  _ ' ' 11 S8 E15 25 s
11 p  1 \ .2 0  5
I ! 1 •d \r\° - 15 Ia> q  j . 10 oz 0.5
1 v
a
• 5 i
0 0
1 3 5 7 9 11 13 15 17 19 21 23 25 27
Day
Baby H - Term
= =-0.08
Z  § 0.06
*  E 0.04
Baby X -T erm
7 9 11 13 15 17 19 21 23 25 27 
Day
Figure 4.9 Graphs showing relationship between the proportion o f apoptotic 
neutrophils and the total neutrophil count in individual infants with 3 or more BAL 
samples. (Solid line indicates absolute neutrophil count, broken line indicates 
percentage o f apoptotic neutrophils.)
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Figure 4.10 Scatterplot showing linear relationship between neutrophil count and 
number o f apoptotic neutrophils. R2=0.5371, p<0.0001
4.4 Viable and necrotic neutrophils
In addition to considering apoptotic neutrophils, it is important to consider that viable 
and necrotic neutrophils may play a role in lung injury and in the development of 
CLD as they are more likely to release inflammatory mediators and agents of tissue 
damage such as elastase, metalloproteinases and reactive oxygen species than cells 
undergoing apoptosis.
4.4.1 Viable neutrophils in BAL samples
There are significantly more viable neutrophils (Annexin V To-Pro 3 -) in preterm 
than term babies (CLD median 0.14 xlO6 cells/ml, mean 0.47 xlO6 cells/ml; RDS 
median 0.37 xlO6 cells/ml, mean 0.47 xlO6 cells/ml; Term median 0.03 xlO6 cells/ml, 
mean 0.04 xlO6 cells/ml; Kruskal-Wallis test, p=0.0006, CLD vs term <0.01, RDS vs 
term<0.001) (Preterm median 0.15 xlO6 cells/ml, mean 0.47 xlO6 cells/ml; Term 
median 0.03 xlO6 cells/ml, mean 0.04 xlO6 cells/ml; Mann-Whitney U-test, 
p=0.0008). This was not unexpected due to the higher total number of neutrophils in 
preterm BAL samples.
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Figure 4.11 Scatterplots showing the viable neutrophil count in BAL samples 
according to (A) diagnosis and (B) gestation. Horizontal lines represent medians.
When the percentage of viable neutrophils is considered as a proportion of the total 
neutrophil population, no significant difference is observed among term, RDS and 
CLD babies (CLD median 62.46%, mean 59.97%; RDS median 59.84%, mean 
57.77%; Term median 50.95%, mean 49.72%; Kruskal-Wallis test, p=0.076), 
however, there is a significantly higher proportion of viable neutrophils in preterm 
infants when considered as a group (Preterm median 61.87, mean 59.62; Term median 
50.95, mean 49.72; Mann-Whitney U-test, p=0.026).
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Figure 4.12 Scatterplots showing the percentage o f the BAL neutrophils which were 
viable according to (A) diagnosis and (B) gestation. Horizontal lines represent 
medians.
When data for the percentage of viable neutrophils are viewed longitudinally over the 
entire length of the ventilation period, it can be seen that all 3 groups of infants have 
similar proportions of their neutrophil population as viable cells initially and that
infants who develop CLD have a proportion of viable neutrophils around a median of 
60% for most of the second, third and fourth weeks of life.
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Figure 4.13 Graphs showing changes in median percentage o f viable neutrophils over 
the course o f the ventilation period according to (A) diagnosis and (B) gestation.
Error bars represent interquartile ranges.
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Once again, with the objective of identifying a possible prognostic indicator for the 
development of CLD, the first 3 days of life were reviewed in detail with respect to 
the percentage of viable neutrophils present, and despite the term group tending to 
have persistently lower percentages of viable neutrophils, there were no significant 
differences observed.
& 60- s !1 40-I
2 
>*
20-
A "35" r6 s B CLD
cLd
Figure 4.14 Scatterplots showing the percentage o f the BAL neutrophils which were 
viable on (A) day 1, (B) day 2 and (C) day 3 o f life in each diagnostic group.
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Figure 4.15 Scatterplot showing the median peak percentage o f viable neutrophils in 
each infant according to diagnostic group.
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When data for individual infants are reviewed, it can be seen that the proportion of 
viable neutrophils in each infant is fairly constant but often falls around the time of a 
total neutrophil count increase (Figure 4.16). This may be related to large numbers of 
neutrophils dying by necrosis causing more neutrophils to be recruited to the site of 
inflammation or possibly the neutrophil count peak coincides with an increase in 
apoptosis of the neutrophils that are present in an attempt to control neutrophil 
numbers at the affected site. There is, however, a linear relationship between the total 
neutrophil count and the absolute number of viable neutrophils present (Figure 4.17).
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Figure 4.16 Graphs showing relationship between total neutrophil count (grey line) 
and the proportion o f the neutrophil population that was viable (black line) for all 
infants with 3 or more BAL samples.
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Figure 4.17 Scatterplot showing linear relationship between total neutrophils and 
number o f viable neutrophils. R2=0.6285, p<0.0001
4.4.2 Necrotic neutrophils in BAL samples
Necrotic cells were those neutrophils which were both Annexin V and To-Pro 3 
positive, indicating disruption of the cell membrane and exposure of DNA.
The absolute number of necrotic cells is significantly higher in preterm infants 
(Preterm median 0.07 xlO6 cells/ml, mean 0.22 xlO6 cells/ml; Term median 0.01 xlO6 
cells/ml, mean 0.02 xlO6 cells/ml; Mann-Whitney U-test, p=0.009) although, once 
again, no difference between the babies with RDS and CLD can be shown (CLD 
median 0.05 xlO6 cells/ml, mean 0.21 xlO6 cells/ml; RDS median 0.17 xlO6 cells/ml, 
mean 0.30 xlO6 cells/ml; Term median 0.01 xlO6 cells/ml, mean 0.02 xlO6 cells/ml; 
Kruskal-Wallis test, p=0.004, RDS vs term <0.01) (Figure 4.18). A large load of 
necrotic neutrophils may be responsible for release of various pro-inflammatory 
factors into the peri-cellular environment. Macrophages which ingest necrotic 
neutrophils are stimulated to release further pro-inflammatory cytokines, rather than 
anti-inflammatory mediators that are released upon phagocytosis of an apoptotic cell. 
Thus, this high load of necrotic neutrophils may help to potentiate the inflammatory 
response, both through the direct consequence of necrosis and the release of the 
neutrophil’s toxic contents and through the phagocytosis of necrotic neutrophils 
causing release of further pro-inflammatory mediators from macrophages.
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Figure 4.18 Scatterplots showing the necrotic neutrophil count in BAL samples 
according to (A) diagnosis and (B) gestation.
The proportion of the neutrophil population that was necrotic was not significantly 
different between the groups (CLD median 24.50%, mean 26.30%; RDS median 
30.43%, mean 27.76%; Term median 24.98%, mean 24.61%; Kruskal-Wallis test, 
p=0.74); (Preterm median 24.91%, mean 26.53%; Term median 24.98%, mean 
24.61%; Mann-Whitney U-test, p=0.706) (Figure 4.18).
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Figure 4.19 Scatterplots showing the percentage o f necrotic neutrophils in BAL 
samples according to (A) diagnosis and (B) gestation.
Although the overall number of necrotic neutrophils was significantly higher in BAL 
from preterm infants (Figure 4.18, above), analysis of the peak percentages of 
necrotic neutrophils showed no significant difference in the peak percentages of 
necrotic neutrophils in preterm infants (CLD mean 47.21%, median 43.37%; RDS 
mean 37.62%, median 36.14%; Term mean 33.11%, median 27.36%; Kruskal-Wallis 
test, p=0.0565)(Preterm mean 43.61%, median 42.28%; Term mean 33.11%, median 
27.36%; Mann-Whitney U-test, p=0.606) (Figure 4.20).
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Figure 4.20 Scatterplot showing peak percentage o f necrotic neutrophils in BAL 
samples, indicating a trend towards a higher percentage o f necrotic neutrophils in 
BAL fluid from babies who developed CLD.
In figure 4.2 IB (below) it can be seen that the highest proportion of necrotic 
neutrophils occurs on day 1 in term infants; whereas preterm infants have the largest 
percentage of necrotic cells on day 27. If only the first 5 days of life are compared, 
preterm infants, both those developing CLD and those whose RDS is resolving, have 
their peak percentage in necrotic cells at day 3. Similarly for apoptotic cells, peak 
percentages of apoptotic cells occur in RDS on day 3 and in CLD on day 27 but on 
day 3 in CLD if only the first 5 days are considered. More detailed review of each of 
the first 3 days of life shows no significant differences in percentage of necrotic 
neutrophils present between term and preterm infants (Figure 4.22).
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Figure 4.21 Graphs showing the median percentage of the BAL neutrophil population 
which is necrotic according to (A) diagnosis and (B) gestation.
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Figure 4.22 Scatterplots showing no significant difference in the percentage o f 
neutrophils which were necrotic on (A) day 1, (B) day 2 and (C) day 3 o f life between 
term and preterm infants.
When individual infants’ data are reviewed (Figure 4.23), the relationship of necrotic 
neutrophils to the total neutrophil count can be seen to change in parallel, i.e. the 
higher the neutrophil count, the larger proportion of the cells are necrotic. This may 
suggest that neutrophil clearance from inflammatory sites, particularly by apoptosis, 
may be impaired, causing neutrophils to build up in numbers and become necrotic 
before being removed by macrophages. Figure 4.24 shows a linear relationship 
between neutrophil count and number of necrotic neutrophils.
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Figure 4.23 Graphs showing neutrophil count (grey line) and percentage necrotic 
neutrophils (black line) for individual infants with at least 3 BAL samples.
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Figure 4.24 Scatterplot showing linear relationship between neutrophil count and 
number o f necrotic neutrophils. R2=0.5960, p<0.0001
In summary, preterm infants have a higher proportion of their BAL neutrophils as 
viable cells and there is a higher percentage of cells undergoing apoptosis in the term 
BAL samples. The proportion of the neutrophils which are necrotic is similar in both 
term and preterm infants but due to higher total neutrophil counts in the preterm 
group, the number of necrotic cells in preterm infants is significantly higher than in 
term babies. There are no significant differences between babies with RDS and CLD, 
which may imply that rates of neutrophil apoptosis may be associated with gestational 
age or with another factor which is common to both RDS and CLD groups.
Overall, preterm infants have slightly later peaks in both proportions of apoptotic and 
necrotic neutrophils than term infants. This may imply that both the process of 
neutrophil apoptosis and apoptotic cell clearance (allowing the uncleared apoptotic 
cells to undergo secondary necrosis) are delayed in preterm infants. It may be that the 
higher neutrophil counts present in preterm infants overwhelm the clearance 
mechanisms in addition to an inherent delay in neutrophil apoptosis compared to term 
infants.
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4.5 Relationship between neutrophil apoptosis and the presence of infection
The presence of 16S rRNA genes has already been temporally related to spikes in the 
total cell count and neutrophil count (Section 3.3.7 and Figures 3.15 and 3.17). I tried 
to clarify further the relationship between the presence of microbial genes in BAL 
samples and the proportion of apoptotic neutrophils present. It is likely that the pro- 
inflammatory factors associated with infection and which promote neutrophil 
recruitment also have an anti-apoptotic effect on the neutrophils e.g. TNFa and IL-lp 
(Colotta et al., 1992). This would have the effect of further increasing neutrophil 
counts.
No statistically significant differences were found in the percentage of the neutrophil 
population that was apoptotic, necrotic or viable between samples where 16S rRNA 
genes were detected and samples where the 16S rRNA gene was not found (Figure 
4.25).
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Figure 4.25 Scatterplots showing percentage o f (A) apoptotic, (B) viable and (C) 
necrotic neutrophils in BAL samples o f  babies in whom 16S rRNA was detected 
compared to those without.
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When looking at longitudinal data for individual babies (Figure 4.26), the percentage 
of apoptotic neutrophils is often low relative to the peak for that baby when the BAL 
sample is positive for 16S rRNA genes or that the percentage of apoptotic cells begins 
to fall once the 16S rRNA gene is detected. However similar variations in the number 
or percentage of apoptotic cells can also be observed in infants in whom infection was 
not detected so this is unlikely to be a significant observation.
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Figure 4.26 Graphs showing percentage o f apoptotic neutrophils (black line) over 
time for individual infants in relation to the presence o f 16S rRNA in BAL fluid (black 
arrows).
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There were also no significant differences in apoptotic (p=0.2483), necrotic 
(p=0.3912) or viable (p=0.6198) neutrophil percentages between babies with or 
without Ureaplasma present in their BAL samples (Figure 4.27).
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Figure 4.27 Scatterplots showing percentage o f (A) apoptotic, (B) viable and (C) 
necrotic neutrophils in BAL samples o f babies in whom Ureaplasma was detected 
compared to those without.
4.6 Neutrophil apoptosis in relation to mode of delivery
The process of labour has been demonstrated to prime/activate neutrophils and thus 
delay apoptosis (Molloy et al., 2004). In addition, it is possible that an undetected 
antenatal infection may precipitate the process of preterm labour, resulting in an 
inflammatory environment present in the lung at delivery and further delay to the 
apoptotic process. It could thus be expected that infants bom following spontaneous 
preterm labour would have fewer apoptotic cells present initially than those bom by 
elective Caesarean section. However, in our cohort there was no difference in the 
percentage of apoptotic cells between spontaneously and electively delivered preterm 
infants on day 1 (Mann-Whitney U-test, p=0.63) (Figure 4.28A) or on day 2 (p=0.74)
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(Figure 4.28B). However, on day 3 the percentage of the neutrophil population that 
was apoptotic was significantly higher in the preterm labour group (p=0.019; 
Caesarean mean 2.18%, median 2.84%; labour mean 12.56%, median 7.37%) (Figure 
4.28C) which is contrary to what might be expected. It is possible that the priming 
effect of labour on neutrophils is no longer active by the third day of life or another 
confounding factor, including small sample size, is producing this effect on neutrophil 
apoptosis at this stage.
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Figure 4.28 Scatterplots showing the percentage o f apoptotic cells present in BAL 
samples ofpreterm infants (A) day 1, (B) day 2 and (C) day 3 o f life, according to 
whether the baby was delivered by elective Caesarean section or following 
spontaneous onset o f  preterm labour.
4.7 Relationship of apoptotic neutrophils to the macrophage population
I have already discussed the positive correlations between the total neutrophil count 
and the number of apoptotic, necrotic and viable neutrophils. The neutrophil 
population is dependent on the presence of macrophages in the lung for neutrophil 
recruitment and also for removal of both apoptotic and necrotic neutrophils. The 
number and type of macrophages present in the lung may have an influence on either 
number or proportion of apoptotic or necrotic cells present. I would expect higher
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numbers of macrophages, particularly mature macrophages, to reduce the number of 
apoptotic or necrotic cells present in the BAL samples due to phagocytosis of these 
cells.
When all babies are compared, there is a positive correlation between CD36+ 
macrophages and numbers of apoptotic (R2=0.330, p<0.0001), necrotic (R2=0.632, 
p<0.0001) and viable neutrophils. Intuitively there should be an inverse relationship 
between these variables as expression of CD36 should impart the ability to 
phagocytose apoptotic cells, however it must be considered that the number of 
apoptotic cells may have overwhelmed the macrophage response and thus the true 
relationship may be obscured. There was no significant relationship between the 
number of mature (HLA-DR +) alveolar macrophages and the number of apoptotic 
cells (R =0.13). Total macrophage count also did not correlate significantly with 
apoptotic or necrotic cell numbers.
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Figure 4.29 Scatterplots showing relationship between CD36 + macrophages and the 
number o f (A) apoptotic and (B) necrotic neutrophils.
Although the relationship between macrophages and apoptotic cells has proved 
difficult to explore, one of the advantages of our study is the ability to look 
longitudinally at individual infants over their entire ventilatory course and observe 
any possible relationships between different cell types.
When individual baby data are reviewed, there is again no clear relationship between 
the macrophage count and the percentage of the neutrophil population that is 
apoptotic (Figure 4.30), however a much clearer relationship exists between the
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macrophage count and the number of apoptotic cells present, with the two absolute 
cell counts appearing to rise and fall almost simultaneously in many cases (Figure 
4.31).
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Figure 4.30 Longitudinal data for babies with 3 or more BAL samples showing the macrophage 
count (solid line) against the percentage o f the neutrophil population which is apoptotic (dotted 
line).
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Figure 4.31 Longitudinal data for babies with 3 or more BAL samples showing the 
macrophage count (solid line) against the total number o f apoptotic neutrophils 
present (dotted line).
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4.8 Sum m ary of m ain findings
1. A significantly higher percentage of the neutrophil population is apoptotic in 
term infants, although there is no difference in the absolute number of 
apoptotic neutrophils between the groups.
2. There are significantly more viable neutrophils in preterm infants, although 
the percentage of the neutrophil population which is viable is not significantly 
different from term infants.
3. There are significantly higher numbers of necrotic neutrophils in preterm 
infants, but again the proportion of the neutrophil population which is necrotic 
is not significantly different in term and preterm infants.
4. No significant differences were shown between infants whose RDS resolved 
and those who developed CLD, suggesting that neutrophil apoptosis may be 
linked to gestation or to another common factor between the groups.
5. Preterm infants have a slightly later peak in proportions of apoptotic and 
necrotic cells than term infants, suggesting a possible delay in the onset of 
neutrophil apoptosis and/or apoptotic cell clearance.
6. There is a positive correlation between CD36 expression on macrophages and 
the number of apoptotic and necrotic cells present, but no such relationship 
between HLA-DR expressing macrophages and apoptotic or necrotic cells was 
demonstrated.
7. Individual babies show a close temporal relationship between increases in 
apoptotic neutrophil count and total macrophage count.
8. There appears to be no difference in the percentage of apoptotic or necrotic 
neutrophils in BAL samples in relation to infection and, in individual babies, 
the relationships between the presence of different types of organism and the 
number or percentage of apoptotic cells is variable and complex.
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4.9 Discussion
4.9.1 Overview
Ongoing inflammation is thought to be important in the pathogenesis of CLD. In 
chapter 3 I described the composition of the cellular component of BAL samples and 
patterns of influx of cells into the airways. Once in the airways, cells must be 
removed again in order for inflammation to be resolved. The removal of neutrophils 
from the airways in the newborn by apoptosis and then phagocytosis by macrophages 
was first described in 1991 by Grigg et al (Grigg et al., 1991). They identified, by 
microscopy, intact, apoptotic neutrophils within macrophages in BAL fluid of 8 
ventilated infants but noted that their findings did not correlate with clinical outcome.
Since then several investigators (Kotecha et al., 2003, Oei et al., 2003) have proposed 
that reduced neutrophil apoptosis and increased neutrophil survival may be the 
mechanism by which neutrophils persist in the lungs of preterm infants and promote 
the development of CLD. However, this has not been a completely consistent finding 
with Cheah et al (Cheah et al., 2005a, Cheah et al., 2005b) finding that high numbers 
of apoptotic cells did not preclude progression to CLD.
This study is the only one to my knowledge which has looked at apoptosis using flow 
cytometry in BAL samples from the lungs of newborn ventilated infants. The study 
also benefits from repeated sampling of the same infants over time so that the natural 
history of the infant’s lung injury and/or its resolution can be observed as it 
progresses. Previous studies of apoptosis in BAL fluid neutrophils (Kotecha et al., 
2003, Oei et al., 2003) have not performed daily samples in the first week of life. 
Even despite this study’s frequent sampling, comparison between term and preterm 
infants is hampered by the very short duration of ventilation in preterm infants.
The use of flow cytometry for assessment of neutrophil apoptosis in neonatal BAL 
samples is just as labour intensive as the preparation of cells for analysis of other 
surface markers as discussed in chapter 3. Again it requires immediate processing of 
BAL samples before any deterioration in the sample can occur and as such is not 
practical for routine use in clinical samples.
260
4.9.2 N eutrophils -  apoptotic, necro tic  and  viable
As shown in chapter 3, preterm infants have higher neutrophil counts than their term 
counterparts, so it is perhaps not surprising that the numbers of viable neutrophils in 
BAL samples are significantly higher in preterm babies. In terms of the percentage of 
the neutrophil population that are viable, there is no significant difference between 
term and preterm infants. These higher absolute numbers of viable neutrophils may be 
responsible for the generation of proteases, ROS and other mediators which mediate 
lung damage. Analysis of these mediators in BAL supernatants is discussed further in 
chapter 5.
A similar picture is seen for the presence of necrotic cells -  with preterm and term 
infants having a similar percentage of their BAL neutrophil population undergoing 
necrosis, however the preterm group of babies have a higher overall number of 
neutrophils and therefore a significantly higher number of necrotic neutrophils 
present. This higher absolute load of necrotic neutrophils may be involved in 
mediating lung injury through release of proteases and other neutrophil granule 
contents into the tissues. In addition, phagocytosis of necrotic neutrophil fragments 
directs macrophages to release more pro-inflammatory mediators, thus exacerbating 
the inflammatory response within the lung (Savill et al., 2002).
With the above in mind, one would expect that preterm infants would have a similar 
percentage of apoptotic cells to their term counterparts and higher absolute numbers 
of apoptotic cells in BAL samples due to higher cell counts. This is not the case. The 
absolute numbers of apoptotic neutrophils in preterm BAL samples are not 
significantly different to those in term babies, however term babies have a 
significantly higher percentage of their BAL neutrophils undergoing apoptosis than in 
preterm babies. This might imply that preterm neutrophils are in some way resistant to 
death by apoptosis, perhaps remaining viable for longer or preferentially undergoing 
death by necrosis instead. I will explore this hypothesis further in cord blood cells in 
chapter 6.
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4.9.3 R elationship to m acrophages
Following apoptosis, effete neutrophils must be taken up by macrophages in order to 
be cleared from the site of inflammation, which in turn facilitates the production of 
anti-inflammatory cytokines by the macrophages and further downregulation of the 
inflammatory response (Haslett, 1999, Fadok et al., 1998).
There appears to be a temporal relationship in individual infants between the number 
of apoptotic neutrophils and the number of macrophages present in the BAL sample. I 
have noted previously (in chapter 3) that neutrophil counts and macrophage counts 
tend to rise and fall in close relationship to each other and also (in this chapter) that 
there is a linear relationship between total neutrophil count and the number of 
apoptotic neutrophils which may partly explain this relationship.
The phagocytosis of apoptotic neutrophils may be dependent on the expression of 
various cell surface markers on the macrophage which allow the cell to recognise an 
apoptotic neutrophil. These surface markers include CD36 but there are a host of 
other molecules which play a role in this complex recognition process (Vandivier et 
al., 2006). Failing to demonstrate a clear relationship between macrophages with 
different surface markers implies that the process of recognition and phagocytosis of 
apoptotic cells is probably just more complex than cells expressing CD36 alone. The 
inflammatory response, particularly in preterm infants, may simply overwhelm the 
macrophage phagocytosis system’s ability to deal effectively with apoptotic 
neutrophils, allowing more to become necrotic, resulting in further neutrophil and 
monocyte recruitment and obscuring (for the purposes of our study) the 
neutrophil/macrophage interactions that are taking place.
4.9.4 Relationship to infection
Current understanding of the role of inflammatory mediators in the process of 
apoptosis would suggest that the presence of infection would increase the longevity of 
neutrophils, reducing the percentage of the population that is apoptotic. Contrary to 
this, it is also known that certain organisms (e.g P. aeruginosa) are able to induce
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apoptosis in host neutrophils as an “immune evasion” technique (Usher et al., 2002) 
and others eg S. aureus can induce rapid necrosis in host immune cells for similar 
reasons.
The majority of 16S rRNA genes detected in BAL samples were shown on 
sequencing to be from S. epidermidis, an organism that frequently colonises 
indwelling plastic medical devices such as endotracheal tubes and intravenous lines 
and cannulae. As previously discussed, the presence of S. epidermidis in BAL 
samples cannot simply be interpreted as infection in the lungs of the baby concerned 
as it may be a contaminant from the endotracheal tube, unavoidably picked up during 
BAL sampling. The role of S. epidermidis in neutrophil apoptosis is not well 
described, but it is known that S. epidermidis is unable to induce neutrophil apoptosis 
in the way that S. aureus does (Nilsdotter-Augustinsson et al., 2004). Additionally, 
more recently it was demonstrated that apoptotic neutrophils containing S. 
epidermidis produced a pro-inflammatory response by way of TNFa and IL-6 by the 
macrophage when ingested, rather than the expected anti-inflammatory one (Wilsson 
et al., 2008).
The presence of Ureaplasma spp. in a sub-group of the babies may also further 
complicate the interpretation of the relationship between apoptosis in BAL 
neutrophils and infection, as Ureaplasma has been shown to induce apoptosis in lung 
macrophages (Li et al., 2002) but its role in neutrophil apoptosis remains unclear. Five 
infants in our cohort were positive for 16S rRNA and had Ureaplasma detected in 
BAL samples, which is likely to further complicate interpretation of the FACS data on 
BAL cells.
The role of infection in neutrophil apoptosis in the lung is clearly far more complex 
than a simple “infection delays apoptosis” conclusion and merits further investigation 
in an in vitro setting where some of the many interacting factors in the process can be 
controlled or eliminated for study purposes. Some aspects of this process have been 
studied in cord blood neutrophils in chapter 6.
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4.9.5 Conclusion
In this chapter I have described the BAL neutrophil population in terms of cell 
viability, apoptosis or necrosis and showed that preterm infants appear to have a high 
load of necrotic cells and a relatively low proportion of apoptotic neutrophils in BAL 
samples. Both of these factors can be understood to affect the development of CLD in 
preterm infants, although no difference between RDS and CLD groups was found, 
perhaps due to the relatively small number of infants studied and the low number of 
samples available from babies with resolving RDS as they were generally extubated 
very rapidly.
The apparent delay or reduction in neutrophil apoptosis in the preterm group of 
infants will be studied further in an in vitro setting in chapter 6 and possible 
mechanisms for this will be explored.
The relationship between macrophages and neutrophil apoptosis involves numerous 
factors, only a few of which have been studied here. This relationship may require 
further studies using different macrophage markers and possibly different 
methodology to more clearly elucidate the interactions that must be occurring.
The role of infection in neutrophil apoptosis is complex and no single effect of the 
presence of either 16S rRNA microbial genes or Ureaplasma spp. could be identified. 
The type of organism present may significantly alter the response of neutrophils 
entering apoptosis and the subsequent cytokine production by the macrophage after 
phagocytosis.
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Chapter 5 
BAL fluid supernatants
Chapter 5
BAL fluid supernatants
5.1 Introduction
In the preceding two chapters, the focus was on the cellular component of the BAL 
samples, however it is vital that the cells are not studied in isolation as the 
environment in which the cell or cells are found may not only reflect the production 
or release of various chemical mediators by the cell but may also have a profound 
effect on the behaviour of the cells. There is a complex and finely balanced 
interaction between various pro- and anti-inflammatory proteins, particularly 
chemokines, cytokines and proteases which influences the recovery from or 
progression of the inflammatory process in the lung.
Inflammatory mediators, such as cytokines, at sites of inflammation are critical to the 
development and functioning of both the innate and adaptive immune response. These 
mediators are most frequently secreted by immune cells that have encountered a 
pathogen, thus activating and recruiting further immune cells to increase the immune 
response to the pathogen. Cytokines may have different pro- or anti-inflammatory 
effects on different cell types in different situations
I sought to measure various inflammatory mediators within BAL supernatants and 
then attempted to relate these measurements to clinical outcomes of the infants, 
hypothesising that those infants with higher levels of pro-inflammatory mediators 
within the BAL fluid might be more likely to progress to CLD than those with lower 
levels. I also sought to relate levels of inflammatory mediators to the presence or 
absence of microbial genes in the BAL fluid. In light of a previously published 
finding (Kotecha et al., 2003) that BAL fluid may be anti-apoptotic in infants who 
develop CLD, I investigated the relative ability of the BAL supernatants to promote or 
inhibit neutrophil apoptosis.
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5.2 C ytokine m easurem ents
A cytometric bead array (CBA) was used to determine the amounts of 12 potentially 
relevant inflammatory mediators in BAL samples (as described in 2.1.7.3 above). 
CBA is a costly assay and it was not possible to analyse fluid from every one of the 
207 BAL samples I had collected. From previous work (Kotecha et al., 1995, Kotecha 
et al., 1998, Kotecha et al., 1996a, Kotecha et al., 1996b) it was suggested that days 1, 
2, 4 and 7 were likely to yield useful data for comparison with published data and 
between infants in this study cohort. These samples were analysed as well as samples 
from later time points in those babies who were ventilated for longer periods.
It is apparent that measurement of cytokines in BALsupematants is difficult, complex 
and potentially inaccurate due to the mucousy nature of BAL supernatant even after 
centrifugation, the minute amount of BAL fluid returned from tiny preterm infants 
and the dilutional effect of the saline used for lavage. Attempts have been made in the 
past to correct cytokine concentrations for the dilutional effect of saline used for the 
lavage. The ERS guidelines (Haslam and Baughman, 1999, de Blic et al., 2000) 
suggest that no correction be made and this is the approach that has been used in the 
analysis and interpretation of the results of the CBA assay. Virtually all nucleated 
cells, including endothelial and epithelial cells are potent producers of cytokines such 
as IL-1, IL-6, and TNF-a and thus the amount of cytokine in a BAL sample cannot 
consistently be directly related to a variable such as cell count, making any form of 
“correction” of cytokine values of little value.
5.2.1 lnterleukin-1 beta (IL-lp)
Levels of IL-1 P rose steadily over the whole ventilated period in infants who 
developed CLD and by the end of the first week of life (day 7) were statistically 
higher than levels in the same babies on day 1 (Mann-Whitney U-test, p=0.019) 
(Figure 5.1). The small number of samples at later time points prevented similar 
analysis for the whole period.
267
CLD
RDS
Term
p=0.0019
CO.
0 105 15 20 25
Day
Figure 5.1 Graph o f median IL-1 ft concentration against time in term, RDS and CLD 
infants. Error bars represent interquartile ranges. p=0.019 for day 1 vs day 7 values 
for infants developing CLD.
Increased concentrations of IL-1 p in TAF have been associated with the development 
of CLD, possibly through the inhibition of neutrophil apoptosis (Kotecha et al.,
1996b, Cayabyab et al., 2003). There appeared to be a close parallel between levels of 
IL-1 p and percentage apoptotic neutrophils in BAL samples, with peaks occurring 
almost simultaneously in many patients, rather than a definite suppression of 
neutrophil apoptosis being seen when IL-1P levels were high (Figure 5.2).
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Figure 5.2 Graphs showing relationship between IL-lfi (black line) and percentage o f 
the neutrophil population which was apoptotic (grey line) for all babies with 3 or 
more results for each variable.
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5.2.2 Interleukin-8 (IL-8)
There appear to be higher levels of IL-8 in both RDS and CLD infants compared to 
term babies on day 4 (Figure 5.3), although this is not statistically significant. IL-8 
concentrations have previously been shown to be significantly higher in infants who 
develop CLD than in infants whose RDS resolves (Kotecha et al., 1995, Groneck et 
al., 1994).
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Figure 5.3 Graph o f  median IL-8 concentration (pg/ml, log scale) against time in 
term, RDS and CLD infants. Error bars represent interquartile ranges.
In published work, IL-8 was significantly elevated on the first day of life 
(immediately preceding the marked peak in neutrophil count) in babies who 
progressed to CLD in one study (Munshi et al., 1997) but in another study (Kotecha et 
al., 1995), IL-8 was elevated around day 10 coinciding with the neutrophil peak. From 
our data, in the majority of babies IL-8 and the neutrophil count track one another, 
peaking either in the same sample or the neutrophil count peaks shortly after the IL-8 
peak, thus agreeing with previously published findings (Figure 5.4).
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Figure 5.4 Graphs showing relationship between IL-8 (black line) and total 
neutrophil count (grey line) for all babies with 3 or more results for each variable.
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5.2.3 Monocyte Chemoattractant Protein-1 (MCP-1)
MCP-1 levels were significantly higher in term babies compared to infants with RDS 
on day 1 (Kruskal-Wallis test, p=0.024) and in term babies compared to infants who 
developed CLD on day 2 (Kruskal-Wallis test, p=0.049). When the whole preterm 
group was compared with term infants, term infants had significantly higher MCP-1 
levels than preterm babies on day 1 (Mann-Whitney U-test, p=0.011) and day 2 
(p=0.018), but no significant difference was detected between any of the groups by 
the day 4 samples (Figure 5.5).
MCP-1 has also been found to be elevated in airway secretions where Ureaplasma 
urealyticum has been detected (Baier et al., 2001). No such relationship was found in 
our cohort (No Ureaplasma mean 20 140 pg/ml, median 31 880 pg/ml; Ureaplasma 
detected mean 35 870 pg/ml, median 35 110 pg/ml; p=0.53) (Figure 5.17 below).
Levels of MCP-1 measured, particularly in the CLD group of infants from the day 4 
sample onwards, were very high (around 80 000 pg/ml) and 24 out of 103 measured 
values were on or exceeding the maximum range of the standard curve (60 000 
pg/ml). For analysis purposes these data were included however, for this reason, mean 
or median MCP-1 levels may be falsely low in the CLD group as the assay was 
unable to measure accurately at such high values. Non-parametric statistical tests are 
rank tests and thus may still be a reasonably robust method for analysis of these data.
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Figure 5.5 Graph o f median MCP-1 concentration against time in term, RDS and 
CLD infants. Error bars represent interquartile ranges.
5.2.4 Interleukin-6 (IL-6)
IL-6 has previously been found to be dramatically elevated in preterm infants, 
particularly in infants developing CLD early in their ventilator course (Bagchi et al., 
1994) and may be predictive for the development of CLD (Jonsson et al., 1997).
Levels of IL-6 measured in all 3 groups of infants in this study were very similar. 
Possible reasons for the difference between my results and previously published data 
may be due to methodological differences (neither previous study used CBA 
methodology on BAL samples) or because both previous studies were performed 
early on in the “surfactant era” and even the most recent of these two papers, had only 
two thirds antenatal steroid coverage and used surfactant as “rescue” therapy only in 
infants requiring more than 60% inspired oxygen which implies a slightly different 
study population from the one in our study.
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Figure 5.6 Graph o f median IL-6 concentration against time in term, RDS and CLD 
infants. Error bars represent interquartile ranges.
5.2.5 Interleukin-10 (IL-10)
There was a large number of samples (44/108) with undetectable IL-10. There were 
only 4 samples with detectable IL-10 from a total of 3 babies in the term group so 
statistical comparison with the term group was not possible, however it appears that 
levels of IL-10 were markedly lower in term babies than in either of the preterm 
groups.
In contrast to this observation, IL-10 has been reported to rise rapidly over the first 
five days of life (Beresford and Shaw, 2002) but to be significantly lower or even 
undetectable in preterm infants (Jones et al., 1996, Whicher and Evans, 1990) and in 
infants developing CLD (Beresford and Shaw, 2002, McColm et al., 2000). Only 
40.7% of our samples yielded results for IL-10 and the sensitivity of the assay was 
around 300 pg/ml. Lower IL-10 levels in term infants (as seen in median values 
shown in Figure 5.7) are extrapolated and should be interpreted with caution.
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Figure 5.7 Graph o f median IL-10 concentration against time in term, RDS and CLD 
infants. Error bars represent interquartile ranges.
5.2.6 Granulocyte - Colony Stimulating Factor (G-CSF)
There were no significant differences in G-CSF among the groups. Further discussed 
in 5.2.7, below.
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Figure 5.8 Graph o f median G-CSF concentration against time in term, RDS and 
CLD infants. Error bars represent interquartile ranges.
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5.2.7 Granulocyte Macrophage -  Colony Stimulating Factor (GM-CSF)
A small minority of the infants had GM-CSF detectable in their BAL supernatant. 
Only 14 out of 104 (13.5%) samples tested had detectable levels. These 14 samples 
came from 8 individuals (one baby with 3 positive samples, 4 with 2 positive samples 
and 3 with one positive sample each). Four samples (2 each from 2 different babies) 
had only just detectable levels which fell just below the standard curve for GM-CSF 
but have been included in the analysis. All the babies with detectable GM-CSF were 
preterm.
RDSCLD
Figure 5.9 Scatterplot o f all measured GM-CSF concentrations in term, RDS and 
CLD infants.
In a study (Papoff et al., 2001) of 18 preterm ventilated infants, both G-CSF and GM- 
CSF were detectable in BAL supernatant. Babies with RDS had the highest G-CSF 
and GM-CSF levels in the first few days of life which then reduced over time, 
whereas in infants developing CLD, these levels increased steadily. Dexamethasone 
reduced G-CSF and GM-CSF levels but LPS increased them. Hyperoxia did not 
appear to influence these cytokines (Papoff et al., 2001).
In our cohort, G-CSF levels appear to rise in both preterm groups before those with 
RDS are extubated and those developing CLD appear to plateau. GM-CSF was 
detected in too few infants for a trend to be observed.
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5.2.8 Macrophage inflammatory proteins (M IP-la and MIP-ip)
Both these cytokines are present at significantly higher levels in preterm infants than 
term babies on the fourth day of life (Mann-Whitney U-test, MIP-la p=0.041; MIP- 
ip p=0.028) (Figure 5.10 B and D). Levels of both cytokines rise steadily in infants 
developing CLD, throughout their ventilated period.
MIP-la and MIP-lp were expected to be elevated in preterm infants, particularly 
those developing CLD (Baier et al., 2004) and those exposed to hyperoxic conditions 
(D'Angio et al., 1998). Our data confirm statistically significantly higher levels of 
both these cytokines on day 4 of life but unfortunately there were no term or RDS 
infants who were ventilated for long enough to enable comparisons to be made later in 
the clinical course for these infants.
CLD
RDS
Term
10°.
15 20 25100 5
Day
A
Preterm
Term
1 0 °.
20
Day
B
2 7 7
CLD
RDS
Term
1 0 °.
Day
10% Preterm
Term
10 5 -
10 ° -
0 5 10 15 20 25
Figure 5.10 Graph o f median MIP-la (A and B) and M lP-lf (C and D) 
concentrations according to (A and C) diagnosis and (B and D) gestation against 
time. Error bars represent interquartile ranges. In (B) *p=0.041 and in (D)
*p=0.028.
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5.2.9 Tumour necrosis factor alpha (TNF-a)
Levels of TNF-a were not significantly different among the 3 groups of infants but 
TNF-a levels in infants developing CLD rose sharply over the first few days of life 
and throughout the ventilated period, such that by the end of the first week of life, 
levels of TNF-a in babies developing CLD were significantly higher than on day 1 
(CLD Day 1, mean 45.99 pg/ml, median 7.29 pg/ml; Day 7 mean 361.70 pg/ml, 
median 81.32 pg/ml; Mann-Whitney U-test, p=0.016) (Figure 5.11).
In previous studies, TNF-a was undetectable in term controls and low in infants with 
RDS but peaked at day 14 in babies who progressed to CLD (Bagchi et al., 1994). 
TNF-a was elevated in BAL samples taken early in the ventilatory course of preterm 
infants with the worst pulmonary outcomes in one study (Mahieu et al., 2005). Our 
cohort showed no significant difference among the groups, although peak TNF-a 
levels (see 5.2.12) were significantly higher in babies who developed CLD and 
peaked on around day 20 in this group.
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Figure 5.11 Graph o f  median TNF-a concentration (pg/ml, log scale) against time in 
term, RDS and CLD infants. Error bars represent interquartile ranges. p=0.016 for  
day 1 vs day 7 levels in infants developing CLD.
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5.2.10 Fas ligand (FasL)
No significant differences could be observed between levels of FasL among the 
groups. FasL has been studied in neonatal and paediatric blood samples (Ennaciri et 
al., 2006, Hanna et al., 2005, Sarandakou et al., 2003), but not in lung lavage samples 
in this age group. No significant changes in FasL were noted and FasL remained 
relatively constant after the end of the first week of life in the CLD group.
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Figure 5.12 Graph o f median FasL concentration against time in term, RDS and CLD 
infants. Error bars represent interquartile ranges.
5.2.11 Vascular Endothelial Growth Factor (VEGF)
No significant differences in VEGF levels among groups could be seen. This is in 
agreement with published data from Currie et al (Currie et al., 2001) who found no 
difference in VEGF levels between term infants and preterm infants with or without 
CLD, but in contrast to the reduced levels found in infants developing CLD by Lassus 
et al. (Lassus et al., 1999). It has been postulated that either increased or decreased 
VEGF levels can mediate lung injury (Voelkel et al., 2006).
2 8 0
CLD
RDS
Term
10 °.
10
Day
Figure 5.13 Graph o f median VEGF concentration against time in term, RDS and 
CLD infants. Error bars represent interquartile ranges.
5.2.12 Individual infants
Just as it is difficult to adequately compare pooled data from groups of infants for cell 
counts and differential cell counts, it is similarly difficult to adequately compare 
levels of cytokines longitudinally between babies. For this reason, data from 
individual babies was reviewed to identify patterns or relationships between various 
cytokines and clinical diagnosis or infection (Figure 5.14).
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Figure 5.14 Graphs showing cytokine levels (pg/ml) for all babies with 3 or more BAL 
samples in which cytokines were measured. Samples which were positive for 16S rRNA are 
indicated by arrows.
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In most babies who developed CLD, an increase in all the cytokines was observed 
over the first week of life. Thereafter high levels were maintained for almost the 
entire ventilated period. Levels of all the interleukins studied, along with TNF, had 
begun to decline by day 28 or extubation in most infants (left hand panel in Figure 
5.14), whereas levels of other cytokines remained elevated. In the two term infants (H 
and X) all levels are beginning to fall by the time of extubation and well within the 
first week of life.
5.2.13 Peak cytokine levels
Significantly higher peak levels of all the cytokines measured, except GM-CSF where 
the number of samples was too small, were present in preterm infants compared to 
their term counterparts. Infants who developed CLD had significantly higher levels of 
IL-ip, M IP-la and TNF (Figure 5.15) than those whose RDS resolved.
The majority of the highest cytokine peaks occurred in infants who had 16S rRNA 
detected (see 5.2.14).
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Figure 5.15 Scatterplots o f peak cytokine concentrations (pg/ml, log scale) in term, 
RDS and CLD infants. Horizontal lines represent medians. Filled markers indicate 
infants in whom 16S rRNA genes were detected in that sample or an immediately 
adjacent one. Empty markers reflect babies in whom infection was not detected.
5.2.14 Day 1 cytokine data
A more detailed analysis of cytokine levels on the first day of life may be useful as 
these levels may reflect antenatal conditions, such as infection in utero. It could be 
clinically useful if cytokine values in BAL fluid on the first day of life could serve as 
a prognostic indicator.
However, comparing term against preterm infants for levels of all 12 cytokines on day 
1 of life only gives a significant difference only for MCP-1 (p=0.011) with term 
infants having much higher MCP-1 levels than preterm. This fits with a higher 
proportion of macrophages being mature alveolar macrophages in term babies 
(although absolute numbers of macrophages and mature macrophages are similar) 
(section 3.3.4.4). More MCP-1 in the term infants on day 1 could allow resolution of
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the inflammatory process to begin almost immediately by promoting recruitment of 
more mature macrophages and the lower MCP-1 levels in preterm infants may help to 
explain the relative delay in macrophage recruitment in the preterm group.
No child had detectable levels of GM-CSF on day 1 of life.
5.2.15 BAL fluid cytokines in infection
Once again the role of infection in the inflammatory process in the neonatal lung was 
studied in the light of the cytokine values obtained. PCR for the 16S rRNA gene was 
undertaken as described in 2.1.5.2.
Overall, there was significantly more IL-1(3, IL-8, IL-6, G-CSF, MIP-la, MIP-lp and 
TNF detected in samples that were 16S rRNA positive (Figure 5.16). GM-CSF, FasL 
and VEGF showed no significant differences between samples where 16S rRNA 
genes were detected and samples in which they were not found (Figure 5.16).
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Figure 5.16 Scatterplots showing levels o f inflammatory mediators in infants 
according to whether 16S rRNA genes were or were not detected in BAL samples.
This mixture of pro- and anti-inflammatory cytokines in most samples may reflect 
that while there are attempts at resolution of the inflammatory process, the pro- 
inflammatory actions of microbes in the lung are superimposed on this picture. The 
timing of the detection of 16S rRNA genes in BAL samples PCR may lag behind the 
actual appearance of the organism in the lung (BAL samples were obtained at 
intervals of approximately 24 hours during the first week and intervals of 2-4 days 
thereafter). The cytokine response to the presence of a microbe in the lung is rapid 
and it is impossible for us to determine exactly how far into the course of a possible 
infection our observations have been made. The snapshot nature of BAL sampling, 
combined with the fact that only BAL supernatants from days 1, 2, 4, 7 were 
subjected to CBA analysis, may mean that important alterations in cytokine balance 
were missed at times or days when there were no samples analysed.
When data from individual babies were reviewed (Figure 5.14) there did not appear to 
be a consistent relationship between the level of cytokines and the detection of 16S
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rRNA genes in BAL samples. In some infants, a sharp rise in almost all cytokine 
levels coincided with the detection of 16S rRNA genes, however this was not a 
universal finding. This may be because 16S rRNA genes represent colonisation of the 
endotracheal tube, rather than true infection in some infants, or that 16S rRNA genes 
were detected in some infants before an infection became established and a cytokine 
response was mounted. There may have been other factors which altered this 
relationship, such as administration of antibiotics, some of which have anti­
inflammatory effects e.g. erythromycin, or drugs like indomethacin (for PDA 
treatment).
5.2.16 Cytokines in Ureaplasma colonisation or infection
Almost all of the inflammatory mediators tested, apart from MCP-1 (in which the 
result may be affected by around 1 in 4 values being above or close to the upper limit 
of the standard curve for the assay), GM-CSF (in which there were too few results to 
make adequate comparisons), MIP-la and VEGF, show significantly higher levels of 
the inflammatory mediators in samples in which Ureaplasma was detectable in the 
BAL fluid. IL-6 does not quite reach significance.
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Figure 5.17 Scatterplots showing levels o f measured inflammatory mediators in 
neonatal BAL samples according to whether Ureaplasma was detected in the sample. 
Horizontal lines represent medians. Significant p values shown.
5.2.17 Cytokines and mode of delivery
Comparing babies bom by elective Caesarean section where the mother was not in 
labour with babies bom as a result of spontaneous preterm labour, in whom antenatal 
infection could not be ruled out as a cause for preterm labour, there were no 
significant differences in levels of the selected cytokines in BAL fluid between the 
two groups, except for FasL which was significantly higher in babies bom following 
spontaneous preterm labour compared to those delivered electively (p=0.028). Again, 
this is difficult to fully explain and there may be more than one factor responsible for 
this.
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5.3 E lastase in BAL supernatan ts.
Human neutrophil elastase is the most abundant protease found in the lung. It is stored 
in intra-cytoplasmic azurophilic neutrophil granules from where it can be released 
into a phagocytic vacuole or into the surrounding environment at the time of 
neutrophil activation.
Elastase is capable of digesting elastin, an important structural component of lung 
tissue, as well as almost all components of the extracellular matrix including collagen 
types I-IV, fibronectin, laminin and proteoglycans. It may play a role in the 
physiological turnover of connective tissue when produced by tissue macrophages and 
certain stromal cells, however hydrolysis of matrix macromolecules by neutrophil 
elastase most probably represents a pathological process (Janoff, 1983).
Neutrophil elastase activity was measured in all 207 BAL supernatants as described in 
section 2.1.7.1.
Elastase activity was detected in 50/207 (24.2%) BAL samples and in a total of 19 of 
the 32 infants studied. In 13/15 (86.7%) infants who developed CLD there was 
elastase detected in at least one lavage sample, which was significantly more than 
4/11 (36.4%) in preterm infants whose RDS resolved (Chi square test, p=0.0077). 
When all preterm infants are compared to term infants, where only 1/5 had free 
elastase activity in their BAL fluid, this was not significantly different (p=0.0596), 
probably on account of the small numbers of infants in the term control group.
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Elastase 
detected (%)
No elastase 
detected (%)
TOTALS
CLD 13(86.7) 2(13.3) 15
RDS 4 (36.4) 7 (63.6) 11
Term 1(20) 4(80) 5
Died 1(100) 0(0) 1
TOTALS 19 (59.4) 13 (40.6) 32
Table 5.1 Table showing numbers o f infants with and without elastase activity 
detected in at least one BAL sample.
Peak elastase activity was also significantly greater in infants who went on to develop 
CLD compared to both infants with resolved RDS (Mann-Witney U-test, p=0.0131) 
and term controls (p=0.028), as demonstrated in figure 5.16. There was no significant 
difference in the peak elastase activity between preterm infants whose RDS resolved 
and term infants.
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Figure 5.18 A scatterplot o f the peak elastase concentrations for infants with CLD, 
resolved RDS and control infants, demonstrating significantly higher peaks in infants 
developing CLD.
If the presence of elastase is considered in terms of the 50 samples in which elastase 
activity was detected out of the total of 207 samples collected, rather than individual 
patients, the following results are found: in those infants who developed CLD,
295
elastase activity was detected in 37/152 (24.3%) samples and 8/32 (25%) samples 
from infants developing RDS, compared to 1/19 (5.3%) of term control infants. All 4 
samples from the infant who died had elastase present, albeit in very small amounts. 
When elastase activity was present, it was episodic in nature and was only present for 
a small number of samples for each infant. The timing of the activity spikes was also 
extremely variable, with the initial spike of elastase activity (when present) being a 
median of 7.5 days (range 3-27 days, IQR 5-19 days) after birth. No baby had elastase 
present on day 1.
When longitudinal data for individual infants is analysed (figure 5.19) the episodic 
spiking nature of increases in elastase activity can be appreciated. It also appears that 
the timing of increases in elastase activity correlates well with the timing of increases 
in cell count and with the presence of 16S rRNA genes in the sample.
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Figure 5.19 Graphs o f total cell count (solid line), elastase activity (dotted line) and the 
presence o f 16S rRNA (arrows) for individual infants with at least 3 BAL samples and either 
elastase activity or 16S rRNA or both present.
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5.3.1 Elastase and infection
In babies in whom elastase was present, the spike in the elastase activity frequently 
coincided with a spike in the total cell count (Figure 5.19 above) and also in the 
neutrophil count (Figure 5.20). When figure 5.18 is redrawn showing the infection 
status of the individual babies (Figure 5.21), it can be seen that many of the highest 
elastase levels occur in babies who are infected with organisms other than S. 
epidermidis, an organism which tends to be regarded by neonatal clinicians as being 
of low pathogenicity in the lung. However, the peak elastase level does not invariably 
coincide with the presence of microbial DNA.
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Figure 5.20 Graphs for individual infants with 3 or more BAL samples and in whom 
elastase was detected in BAL supernatant. Solid lines represent elastase (nM) and 
broken lines denote the total neutrophil count (million/ml).
303
1 0 3-
102-
_a>
reo(/>
U)o
a></>re
m
| l 0 1
rea>a.
10°.
^ 7
5® 0
^ • 5 H — £.
5 ^
CLD
■Bn ^ m n
1 -  P. aeruginosa  
2 - H .  influenza
3 = E. coli
4 = Enterococcus
5 = S. epidermidis
6 = Mixed
7 = Unknown
A  6 
- -A'4 -AA
RDS Term
Figure 5.21 Scatterplot showing log ofpeak elastase activity level for each infant in 
whom elastase was detected. Solid markers indicate babies in whom peak elastase 
level co-incided with detection o f 16S rRNA genes in the BAL sample. Markers with a 
cross in the centre indicate infants in whom 16S rRNA was detected but this was not 
coincident (or one day before or after) with the peak elastase level. Open markers 
indicate that 16S rRNA genes were not detected in that infant.
5.3.2 Elastase and apoptosis or necrosis
Elastase peaks are frequently temporally associated with peaks in the neutrophil count 
(Figure 5.20). Elastase has been implicated in the process of apoptosis, through its 
ability to stimulate or induce apoptosis (Trevani et al., 1996, Yang et al., 1996) and 
through cleavage of cell surface antigens eg CD 16 (Middelhoven et al., 2001) and is 
released during cell death by necrosis, so elastase levels were plotted against both 
apoptotic and necrotic neutrophil percentages in order to assess a possible relationship 
between elastase and either apoptosis or necrosis of lung neutrophils (Figures 5.22 
and 5.23). In some infants a temporal relationship between apoptosis or necrosis of 
neutrophils and the presence of elastase could be observed but this pattern was not as 
consistent as the relationship between elastase and the neutrophil count.
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5.4 A poptotic activity of BAL fluid -  the  Sheffield “bioassay”
The environment in which the cells are found may have important effects on the 
initiation and progress of apoptosis. For this reason, the apoptotic activity of BAL 
fluid (182 samples in total) against freshly isolated adult neutrophils was assessed in 
an assay performed by Sharon Gill, in Sheffield, as described in materials and 
methods (2.1.7.2). The percentage of the adult neutrophils that were apoptotic was 
assessed on cytospins by light microscopy at the outset and then after 5 and 20 hours 
of exposure to the BAL supernatant.
Only 9/182 samples showed a higher percentage of apoptotic neutrophils than the 
saline control at 5 hours and just 3 samples at 20 hours. However, when the “fold 
change” in apoptotic cells was measured between the 5 and 20 hour time points in 
each sample and compared to the fold change in the saline control over the same 
period, 96 samples had greater fold change in the percentage of apoptotic neutrophils 
than their respective controls -  i.e relatively proapoptotic BAL fluid (Figure 5.24 and 
Table 5.2). All the following results for pro- or anti-apoptotic activity of BAL fluid 
refer to fold change.
Among samples from babies who developed CLD, 71/135 (52.6%) were pro­
apoptotic compared with 11/28 (39.3%) from RDS infants -  this was not statistically 
significant. In the term group, 14/15 (93.3%) samples were pro-apoptotic and this was 
significantly more than either CLD (p=0.0025) or RDS groups (p=0.0006). None of 
the 4 samples from the infant who died was pro-apoptotic.
309
Pro-
apoptotic 
BAL (%)
Anti- 
apoptotic 
BAL (%)
TOTALS
CLD 71 (52.6) 64 (47.4) 135
RDS 11 (39.3) 17 (60.7) 28
Term 14 (93.3) 1 (6.7) 15
Died 0(0) 4(100) 4
TOTALS 96 (52.7) 86 (47.3) 182
Table 5.2 Table showing the number o f  BAL supernatants in each diagnostic group 
which displayed either relative pro- or anti-apoptotic activity compared to saline 
controls.
The pattern of pro- and anti-apoptotic samples in individual infants can be seen in the 
bar graphs in Figure 5.24. Term infants (H and X) appear to have BAL fluid that is 
consistently relatively pro-apoptotic when compared to their saline control. Preterm 
infants tend to have a more mixed picture with some samples relatively pro-apoptotic 
and others relatively anti-apoptotic. It is noticeable in Figure 5.24 that in many of the 
preterm infants, particularly babies BB, CC, L, N, O, W and Y, although early 
samples are strongly pro-apoptotic, later samples become more anti-apoptotic.
This experiment was conducted using adult neutrophils in vitro. It is known and will 
be shown again in chapter 6 that neutrophils from newborn infants have different 
apoptotic rates and responses to adult neutrophils, so data from this series of 
experiments must be interpreted in light of this.
In Figure 5.24, it is also noticeable that in samples from which 16S rRNA microbial 
genes were isolated, the levels of apoptotic activity are among the most anti-apoptotic 
for that individual infant.
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It is noticeable in Figure 5.25, particularly among the CLD group of infants, that the 
day/sample on which cytokine levels are highest is almost always the day on which 
apoptotic activity in BAL supernatants, as assessed by the bio-assay, is the lowest. To 
illustrate this (Figure 5.25), IL-8 was chosen to be plotted against the BAL fluid 
apoptotic activity, but almost identical graphs could be drawn for other pro- 
inflammatory mediators. However, this trend is, once again, not a completely 
consistent finding, raising the possibility that it is not only the composition of the 
supernatant that affects or controls the process of apoptosis, but the properties of the 
neutrophils themselves may be inherently important.
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Figure 5.25 Graphs showing the apoptotic activity o f BAL supernatants (blue bars) and the level of 
proinflamatory cytokines (IL-8 shown) measured by CBA in the samples (black lines).
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5.4.1 BAL fluid apoptotic activity and  apopto tic  neutrophil counts
In Figure 5.26 the BAL fluid apoptotic activity (fold change) has been plotted 
alongside the number of apoptotic neutrophils present in that BAL sample. There does 
not appear to be a clear relationship between the number of apoptotic neutrophils 
present in preterm BAL fluid and the apoptotic activity of the BAL sample. However, 
in the two term infants (H and X), the highest number of apoptotic neutrophils 
correspond to the day on which the highest pro-apoptotic activity as seen in BAL 
fluid. This may be a chance finding due to the very small number of term infants 
which were studied but may also indicate that neutrophils in term infant lungs are able 
to respond appropriately to pro-apoptotic stimuli in the BAL fluid more effectively 
than neutrophils in preterm lungs.
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Figure 5.26 Graphs showing BAL fluid apoptotic activity (blue bars) and the 
percentage o f apoptotic neutrophils (black line) in each BAL sample.
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5.5 Sum m ary of key findings
1. Levels of MCP-1 were significantly higher in term infants on the first 2 days 
of life than in their preterm counterparts.
2. Levels of IL-10 were lowest in term infants, but not significantly so.
3. Levels of MIP-1 a and MIP-1 p were significantly higher in preterm infants 
than in term babies on day 4.
4. A minority of samples (14/104) had GM-CSF detectable.
5. Levels of other cytokines measured, namely IL-lp, IL-8, IL-6, TNF, G-CSF, 
FasL and VEGF generally increased steadily throughout the period of 
ventilation in infants developing CLD.
6. Peak cytokine levels were highest among infants developing CLD, especially 
in association with the detection of 16S rRNA genes in the BAL sample.
7. BAL samples from infants in whom either 16S rRNA microbial genes or 
Ureaplasma spp. were identified had statistically higher levels of almost all 
the mediators tested.
8. Neutrophil elastase activity was detected in a minority of samples in episodic 
spikes, temporally associated with increasing cell counts and the presence of 
infection but there was a much less obvious relationship between the 
percentage of apoptotic or necrotic neutrophils and the presence of elastase in 
BAL fluid.
9. There was a significant relationship between the detection of elastase in BAL 
supernatants and the development of CLD.
10. Significantly more BAL supernatants from term babies showed pro-apoptotic 
activity than those from preterm infants, but there did not appear to be a clear 
relationship between apoptotic neutrophils in BALsamples and the recorded 
BAL fluid apoptotic activity.
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5.6 Discussion
5.6.1 Introduction
The inflammatory environment in the lung is likely to be critical to the development 
of CLD. Not only do proteins like elastase have a direct effect on lung tissue, but the 
cytokine balance in the lung will have a marked effect on the composition of the 
cellular inflammatory response and the behaviour of those cells, thus contributing to 
the resolution or maintenance of the inflammatory response.
5.6.2 Cytokines
A large number of publications have studied cytokines in the neonatal lung under 
various conditions and reported generally that, although multiple pro-inflammatory 
and chemotactic factors are present in the airspaces of ventilated preterm infants, they 
are present in higher concentrations in those who develop CLD. Infants who develop 
CLD are also generally felt to be relatively lacking in the anti-inflammatory mediators 
which should promote resolution of their lung disease by various mechanisms 
including enhanced neutrophil apoptosis.
In this study, only MCP-1, MIP-la and MIP-lp yielded statistically significant results 
for the differences between term and preterm infants. This may be partly as a result of 
the small number of infants studied as well as the fact that inflammatory mediators 
were measured only on selected days, raising the possibility of a significant peak in 
levels having been missed.
Peak levels of all the cytokines measured were significantly higher in infants 
developing CLD which may be related to the higher incidence of infection and higher 
cell counts in this group of infants.
Our longitudinal data for MCP-1 showed significantly higher levels of MCP-1 in term 
infants compared to infants bom preterm on the first 2 postnatal days, but there was 
no difference between babies with RDS and those who go on to develop CLD. MCP-1 
was measured in serial TAF samples from 56 preterm newborns by Baier et al (Baier
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et al., 2001, Baier et al., 2002, Baier et al., 2004) who noted that MCP-1 rose over the 
first week of life and the highest levels were found in infants who developed CLD. 
Similarly, I found a marked increase in MCP-1 levels after day 2 and from day 4 
onwards; some of the highest levels of MCP-1 were obtained from CLD infants, in 
concordance with the Baier papers. They showed a marked difference between RDS 
and CLD groups but their study lacked term controls.
Another study of MCP-1 levels in term infants with congenital diaphragmatic hernia 
showed a relationship between high levels of MCP-1 and severe pulmonary 
hypoplasia with persistent pulmonary hypertension but even the highest levels of 
MCP-1 in this study were of the order of 102-103 pg/ml rather than 104-105 pg/ml as in 
our infants (Okawada et al., 2007). This may be related to the fact that our control 
group is very small but also that these infants had surgery for their gastroschisis 
within hours of birth -  usually before the first BAL sample was obtained, in keeping 
with our study protocol. Animal studies show elevated MCP-1 levels following soft 
tissue injury and surgical trauma (Kobbe et al., 2008, Kotzampassi et al., 2009) and 
this may be the mechanism of the elevated levels seen in our term infants.
MIP-la and MIP-ip levels were expected to be elevated in preterm infants, 
particularly those developing CLD (Baier et al., 2004) and our data does confirm 
higher levels of both these cytokines on day 4 but there are insufficient data to make 
further comparisons.
One might expect that levels of pro-inflammatory cytokines might be dramatically 
increased in infants developing CLD while anti-inflammatory mediators may be 
reduced in concentration. This was not the case in our cohort and may reflect the very 
high cell counts in the CLD group compard to term infants -  the amount of anti- 
inflamatory cytokines present may indeed be relatively low compared to pro- 
inflammatory cytokine levels but still elevated compared to term controls. There may 
be dysregulation of cytokine production on account of the profuse inflammatory 
response in the neonatal lung which may cause cells and cytokines to interact in ways 
that can not or have not yet been reproduced in vitro.
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It is important to note that levels of inflammatory mediators are affected by a wide 
variety of other clinical factors, including the administration of antenatal steroids 
(Kramer, 2008), mode of ventilation (Capoluongo et al., 2005, Lista et al., 2008), 
oxygen concentration (Bhandari and Elias, 2006), pulmonary haemorrhage (Baier et 
al., 2002), drugs and medications including azithromycin (Aghai et al., 2007, Ballard 
et al., 2007), indomethacin (Sirota et al., 2001) and melatonin (Gitto et al., 2005) but 
may be unaffected by others e.g. nitric oxide (Truog et al., 2007).
The presence or absence of antenatal infection and the presence of postnatal systemic 
or isolated pulmonary infection may all play an important role in the alteration of 
cytokine expression in the lung (Kramer, 2008). I have shown a significant elevation 
in levels of almost all the mediators studied in infants in whom Ureaplasma or 16S 
rRNA genes were detected -  this may be a contributory factor to the ongoing 
inflammatory process and highlight a possible reason for the significant relationship 
between the presence of Ureaplasma or other microbes and the development of CLD.
All of the above mentioned clinical factors may have contributed to the lack of 
marked difference between RDS and CLD groups of infants in our cohort and the 
cohort was too small to control for such a large number of possible confounders.
A caveat to all the cytokine experiments and results is that the amount of cytokine 
detected may not always be clinically relevant as the amount detected may not be 
proportional to its biological activity due to variable degrees of tissue binding, the 
availability of receptors and the presence of inhibitors or enhancers of cytokine 
activity which may be unmeasured or even unknown.
5.6.3 Elastase
There is much evidence to support the role of elastase as part of the complex 
pathogenesis of CLD. In the pre-surfactant era very high elastase activity was 
detected in the majority of lung lavage samples from infants with RDS, particularly in 
those infants who developed CLD (Merritt et al., 1983, Ogden et al., 1984,
Watterberg et al., 1994). However more recently, following the introduction of 
routine use of exogenous surfactant in extremely preterm infants, the pattern of
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elastase activity appears to have changed. A number of recent studies have found 
elastase in only a minority of samples from the lungs of preterm infants and no 
relationship to the development of CLD in these infants (Speer et al., 1993, Sveger et 
al., 2002, Sluis et al., 1994, Groneck et al., 1994). This may be as a result of changing 
neonatal practices such as exogenous surfactant administration and gentler ventilator 
techniques as well as a changing, more premature, neonatal population and 
increasingly specific laboratory methods for the detection of neutrophil elastase 
activity.
Our data appear to agree with this trend for fewer samples exhibiting elastase activity, 
with only around one quarter of samples and 19 out of 32 infants having detectable 
elastase activity. There was however a significant relationship between the presence 
of elastase and the development of CLD in the preterm group.
Previous studies in so-called “new” CLD have only examined elastase activity at 
single points in time (Sluis et al., 1994, Speer et al., 1993, Griese et al., 1998) or taken 
up to four samples from individual infants and frequently there were large gaps 
between time points (Sveger et al., 2002, Groneck et al., 1994).
This component of our study benefits from more frequent BAL sampling, enabling 
patterns to be evaluated in individual infants over time as well as being more likely to 
detect the brief increases in elastase which occur. These brief rises may be missed by 
“one o ff’ sampling or overlooked in studies with large time gaps between samples.
The temporal relationship between cell counts and elastase activity is present in at 
least half of the infants studied. Elastase peaks are also frequently, but not invariably, 
associated with the presence of microbial genes in the BAL supernatants. Elastase is a 
product of neutrophil degranulation and a high neutophil load, possibly provoked by 
the presence of a pathogen in the respiratory tract, may produce sufficient elastase to 
overwhelm the natural elastase inhibitors, such as alpha-1-anti-trypsin, which would 
normally serve to neutralise its tissue damaging effects. Additionally the release of 
elastase potentiates the inflammatory response and enhances the recruitment of further 
inflammatory cells (Nakamura et al., 1992).
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5.6.4 Apoptosis -  the “ Sheffield bio-assay”
In the only previous paper to study the effect of neonatal BAL supernatants on 
apoptosis of purified adult neutrophils, Kotecha et al (Kotecha et al., 2003) obtained 
134 samples from 45 ventilated term and preterm neonates (in addition to a group of 
babies undergoing ECMO) and found that BAL fluid from babies whose RDS 
resolved was pro-apoptotic to adult neutrophils and CLD BAL fluid was not. Our 
cohort of 182 samples from 32 babies represents more samples per baby on average 
than the previous study but we found very few samples which were considered pro- 
apoptotic i.e. resulting in a higher proportion of apoptotic neutrophils than the saline 
control -  only 9/182 samples at 5 hours and 3 at 20 hours. This was despite no 
obvious changes to the method used in the Kotecha et al paper, but subtle differences 
in patient population, BAL technique, reagents, purification of adult neutrophils or 
conduct of the assay can not be completely excluded from the list of reasons for 
differing findings. Neutrophils are highly sensitive cells to a wide variety of stimuli 
and some aspect of our experiment may have caused a degree of cell activation and 
thus a failure to show any pro-apoptotic effect of the supernatants.
The use of calculated rates of change in apoptosis between the 5 hour and 20 hour 
time points in our cohort produces a significant difference between term and preterm 
infants but no difference between RDS and CLD groups. High levels of cytokines 
(e.g. IL-8) in the BAL fluid tended to correlate with more anti-apoptotic activity in the 
BAL supernatant, which may be related to the presence of infection, as samples from 
which 16S rRNA genes were isolated were among the most anti-apoptotic samples in 
each individual baby. The relationship between apoptotic neutrophils and BAL 
supernatant apoptotic activity was more difficult to interpret, although there was the 
impression of a better response by term neutrophils to the pro-apoptotic nature of the 
BAL supernatant. Although inconclusive in this study, it is possible that term 
neutrophils are able to respond better to pro-apoptotic signals in their surroundings 
than neutrophils from more preterm infants.
The “Sheffield bio-assay” used purified adult neutrophils, however the results of this 
in vitro experiment may not be able to be extrapolated directly to preterm neutrophils, 
as neutrophils from preterm infants may exhibit some significant differences in their
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ability to undergo apoptosis, compared to either adult or term neutrophils. (The 
differences between term newborn and adult neutrophils will be explored further in 
chapter 6 and this may be exaggerated in more preterm infants).
This in vitro experiment, however, may offer better insights into the response of lung 
neutrophils in vivo than experiments using individual cytokines or chemokines in 
vitro, as BAL supernatant constituents are a mixture of pro- and anti-inflammatory 
substances which can be quantified by methods such as CBA, used here.
5.6.5 Conclusion
This chapter has focussed on the BAL supernatant which reflects the environment in 
which the BAL cells are found. Various cytokines as well as neutrophil elastase were 
measured in the supernatants and the relative apoptotic activity of the supernatants 
against adult neutrophils was also assessed.
The relationship between cytokines and the development of CLD is complex and 
influenced by a wide variety of factors, particularly in relation to the clinical 
management of the infant. Further progress in neonatal intensive care may result in 
methods of management which further reduce the pro-inflammatory nature of the 
exudates within the alveoli and lead to a reduction in or amelioration of CLD.
Although elastase seems less important in the pathogenesis of “new” CLD, it is still a 
mechanism by which lung tissue damage can be mediated. Elastase may also 
contribute to the overall pro-inflammatory environment within the lung by being 
chemotactic for inflammatory cells and by regulating the activity of cytokines and 
chemokines (Nakamura et al., 1992, Pham, 2006).
The relative pro- or anti-apoptotic ability of BAL supernatants was also studied and a 
temporal relationship between low apoptotic activity and higher cytokine levels and 
the presence of microbial genes was seen in individual infants. However, this was not 
a completely consistent finding and raises the possibility that neutrophil apoptosis 
may not be completely regulated by factors external to the cell.
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Overall, the relationship between the studied constituents of BAL supernatants and 
CLD is complex and reflects the multi-factorial nature of the disease. In order to 
control for the very wide variety of influences on the content of the BAL supernatant, 
many in vitro studies have been conducted, but these ignore the complex and multi­
facetted interactions between components of the BAL supernatant, between the 
different types of BAL cells and their environment and the impact of clinical variables 
such as changing modes of ventilation and the administration of drugs whose 
deliberate effect or unintended side-effect may be pro- or anti-inflammatory.
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Chapter 6 
Cord blood
Chapter 6 
Cord blood
6.1 Introduction
In chapters 3 and 4 I showed that, while large numbers of neutrophils continue to be 
present in the lungs of preterm infants who progress to CLD, the proportion of the 
neutrophil population which is undergoing apoptosis is significantly reduced in 
preterm infants compared to those bom at term. Additionally in chapter 5, it was seen 
that neutrophil apoptosis is not always directly related to the levels of various pro- or 
anti-apoptotic influences in the supernatant. One possible explanation for this could 
be that neutrophls in the preterm infant are inherently more resistant to apoptosis, 
possibly due to a degree of immaturity of one or more parts of the apoptotic pathways.
It has previously been shown that cord blood neutrophils are relatively resistant to 
apoptosis when compared to adult neutrophils (Molloy et al., 2005, Molloy et al., 
2004, Koenig et al., 2005, Luo et al., 2003, Hanna et al., 2005, Allgaier et al., 1998) 
but there is also a single paper that reports exactly opposite findings (Uguz et al., 
2002). Many of these studies had investigated aspects of the role of infection in this 
process in vitro and some have attempted to investigate the possible mechanism for 
the differences observed. Most investigations have concentrated on factors external to 
the neutrophil (labour, infection, medications, cytokines, Fas and colony stimulating 
factors) while two (Luo et al., 2003, Hanna et al., 2005) have looked more closely at 
the caspases and the Bcl-2 family of proteins.
In this chapter, I have examined the effect of maturity upon the ability of neutrophils 
to undergo apoptosis by comparing neutrophils isolated from newborn term cord 
blood and adult blood. In particular I have examined:
the changes in the rate of apoptosis related to infection, using LPS to mimic 
some of the effects of infection
levels of activated caspase 3, the most central workhorse of the caspases in the 
apoptotic process
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the amount of Bax present, a pro-apoptotic member of the Bcl-2 family of 
proteins
amounts of RNA present for both caspases and the Bcl-2 family of proteins 
using a ribosomal protection assay (RPA)
the amounts of some of the Bcl-2 proteins in adult and cord neutrophils using 
reverse transcription and quantitative PCR techniques.
6.2 Results 
6.2.1 Patient information/demographics
Cord blood was collected (as detailed in section 2.2) in the first few minutes 
following delivery of term infants by elective Caesarean section. The most common 
indication for Caesarean section was in mothers who had had a previous Caesarean 
and had opted for this mode of delivery in their subsequent pregnancy. None of the 
women was in labour at the time of operation, since the process of labour may be 
responsible for activation of neonatal neutrophils (Molloy et al., 2004), nor did they 
have any identified risk factors for infection, another potential activator of neonatal 
neutrophils.
In accordance with ethical guidelines and so as not to delay sample collection, verbal 
assent was obtained from the mother in advance of the cord blood being collected and 
written consent was obtained post-operatively, later the same day. Cord blood 
samples were collected and then processed in parallel with peripheral venous blood 
samples from adult volunteers as in section 2.2, ensuring cord neutrophils and adult 
control neutrophils were exposed to identical experimental conditions as far as 
possible.
6.2.2 Purity of neutrophil preparations
There is considerable debate about whether neutrophil preparations should be 
completely free from other cell types, particularly monocytes, in experiments of this 
nature because of the ability of these macrophages to produce cytokines which may 
activate neutrophils and alter experimental results (Sabroe et al., 2004). I elected to try
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to obtain the purest possible neutrophil preparations, without resorting to magnetic 
bead separation or other processes, such as flow sorting, which required extensive 
handling/manipulation of the neutrophils and could result in cell activation.
Using the technique detailed in section 2.2.2, it was possible to obtain a population of 
cells consisting of in excess of 97% neutrophils with negligible activation of the 
neutrophils. Any contaminating cells were usually eosinophils, very occasional 
monocytes, or, in the case of cord blood samples, immature (nucleated) red blood 
cells. There was no significant difference in the percentage of contaminating cells 
between adult and cord blood samples (Adult mean 0.84%, median 0.80%; cord mean 
1.89%, median 1.40%; p=0.329) (Figure 6.1).
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Figure 6.1 Flow cytometer (forward scatter vs side scatter) plots showing (A) whole 
blood and (B) adult or cord neutrophil preparations. The lack o f lymphocyte and 
monocyte populations in the prepared neutrophils can be clearly seen.
6.2.3 Phenotyping of cord blood
Using flow cytometry I compared the surface expression of relevant cell surface 
markers (CD 15, CD 16, CD 14, CD1 lb, TLR2 and TLR4) and combinations of these 
markers (CD 14/15, CD 15/16, and CD 14/16) between 7 paired samples of cord and 
adult neutrophils in order to assess whether there was any difference in surface 
marker expression between the two types of sample immediately after neutrophil
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separation. No significant differences in the chosen markers were observed (Figure 
6.2).
□  Adult 
^  Cord
Figure 6.2 Bar graph showing median relative expression o f various neutrophil cell 
surface markers in cord and adult neutrophils. Error bars show interquartile ranges. 
There are no statistically significant differences between any o f the pairs. (n=7 pairs)
6.2.4 Neutrophil apoptosis in cord and adult blood
Neutrophil apoptosis was quantified after neutrophil purification (time 0) and again 
after 6 and 20 hours in culture, by means of flow cytometry using annexin-V and To- 
Pro 3 staining (see methods 2.1.4.2 and 2.1.4.3) in 8 paired cord and adult blood 
samples. The proportion of apoptotic cells was also confirmed by light microscopy of 
cytospin preparations.
The percentage of apoptotic neutrophils in cord and adult blood immediately after 
neutrophil isolation was similar in both cord and adult blood (Adult mean 4.90%, 
median 3.34%, range 2%-12.97%; cord mean 4.62%, median 3.01%, range 0.51%- 
12.00%, p=0.73, Mann-Whitney U-test).
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It was not unexpected therefore that the percentage of necrotic cells and the viable 
percentage were also not significantly different (necrotic adult mean 2.02%, median 
1.45%; cord mean 1.47%, median 1.08%, p=0.95; viable adult mean 90.20%, median 
92.77%; cord mean 86.60%, median 92.06%, p=0.80, Mann-Whitney U-test) between 
the two groups at the outset.
Following 6 hours in culture the percentage of apoptotic cells among the adult 
neutrophils was significantly higher than in cord neutrophils (adult mean 40.08%, 
median 42.38%; cord mean 15.58%, median 13.36%; p=0.0013, Mann-Whitney U- 
test) (Figure 6.3). The percentage of necrotic cells was similar (adult mean 2.39%, 
median 1.07%; cord mean 3.71%, median 1.66%; p=0.3659, Mann-Whitney U-test) 
(Figure 6.4) and the percentage of viable neutrophils remaining was therefore 
significantly higher among the cord neutrophils (adult mean 55.85%, median 53.97%; 
cord mean 78.77%, median 82.42%; p= 0.0127, Mann-Whitney U-test) (Figure 6.5).
After 20 hours in culture the adult neutrophils continued to have a significantly higher 
percentage of apoptotic cells (adult mean 41.22%, median 46.24%; cord mean 
21.64%, median 23.20%; p=0.020, Mann-Whitney U-test) (Figure 6.3) and a 
significantly lower percentage of viable cells (adult mean 30.33%, median 29.42%; 
cord mean 57.18%, median 56.66%; p=0.0027, Mann-Whitney U-test) (Figure 6.4). 
The percentage of necrotic cells among adult neutrophils was slightly higher than in 
cord blood (adult mean 23.67%, median 25.24%; cord mean 16.06%, median 
15.30%) but this was not statistically significant (p=0.155, Mann-Whitney U-test) 
(Figure 6.5).
Addition of 50 ng/ml LPS to the culture medium resulted in a statistically significant 
reduction in the percentage of apoptotic neutrophils in adult samples at both 6 and 20 
hours (6 hours - adult mean 40.08%, median 42.38%; adult LPS mean 13.44%, 
median 11.12%; p=0.0002, Mann-Whitney U-test) (20 hours - adult mean 41.22%, 
median 46.24%; adult LPS mean 24.29%, median 22.06%; p= 0.0207, Mann-Whitney 
U-test) (Figure 6.3). In cord blood neutrophils, the same conditions resulted in no 
significant difference in the percentage of apoptotic cells at 6 hours (cord mean 
15.58%, median 13.36%; cord LPS mean 11.31%, median 6.93%; p= 0.180, Mann- 
Whitney U-test) but there was a statistically significant reduction in the percentage of
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apoptotic cells by 20 hours when LPS was added to cord blood neutrophils in culture 
(Cord mean 21.64%, median 23.20%; Cord LPS mean 7.89%, median 4.96%; p= 
0.0260, Mann-Whitney U-test) (Figure 6.3). There was no significant difference in the 
percentage of necrotic cells present in any of the cultures at either 6 (adult vs adult 
LPS: adult mean 2.39%, median 1.07%, adult LPS mean 3.35%, median 1.40%; p= 
0.792; cord vs cord LPS: cord mean 3.71%, median 1.66%; cord LPS mean 5.11%, 
median 2.93%; p= 0.423, Mann-Whitney U-test) or 20 hours (adult vs adult LPS: 
adult mean 23.67%, median 25.24%, adult LPS mean 26.13%, median 22.62%; p= 
0.959; cord vs cord LPS: cord mean 16.06%, median 15.30%; cord LPS mean 
18.30%, median 17.88%; p= 0.699, Mann-Whitney U-test) (Figure 6.5).
As a result of the large reduction in apoptosis in adult cells after the addition of LPS 
and the negligible change in apoptotsis in cord blood cells to which LPS had been 
added, the significant difference seen between adult and cord neutrophil apoptosis at 6 
hours of culture was not present when LPS was added to both adult and cord 
neutrophils (adult mean 13.44, median 11.12; cord mean 11.31, median 6.93; p= 
0.345, Mann-Whitney U-test) (Figures 6.3, 6.4 and 6.5) however, the significant 
difference in apoptosis between the two types of samples was apparent at 20 hours 
when neutrophils were cultured with LPS (adult LPS mean 24.29, median 22.06; cord 
LPS mean 7.89, median 4.95; p= 0.0013, Mann-Whitney U-test) (Figure 6.3). There 
was no significant difference in the percentage of necrotic cells between the two 
sample types at either time point (6 hours adult LPS vs cord LPS p= 0.0811; 20 hours 
adult LPS vs cord LPS p= 0.796, Mann-Whitney U-test). The percentage of viable 
cells was not significantly different at 6 hours (p= 0.846) or 20 hours (p= 0.302).
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Figure 6.3 Graph showing the percentage o f apoptotic cells in cultured cord and 
adult neutrophils at three time points, with and without addition o f LPS. (n= 8 pairs)
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Figure 6.4 Graph showing the percentage o f viable cells in cultured cord and adult 
neutrophils at three time points, with and without addition o f LPS. (n= 8 pairs)
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Figure 6.5 Graph showing the percentage o f necrotic cells in cultured cord and adult 
neutrophils at three time points and two conditions (with and without addition o f  
LPS). (n= 8 pairs).
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Figure 6.6 Bar graphs showing the relative proportions o f apoptotic, necrotic and 
viable neutrophils in cultured adult and cord cells at (A) time 0, (B) 6 hours and (C) 
20 hours. (n= 8 pairs)
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6.2.5 Extended time points
In one adult/cord pair, the neutrophils were continued in culture for 42 hours in order 
to observe any further changes (Figure 6.7 A, B and C). Although this is only a single 
pair of samples, in both adult and cord neutrophils incubated with medium alone, the 
percentage of apoptotic cells reaches a peak at around 20 hours before beginning to 
fall again as viable cells steadily decrease and the proportion of necrotic cells 
increases. This probably reflects an increasing number of apoptotic cells undergoing 
secondary necrosis in the absence of macrophages to remove the apoptotic cells by 
phagocytosis.
q  Necrotic
■ Apoptotic
■  Viable
3 3 7
The addition of LPS to both adult and cord cells appears to delay the peak in 
apoptosis to around the 28 hour time point (Figure 6.1 A). LPS can be seen to be 
increasing the proportion of viable cells quite markedly compared to adult cells in 
medium alone (Figure 6.7C). Cord neutrophils with and without LPS have very 
similar proportions of viable cells throughout the time period.
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Figure 6.7 Graphs showing the percentage o f (A) apoptotic, (B) necrotic and (C) 
viable neutrophils in adult and cord cells with and without the addition o f LPS over a 
period in culture o f 42 hours.
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6.2.6 Possible mechanism s for delayed apoptosis in cord  blood
6.2.6.1 Bax
An early and critical step in the so-called intrinsic apoptosis pathway is the activation 
of Bax. Bax activation allows Bax to pierce holes in the outer mitochondrial 
membrane allowing for cytochrome c to be released and combine with Apaf 1. This 
complex in turn is able to activate caspase 9.
I chose to examine Bax activation in 8 paired samples of purified adult and cord 
neutrophils by flow cytometry, as described in section 2.2.4A
Immediately following neutrophil separation, there was no significant difference in 
the expression of Bax in adult and cord neutrophils (Adult mean 38.89%, median 
5.01%; cord mean 35.92%, median 11.04%; p=1.00).
After 6 and 20 hours in culture with medium alone there was no significant difference 
between the percentage of cells expressing Bax in adult and cord samples (p=0.06 at 6 
hours and p=0.09 at 20 hours), despite the percentage of apoptotic cells in these 
samples being significantly different (see 6.2.4 above). One might expect a significant 
increase in the percentage of cells expressing Bax when the percentage of apoptotic 
cells in the sample is significantly inceased, however this was not seen.
At 6 hours, more adult neutrophils cultured in medium alone expressed Bax than adult 
neutrophils cultured with LPS. This was a statistically significant difference 
(p=0.031) consistent with the observation that there are significantly more apoptotic 
cells among medium cultured adult neutrophils than among those cultured with LPS. 
After 20 hours there was no significant difference between the 2 conditions (p=0.15), 
despite a significant difference being observed in the percentage of apoptotic cells 
present (see 6.2.4 and Figure 6.3 above). This raises a number of questions: is there a 
delay between Bax activation and the appearance of apoptosis detectable by flow 
cytometry or does this reflect a maximal activation of Bax within the neutrophil at 20 
hours or is there another, anti-apoptotic, factor acting in opposition to the pro- 
apoptotic effects of Bax?
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Cord neutrophils cultured with LPS had similar levels of Bax activity to cord 
neutrophils cultured in medium only (6 hours p=0.5887; 20 hours p= 0.1797).
These results suggest that a difference in Bax is probably not the reason for the 
differences observed in rates of apoptosis between cord and adult neutrophils, 
although the reduction in apoptosis in the presence of LPS, particularly in adult 
neutrophils at 6 hours, may be related to a reduction in Bax activity, but this is not 
observed in cord blood.
Adult 
Cord 
-Q- Adult LPS 
Cord LPS
At 6 hours, p=0.031 for adult vs 
adult LPS.
Figure 6.8 Graphs showing the percentage o f cells with detectable Bax activity at 3 
time points, with and without LPS.
6.2.6.2 The Bcl-2 family of apoptotic proteins
The Bcl-2 family of proteins, which includes Bax, is central to the so-called intrinsic 
pathway of apoptosis. I chose to further investigate this family of molecules in cord 
and adult neutrophil preparations.
RNA was extracted from purified cord and adult neutrophils (4 pairs) as explained in 
section 2.2.5. The extracted RNA was frozen and then sent to Sheffield, where it was 
used in RNase protection assay (RPA) and RT-PCR, performed by Vanessa Singleton 
and Dr Lynne Prince, in order to further investigate the possible differences in the 
Bcl-2 family of proteins between the two types of cells. RNA was only extracted from 
fresh neutrophils, not from cells which had been left to apoptose in culture, because of
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the very large number of neutrophils required to obtain sufficient RNA for the assays 
and in order to assess if any differences exist between adult and cord neutrophils at 
baseline, rather than once apoptosis has commenced.
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Figure 6.9 Photograph o f  RPA autoradiograph showing larger amounts o f Bcl-xl in 
cord and Mcl-l in adult lanes.
An equal load of RNA was placed in each lane of the gel, however it can be seen in 
Figure 6.9 that “housekeeping” genes such as GAPDH are expressed in greater 
quantities in cord neutrophils; this may be because cord neutrophils are more 
transcriptionally active and may have a higher proportion of their RNA present as 
mRNA, rather than rRNA, explaining the higher global gene expression in the cord 
samples.
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Looking at the four pairs of samples that were subjected to this analysis, and allowing 
for the relatively heavier staining of the cord lanes, there appear to be larger amounts 
of both the anti-apoptotic proteins Bcl-xl and Al (bfl-1) in cord blood neutrophils and 
higher levels of Mcl-1 in adult neutrophils.
These perceived differences were further analysed by RT-PCR as described in section 
2.2.5.3, the results of which are summarised in Figure 6.10. When normalised for 
either GAPDH or p-actin, Bcl-xl was significantly upregulated in the cord neutrophils 
and Mcl-1 was significantly more abundant in adult neutrophils. There was no 
statistically significant difference in Al or in GAPDH between adult and cord cells. 
GAPDH and H IFla are both induced by hypoxia but were not statistically 
significantly different between the two groups, indicating that the relative hypoxia of 
the intra-uterine environment was not likely to be the cause of the differences 
observed. HIF 2a, along with HIF la, is also a key regulator of the transcriptional 
response to hypoxia (Bracken et al., 2005, Scortegagna et al., 2003), however HIF la  
and HIF 2a have unique targets and different biological effects (Patel and Simon, 
2008) and it is mainly HIF la  which regulates neutrophil survival (Walmsley et al., 
2005).
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Figure 6.10 Graphs showing median fo ld  change in (A) Bcl-xl, (B) A-l, (C) Mcl-1, 
(D) HIF-la, (E) HIF-2a and (F) GAPDH for cord and adult neutrophil RNA 
subjected to RT-PCR. (n=4)
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6.2.6.3 Caspase 3
Caspase 3 is a central executioner of apoptosis which cleaves many key cytoskeletal 
components at an Asp-Xaa-Xaa-Asp (DXXD) motif (Cohen, 1997). Caspase 3 
activation by cleavage of pro-caspase 3 is an early apoptotic event. I chose to study 
this caspase further due to its probable central role in the “final common pathway” of 
both intrinsic and extrinsic proposed pathways of apoptosis.
Caspase 3 was measured by flow cytometry at each of the three time points (0, 6 and 
20 hours) in neutrophils purified from 8 pairs of cord and adult blood samples using 
Apo Logix ™ - SR Sulforhodamine Caspase Detection Kit (Peninsula Laboratories 
Inc, California, USA) as described in chapter 2, section 2.2.4.3.I.
There was no significant difference in MFI or the percentage of cells positive for 
activated caspase 3 at any of the time points or conditions, despite the significant 
differences observed in the percentage of apoptotic cells in section 6.2.4 above.
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Figure 6.11 Graph showing percentage o f cells expressing caspase 3 at 3 time points, 
with and without LPS.
6.2.6A. Other caspases
Similar to the Bcl-2 family, the caspases were also analysed by RPA methodology by 
Vanessa Singleton in Sheffield, using RNA extracted and frozen in Cardiff from 
neutrophils which were isolated from 4 pairs of cord and adult blood samples. Again, 
despite equivalent loading of RNA, the cord neutrophils appear to have higher
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amounts of the loading controls GAPDH and L32. Caspases 1, 4 and 8 are expressed 
highly in both cord and adult neutrophils but differences in caspases between cord and 
adult neutrophils are difficult to elucidate from this assay. These findings have not 
been further analysed by RT-PCR.
Caspases Caspases
GAPDH
GAPDH
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I
Figure 6.12 Photograph o f autoradiograph o f RPA for caspases, showing high 
expression o f caspases 1, 4 and 8 in adult and cord lanes.
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6.3 Sum m ary of m ain findings
1. I confirmed that cord blood neutrophils from term infants undergo apoptosis 
less readily than adult neutrophils.
2. Apoptosis in adult neutrophils can be delayed by the addition of LPS (seen 
clearly by 6 hours), but this effect appears to be delayed in onset in cord 
neutrophils (only seen at 20 hours).
3. A similar proportion of both cord and adult neutrophils have Bax and caspase 
3 activity detected despite higher levels of apoptosis in adult neutrophils.
4. Adult and cord blood have differing expression o f  anti-apoptotic proteins of 
the Bcl-2 family, specifically cord neutrophils have higher levels of the anti- 
apoptotic protein Bcl-xl and lower levels of the pro-apoptotic protein Mcl-1. 
These differences cannot be attributed solely to the relative hypoxia of intra­
uterine life.
6.4 Discussion
6.4.1 Introduction
Apoptosis in cord blood neutrophils has been studied by a number of groups, with the 
majority finding that cord neutrophils were relatively resistant to apoptosis compared 
to neutrophils from adult peripheral blood (Allgaier et al., 1998, Hanna et al., 2005, 
Koenig et al., 2005, Luo et al., 2003, Molloy et al., 2004, Molloy et al., 2005), 
however one group found exactly the opposite (Uguz et al., 2002) for reasons which 
remain unclear, but may be methodological. The method o f neutrophil separation may 
have a profound effect on neutrophil activation and thus the ability of the cells to 
undergo apoptosis. “Contamination” of neutrophil preparations with monocytes may 
also produce altered results in apoptosis experiments as monocytes are a source of 
cytokines and other inflammatory mediators which prolong neutrophil survival 
(Sabroe et al., 2004). It is possible that these studies differed in their results because 
of the way in which the neutrophils were purified and handled prior to commencing 
the apoptosis experiments.
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I elected to use umbilical cord blood from infants bom at term by elective Caesarean 
section to healthy mothers for two main reasons:
- cord blood is available in sufficient quantities at delivery without 
compromising the health or medical care of the mother or baby (the cord and 
the blood contained therein are normally disposed of following inspection by 
the delivering midwife) (range <5 -  60 ml per cord, average 20 -  25 ml per 
cord in experienced hands).
- babies delivered by Caesarean section prior to the onset of labour are the least 
likely to have neutrophils which have been primed or activated either by 
infection or the process of labour.
6.4.2 Neutrophil apoptosis
I confirmed the findings of published studies by using flow cytometry to assess 
neutrophil apoptosis in preparations of cord and adult neutrophils which were 
effectively free of monocyte contamination, which may have altered rates of apoptosis 
of the neutrophils in culture (Sabroe et al., 2004).
Cord blood neutrophils did indeed undergo apoptosis less readily that those from adult 
peripheral blood and also appeared less able to respond to the addition of LPS. This 
hyporesponsiveness o f neonatal neutrophils to LPS has previously been described by 
Molloy et a l (Molloy et al., 2008) in a paper published shortly before our experiments 
had been completed. They attributed this relative lack of response to LPS to the 
failure of neonatal neutrophils to upregulate TLR 4 in response to sepsis (Molloy et 
al., 2006, Viemann et al., 2005). I found a similar expression of TLR 2 and 4 and 
CD 14 on cord and adult neutrophils, suggesting that the poor response to LPS that 
was witnessed in cord neutrophils is mediated by intracellular mechanisms, rather 
than the neutrophils being unable to respond to the stimulus.
6.4.3 Mechanisms for the delay in neonatal neutrophil apoptosis
Luo et a l (Luo et al., 2003) used RT-PCR and enzymatic assays to describe a 
reduction in caspase 3 mRNA and functional activity as a possible cause for the delay 
in Fas mediated neutrophil apoptosis in cord neutrophils. Hanna et al (Hanna et al.,
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2005) described reduced expression of the Fas receptor in neonatal neutrophils as well 
as reduced expression of caspase 3 and the pro-apoptotic proteins Bax, Bad, and Bak 
by flow cytometry.
I found no significant difference in caspase 3 activation between adult and cord 
samples, either in fresh neutrophils or those allowed to undergo apoptosis in culture. 
The results of the RPA appeared to agree with this finding, but suggest that further 
investigation of other caspases may yield more useful results.
The Bcl-2 family comprises both pro- and anti-apoptotic member proteins. Bax is a 
pro-apoptotic protein which, following activation by Bid, makes holes in 
mitochondrial membrane. Our data show that levels of Bax activation are remarkably 
similar in cord and adult neutrophils, especially when the delay in apoptosis in cord 
neutrophils is considered. This raises the question of whether there is another, anti- 
apoptotic, factor acting in cord blood to produce the delay in apoptosis which I 
observed.
The delay in cord neutrophil apoptosis may be partly explained by the significant 
increase in Bcl-xl which I observed in cord neutrophils. Bcl-xL appears to be the 
dominant regulator of apoptosis and has been called the “survival protein” because of 
its cell death repressor activity. Bcl-xl has been shown to compete with Bax and 
prevent the binding of Bax to the mitochondrial membrane (Billen et al., 2008), thus 
delaying or preventing apoptosis. This may be the mechanism by which cord blood 
neutrophils experience a delay in apoptosis and still have the similar levels of Bax 
activation which I have described.
Bax and Bcl-xl have been studied in adult and neonatal rat cardiac myocytes, where 
neonatal cells have high levels of both Bcl-xl and Bax but with age, Bcl-xl is 
maintained but Bax levels are barely detectable in adult rat hearts (Cook et al., 1999). 
In neuronal tissue Bcl-xl is not downregulated in the adult rat although Bax levels are 
20- to 140-fold lower in adult compared to neonatal rat tissues (Vekrellis et al., 1997). 
Adult peripheral blood neutrophils have previously been shown to express very low 
levels of both Bcl-xl and Bax, as well as Bcl-2, Bik and caspase 2 (Santos-Beneit and 
Mollinedo, 2000), although an earlier study found only Bax and no other Bcl-2 family
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members in adult neutrophils (Ohta et al., 1995). Apart from the Hanna et al (Hanna 
et al., 2005) paper, there have been no published comparisons, to our knowledge, 
looking in detail at the Bcl-2 proteins in adult and neonatal neutrophils.
Additionally, I have shown levels of Mcl-1 protein are significantly increased in adult 
neutrophils when compared to cord cells. Mcl-1 is generally an anti-apoptotic member 
of the Bcl-2 family (Michels et al., 2005) and had been described as being essential 
for the survival of neutrophils (Dzhagalov et al., 2007). It promotes cell survival by 
interfering in the cascade of events leading to release of cytochrome c from 
mitochondria. However, Mcl-1 can also be cleaved by caspases during apoptosis to 
produce a cell death promoting molecule (Michels et al., 2005) and this may also be 
significant in explaining the differences observed between adult and cord neutrophil 
apoptosis. The cell death promoting activity of Mcl-1 may be partly responsible for 
adult neutrophils undergoing apoptosis more readily than cord neutrophils.
Hypoxia inducible factor (HIF) is an oxygen-sensitive transcription factor which 
regulates cell responses to hypoxia and is upregulated under conditions of low oxygen 
tension (Walmsley et al., 2008). HIF-la promotes neutrophil survival but the 
mechanism of this has yet to be fully elucidated (Mecklenburgh et al., 2002, 
Walmsley et al., 2005a, Walmsley et al., 2005b). The fact that HIF-la is not 
upregulated in cord neutrophils indicates that the significantly prolonged survival of 
cord neutrophils is unlikely to be due to the relative hypoxia of the intra-uterine 
environment. A study of guinea pig fetuses failed to show increased expression of 
Bcl-xl following hypoxia, although Bax expression was increased by hypoxic 
conditions (Abedin et al., 2005). HIF-2a shows upregulation in cord neutrophils but it 
appears to be less important in neutrophils than H IF-la (Mecklenburgh et al., 2002, 
Walmsley et al., 2005a, Walmsley et al., 2005b).
Al (bfl-1) has been previously studied and found in similar amounts in adult and cord 
neutrophils (Hanna et al., 2005). I initially tried to study this protein by flow 
cytometry but no effective antibody was available for this purpose. Levels of A-l are 
not significantly different between adult and cord blood in our study when the results 
of the RT-PCR are reviewed.
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6.4.4 Conclusion
This chapter aimed to examine the effect of maturity (term newborn vs adult) on the 
ability of neutrophils to undergo apoptosis, in light of the significantly lower 
percentage of the neutrophil population that was apoptotic in BAL samples from 
preterm infants.
Neonatal neutrophils displayed a delay in apoptosis when compared to adult 
neutrophils and were also hyporesponsive to the pro-survival effects of LPS.
The differences in the Bcl-2 family members between adult and cord neutrophils may 
be the most significant of the factors investigated in explaining the delay in apoptosis 
in term cord neutrophils. It is interesting to observe the differential use of the Bcl-2 
family of proteins in promoting neutrophil survival between adults and newborn 
infants. It would be a useful addition to this study to investigate the same Bcl-2 family 
members in cord blood taken from preterm infants to assess whether a decrease in 
gestation would further alter the regulation of apoptosis in preterm infants compared 
to term babies.
351
Chapter 7 
Final Discussion
Chapter 7 
Final Discussion
7.1 Overview
In this thesis, I have sought to examine the inflammatory process in the lungs of 
ventilated newborn infants. I have described both the cellular and supernatant 
components of bronchoalveolar lavage samples from term and preterm infants and 
focused on the relationship of various components of the pulmonary inflammatory 
response to the pathogenesis of CLD. I have paid particular attention to the role of 
infection in lung disease of preterm infants and tried to identify a predictive factor for 
the development of CLD. I have focused more specifically on the role of neutrophil 
apoptosis in CLD and have sought to understand the mechanism for the delay in 
neutrophil apoptosis in newborn infants and how this may impact on lung disease. I 
used flow cytometry, a technique not previously reported in the study of neonatal 
BAL, to accurately describe the cellular component of BAL samples and to study 
neutrophil and macrophage surface markers in BAL samples as well as neutrophil 
apoptosis in BAL samples. I have also attempted to study apoptosis in neonatal 
neutrophils in the in vitro setting to discover reasons for their delayed apoptosis.
7.2 Initiation of the inflammatory response
Initially I confirmed previously published findings (Merritt et al., 1983, Kotecha et 
al., 2003, Amon et al., 1993) which showed that the total cellular load, as well as the 
number of both neutrophils and macrophages, in the lungs of ventilated preterm 
infants is much greater than their term counterparts but I failed to show a significant 
difference between preterm infants whose RDS resolves and those who go on to 
develop CLD. This lack of a significant result may be due to the small numbers in 
each patient group in our cohort. However, our study has the advantage of daily 
sampling in the first week of life which may have detected changes in cell influx that 
would have been missed by less the frequent sampling protocols used in other studies 
(Kotecha et al., 2003). Many of the studies of the cellular components of BAL 
samples mentioned above date from 5-10 years ago and have a cohort of infants with
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RDS that are ventilated for longer periods than in this study -  this may imply subtle 
differences in the studied population or in the care offered to these infants in different 
intensive care units at different times. Also this study cohort was slightly atypical, 
even for the Welsh Regional Neonatal Unit, as a significant proportion of the enrolled 
infants had not received a full course of antenatal steroids, which may have had an 
impact on the initiation of the pulmonary inflammatory response in these infants.
RDS is a neutrophil-dominant pathology (Amon et al., 1993) and it is likely that it is 
the persistence of neutrophils and their impact on enhancing and maintaining the 
ongoing inflammatory process that allows for the development of the lung injury that 
characterises CLD (Haslett, 1999, Serhan and Savill, 2005). I showed that 
significantly fewer neutrophils from the preterm lung have surface expression of TLR 
2 and TLR 4 which are important in mediating the recognition of pathogens in the 
lung so that possibly despite increased neutrophil numbers the response of the preterm 
infant to an invading micro-organism may be impaired and thus allow an infection to 
become established rather than rapidly cleared. Although in freshly isolated cord 
blood neutrophils there were no significant differences in TLR 2 and 4 expression 
when compared to freshly isolated adult neutrophils there appear to be differences in 
expression in neutrophils found in term and preterm lungs. It would therefore be 
useful to compare preterm and term cord blood neutrophils to assess whether the 
difference observed in BAL neutrophils is related to gestation and maturation or 
occurs as a result of failure of the preterm neutrophils to upregulate TLR 2 and 4 
expression in response to the environment in the lung.
Part of the strength of this study is the repeated samples taken from babies, 
particularly in the first week of life which enabled me to look more closely at 
individual infants and identify sudden increases in cell count which often coincided 
with the presence of microbial DNA in the BAL fluid. I was also able to show that the 
peak in total, neutrophil and macrophage counts was delayed in infants who 
developed CLD, more than either those babies with RDS or those bom at term. This 
may be because cell influx continues over a longer period in CLD infants, to reach a 
higher peak, and the inflammatory process continues long after this process has 
received a signal to begin resolution in the other groups of babies. This prolongation 
of cell influx is likely to be contributed to by the presence of infection or colonisation
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with micro-organisms. The presence of an endotracheal tube in the ventilated neonate 
provides a portal of entry for infection as well as an indwelling foreign body for 
maintenance of infection or colonisation (in addition to the multiple venous access 
devices frequently present in these infants). Infants developing CLD were ventilated 
for a longer period, allowing increased opportunity for colonisation or infection with 
microbes and therefore may have required ongoing ventilation, thus worsening CLD, 
which required ongoing intubation in a self-perpetuating cycle.
7.3 Maintenance of the inflammatory response
I found a significant association between the presence of microbial DNA in BAL 
samples and CLD, particularly when microbial DNA was detected beyond the first 3 
days of life. This implies an important role for hospital-acquired, late-onset neonatal 
infection in the development of CLD, probably related to the persistence of the 
endotracheal tube in these long term ventilated patients. Episodes of microbial 
infection or colonisation were temporally associated with further increases in total, 
neutrophil and macrophage counts, exaggerating the inflammatory response and lung 
injury in these babies.
Similarly the presence of Ureaplasma spp. in BAL samples was also associated with 
CLD. This may be partly as a result of Ureaplasma being a well recognised cause of 
preterm labour (Kirchner et al., 2007), but antenatal infection or colonisation with this 
organism may start the inflammatory cascade before birth in the most immature lungs 
and this is then further exaggerated by the routine activities of clinical neonatology, 
such as ventilation and the provision of supplemental oxygen, which are known to be 
pro-inflammatory (Davis et al., 1991, Jobe and Bancalari, 2001).
Integral to the maintenance of the inflammatory response are various cellular 
messengers including cytokines and growth factors. I found significantly elevated 
peak levels of numerous pro-inflammatory mediators, but also of anti-inflammatory 
cytokines, like IL-10 in preterm infants who developed CLD. I believe this reflects 
complete dysregulation of the inflammatory process and cells may be unable to 
respond to anti-inflammatory stimuli because of the sheer size of the ongoing pro-
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inflammatory reaction. The presence of microbial DNA in BAL samples was 
associated with further increases in cytokine levels
7.4 Tissue damage
I studied only one major mediator of tissue damage in BAL samples, namely elastase. 
Neutrophil elastase activity was detected in a minority of samples in episodic spikes, 
temporally associated with the presence of infection but there was a significant 
relationship between the detection of elastase in BAL supernatants and the 
development of CLD. There was also a noticeable link between the presence of 
microbial DNA from species other than S. epiderm idis and the highest elastase levels, 
adding a further possible mechanism for the association seen between infection and 
CLD. Historically, elastase was considered one of the most important mediators of 
lung injury in preterm ventilated infants (Merritt et al., 1983, Ogden et al., 1984, 
Watterberg et al., 1994), however, more recently the role of elastase in CLD in the era 
of antenatal steroid and postnatal surfactant treatment has become less prominent 
(Speer et al., 1993, Sveger et al., 2002, Sluis et al., 1994). The uncontrolled release of 
neutrophil elastase into lung tissue is still a cause of lung tissue injury and the 
association of peaks in elastase with the presence of microbial DNA confirms the 
importance of microbial infection or colonisation in the pathogenesis of CLD.
The reason for uncontrolled neutrophil elastase release in the lung may be speculated 
to be due to large numbers of neutrophils present in the lung, particularly neutrophils 
dying by necrosis. This was not clearly shown by data from this cohort.
A commonly held view of the pathogenesis of CLD is that it is a process of aberrant 
lung development (Jobe and Bancalari, 2001) contributed to by numerous pro- and -  
anti-inflammatory mediators and growth factors present in the preterm lung. My 
findings of elevated peak levels of a number of cytokines in infants developing CLD 
would support this view. Additionally the significantly higher cytokine levels 
demonstrated in BAL samples where 16S rRNA or Ureaplasma were isolated, along 
with the higher neutrophil counts associated temporally with infection, may allow 
aberrant repair of elastase damaged tissues due to abnormally high levels of cytokines
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present or lack of resolution because of ongoing neutrophil recruitment in response to 
high levels of, particularly pro-inflammatory, cytokines.
7.5 Resolution of inflammation
The reason for this ongoing response in what are frequently the smallest and most 
immature infants may be related in part to my findings among the 
monocyte/macrophage population. I showed that the macrophages have a more 
immature phenotype in preterm infants and that term infants have a higher proportion 
of mature alveolar macrophages from as early as the first day of life. In fact, this was 
one of the only differences between the BAL samples of term and preterm infants at 
this early stage, although probably not clinically useful as a prognostic indicator of the 
future development of CLD as no differences were shown between RDS and CLD 
infants. The presence of mature macrophages in the lung may allow the process of 
resolution of pulmonary inflammation to begin very early in the ventilator course in 
term infants, by allowing phagocytosis of apoptotic neutrophils and production of 
anti-inflammatory cytokines. This process of resolution is likely to be reflected as an 
improvement in the infant’s clinical status and facilitates rapid extubation and thus 
further reduction in the pro-inflammatory stimuli associated with prolonged 
ventilation, which include barotrauma, hyperoxia and secondary infection.
I hypothesise that the more immature monocyte-like cells may also be able to produce 
an exaggerated cytokine response (Maus et al., 2002b, Maus et al., 2001, Rosseau et 
al., 2000a, Rosseau et al., 2000b) and be less able to phagocytose apoptotic 
neutrophils (Hallwirth et al., 2004), thus less able to provide an anti-apoptotic signal 
to promote resolution of inflammation (Haslett, 1999). This was not apparent from 
this study, but nevertheless may merit further investigation by in vitro  studies of the 
ability of immature macrophages to interact with apoptotic neutrophils from cord 
blood of both term, initially, and then preterm infants.
A recent study (Kevill et al., 2008) has shown that macrophage migration inhibitory 
factor may be an important protective factor in the development of CLD in both a 
mouse model and in human infants. This may serve to support my hypothesis that the 
presence of immature macrophages in the newborn lung is a critical component of the
357
pathogenesis of CLD. G-CSF and GM-CSF are known to promote macrophage 
maturation, however their presence in the lung may also make a considerable 
contribution to the accumulation of neutrophils, thus negating any positive effect from 
these mediators (Papoff et al., 2001).
The clearance of neutrophils from the site of inflammation is vital to the resolution of 
the inflammatory process. Part of this process is the death of neutrophils by apoptosis 
and their subsequent phagocytosis by macrophages. I hypothesised that there may be 
a disruption or dysregulation of neutrophil apoptosis in infants who develop CLD 
(Kotecha et al., 2003) as a result of factors inherent in the neutrophil, dysfunctional 
macrophage recognition or phagocytosis of apoptotic neutrophils or factors related to 
the inflammatory environment in which the neutrophils are found.
I showed that a significantly higher percentage of the neutrophil population was 
apoptotic in term infants compared to preterm babies. Having more of the neutrophil 
population undergoing apoptosis renders fewer neutrophils available to actively 
contribute to the inflammatory process and tissue injury (Whyte et al., 1993, 
Dransfield et al., 1995). This, in combination with a large number of mature 
macrophages available to remove these effete neutrophils before they become 
secondarily necrotic (Matute-Bello et al., 1997), allows for the resolution of 
inflammation to begin.
Preterm infants had higher peak neutrophil counts and lower percentages of apoptotic 
neutrophils, which would effectively leave higher numbers of viable neutrophils 
present in the airways. These neutrophils are however inefficient in responding to 
microbial pathogens (Anderson et al., 1990, Levy et al., 1999), for reasons including 
their cell surface receptor expression (particularly TLRs), but also other factors not 
studied in this thesis e.g. adherence, chemotaxis, phagocytosis and non-oxygen 
dependent bactericidal activity (Anderson et al., 1990, Levy et al., 1999). The 
neutrophils are also delayed in entering the process of apoptosis. These factors allow 
neutrophil numbers to accumulate and potentially release their toxic contents causing 
a further escalation in the pro-inflammatory environment and further lung injury. 
These large numbers of neutrophils remain active at the site of inflamation (Liles et 
al., 1996, Leavey et al., 1998, Kasahara et al., 1997) until they eventually undergo
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apoptosis but then may not be able to be effectively taken up by the immature 
mononuclear phagocytes so then undergo secondary necrosis, further exaggerating the 
inflammatory problem. I showed that preterm infants do indeed have higher numbers 
of necrotic neutrophils present in BAL samples.
There appears to be a dysregulated relationship between apoptotic neutrophils, the 
mononuclear phagocyte population and the presence of infection, possibly because 
the system is completely overwhelmed by the numbers of neutrophils present and its 
regulation may be far more complex than originally thought.
I showed that the proportion of apoptotic neutrophils in preterm BAL samples reached 
a peak later than in term infants. This appears to be consistent with previously 
published findings that apoptosis is delayed in neonatal neutrophils from umbilical 
cord blood in vitro when compared to adult cells (Allgaier et al., 1998, Hanna et al., 
2005, Luo et al., 2003, Molloy et al., 2004). I was able to confirm these in vitro 
findings and went on to investigate possible reasons for this delay.
I found that the Bcl-2 family of proteins, particularly the anti-apoptotic proteins Bcl- 
xl and Mcl-1, are differentially expressed in term cord blood and adult neutrophils. 
The action of Bcl-xl in preventing permeablisation of the mitochondrial membrane by 
activated Bax may be critical in the delay in neutrophil apoptosis seen in cord 
neutrophils. This difference in Bcl-2 expression between cord and adult blood had not 
previously been described.
The addition of LPS to in vitro experiments with cord and adult neutrophils to mimic 
some of the effects of infection showed a very small further delay in apoptosis in cord 
neutrophils. This highlighted the hyporesponsiveness of infant neutrophils to infective 
stimuli and the likelihood that infection could further contribute to delayed neutrophil 
apoptosis.
The environment within the lung may also exert a significant influence on the 
resolution of pulmonary inflammation. I studied the BAL supernatants to determine 
their relative pro- or anti-apoptotic activity and found that significantly more 
supernatants had pro-apoptotic activity among the term population. It therefore
359
appears that resolution of the inflammatory response in the preterm lung is hampered 
not only by an inherent delay in neutrophil apoptosis within the neutrophil itself but 
also that the cell finds itself in an environment which supplies anti-apoptotic stimuli 
external to the neutrophil as well.
In summary, it would seem that the inflammatory process in the neonatal lung is 
characterised by a series of interconnecting circles of failure of resolution of an 
inflammatory process causing, and in turn caused by, an increase in pro-inflammatory 
stimuli.
7.6 Difficulties and limitations
No discussion would be complete without a review of some of the difficulties 
experienced in the conduct of this piece of work.
The collection of BAL samples, particularly on a daily basis in the first week of life 
and then the process of preparing the samples for FACS analysis, is necessarily time 
consuming and labour intensive, frequently being undertaken outside of normal 
working hours, which may make this technique not well suited for routine clinical 
use. In my view these daily samples were an important element of this study and 
provided useful information particularly in the term and RDS group of infants. Term 
and RDS babies were only ventilated for very short periods. Perhaps this cohort are 
not a true representation of the duration of ventilation in RDS because of the small 
sample size, or perhaps ongoing improvements in neonatal care are truly having an 
impact in this group of infants, but in view of this short ventilation period, if sampling 
had taken place less frequently, there would have been very little data on the term or 
RDS babies at all.
Neonatal BAL is frequently performed on the smallest, sickest infants from whom a 
sample of any type will be small and often difficult to obtain and ethical issues around 
consent for this sort of study will always be raised. Flow cytometry is not a technique 
that has been used previously in the analysis of preterm neonatal lung lavages, 
although it has been used to some extent in adult sputum studies. It took some time to 
establish appropriate processing techniques, including the use of DTT, and FACS
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staining and settings for this somewhat unusual sample type, particularly in view of 
the very tiny sample volumes obtained. The use of multi-colour (3-colour in this 
study) flow cytometry techniques enabled multiple antigens to be detected 
simultaneously, thus making good use of small samples. This was complicated by the 
high level of auto-fluorescence seen in both neutrophils and macrophages in these 
samples and fluorophores must be chosen with care in order to minimise the amount 
of FACS compensation required.
7.7 Future studies
This thesis has raised a number of questions which I believe could be further 
investigated:
I have identified a relative immaturity in lung macrophage populations in preterm 
infants. Unfortunately because of small sample sizes there were very few babies in 
whom these cells could be fully characterised. It would be interesting to fully 
characterise lung macrophages, using a large panel of potentially significant 
antigens/antibodies eg. CD 14, CD36 and HLA-DR, along with CD31, CD44 and the 
“PS-receptor” among others, in a population of ventilated infants of various 
gestational ages to ascertain whether increasing prematurity increases macrophage 
immaturity. Exposure to antenatal infection has been reported to precipitate migration 
of macrophages to the lung in the fetus (Alenghat and Esterly, 1984) and 
characterisation of macrophage maturity in the first few days of life in infected and 
uninfected premature infants might show marked differences and help to explain later 
responses to the inflammatory stimuli of routine preterm neonatal care.
The relationship between macrophages and neutrophil apoptosis involves numerous 
factors, including properties of both the neutrophil and the macrophage, their 
interaction and their environment (Vandivier et al., 2006). The interactions between 
apoptotic neutrophils and the macrophages which should engulf them are known to be 
complex (Vandivier et al., 2006) and are perhaps best studied in an in vitro setting 
where some of the many interacting factors in the process can be controlled or 
eliminated for study purposes. There may be further neutrophil dependent factors, 
such as altered surface antigen expression which, after the delay in apoptosis, prevent
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effective recognition and therefore removal of the neutrophils by phagocytes. 
Observation of neutrophil-macrophage interactions in term and preterm blood cells 
would appear to be a logical extension of this work.
I have noted a relationship between the presence of Ureaplasma and the development 
of CLD. This remains a controversial area of neonatal practice. The natural history of 
untreated Ureaplasma colonisation is unclear. One of our studied infants, who 
developed CLD, had no treatment for Ureaplasm a but was noted to have cleared the 
organism from his pulmonary secretions by 112 days of age in a sample taken for 
other clinical purposes. While this lack of clarity over the role of Ureaplasma in 
neonatal lung disease exists, it could still be ethically acceptable to observe the natural 
history of Ureaplasma colonisation in affected infants. There is little evidence 
(Mabanta et al., 2003) that treatment for U reaplasm a is useful in preventing the 
development of CLD but this is based on only 37 colonised patients from 2 studies 
where treatment protocols differed too much for the infants’ data to be analysed 
together as part of the review. A well-designed clinical trial of treatment of this 
organism in the preterm neonatal population is warranted, although the effects of 
Ureaplasma in the preterm lung may begin antenatally and treatment, even from birth 
before Ureaplasma colonisation status is known, may be too late to prevent CLD.
All our in vitro studies of neutrophil apoptosis were conducted using cord blood from 
term infants collected following elective Caesarean section. I would like to assess the 
impact of decreasing gestational age on the delay in neutrophil apoptosis and its 
causes, particularly the Bcl-2 proteins. Working with preterm cord blood will be more 
challenging than in term infants for a number of reasons:-
Significantly preterm infants are not often delivered by elective Caesarean 
section and those that are, are often in situations of severe fetal compromise or 
maternal ill health, so samples might not be easily obtained from this group. 
An extremely preterm or severely compromised fetus frequently has a very 
small, thin umbilical cord which will yield only a very small blood sample. 
This may drive the development of methods of separating neutrophils from 
and working with very small amounts of cord blood. This small sample 
methodology might then be useful in working with blood samples from infants 
and children -  currently prevented by the need for large blood samples.
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Infants who are bom spontaneously preterm often do so because of antenatal 
infection or inflammation which may be clinically undiagnosed (Goldenberg 
et al., 2000). Methods of identifying these infants and/or their mothers will be 
important in differentiating the potential anti-apoptotic effect of infection from 
a gestational delay in apoptosis.
I would also like to be able to observe the “maturation” of neutrophil apoptosis in 
infants and children to determine at what point it reaches adult rates. Again, this 
would require the ability to work with very small blood samples for clinical and 
ethical reasons.
The therapeutic use of cytokine analogues or antagonists has been effective in 
inflammatory diseases of adults e.g. rheumatoid arthrititis (Drynda et al., 2002). It has 
been suggested that similar interventions may be beneficial in the neonate. The effects 
of such drugs in reducing the inflammatory response may be beneficial but this may 
have to be traded against a further reduction in the ability of the infant to combat 
pathogens. The administration of substances which will act externally to the 
neutrophil to attempt to enhance apoptosis (e.g. FasL) may still be unable to 
overcome the anti-apoptotic effect of proteins like Bcl-xl which are having their effect 
at a mitochondrial membrane level.
7.8 Final summary
In this thesis I have sought to understand aspects of the inflammatory process in the 
neonatal lung by analysis of bronchoalveolar lavage fluid and cells.
I have performed detailed longitudinal analysis of cells types and counts in the 
airways of ventilated neonates using flow cytometry -  a technique not previously used 
for analysis of neonatal BAL cell phenotypes. I have established a reliable method for 
the use of flow cytometry in the very small samples obtained from neonatal BAL and 
shown that the use of DTT as a mucolytic in these samples has no significant effect on 
the detection of specific cell surface markers by flow cytometry. I have sought and 
found relationships between the presence of either 16S rRNA genes or Ureaplasma in 
BAL samples and the development of CLD.
363
I have found significantly elevated peak levels of a number of different cytokines in 
BAL supernatants from preterm infants and more pro-apoptotic activity against adult 
neutrophils in BAL supernatants from term infants.
I have focused on the role and process of neutrophil apoptosis in infants at risk of 
developing CLD and found a delay in apoptosis in lung neutrophils in preterm infants 
and confirmed a delay in neutrophil apoptosis in blood neutrophils of term infants 
compared to adults. I have shown that this delay might be due to differential 
expression of anti-apoptotic proteins Bcl-xl and Mcl-1 between cord and adult 
neutrophils, something which has not previously been described.
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INFORMATION SHEET FOR PARENTS/GUARDIANS Ver 3
Principle Investigators: Professor Sailesh Kotecha, Consultant Neonatologist
Contact Details: Neonatal Unit, 029 20 74 3374
1. Study Title
Is chronic lung disease of prematurity a consequence of immature regulation of 
neutrophil apoptosis in preterm infants?
2. Invitation
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part.
Thank you for reading this leaflet.
3. What is the purpose of the study?
Chronic lung disease (CLD), a common disease of premature babies, is characterised 
by prolonged oxygen dependency. Cells of inflammation, called neutrophils, are 
increased in the lungs of babies who develop CLD. Neutrophils are removed from the 
lungs by a process called apoptosis. We recently showed that the removal of 
neutrophils by this process of apoptosis is increased in babies who recover from their 
lung disease but not in those who develop CLD. In addition, cells called macrophages, 
which remove the apoptotic neutrophils, were increased in babies who recovered from 
their breathing difficulties but not if they developed CLD. We wish to determine 
whether CLD develops due to immaturity of factors that normally regulate this 
process called apoptosis. In particular, we wish to determine if apoptosis of 
neutrophils is related to the prematurity of the baby.
Using blood and lung washings from babies who do and do not recover from their 
lung disease, we will identify whether any factors important in neutrophil apoptosis 
are deficient or the macrophages are immature in babies who develop CLD. The 
results will help us understand why some babies progress to develop CLD whilst 
others recover and may help us develop therapies which can enhance apoptosis.
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4. Why have I and/or my baby been chosen?
We wish to obtain samples from two groups of babies:
(a) babies who are bom at or less than 32 weeks gestation and who need help with 
their breathing with breathing machines because of under-developed lungs, or
(b) babies who need help with their breathing with breathing machines because of 
non-breathing problems e.g. surgery.
As your baby may fall into one of these two groups, we would like to invite you to 
take part in our study.
5. Does my baby have to take part?
It is up to you to decide whether or not you want your baby to take part. If you do 
decide that your baby can take part, you will be given this information sheet to keep 
and be asked to sign a consent form. If you decide for your baby to take part, you are 
still free to withdraw your baby at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care 
that your baby receives.
6. What will happen if my baby takes part?
(a) If at all possible, we would like to obtain blood (about a teaspoon) from the 
umbilical cord when the baby is bom.
(b) We would also like to obtain 0.5 -  1.0 ml of blood (5 ml is a teaspoon) if and only 
if the baby is having blood taken for other routine blood tests. We would like to 
obtain blood daily for the first week and twice weekly thereafter for the first month.
(c) We would also like to obtain lung fluid from your baby whilst the baby remains on 
a breathing machine. The fluid will be obtained daily for the first week and twice 
weekly thereafter or until your baby is removed from the breathing machine, 
whichever occurs first. The breathing tube is often sucked out by the nurses to prevent 
it from blocking. We would replace this suctioning wherever possible so it does not 
need to be performed twice. In order to compare the results with other baby’s results, 
we have standardised this method of suctioning: the baby will be placed on his/her 
back and turn the head to the left side to encourage the suction tube to go down the 
right lung. We will then gently place a suction tube through the breathing tube into the 
lungs and through the tube insert saline (salt water). The amount of saline is based on 
the baby’s weight using 1 ml for each kilogram of the baby’s weight (one teaspoon is 
5 ml). After instilling the saline, we will suck up as much fluid as possible and repeat 
the procedure once more. The returned fluid will consist of the saline and will also 
have the baby’s lung fluid which we can use for our research.
We will monitor the baby’s heart rate and oxygen saturation during the procedure and 
sometimes the baby may need a little more oxygen (usually 5 -  10%) for a short 
period of time.
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7. Will this affect my or my baby’s treatment?
The medical care of you or your baby will not be affected by this study. The 
information from this study will not be used to diagnose or treat you or your baby.
8. What will happen to the samples collected?
We will first separate the cells and fluid from the samples collected. We will 
determine the proportion of different cells types and also how many neutrophils are 
apoptotic by using modem techniques which can look at the small number of cells 
obtained from small babies. We will use the fluid to measure or identify proteins 
which promote or inhibit apoptosis. Some fluid and cell samples will be sent to 
Professor Moira Whyte’s group in Sheffield as they have specific expertise in 
apoptosis of neutrophils. They will work together with us in identifying any particular 
factors which may be increased or decreased in babies who develop CLD.
9. What are the risks of my baby taking part?
Babies who receive mechanical ventilation are monitored closely for their heart rate 
and oxygen levels. The risks are similar to those of routine suctioning that the baby 
may have. Sometimes the babies may need extra oxygen, typically 5 -  10%, for 5 -  
10 minutes and sometimes especially when the suction tube is placed the heart rate 
may drop for a few seconds (usually less than 30 seconds). We would monitor the 
baby throughout the procedure and stop it if the baby becomes unwell in any way.
10. What if something goes wrong?
If your baby is harmed by taking part in this research project, there are no special 
compensation arrangements. If your baby is harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you or your baby have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be 
available to you.
11. Will my baby’s taking part be kept confidential?
All information which is collected about your baby during the course of the research 
will be kept strictly confidential. Any information about your baby which leaves the 
hospital will have your and the baby’s name and address removed so that you cannot 
be recognised from it. We will assign a number to each baby and use this to label the 
samples obtained for the study.
12. What will happen to the results of the study?
We will publish the results in reputable medical journals and present the data at 
scientific and medical meetings. Your baby’s name and details will NOT be revealed 
at any stage. Please let us know if you would like a copy of the report.
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13. Who is paying for the study?
The study is funded by the Wellcome Trust which is a major medical charity in the 
UK.
14. Who had reviewed the study?
This study has been reviewed by the South East Wales Research Ethics Committee 
and also by the Wellcome Trust who have funded the study.
15. Who can 1 contact for further information?
You may contact Professor Sailesh Kotecha by asking one of the staff on the neonatal 
unit or by telephoning 029 20 74 3374 or by email rKotechaS@Cardiff.ac.uk") or by 
mail to: Professor Sailesh Kotecha, Neonatal Unit, Heath Hospital, Heath Park, 
Cardiff CF14 4XN.
Thank you for taking time to read this information leaflet at such a difficult time. 
Please do not hesitate to ask Professor Sailesh Kotecha or Dr Nicola Maxwell if you 
would like to discuss anything further.
Dr Nicola Maxwell Professor Sailesh Kotecha
Clinical Research Fellow Consultant in Neonatal Medicine
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C aerdydd a 'r  Fro
C a rd iff and Vale 
U n ivers ity  H ea lth  Board
Eich cyf/Your ref 
Ein cyf/Our ref
Welsh Health Telephone Network 1872 
Direct Line/Llinell uniongychol
Ysbyty Athrofaol Cymru
University Hospital of Wales
Heath Park,
Cardiff, CF14 4XW 
Phone 029 2074 7747 
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Parc Y Mynydd Bychan, 
Caerdydd, CF14 4XW 
Ffon 029 2074 7747 
Ffacs 029 20743838
Minicom 029 2074 3632
Patient Identification Number for this study:
CONSENT FORM
Is chronic lung disease of prematurity a consequence of immature regulation 
of neutrophil apoptosis in preterm infants?
Name of R e se a rc h e r :  P ro fe s s o r  S a ile sh  K o techa ,  C o n s u l ta n t  N eonato log is t ,  
N eonatal Unit, Heath H ospita l ,  Cardiff CF14 4XN
P le a se  initial box
1. I confirm that I have read and understand the information sheet dated 
6th September 2005 (version 3) for the above study and have had the 
opportunity to ask questions.
2. I understand that my baby’s participation is voluntary and that I am 
free to withdraw my baby at any time, without giving any reason, 
without my baby’s medical care or legal rights being affected.
3. I understand that sections of any of my baby’s medical notes may 
be looked at by the research individuals I give permission for
these individuals to have access to my baby’s records.
4. I agree for my baby to take part in the above study.
□
□
□
□
Name of Parent/Guardian Date Signature
Name of Person taking consent 
(if different from researcher)
Date Signature
Researcher Date Signature
1 for patient, 1 for researcher, 1 to be kept with hospital notes.
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INFORMATION SHEET FOR PARENTS/GUARDIANS Version 1 (6th
December 2005) -
NORMAL TERM CONTROLS
Principle Investigators: Professor Sailesh Kotecha, Consultant Neonatologist
Contact Details: Neonatal Unit, 029 20 74 3374
3. Study Title
Is chronic lung disease of prematurity a consequence of immature regulation of 
neutrophil apoptosis in preterm infants?
4. Invitation
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part.
Thank you for reading this leaflet.
3. What is the purpose of the study?
Chronic lung disease (CLD), a common disease of premature babies, is characterised 
by prolonged oxygen dependency. Cells of inflammation, called neutrophils, are 
increased in the lungs of babies who develop CLD. Neutrophils are removed from the 
lungs by a process called apoptosis. We recently showed that the removal of 
neutrophils by this process of apoptosis is increased in babies who recover from their 
lung disease but not in those who develop CLD. In addition, cells called macrophages, 
which remove the apoptotic neutrophils, were increased in babies who recovered from 
their breathing difficulties but not if they developed CLD. We wish to determine 
whether CLD develops due to immaturity of factors that normally regulate this 
process called apoptosis. In particular, we wish to determine if apoptosis of 
neutrophils is related to the prematurity of the baby.
Using blood and lung washings from babies who do and do not recover from their 
lung disease and comparing these to umbilical cord blood from healthy babies bom at 
term, we will identify whether any factors important in neutrophil apoptosis are 
deficient or the macrophages are immature in babies who develop CLD. The results 
will help us understand why some babies progress to develop CLD whilst others 
recover and may help us develop therapies which can enhance apoptosis.
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4. Why have I and/or my baby been chosen?
We wish to obtain samples from three groups of babies:
(c) babies who are bom at or less than 32 weeks gestation and who need help with 
their breathing with breathing machines because of under-developed lungs, or
(d) babies who need help with their breathing with breathing machines because of 
non-breathing problems e.g. surgery.
(e) babies bom at term (more than 37 weeks gestation) who are healthy
We would like to ask you to join our study as you have had a normal pregnancy and 
use the blood from the umbilical cord as controls (group c) to compare the results 
from premature babies (groups a and b).
5. Does my baby have to take part?
It is up to you to decide whether or not you want your baby to take part. If you do 
decide that your baby can take part, you will be given this information sheet to keep 
and be asked to sign a consent form. If you decide for your baby to take part, you are 
still free to withdraw your baby at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care 
that your baby receives.
What will happen if my baby takes part?
We would like to obtain blood (about a teaspoon) from the umbilical cord when the 
baby is bom.
7. Will this affect my or my baby’s treatment?
The medical care of you or your baby will not be affected by this study. The 
information from this study will not be used to diagnose or treat you or your baby.
8. What will happen to the samples collected?
We will first separate the cells and fluid from the blood samples collected. We will 
determine the proportion of different cell types and also how many neutrophils are 
apoptotic by using modem techniques which can look at the small number of cells 
obtained from babies. We will use the fluid to measure or identify proteins which 
promote or inhibit apoptosis. Some fluid and cell samples will be sent to Professor 
Moira Whyte’s group in Sheffield as they have specific expertise in apoptosis of 
neutrophils. They will work together with us in identifying any particular factors 
which may be increased or decreased in babies who develop CLD.
9. What are the risks of my baby taking part?
The cord blood sample will be taken after the umbilical cord has been cut and is not 
harmful or painful for you or your baby.
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10. What if something goes wrong?
If your baby is harmed by taking part in this research project, there are no special 
compensation arrangements. If your baby is harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you or your baby have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be 
available to you.
11. Will my baby’s taking part be kept confidential?
All information which is collected about your baby during the course of the research 
will be kept strictly confidential. Any information about your baby which leaves the 
hospital will have your and the baby’s name and address removed so that you cannot 
be recognised from it. We will assign a number to each baby and use this to label the 
samples obtained for the study.
12. What will happen to the results of the study?
We will publish the results in reputable medical journals and present the data at 
scientific and medical meetings. Your baby’s name and details will NOT be revealed 
at any stage. Please let us know if you would like a copy of the report.
13. Who is paying for the study?
The study is funded by the Wellcome Trust which is a major medical charity in the 
UK.
14. Who had reviewed the study?
This study has been reviewed by the South East Wales Research Ethics Committee 
and also by the Wellcome Trust who have funded the study.
15. Who can 1 contact for further information?
You may contact Professor Sailesh Kotecha by asking one of the staff on the delivery 
suite or by telephoning 029 20 74 3374 or by email (KotechaS@Cardiff.ac.uk) or by 
mail to: Professor Sailesh Kotecha, Neonatal Unit, Heath Hospital, Heath Park, 
Cardiff CF14 4XN.
Thank you for taking time to read this information leaflet. Please do not hesitate 
to ask Professor Sailesh Kotecha or Dr Nicola Maxwell if you would like to 
discuss anything further.
Dr Nicola Maxwell Professor Sailesh Kotecha
Clinical Research Fellow Consultant in Neonatal Medicine
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G I G
C Y M R U
NHS
W A L E S
B w rdd  lechyd Prifysgol 
C aerdydd  a 'r  Fro
C a rd iff and  Vale 
U n ive rs ity  H ea lth  Board
Eich cyf/Your ref 
Ein cyf/Our ref
Welsh Health Telephone Network 1872 
Direct Line/Llinell uniongychol
Ysbyty Athrofaol Cymru
University Hospital of Wales
Heath Park,
Cardiff, CF14 4XW 
Phone 029 2074 7747 
Fax 029 2074 3838 
Minicom 029 2074 3632
Parc Y Mynydd Bychan, 
Caerdydd, CF14 4XW 
Ffon 029 2074 7747 
Ffacs 029 20743838
Minicom 029 2074 3632
Patient Identification Number for this study:
CONSENT FORM - Controls
Is chronic lung disease of prematurity a consequence of immature regulation of 
neutrophil apoptosis in preterm infants?
Name of R e se a rc h e r :  P r o f e s s o r  S a i le sh  K o tech a ,  C o n s u l ta n t  N eonato log is t ,
N eonata l Unit, Heath  H ospita l ,  Cardiff CF14 4XN
P le a s e  initial box
1. I confirm that I have read and understand the information sheet dated 
6th December 2005 (version 1) for the above study and have had the 
opportunity to ask questions.
2. I understand that my baby’s participation is voluntary and that I am 
free to withdraw my baby at any time, without giving any reason, 
without my baby’s medical care or legal rights being affected.
3. I understand that sections of any of my baby’s medical notes 
may be looked at by the research individuals I give permission for 
these individuals to have access to my baby’s records.
4. I agree for my baby to take part in the above study.
□
□
□
□
Name of Parent/Guardian Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 for patient, 1 for researcher, 1 to be kept with hospital notes.
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Appendix 2 
Flow cytometry staining templates
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Delayed Neutrophil Apoptosis may predispose to Lung Injury in Chronic Lung 
Disease of Prematurity
Nicola C. Maxwell, Philip L. Davies, O. Brad Spiller, Eamon P. McGreal, Sailesh 
Kotecha
Department o f  Child Health, C ardiff University, Cardiff, United Kingdom  
Introduction:
The pathogenesis of Chronic Lung Disease of prematurity (CLD) involves 
interactions between numerous factors. Neonatal Respiratory Distress Syndrome 
(RDS) is characterised by alveolar neutrophil (PMN) infiltration, which disappears as 
RDS resolves (1). Persistence of PMN infiltration is strongly associated with the 
development of CLD (2,3). PMN apoptosis is important in regulation and resolution 
of inflammation. Apoptosis causes functional downregulation of PMN. Recognition 
and clearance of PMN by macrophages further downregulates the inflammatory 
response. Developmental immaturity of the neonatal immune system is well 
recognised (4). Several recent studies have shown reduced apoptosis, both 
spontaneous and induced, in neonatal compared to adult neutrophils (5,6,7,8). The 
reasons for this are unclear. There is currently no published data regarding rates of 
apoptosis in preterm neutrophils.
Hypotheses:
There is increasing dysregulation of neutrophil apoptosis with decreasing gestational 
age.
Dysregulation of neutrophil apoptosis in preterm infants contributes to development 
of CLD.
Aim:
We compared rates of apoptosis of PMN between adult peripheral blood and cord 
blood from term infants and tried to elucidate underlying mechanisms for the 
differences noted.
Method:
PMN were isolated from adult peripheral blood and from umbilical cord blood from 
term infants delivered by elective caesarean section (n= 6 adult/cord pairs). PMN 
were cultured in the presence or absence of lipopolysaccharide (LPS)(50ng/ml) and 
assessed at baseline and then 6, 12 and 20 hours from commencement of culture for 
apoptosis by flow cytometry, using Annexin-V-PE (MBL International) and To-Pro-3 
(Invitrogen). Cells positive for Annexin-V and To-Pro-3 were considered necrotic and 
those positive for Annexin-V alone were apoptotic. Activity of the apoptotic effector, 
caspase 3 (Apo-Logix®, Peninsula Laboratories) and anti-apoptotic regulator, Bax 
(monoclonal phycoerythrin-conjugated mouse anti human Bax (2D2), Santa Cruz 
Biotechnology), were similarly assessed.
Results:
PMN from cord blood underwent apoptosis at a significantly slower rate than adult 
PMN (p<0.02 at 6, 12 and 20 hours) although there was no significant difference in 
the number of apoptotic cells in the fresh samples (p=NS). The addition of LPS 
reduced adult PMN apoptosis significantly by 12 hours (p=0.04) but did not reduce 
cord PMN apoptosis. Caspase 3 is a key executioner of apoptosis and its activation is 
an early apoptotic event. It is able to activate other caspases as well as cleave 
cytoskeletal components. Caspase 3 activation reaches similar levels in cord and adult 
neutrophils undergoing apoptosis in culture, both with and without LPS. However,
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despite similar levels of caspase 3 activation, neonatal neutrophils remain resistant to 
apoptosis. Possible mechanisms for this are neonatal caspase 3 is inefficient or a 
molecule or pathway necessary for apoptosis but distal to caspase 3 activation is 
deficient or inhibited. Bax is a pro-apoptotic member of the Bcl2 group of apoptotic 
regulators. Within the cell, mitochondria sequester pro-apoptotic proteins e.g. 
cytochrome c which are released under the influence of Bax. Bax activity, similar to 
adult levels is seen in cord blood neutrophils in culture, despite levels of apoptosis in 
cord neutrophils being suppressed. The significance of this result has yet to be 
assessed.
Conclusion:
Term infant PMN undergo apoptosis at a slower rate than adult PMN. These 
differences were not due to caspase 3 or Bax activity suggesting an alternative 
mechanism for the differences in apoptosis we have noted. This may be exaggerated 
with decreasing gestation, hence contributing to the development of CLD.
Future aims/questions:
Determine the impact of gestational age on the rate of neutrophil apoptosis 
(spontaneous and induced). We will compare neutrophil apoptosis in preterm infants 
bom following spontaneous preterm labour, where subclinical infection is a leading 
cause of preterm delivery, with neutrophil apoptosis in infants bom electively preterm 
for a maternal indication or foetal growth restriction.
Further investigate possible mechanisms for alterations in the rate of neutrophil 
apoptosis in infants. Term cord blood neutrophils undergo apoptosis more slowly than 
adult neutrophils but levels of caspase 3 activation appear remarkably similar. This 
initial data implies that there may be a defect in the apoptotic pathway distal to 
caspase 3. We plan to investigate other caspases as well as other pro-(Bak, Bad) and 
anti-apoptotic (Al, BclXL) Bcl2 family members to possibly explain the mechanism 
of reduced apoptosis in cord neutrophils.
Dr Maxwell is supported by the Wellcome Trust and Dr Davies by Arriva 
Pharmaceuticals.
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The Role of Proteases in the Development of Chronic Lung Disease of 
Prematurity
Philip L. Davies, O. Brad Spiller, Nicola C. Maxwell, Sailesh Kotecha 
Department o f  Child Health, C ardiff University, Cardiff, United Kingdom
Introduction
Proteases are enzymes that hydrolyse proteins. They are produced by a number of cell 
types within the lung, including inflammatory cells such as neutrophils, where they 
play a key role in host defence and airway remodelling. An imbalance of neutrophil 
proteases (elastase and matrix metalloproteinases, MMP-9) and anti-proteases (alpha 
1-antitrypsin and tissue inhibitors of matrix metalloproteinases, TIMPs) has been 
implicated in the development of classical Chronic Lung Disease of prematurity 
(CLD). “New” CLD affects extremely preterm infants and is thought to represent an 
aberration of lung growth.
Aims
To assess the proteolytic balance in infants with new CLD and to examine 
relationships between proteolytic changes.
Methods
Ventilated preterm infants (<32 weeks gestation) and term controls underwent serial 
bronchoalveolar lavages (BAL) performed until extubation. Elastase activity assays 
were performed using a specific chromogenic substrate (Bachem, St Helens, UK) 
against a standard curve of neutrophil elastase (Athens Research and Technology,
GA, USA). Total MMP-9 and MMP-9/TIMP-1 ELIS As (R&D Systems, Minneapolis, 
USA) were performed on all samples .
Results
48 infants were recruited. 20 developed CLD, 17 had respiratory distress syndrome 
(RDS) that resolved, 5 died and 6 were term controls. The demographic profile of 
these infants is shown on table 1. Peak total MMP-9 was significantly greater in 
infants who developed CLD (median 763ng/ml) compared to infants with resolved 
RDS (median 47ng/ml), p=0.003, figure 1. Peak MMP-9/TIMP1 complex was also 
significantly greater in CLD infants (median 29.9ng/ml) compared to resolved RDS 
infants (median 1.5ng/ml), p=0.004. Elastase activity was only detected in a minority 
of samples but was present in at least one sample from more CLD infants (10/20) than 
resolved RDS infants (2/17), p=0.013.
Peaks of MMP-9, MMP-9/TIMP-1 complex and elastase tended to coincide and 
frequently occurred late figure 2. There was a strong correlation between log MMP-9 
and log MMP-9/TIMP-1 R=0.89 and a moderate correlation between log elastase 
activity and log MMP-9 R=0.63.
Conclusions
Peak MMP-9, MMP-9/TIMP-1 complex and elastase were increased in CLD infants 
although protease levels were generally less than in classical CLD. Episodic peaks in 
MMP-9 concentrations occurred for individual infants who underwent longitudinal 
sampling and these were temporally related to concentrations of MMP-9/TIMP-1 
complex and if present neutrophil elastase activity. It remains to be seen if these 
smaller increases in proteases adversely affect lung growth that occurs in “new” CLD. 
Speculation
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The underlying cause of the episodic increases in proteolytic activity continues to be 
investigated, however, infection remains a likely factor. Proteases are key to the 
neutrophil’s bactericidal activity and we speculate that infection triggers proteolytic 
release that may cause lung injury.
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Comparison of Neutrophil Elastase in Adults and Cord Blood from Term Infants
Philip L. Davies, Nicola C. Maxwell, O. Brad Spiller, Sailesh Kotecha 
Department o f  Child Health, C ard iff University, Cardiff, United Kingdom
Introduction
Neutrophil elastase (HNE) is important in the antimicrobial defence of the lung and 
may also be important in the development of chronic lung disease of prematurity 
(CLD). Infants are at greater risk of lung infection than adults and infant maturity is 
important in the changing pattern of CLD.
Aims
To assess differences in newborn and adult neutrophil elastase that may account for 
differences in lung pathology.
Methods
Neutrophils were isolated from newborn cord and adult blood using histopaque-1077 
(Sigma Aldrich, Irvine,UK) and the cells resuspended to a million cells/ml in Hanks 
buffered saline. Cells were stimulated with the following inflammatory stimulants: 
N-formyl-methionyl-leucyl-phenylalanine (fMLP), cytochalasin B, cytochalasin B 
and fMLP, cytochalasin B and lipopolysaccharide (LPS) or cytochalasin B and 
interleukin-8 (IL-8) at 1:1000 for 10 minutes or they received no stimulation. 
Stimulants were chosen as they represented a spectrum of potency in their ability to 
activate neutrophils. The solution was centrifuged at 13000rpm for 10 minutes and the 
supernatant removed. The cell pellet was then dissolved using distilled water and 
Triton X for two hours. Elastase activity was determined using a specific 
chromogenic substrate, Sue -  Ala -  Ala -  Pro -  Val - pNA (Bachem, St Helens, UK) 
on the supernatant and cellular fractions.
Results
Ten full term cord blood samples and ten adult blood samples were analysed. The 
total elastase present in unstimulated neutrophils was significantly lower from cord 
blood (mean 15.2 +/-5.2nM) compared to adult blood (25.2 +/-8.4nM), p=0.007. 
Cytochalasin B in combination with fMLP proved to be the most effective stimulus. 
The proportion of neutrophil elastase released by cord blood and adult blood was not 
significantly different for any of the stimuli. (fMLP 15.9% cord vs 12.2% adult; 
cytochalasin B 12.6% vs 8.9%; cytochalasin B and fMLP 66.3% vs 72.7%; 
cytochalasin B and LPS 14.0% vs 10.9% and cytochalasin B and IL-8 21.3% vs 
20.9%).
Conclusions
Adult neutrophils contain significantly greater total elastase than cord blood 
neutrophils, although similar proportions of elastase are released by the different 
inflammatory stimulants.
Reduced elastase content of neutrophils with reduced maturity may be important in 
explaining differences in lung pathology observed in the neonatal lung.
The study was sponsored by Arriva Pharmaceuticals and a grant by the Wellcome 
Trust.
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Ureaplasma in Chronic Lung Disease of Prematurity -  Strains, Resistance and 
Treatment
Nicola C. Maxwell, Michael L. Beeton, O. Brad Spiller and Sailesh Kotecha 
Department o f  Child Health, School o f  Medicine, C ardiff University, Cardiff, United 
Kingdom
Background:
The role of Ureaplasma in chronic lung disease of prematurity (CLD) remains 
controversial. In 2005, a meta-analysis (2216 babies, 23 studies) showed an odds ratio 
of 2.83 (2.29-3.51) for the relationship between the presence of Ureaplasma and CLD 
at 28 days of life (1).
Less is known about the role of antimicrobial treatment for the prevention of CLD. 
Two randomised controlled trials (2,3) of erythromycin used to eradicate Ureaplasma 
and prevent CLD have been performed. Together the studies include only 37 
colonised patients. There was no significant reduction in CLD with treatment in either 
study -  disparate study designs prevented the results from being combined in the 
meta-analysis (4).
Aim:
To further elucidate the role of Ureaplasma in CLD by examining different strains and 
the relationship between its treatment and clinical outcome.
Method:
Serial bronchoalveolar lavage (BAL) was performed on 26 infants <32 weeks 
gestation. BAL fluid was cultured for presence of Ureaplasma and confirmed by 
polymerase chain reaction (PCR). Further PCR was used to determine species, either 
Ureaplasma parvum (Up) or Ureaplasma urealyticum (Uu). All isolates were tested 
for antibiotic resistance using a novel microbroth dilution method.
Results:
Of 26 infants, 10 had Ureaplasma isolated from BAL. Moderate or severe CLD 
developed in 8/9 infants with Ureaplasma and 7/16 infants without (p=0.027). 
Sequencing showed 7/10 were Up and 2/10 Uu (1 not identifiable). Five of the infants 
received treatment for Ureaplasma, at the discretion of the infant’s consultant 
neonatologist, from day 5 of life at the earliest. Ureaplasma was successfully 
eradicated following treatment in 2 babies (both Up, one treated with erythromycin 
and the other with clarithromycin) and it recurred after treatment in a third (Uu). In 
one infant a highly erythromycin resistant strain of Up was isolated. One infant died. 
All surviving treated infants developed CLD. Up appeared to clear spontaneously 
from a sixth infant. The mutation thought to be responsible for eruthromycin 
resistance was characterised and a 6 base pair (corresponding to 2 amino acids -  Arg 
and Gin) deletion, was characterised.
Conclusion:
Up is the more frequently isolated Ureaplasma in preterm infants. Erythromycin 
resistance was noted in one infant and the molecular mechanism characterised. 
References:
1. Schelonka RL et al. Critical appraisal of the role of Ureaplasma in the development 
of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 
2005 Dec;24(12): 1033-9.
411
2. Lyon AJ et al. Randomised trial of erythromycin on the development of chronic 
lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998 
Jan;78(l):F10-4.
3. Jonsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and 
respiratory morbidity in high-risk preterm neonates. Acta Paediatr. 1998 
Oct;87(10): 1079-84.
4. Mabanta CG et al. Erythromycin for the prevention of chronic lung disease in 
intubated preterm infants at risk for, or colonized or infected with Ureaplasma 
urealyticum. Cochrane Database Syst Rev. 2003(4):CD003744.
Dr Maxwell is supported by the Wellcome Trust.
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The Relationship between Chronic Lung Disease of Prematurity and Ureaplasma 
s p p A Survey of Senior Neonatologists
Nicola C. Maxwell, Diane E. Nuttall, O. Brad Spiller and Sailesh Kotecha 
Department o f  Child Health, School o f  Medicine, C ardiff University, Cardiff, United 
Kingdom  
Background:
A 1995 meta-analysis (1479 babies, 17 studies) (1) found a significant association 
between chronic lung disease of prematurity (CLD) at 28 days of life and Ureaplasma 
urealyticum  colonisation. In 2005, a further meta-analysis (2216 babies, 23 studies) 
showed an odds ratio of 2.83 (2.29-3.51) for the relationship between the presence of 
Ureaplasma and CLD at 28 days of life (2). Two randomised controlled trials (3,4) 
were included in a Cochrane review of erythromycin used to eradicate Ureaplasma 
and prevent CLD (5). Together the studies included only 37 colonised patients and 
there was no significant reduction in CLD with treatment in either study -  disparate 
study designs prevented the results from being combined in the meta-analysis.
Aim:
To seek the views of senior UK neonatologists on whether Ureaplasma spp. is 
important in the development of chronic lung disease of prematurity and to gauge the 
need for a randomised control trial to determine if CLD can be prevented by treatment 
of Ureaplasma.
Method:
A structured questionnaire consisting of 18 questions was sent to 300 consultant 
neonatologists and paediatricians with a special interest in neonatology working in 
UK neonatal units.
Results:
Fifty seven percent (172/300) of questionnaires were returned. Of the 172 
respondents, 137 were consultant neonatologists while the remainder were 
paediatricians with a special interest in neonatal medicine. One hundred and twenty 
five worked in level 3 intensive care units.
Most respondents felt that there was neither evidence in favour of Ureaplasma spp. 
causing CLD nor any evidence to show that it did not. The respiratory colonisation 
rate of preterm infants with Ureaplasma spp. was unclear as few units tested for the 
organism regularly. Of the 102 respondents who said they ever tested for Ureaplasma, 
the samples sent varied widely in type and timing. Endotracheal secretions were the 
most frequent Sample sent for testing, with many units sending more than one sample 
type. The most common time to send a sample for Ureaplasma was in relation to the 
patient’s clinical condition rather than samples being sent routinely. Only 49/172 
(28%) consultants were able to estimate the number of infections seen each year, with 
most saying they were unable to answer the question due to lack of testing. Fifty nine 
percent (59%) said that they would be interested in an affordable test to identify 
Ureaplasma spp.. There was a very strong call (68%) for a randomised trial involving 
infants bom between 23 -  28 weeks gestation to address this controversy. A majority 
of consultants favoured erythromycin as a treatment for Ureaplasma with the duration 
of treatment chosen as 7-14 days (range 3-28 days, mode 14 days). Just under half 
were concerned about possible adverse effects of dmg treatment to eradicate 
Ureaplasma spp. in this group of patients, with most respondents concerned about 
gastrointestinal effects of erythromycin, antibiotic resistance, alterations to normal
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microbial flora and phlebitis causing difficulties with venous access in the smallest 
preterm infants.
Within a trial, a majority (71/117) were in favour of delaying the start of treatment 
until results of testing for U reaplasm a were available, however opinion was divided 
(Yes 48, No 45, Don’t know 24) as to whether such a delay in starting treatment 
would mean that it would be too late to be of benefit.
Conclusion:
There is no clear view among neonatologists regarding the role of Ureaplasma spp. in 
the development of CLD. However, there was a clear call for a randomised controlled 
trial to determine if eradication of Ureaplasma spp. decreases the development of 
CLD.
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Appendix 4 
Table of data
Clinical information
Babv Gestation
Weieht
Diagnosis
Vent. Oxvcen
dPROM
Antenatal
infection
Deliveryfkfi) Davs davs susDected
A Term 2.8 Term 2 2 no no Vaginal
B 25+5 0.74 CLD 22 44 yes yes Vaginal
C 31+2 1.92 RDS 1 0 yes yes Vaginal
D 25+4 0.84 RDS 12 12 no no Vaginal
E 28 0.91 CLD 3 20 no no Caesarean
F 31 1.69 RDS 2 3 yes yes Caesarean
G 25+3 1.04 CLD 31 63 no no Vaginal
H Term 3 Term 9 30 no no Caesarean
I 26+6 1 RDS 18 47 no no Vaginal
J 27 0.7 RDS 18 32 yes yes Caesarean
K Term 2.81 Term 3 3 no no Caesarean
L 27 0.85 CLD 35 36 no no Caesarean
M 28+4 1.31 RDS 5 2 yes yes Vaginal
N 25+3 0.79 CLD 29 67 no yes Vaginal
O 26 0.74 CLD 58 101 yes yes Vaginal
P 26+5 0.87 Died 5 5 no yes Vaginal
9 25+4 0.76 CLD 43 107 no no Vaginal
R 29+3 1.02 CLD 44 107 no no Caesarean
S 26+4 0.89 RDS 10 18 no yes Caesarean
T 26+4 1.04 RDS 13 18 no yes Caesarean
U 28+3 1.18 CLD 17 75 no yes Caesarean
V 28+3 1.08 CLD 12 75 no yes Caesarean
w 24+4 0.69 CLD 49 89 no no Vaginal
X Term 2.63 Term 5 2 no no Vaginal
Y 26+2 0.9 CLD 88 154 no yes Vaginal
Z 26+2 1.08 CLD 28 69 no yes Vaginal
AA Term 2.57 Term 4 1 no no Caesarean
BB 23+4 0.56 CLD 45 86 no no Vaginal
CC 27+1 1.23 CLD 36 109 no no Caesarean
DD 28 0.91 RDS 16 44 no no Caesarean
EE 24+2 0.67 CLD 39 45 no no Vaginal
FF 27+1 1.18 RDS 1 1 no no Vaginal
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Babv Dav Gest Wt Dx Cell count Abs CD14 Abs CD36 Abs HLADR PMN%
A 1 38 2.8 Term 1.04 0.1401 0.053664
AA 1 38.428 2.57 Term 0.6857 0.0644 0.0445705 0.07083281 9.06
2 38.428 0.7182 0.1366 0.05307498 0.1217349 26.48
B 1 25.714 0.74 CLD 4.66 0.1154 0.270746
2 25.714 9.99 0.2804 0.403596
3 25.714 2.4 0.3333 0.20064
4 25.714 3.24 0.2828 0.308124
5 25.714 5.88 1.059 0.944328
6 25.714
7 25.714 1.22 1.0325 0.179096
9 25.714 1.34 1.2726 0.230212
BB 1 23.57 0.56 CLD 2.35 0.1859 0.13583 0.120085 24.62
2 23.57 0.9429 0.8766 0.05035086 0.0452592 41.73
3 23.57 2.5667 1.2912 0.23921644 0.16503881 33.3
4 23.57 4.1625 1.2672 0.39585375 0.46953 40.81
5 23.57 9.675 3.0495 2.145915 1.124235 59.97
6 23.57 5.9 1.1526 1.14932 1.4278 5.5
7 23.57 4.44 2.0517 1.044732 1.070484 22.13
9 23.57 4.5 2.9673 1.18935 1.0701 40.68
13 23.57 2.08 3.8064 0.625872 0.622128 13.89
16 23.57 1.5 4.192 0.3255 0.3681 40.56
20 23.57 3.75 5.628 0.75 0.823875 45.41
23 23.57 0.7 6.0237 0.1785 0.16723 28.26
C 1 31.857 1.92 RDS 1.14 0.0769 0.026562
CC 2 27.143 1.23 CLD 0.9667 0.4822 0.04205145 0.02494086 17.64
3 27.143 0.8462 0.4593 0.03494806 0.03697894 11.54
4 27.143 0.71 0.4492 0.063545 0.037204 10.34
5 27.143 1.54 0.3255 0.165704 0.141218 12.64
6 27.143 1.42 0.6204 0.169406 0.30317 11.44
7 27.143 1.8923 0.4235 0.26094817 0.30712029 1.86
9 27.143 1.5938 0.9513 0.26887406 0.6526611 12.62
13 27.143 0.7538 2.3166 0.12558308 0.23450718 6.67
16 27.143 1.8789 4.3984 0.50899401 0.79007745 15.42
20 27.143 0.8867 5.738 0.20163558 0.3795076 28.37
D 2 25.57 0.84 RDS 2 0.1572 0.1442
3 25.57 1.46 0.2148 0.046574 0.1898 1.91
4 25.57 3.2 0.196 0.1792 0.28128 11.76
5 25.57 3.14 0.578 0.2198 0.20567 28.5
6 25.57 2.04 0.7926 0.073032 0.04386 58.39
7 25.57 3.33 0.6265 0.177156 0.113886 35.21
DD 1 28 0.91 RDS 0.5333 0.04042414 0.03050476 2.57
2 28 0.7 0.2152 0.05908 0.01932 5.06
E 1 28 0.91 RDS 4.4 0.0684 0.30448
NC% % debris CD14hiMNC Abs PMN Abs MNC Abs mono PMN:MNC Elastase 16s Uu
0 0 0
10.33 80.61 1.49 0.0621244 0.0708328 0.0102169 2.23703704 0 1 0
16.95 56.57 1.62 0.1901794 0.1217349 0.0116348 5.13178295 0 0 0
0 1 0
0.295 1 0
5.5 0 0
58.1 0 0
20.655 0
6.44 0 0
0 0
0 0 0
5.89 69.49 4.85 0.57857 0.138415 0.113975 4.17996604 0 0 0
7.64 50.63 8.74 0.3934722 0.0720376 0.0824095 5.46204188 0 0
9.32 57.38 9.26 0.8547111 0.2392164 0.2376764 4.3134715 0 0
11.28 47.91 11.24 1.6987163 0.46953 0.467865 4.32767762 0 0 0
25.84 14.19 21.69 5.8020975 2.50002 2.0985075 2.32082043 0.19 1 0
39.12 55.38 16.26 0.3245 2.30808 0.95934 0.14059305 0 1 0
61.64 16.23 10.34 0.982572 2.736816 0.459096 0.35902012 0 1 0
26.43 32.89 1.8306 1.18935 1.62915499 0 1 0
30.09 56.02 27.56 0.288912 0.625872 0.573248 0.50380849 0 1 0
24.54 34.9 20.78 0.6084 0.3681 0.3117 1.69140951 0 0 0
29.87 24.72 25.82 1.702875 1.120125 0.96825 1.52025444 0 0 0
25.63 46.11 23.83 0.19782 0.17941 0.16681 1.10261412 0 0 0
0 0 0
5.63 76.73 5.34 0.1705259 0.0544252 0.0516218 3.13321492 0 1 0
4.48 83.98 4.49 0.0976515 0.0379098 0.0379944 2.57589286 0 1 0
8.95 80.71 4.98 0.073414 0.063545 0.035358 2.20940171 0.245 1 0
13.66 73.7 2.19 0.194656 0.210364 0.033726 0.92532943 0.53 1 0
21.35 67.21 2.82 0.162448 0.30317 0.040044 1.10960233 0 1 0
16.23 81.91 1.46 0.0351968 0.3071203 0.0276276 0.54705882 0 1 0
40.95 46.43 0.2011376 0.6526611 1.20534862 0 0
31.11 62.22 11.25 0.0502785 0.2345072 0.0848025 0.27493817 0 0 0
42.05 42.53 24.61 0.2897264 0.7900775 0.4623973 0.38588589 0 1 0
42.8 28.83 23.94 0.2515568 0.3795076 0.212276 0.93016393 0 0 0
7.21 92.79 0.1442 0 0 0
19.93 78.16 0.027886 0.290978 0.09583542 0 0 0
18.06 70.18 0.37632 0.57792 0.65116279 1.59 1 0
15.14 56.36 0.8949 0.475396 1.88243065 2.12 0 0
16.9 24.71 1.191156 0.34476 3.45502959 18.69 0 0
12.36 52.43 1.172493 0.411588 2.8487055 0 1 0
7.58 89.85 0.0137058 0.0404241 2.35779817 0 0 0
8.44 86.5 1.96 0.03542 0.05908 0.01372 2.28959276 0 0 0
0 0 0 0
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Day Gest Wt Dx Cell count Abs CD14 Abs CD36 Abs HLADR PMN%
1 28.57 1.31 RDS 9 0.4216 2.6901 3.7953 40.11
2 28.57 1.6222 0.4662 0.14908018 0.20212612 55.21
3 28.57 1.12 0.7701 0.10864 0.224 52.62
1 25.428 0.79 CLD 2.6364 0.0969 0.85498452 0.48694308 36.8
2 25.428 0.3429 0.0037719 0.01676781 10.53
3 25.428 2.3091 0.4257 0.03117285 0.09767493 18.57
4 25.428 10.9091 0.278 0.72763697 0.981819 59.27
5 25.428 7.0077 0.442 0.45409896 0.26348952 46.56
6 25.428 5.8 0.63 0.4031 0.47966 60.78
7 25.428 7.8 0.5411 0.5343 0.20592 42.42
13 25.428 3.6667 0.7605 0.83564093 0.97680888 50.47
1 26 0.74 CLD 0.3636 0.0395 0.00785376 0.00705384 7.41
2 26 2.65 0.2618 0.20405 0.249895 33.79
3 26 2.9846 0.3078 0.28413392 0.20802662 34.61
5 26 0.6667
6 26 1.7143 0.3042 0.06325767 0.06754342 25.67
7 26 10.1 1.4798 0.59893 0.15756 69.15
9 26 5.3571 0.6813 0.32731881 0.32946165 58.2
13 26 1.3143 2.509 0.14207583 0.07162935 58.98
16 26 2 4.9104 0.391 0.6344 27.09
20 26 0.6667 10.706 0.17634215 0.35248429 1.11
23 26 1.2333 1.1799 0.05907507 0.04045224 4.21
27 26 0.1833 57.64
31 26
1 26.714 0.87 Died 2.3182 0.035 0.02040016 0.02735476 3.9
2 26.714 3.825 0.0736 0.055845 0.0677025 3.69
3 26.714 5.3333 0.3717 0.43679727 1.50772391 1.84
5 26.714 12.3
1 25.57 0.76 CLD 1.4571 0.2226 0.04050738 0.08626032 1.1
2 25.57 2.16 0.3074 0.26028 0.150768 2.8
3 25.57 1.44 0.7851 0.286848 0.398736 0.75
4 25.57 0.775 0.208 0.0501425 0.0712225
5 25.57 0.7429 0.304 0.04249388 0.09033664 4.76
6 25.57 0.8 1.8912 0.19264 0.41368 3.87
7 25.57 0.35 44.19
9 25.57 2.6286 3.6153 0.96233046 1.42838124 14.01
13 25.57 0.4133 4.1925 0.16403877 0.20850985 8.98
16 25.57 0.3 3.7888 0.06198 0.06339 27.31
20 25.57 0.08
23 25.57 0.1333
27 25.57 0.7143 7.5168 0.30229176 0.32036355 15.32
MNC% % debris CD14hiMNC Abs PMN Abs MNC Abs mono PMN:MNC Elastase 16s Uu
44.44 15.45 33.24 3.6099 3.9996 2.9916 0.90256526 0 0 0
25.52 19.27 10.99 0.8956166 0.4139854 0.1782798 2.16340125 0 0 0
49.69 15.56 0.589344 0.556528 0.174272 1.05896559 0.745 0 0
36 27.2 5.7 0.9701952 0.949104 0.1502748 1.02222222 0 0 1
10.06 79.41 0.0361074 0.0344957 1.04671968 0 0 1
4.23 77.2 1.28 0.4287999 0.0976749 0.0295565 10.5511364 0 0 1
9 31.73 4.91 6.4658236 0.981819 0.5356368 10.2720971 15.13 1 1
19.27 34.17 6.72 3.2627851 1.3503838 0.4709174 2.41619097 28.765 1 1
8.27 30.95 5.67 3.52524 0.47966 0.32886 7.81233933 17.1 1 1
6.85 50.73 4.72 3.30876 0.5343 0.36816 6.98846787 21.045 0 1
31.2 18.33 16.34 1.8505835 1.1440104 0.5991388 1.61762821 43.095 0 0
2.7 89.89 0.0269428 0.0098172 2.74444444 0 1 1
21.32 44.89 0.895435 0.56498 1.58489681 0 0 1
9.52 55.87 1.0329701 0.2841339 4.89533239 0 0 1
0 0 0.5
11.34 62.99 0.4400608 0.1944016 2.26366843 3.11 0 0.5
17.47 13.38 6.98415 1.76447 3.95821408 0 1 1
9.92 31.88 3.1178322 0.5314243 5.86693548 6.73 0 1
29.36 11.66 0.7751741 0.3858785 2.00885559 0 0 1
31.72 41.19 0.5418 0.6344 0.91028226 0 0 1
61.84 37.05 0.0074004 0.4122873 0.01794955 0 0
6.47 89.32 0.0519219 0.0797945 0.65069552 0 0 0.5
14.62 27.74 0.0267985 0 0 0.5
21.92 78.08
2.44 93.66 0.0904098 0.0565641 1.59836066 0.865 0 0
1.77 94.54 0.1411425 0.0677025 2.14534884 0.975 0 1
28.27 69.89 0.0981327 1.5077239 0.12707182 0.815 0 1
26.93 60.77 0.83 0 1
14.73 84.17 0.0160281 0.2146308 0.07467753 0 0 1
13.33 83.87 0.06048 0.287928 0.21005251 0 0 1
36.91 62.34 0.0108 0.531504 0.0203197 0 0 1
9.19 90.81 0.0712225 0 0 1
12.16 83.08 0.035362 0.0903366 0.86861314 0 0 1
51.71 44.42 0.03096 0.41368 0.11292676 0 0 0.5
17.23 38.58 0.154665 0.060305 2.56471271 0 0 1
54.34 31.65 0.3682669 1.4283812 0.31307263 0 0 1
50.45 40.57 0.0371143 0.2085099 0.23538663 0 0 0
23.49 49.2 0.08193 0.07047 1.16262239 0 0 0
0 0 0
0 0 0
49.64 35.04 0.1094308 0.3545785 0.30862208 0 0 0
Babv
R
W
Dav Gest Wt Dx Cell count Abs CD14 Abs CD36 Abs HLADR PMN%
1 29.428 1.02 CLD 1.8267 0.0323 0.11398608 0.10211253 13.49
2 29.428 0.3733 0.0514 0.01224424 0.00627144 3
3 29.428 1.0625 0.1089 0.051 0.0204 3.63
4 29.428 0.3538 0.4128 0.02614582 0.0263581 20.46
5 29.428 0.6 1.332 0.06768 0.06684 41.03
6 29.428 1.04 1.4736 0.111384 0.042224 45.09
7 29.428 0.36 1.3461 0.044316 0.03888 17.11
9 29.428 0.3857 1.0827 0.05087383 0.05226235 12.4
13 29.428 1.0909 1.6575 0.12959892 0.13570796 40.98
16 29.428 0.9231 10.0672 0.32926977 0.10144869 41.73
20 29.428 1.875 5.026 0.4344375 0.1725 43.31
1 26.57 0.89 RDS 7.725 0.1992 1.259175 1.1672475 42.74
2 26.57 3.3 0.3808 0.30789 0.33891 25.09
3 26.57 3.575 0.5628 0.3557125 0.452595 52.09
1 26.57 1.04 RDS 0.5385 0.1865 0.0609582 0.03225615 12.06
2 26.57 1.3 0.1534 0.078 0.0832 6.62
3 26.57 0.6909 0.1908 0.02922507 0.03551226 11.39
4 26.57 0.4867 0.372 0.04755059 0.07013347 22.04
5 26.57 2.93 0.7345 0.359511 0.352772 69.55
6 26.57 2.1 1.0992 0.42315 0.35091 40.28
7 26.57 0.6286 0.609 0.07568344 0.08900976 30.44
1 28.428 1.18 CLD 0.6 0.0886 0.05118 0.02598 3.44
2 28.428 1.05 0.1168 0.028875 0.05565 5.59
3 28.428 0.4429 0.2094 0.02449237 0.02493527 4.55
4 28.428 0.6 0.2916 0.0231 0.04194 2.89
1 28.428 1.04 CLD 0.6154 0.0601 0.01396958 0.0230775 2.24
2 28.428 0.5385 0.2034 0.02600955 0.0341409 7.42
3 28.428 0.3333 0.3657 0.01246542 0.27
4 28.428 2.3714 0.4732 0.14536682 0.22030306 35.46
5 28.428 1.6667 0.397 0.02866724 0.16150323 4.05
3 24.57 0.69 CLD 0.633 0.6372 0.1137501 0.1998381 4.25
4 24.57 1.45 0.3384 0.04234 0.061625 4.17
5 24.57 1.6167 0.6895 0.21211104 0.17767533 39.78
6 24.57 3.8636 1.0254 0.24765676 0.164203 67.66
7 24.57 1.525 1.134 0.0666425 0.0468175 23.31
9 24.57 1.1333 1.8027 0.09576385 0.033999 19.53
13 24.57 1.97
16 24.57 0.5 0.4672 0.0481 0.0249 0.36
20 24.57 2.1667 2.766 0.25003718 0.33735519 56.85
23 24.57 2.625 8.7906 0.4704 0.5200125 21.89
27 24.57 1.57 20.8332 0.585767 0.557664 37.48
MNC% % debris CD14hiMNC Abs PMN Abs MNC Abs mono PMN:MNC Elastase 16s yu
6.24 80.27 0.2464218 0.1139861 5.29019608 0 0 0
3.28 93.72 0.011199 0.0122442 1.50753769 0 0 0
4.8 91.57 0.0385688 0.051 1.87113402 0 0 0
7.45 72.09 0.0723875 0.0263581 4.15010142 0 0 0
14.64 44.33 0.24618 0.08784 2.80259563 0 0 0
15.92 38.99 0.468936 0.165568 2.83228643 0 0 0
18.11 64.78 0.061596 0.065196 0.94478189 0 0 0
13.55 74.05 0.0478268 0.0522624 2.80542986 0 0 0
12.44 46.58 0.4470508 0.135708 3.77348066 1.91 0 0
35.67 22.6 0.3852096 0.3292698 1.27497709 25.53 0 0
23.17 33.52 0.8120625 0.4344375 2.8739217 48.7 0 0
18.11 39.15 3.301665 1.3989975 2.36002209 0 0 0
10.27 64.64 0.82797 0.33891 0 0 0
12.66 35.25 1.8622175 0.452595 6.20858164 2.25 0 0
11.32 76.62 0.0649431 0.0609582 1.75036284 0 0 0
6.4 86.98 0.08606 0.0832 2.35587189 0 0 0
6.22 82.39 0.0786935 0.042974 1.83118971 0 0 0
14.41 63.55 0.1072687 0.0701335 1.94871795 0 0 0
12.27 18.18 2.037815 0.359511 6.11697449 1.375 1 0
22.3 37.42 0.84588 0.4683 1.80627803 1.225 1 0
14.16 55.4 0.1913458 0.0890098 3.66305656 0 1 0
8.53 88.03 3.44 0.02064 0.05118 0.02064 0.88431877 0 0 0
5.3 89.11 0.7 0.058695 0.05565 0.00735 2.07037037 0 0 0
5.63 89.82 0.81 0.020152 0.0249353 0.0035875 3.20422535 0 0 0
8 89.11 3.87 0.01734 0.048 0.02322 0.36125 0 1 0
3.75 94.01 2.6 0.013785 0.0230775 0.0160004 1.19148936 0 0 0
10.32 82.26 8.87 0.0399567 0.0555732 0.047765 0.71899225 0 0 0
11.34 88.39 2.48 0.0008999 0.0377962 0.0082658 0.02380952 0 0 0
14.77 49.77 8.78 0.8408984 0.3502558 0.2082089 2.40081246 41.44 1 0
12.34 83.61 5.41 0.0675014 0.2056708 0.0901685 0.32820097 0 1 0
31.57 64.18 0.0269025 0.1998381 0.15103056 0 0 0
22.21 73.62 7.58 0.060465 0.322045 0.10991 0.18775326 0.135 0 0
20.51 39.71 5.34 0.6431233 0.3315852 0.0863318 1.93954169 0.07 0 0
66.47 -34.13 12.73 2.6141118 2.5681349 0.4918363 1.01790281 2.345 0 1
57.37 19.32 54.48 0.3554775 0.8748925 0.83082 0.40630992 0 0 1
26.26 54.21 23.62 0.2213335 0.2976046 0.2676855 0.74371668 0 0 0
52.2 45.83 16.88 0 0 0
9.62 90.02 0.0018 0.0481 0.06282723 0 0 0
15.57 27.58 4.57 1.231769 0.3373552 0.0990182 5.69639279 7.83 0 1
19.81 58.3 14.22 0.5746125 0.5200125 0.373275 1.39338001 0.295 0 1
41.52 21 0.588436 0.651864 0.9026975 0 1
Babv
X
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Day Gest Wt Dx Cell count Abs CD14 Abs CD36 Abs HLADR PMN%
1 38 2.65 Term 0.4273 0.0643 0.0029911 0.14720485 5.66
2 38 0.3333 0.2062 0.01279872 0.05772756 7.04
3 38 0.2258 0.2313 0.00704496 0.03269584 9.26
4 38 0.0714 0.7088 0.00957474 0.00588336 7.95
5 38 0.2941 2.1185 0.01196987 0.04396795 35.29
1 26.286 0.91 CLD 1.2154 0.052 0.06709008 0.0474006 1.39
2 26.286 1.0667 0.0948 0.02858756 0.02485411 1.52
3 26.286 1.4154 0.3993 0.20070372 0.36078546 0.77
4 26.286 1.4 0.4004 0.23674 0.5614 7.56
5 26.286 0.6643 0.7255 0.1155882 0 .2 2 9 9 1423 13.37
6 26.286 1.4231 0.888 0.35506345 0.35136339 9.47
7 26.286 1 0.4165 0.095 0.0351 2.67
9 26.286 0.1818
13 26.286 2.51 1.3676 0.225649 0.270076 15.38
20 26.286 5.3333 8.726 1.24372556 0.97386058 65.64
23 26.286 2.2909 14.49 1.23387874 1.42745979 31.7
27 26.286 9.1667 25.137 1.59958915 0.77825283 79.7
1 26.286 1.08 CLD 1.1455 0.0719 0.06930275 0.0368851 6.84
2 26.286 0.24 0.1808 0.016704 0.043368 10.11
3 26.286 0.5857 0.5283 0.10794451 0.17301578 1.84
4 26.286 0.5875 0.8828 0.14634625 0.216435 4.52
5 26.286 0.2917 1.153 0.06405732 0.13520295 1.96
6 26.286 0.5278 1.1886 0.09284002 0.18847738 7.77
7 26.286 5.4 4.0404 1.72314 1.01736 56.17
9 26.286 2.1875 2.4399 0.343 0.1771875 37.33
13 26.286 0.7667 3.2968 0.14889314 0.16277041 49.91
16 26.286 1.8182 1.3552 0.29891208 0.2981848 55.28
MNC% % debris CD14hiMNC Abs PMN Abs MNC Abs mono PMN.MNC Elastase 16s Uu
34.45 59.89 25.76 0.0241852 0.1472049 0.1100725 0.21603053 0 0 0
17.32 75.64 1.99 0.0234643 0.0577276 0.0066327 2.5323741 0 0 0
14.48 76.26 5.68 0.0209091 0.0326958 0.0128254 1.29691877 0 0 0
13.41 78.64 0.0056763 0.0095747 1 0 0 1
14.95 49.76 5.05 0.1037879 0.043968 0.0148521 5.82343234 1.37 0 1
5.52 93.09 0.99 0.0168941 0.0670901 0.0120325 1.26363636 0 0 0
2.68 95.8 1.32 0.0162138 0.0285876 0.0140804 0.88888889 0 0 0
25.49 73.74 17.58 0.0108986 0.3607855 0.2488273 0.04333146 0 0 0
40.1 52.34 28.12 0.10584 0.5614 0.39368 0.21129122 0 0 0
34.61 52.02 29.69 0.0888169 0.2299142 0.1972307 0.42566062 0 1
24.95 65.58 9.35 0.1347676 0.3550635 0.1330599 0.48663926 0 1 1
9.5 87.83 0.89 0.0267 0.095 0.0089 2.1023622 0 0 1
100 0 0 1
10.76 73.86 4.83 0.386038 0.270076 0.121233 2.32326284 0.805 0 1
23.32 11.04 21.2 3.5007781 1.2437256 1.1306596 5.14823529 42.21 0 1
62.31 5.99 52.27 0.7262153 1.4274598 1.1974534 0.54920305 0.585 0 0.5
32.49 17.37 7.3058599 2.9782608 1.5922558 2.45306248 44.665 1
6.05 87.11 1.55 0.0783522 0.0693028 0.0177553 3.48979592 0 0 0
18.07 71.82 0.024264 0.043368 1.93307839 0 0 0
29.54 68.62 13.51 0.0107769 0.1730158 0.0791281 0.09823812 0 0 0
36.84 58.64 34.46 0.026555 0.216435 0.2024525 0.12932761 0 0
46.35 51.69 0.0057173 0.135203 0.05172869 0 0 1
35.71 56.52 10.34 0.0410101 0.1884774 0.0545745 0.42762796 0 0 1
35.89 7.94 21.98 3.03318 1.93806 1.18692 1.56505991 0.905 0 1
15.68 46.99 8.59 0.8165938 0.343 0.1879063 3.90073145 0 0 1
21.23 28.86 17.91 0.38266 0.1627704 0.137316 2.35091851 0 0 1
16.44 28.28 3.21 1.005101 0.2989121 0.0583642 3.89021816 2.925 0 0.5
Babv Pay IL-lb IL-8 MCP-1 IL-6 IL-10 GCSF GMCSF
A 1 70.3453 5791.58 9357.713 726.3317 1.28464 287.3604 0
AA 1 67.2839 10360.1 30647.22 3120.22 0 999.6245 0
2 131.912 17922.9 56478.3 2187.09 0 432.5354 0
B 1 1369.23 35459.7 39885.23 18899.85 513.643 17313.54 0
2
o
347.935 14407.6 67580.27 4094.246 315.355 2609.948 0
o
4
5
1680.52 79409.7 83389.4 3105.888 81.1012 7499.903 0
6
7 626.473 26324.7 19828.29 2085.096 18.3552 2452.839 0
9 118.502 21817.1 20113.5 731.0233 20.1529 1365.972 0
BB 1 99.015 24492.8 15422.08 10793.76 162.178 5739.828 0
2 63.3337 8623.21 5718.847 3249.34 10.0621 663.9006 0
3
4
5
906.752 65683.2 66179.76 9303.98 200.41 13165.38 0
6
7 2288.26 132500 78821.06 11333.99 246.783 9921.275 0
9
13
2005.72 73942 86587.49 5663.87 16.0848 7418.799 0
16
20
1745.54 23763 54218.06 2482.1 16.6085 2506.602 0
C
23
1
1142.64
13.5776
17904.5 38582.13 1200.23 0
1.83212
2050.711
115.714
0
0
CC 2 356.817 19123.7 10652.95 4219.38 0 3160.365 0
3
4
5
3639.54 92231 29267 18924.49 0 19140.1 0
6
7 3788.77 131949 78085.17 25819.98 0 35034.01 42.28798
9
13
16
20
273.926 51668.3 83775.25 2240.68 0 3820.884 14.42969
D 2
q
150.951 44122.5 63909.42 1749.58 0 714.3317 0
o
4
5
882.921 30049.3 46875.42 2057.29 21.679 9927.382 0
6
7 3399.44 185004 86587.49 12349.06 59.0532 17456.6 4.244753
DD 1 38.8554 317.286 980.2672 784.37 0 253.4785 0
E
2
1
63.5926 587.193 3319.148 88.57 0 443.6557 0
IIP1a MIP1b TNF FasL VEGF ADODt. Viable Necr. TrvDan b
73.53495 12.967 21.545 22.2832 16.11 57.59 26.3
67.03882 410.1023 0 15.896 0 18.57 56.95 24.48 60
156.7855 667.0431 0 15.141 0 36.74 46.86 16.4 13
1944.285 29416.92 174.02 28.484 19.0176 16.77 4.35 78.87
1346.411 34843.9 65.707 70.357 61.5526 12.12 45.53 42.35
10.92 63.49 25.6
3973.557 11465.47 129.1 88.974 680.654 1.04 51.08 47.89
33.15 37.02 29.82
1433.041 7657.434 97.006 36.301 554.879 4.96 14.15 80.89
966.874 6689.456 19.931 44.943 948.17 23.32 34.62 39.06
279.1318 2719.13 26.58 38.865 1140.33 37.56 50.41 12.03 20
117.7689 1021.48 0 14.914 898.749 18.01 57.05 24.94 10
24.92 49.51 25.57 7
3609.863 40248.5 96.671 63.383 1881.72 3.69 75.43 20.88 10
20.46 40.61 38.93 21
20.74 61.05 18.21 5
931.0261 11719.34 61.677 57.452 2140.82 11.91 62.76 25.33 1
1040.887 8696.06 22.692 67.615 1336.62 22.57 59.34 18.09 7
18.98 55.44 25.57 5
462.8169 2023.44 51.521 32.821 1268.35 22.89 64.47 12.63 20
11.28 66.02 22.7 5
335.0952 1116.11 56.254 33.765 1334.43 16.87 68.69 14.44
0 6.2873 12.007 74.8955 15.82 45.76 38.42
920.2394 7567.88 18.702 4.2836 383.207 41.47 51.07 7.45 16
44.87 48.5 6.64 19
4577.63 49289.11 35.482 9.0961 684.304 14.47 64.74 20.59 10
19.88 57.54 22.58 13
34.02 43.82 22.15 24
4335.386 42457.32 284.33 28.439 572.267 31.06 52.38 16.55 26
339.0553 7063.16 9.2881 28.459 460.231 12.2 49.78 38.02 22
12.56 44.09 43.35 26
18.97 48.66 32.37 6
13.56 57.17 29.27 8
224.6558 2522.99 12.255 20.656 493.055
756.5183 7329.29 255.78 24.736 254.104 1.44 78.29 20.27
19.81 66.93 13.25
2.91 82.96 14.13
6013.286 49363.74 413.61 24.736 1694.84 2.37 66 31.63
0 215.1048 0 6.3762 0 75.96 19.08 4.96
0 238.0457 0 5.3184 0 24.89 71.97 3.15
Babv Dav IL-1b IL-8 MCP-1 lL-6 IL-10 GCSF GMCSF
EE 3
4
5
6 
7 
9
13
16
20
23
27
1
2
1
338.579
63.4184
22.2318 3105.11 9488.682 5475.228
86.1295
6.50981
3.11689 474.3641
2
o
87.5256 8941.62 7887.289 2081.767 1.41099 938.1691
O
4
5
77.1358 12683.6 54668.43 687.8007 5.43472 349.0121
6
7 1615.28 38019.6 81261.92 3108.139 8.93513 4518.812
9 8332.43 95571.6 37011.96 13466.67 106.251 10636.46
13
16 5148.59 56646.7 19292.82 7723.785 10.771 2581.205
20
23 364.984 15251.6 10686.56 701.5599 4.61282 473.7879
1 28.2494 12107.1 84659.09 1262.209 2.25331 195.2502
2 33.8466 8478.34 87071.26 749.5756 1.55839 370.0079
3
4 16.8804 930.68 34320.52 0 159.3419
5
1 254.798 24345.1 18707.41 9499.261 56.067 4412.863
2 501.337 35145.4 36755.46 6112.386 38.8139 4042.045
1 685.144 31984.4 8740.148 6965.2 60.0532 5672.353
2
n
110.866 11111.6 20010.33 1710.67 0 601.4726
0
1 62.4272 5794.9 40311.03 3146.57 0 5449.13
2 141.302 13529.2 60755.49 2774.52 0 1018.798
1 11.7697 821.906 9565.874 2290.855 1.91635 255.5058
2
Q
31.6056 2076.36 5493.408 395.7495 1.28464 227.8807
o
4
5
24.4007 1331.34 19096.65 1.81107 134.6008
6
7 41.5838 4329.26 30993.81 67.44605 1.53731 266.1144
9 337.905 31398.4 27346.43 3219.753 6.72065 893.0032
13
16 33336 192968 37778.13 28622.4 116.938 7244.606
20 16318.5 193191 38796.64 16959.23 172.928 3031.001
23
27 160.507 28144.5 2125.917 10.1589 3685.525
MIPIa MIPIb TNF FasL VEGF
986.205
71.12916
25.90698
227.9487
541.2549
1634.322
61.191
37.482
8.042
19.542
50.377
13.804
15.13
15.067
125.2857 603.366 9.0222 30.007
923.9442
7769.511
4596.657
53658.43
57.301
3235.6
41.781
23.067
2642.343 6152.206 121.91 29.817
330.775
111.7811
103.0809
1746.757
27.60369
26.19826
43.261
10.39
8.5206
25.884
22.463
26.739
27.25434 18.67242 6.7658 20.976
592.5209
987.2346
740.4218
654.5011
8447.685
10510.16
9866.704
4475.305
14.838
25.233
59.784
8.3672
18.983
21.292
20.656
37.581
21.62116
138.602
8 .0 2 6 7 9 2
39.26208
342.4276
468.6029
402.5254
461.9162
5.0575
8.6346
19.372
9.0961
8.0747
13.268
24.21571 237.5009 6.2873 16.519
104.8643
352.5429
466.4498
2004.27
6.424
138.44
17.561
27.913
5000.025
13361.6
21441.41
14429.79
1157.3
1956.1
32.421
29.055
475.3381 6045.653 26.125 27.057
Apopt. Viable Necr. Trypan blue %
3.09 61.87 35.04
6.88 76.06 17.05 33
9.61 63.45 26.95 4
9.87 57.39 32.74 29
5.55 74.54 19.91 10
1.02 74.07 24.91 8
6.5 71.03 22.47 12
11.19 75.02 13.79 20
7.06 63.46 29.48 10
9.88 75.47 14.65 14
4.47 48.65 46.88
71.3227 4.64 59.84 35.52
8.8505 9.93 55.26 34.81 1
1.15808 5.22 48.19 46.59 10
96.9955
7.78 67.69 24.53
676.237 7.19 80.73 12.09
18.33 56.54 25.13
1.01 81.64 17.35
295.252 4.91 83.2 11.89
237.445 18.9 54.75 26.35
6.39 82.69 10.92
635.785 8.47 71.48 20.05
8.57 77.95 13.48
1207.41 35.01 1.49 63.51
15.6269 26.08 46.56 27.36 7
53.4908 14.84 77.14 8.02
35 47.75 17.25
296.374 24.67 60.06 15.28
18.44 60.88 20.67
153.498 12.96 56.61 30.43
1119.84 4.06 64.82 31.12 0
335.067 1.86 77.56 20.58 3
893.059 3.81 31.59 64.6
6.89 52.64 40.47
6.41 60.67 32.92
8.76 54.15 37.1
20.23 63.41 16.36 40
47.2863 25.88 55.21 18.91
10.06 64.34 25.61
106.199 12.38 64.96 22.65
3.09 45.45 51.47 14
5.84 82.33 11.84 10
288.848 2.11 85.99 11.91 10
579.846 2.22 70.69 27.1
13.81 41.76 44.43 6
669.309 8.74 56.72 34.54 25
1019.44 3.92 69.7 26.38 21
2.73 46.9 50.37 6
777.191 4.82 42.07 53.11 12
Babv Dav
M
2
3
1
2
3
4
5
6 
7
13
1
2
3
5
6 
7 
9
13
16
20
23
27
31
1
2
3
5
1
2
3
4
5
6 
7 
9
13
16
20
23
27
IL-1b
273.926
124.594
207.614
392.057
26.852
IL-8
16401.8
6919.68
10714.1
37093.7
2131.1
MCP-1
5223.152
9232.669
26778.24
7496.631
2618.888
IL-6
415.567
5167.14
4303.66
17969.13
393.87
IL-10
130.993
118.781
2.4218
GCSF
1835.002
1981.244
793.8428
8208.728
311.7069
193191 43676.73 12198.34 60.4695 6088.746
189526 63984.86 14608.9 138.04 6600.545
58.4122
159.175
5281.37 
9765.82
6167.101
23200.36
1238.81
1915.4 10.8715
241.5797
344.5804
341.922 4062.26 9068.367 351.31 19.2985 416.292
4442.42
856.757
185004
56335.5
69454.22
34978.82
30890.39
8885.19
264.828
21.8695
17911.85
2338.501
457.193 41024.9 60069.54 6724.83 12.4902 4068.202
41.8342
665.263
3429.2
97812.1
7987.335
33085.38
1561.2
7657.78
1797.43
3340.301
435.304
68.7086
23076.5
9484.19
1314.637
1879.586
15873.79
599.88
137.325
6.25326
9372.803
523.3198
240.77 12845.2 12335.42 404.22 616.0955
506.021
1544.71
12276.6
185004
14324.4
86587.49
1000.8
19336.03 244.307
1673.41
4591.594
GMCSF
2391.824
IIRIa MIP1b INF FasL VEGF ADODt. Viable Necr. TrvDan t
346.6835 6727.049 35.482 28.439 29.97 29.17 40.86 15
143.7725 1349.538 17.483 3.63 76.75 19.62
305.0347 4110.534 28.439 12.07 44.13 43.8
240.4603 2286.719 43.606 34.17 52.7077 5.85 52.55 41.6
39.35374 408.8727 12.602 16.393 19.6392 14.48 75.45 10.06
6.84 73.06 20.1
11967.36 20293.35 2897.2 28.77 193.845 12.94 65.7 21.37 24
12.63 69.79 17.58 22
8.68 75.3 16.02 26
4360.481 20922.27 1204.6 32.358 137.958 14.89 64.5 20.61 10
14.48 63.69 21.83 23
43.01135 1060.48 9.0961 124.127 16.83 49.63 33.53
155.2199 2120.36 29.723 607.278 21.2 37.8 41 0
16.38 54.74 28.89 24
387.0964 2230.48 22.027 8.265 193.711 28.46 42.72 28.83 20
8.23 62.83 28.94 0
7053.178 92613.4 2169.2 92.435 1224.8 13.21 58.2 28.59 10
1244.092 17512.58 73.7 73.546 1597.68 5.07 59.49 35.45 24
8.5 47.26 44.25 15
2391.824 18908.7 23.767 105.92 2144.54 3.22 44.97 51.81 4
16.21 42.11 41.68 10
3.78 89.06 7.16 10
31.61 43.45 24.94 8
20.57 50 29.43 10
3.281953 352.751 9.0961 12.0928 5.86 87.67 6.47 0
892.6255 8206.822 102.96 16.727 423.907 7.05 73.41 19.54 15
15.7 56.37 27.93 23
13.42 61.99 24.6 40
328.9038 2743.22 279.62 63.572 114.061 7.09 62.96 29.95 5
131.3102 1722.33 37.938 64.706 161.763 33
2.78 50.85 46.37 25
868.9397 3223.84 22.385 86.466 236.161 1.68 67.33 30.99 33
2.39 75.76 21.85 30
13.09 39.12 47.79 30
488.3682 2269.48 87.871 9.0961 12.0928 6.64 71.83 21.53 10
2158.619 36653.75 206.97 47.101 577.519 5.8 40.61 53.6 10
10.06 38.36 51.58 5
13.28 72.49 14.23 9
20.55 40.45 39 10
17.05 47.85 35.11 12
8.78 54.59 36.64 0
Babv
R
Day
W
IL-1b IL-8 MCP-1 IL-6
1 72.4645 18067.1 14745.81 48815.75
2 39.6001 3521.59 6076.826 3155.34
3
4 43.5503 5004.91 4778.048 983.77
5
6
7 150.627 8931.41 11781.22 1742.27
9
13 128.836 25723.7 18066.92 678.19
16 937.448 54547.8 4411.24
20 122.587 12728.7 8938.113 234.75
1 1142.61 66768.2 2448.245 79746.64
2 207.614 20091.7 3194.109 13818.05
3
1 47.2738 1839.36 2533.188 3033.93
2 41.8342 5108.11 3960.932 1422.33
3
4 110.801 17502.7 34483.25 2672.97
5
6
7 688.382 42143.7 25784.96 3440
1 39.1144 2868.02 8881.734 3790.36
2 307.083 38019.2 28663.16 12819.41
3
4 123.105 15569.2 75536.47 1891.91
1 36.8479 852.298 1965.794 681.51
2 46.5616 2785.93 6788.126 396.43
3
4 4338.46 96904 86587.49 29753.72
5
3
4 1478.2 76891.9 69786.89 11096.57
5
6
7 180.934 21607 79751.89 6731.88
9 169.342 29281.5 32059.77 7432.92
13
16
20
23
27
IL-10 GCSF
10585.01
731.1819
347.1425
498.9029
865.8677 
30.8679 2349.823 
854.4819 
1142.94 8059.041 
106.616 432.5354
471.899
237.3306
1155.091
2625.433 
155.8703 
6028.411
432.5354
150.7863
263.6821
20.6792 16959.57
23.0121 5195.561
51.1499 10557.16 
5595.771
GMCSF
26.36942
504.6747
1126.475
8.323102
IIP1a MIP1b INF FasL VEGF Apopt. Viable Necr. Trvpan fa
116.2804 1651.79 8.3672 16.69 61.9828 12.14 79.35 8.51 1
369.3827 9.8517 119.75 16.19 79.72 4.09 13
5.88 88.44 5.69 2
54.40025 640.0856 9.2473 277.038 9.01 70.31 20.68 7
18.5 62.15 19.36 4
10.91 70.56 18.53 5
36.46294 425.5881 10.003 371.391 13.14 74.35 12.52 6
8.57 74.75 16.68 14
276.3569 1591.569 7.4717 389.116 8.57 82.25 9.18 20
476.5146 5796.178 301.52 6.6028 354.98 18.11 49.25 32.64 5
425.7794 3050.638 18.369 10.041 590.648 5.25 66.52 28.23 31
917.1643 15350.11 129.06 52.919 105.308 9.75 37.85 52.4 9
456.1475 5055.731 35.482 28.439 12.0928 8.36 59.86 31.77 30
20.33 51.05 28.63 22
251.81 11.212 58.9195 13.74 76.33 9.93 7
26.36942 476.63 9.0961 12.0928 19.38 71.1 9.52 0
33.84 52.29 13.87 24
504.6747 1533.07 18.918 243.601 10.46 64.95 24.6 20
16.55 47.31 36.14 20
9.52 69.06 21.42 27
1126.475 3649.41 48.58 9.0961 1468.57 15.99 50.5 33.51 31
302.2801 13.252 261.982 20.78 75.41 3.81 38
691.1722 3197.463 22.385 9.0961 1356.53 15.19 80.82 3.99 90
4.68 72.85 22.46 2
226.3265 2430.072 11.335 25.039 506.183 4.48 64.57 30.95 10
264.4277 8.4162 49.7291 15.25 80.94 3.82 10
5.384719 347.0156 8.1895 128.065 25.78 54.79 19.44 5
4.06 40.74 55.2 2
3865.137 11852.41 1596.3 23.527 849.296 19.89 54.37 25.74 20
9.15 72.47 18.37 10
13.5 63.38 23.12 8
2556.513 29768.62 48.784 36.523 440.538 7.15 71.52 21.33 2
11.12 67.05 21.84 15
24.99 41.87 33.15 10
1053.521 15901.91 54.003 26.776 1678.21 16.64 40 43.37 20
1081.252 7579.35 291.49 14.687 669.423 21.13 51.4 27.48 15
12.92 46.29 40.79 18
12.78 44.76 42.46
17.52 47.34 35.14
19.67 62.94 17.39 4 4
33.61 41.16 25.22 25
Babv Dav
X
IL-lb IL-8 MCP-1 IL-6 IL-10 GCSF GMCSF MIPla MIPIb TNF FasL VEGF ADODt. Viable Necr. TrvDan b
1 19.6008 691.022 13079.19 1.53733 120.1563 158.1623 8.703 24.965 385.614 16.97 32.74 50.3 8
2 22.5722 2117.94 20166.29 138.4903 8.36243 154.9888 6.9025 24.996 737.867 46.11 25.77 28.11 13
3 50.91 23.62 25.47 10
4 15.0277 261.314 7403.957 116.2691 1.56379 145.9215 5.9911 20.438 401.871 6
5 39.91 45.28 14.81
1 41.3809 1718.32 5794.052 684.63 385.538 290.81 10.985 149.509 19 77.08 3.93 2
2 54.1381 12086.4 9171.079 2176.7 853.6112 36.88588 398.63 14.073 360.45 9.6 80.51 9.89 1
3 9.93 68.82 21.26 5
4 75.3137 18581.6 86587.49 1018.47 767.0267 145.5488 782.89 12.614 36.448 930.697 21.81 52.84 25.35 45
5 12.69 63.53 23.78 25
6 13.74 70.56 15.7 50
7 655.226 16574.1 52571.67 2010.63 1330.713 14.42969 245.7596 638.37 74.774 9.0961 1020.42 4.1 94.43 1.46 32
9 20
13 3934.43 185004 83880.55 61662.2 32.6295 23925 17.82991 2281.298 15948.95 356.98 30.932 1644.95 6.22 85.36 8.42
20 71.3 11.41 17.28 33
23 1067.36 53043.9 39603.76 10640.51 150.656 3172.669 1803.527 17549.26 428.04 53.523 1347.78 50.65 15.56 33.78
27 70.42 11.75 17.82
1 14.3493 1099.07 3716.362 516.1106 1.32675 264.7174 210.2991 6.5379 12.259 275.243 7.01 82.17 10.82 1
2 17.9001 1186.54 2832.449 48.79873 248.2527 164.5094 7.062 12.795 163.564 14.68 65.2 20.12 5
3 12.48 69.89 17.62 25
4 18.4565 2753.83 20627.46 2.48502 150.2061 179.9238 8.2927 22.304 592.7 25.9 44.81 29.29 13
5 23.07 52.47 24.46 10
6 10.65 54.59 34.77 32
7 10000 77694.1 44356.23 14747.83 65.3212 5702.108 0.6681 1958.48 242.79 25.003 1253.67 28.6 32.87 38.54 50
9 19.99 72.86 7.15 2
13 3359.88 53356 42489.39 2588.161 12.9243 2194.781 0.606476 2060.488 59.33 28.516 1772.1 25.41 57.67 16.92 4
16 19.14 56.87 24 10
